Unnamed: 0
stringlengths 3
8
| Date
stringlengths 23
23
| Article_title
stringlengths 1
250
| Stock_symbol
stringlengths 1
5
| Url
stringlengths 44
135
| Publisher
stringclasses 1
value | Author
stringclasses 1
value | Article
stringlengths 1
343k
| Lsa_summary
stringlengths 3
53.9k
| Luhn_summary
stringlengths 1
53.9k
| Textrank_summary
stringlengths 1
53.9k
| Lexrank_summary
stringlengths 1
53.9k
| uuid
stringlengths 36
36
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|
723500.0
|
2018-02-18 00:00:00 UTC
|
A Landmark Marijuana Lawsuit Has Been Filed Against Jeff Sessions and the DEA
|
DEA
|
https://www.nasdaq.com/articles/landmark-marijuana-lawsuit-has-been-filed-against-jeff-sessions-and-dea-2018-02-18
|
nan
|
nan
|
There are few industries with a faster growth rate at the moment than legal marijuana. In a 2017 report from Marijuana Business Daily titled "Marijuana Business Factbook 2017," it was forecast that U.S. legal cannabis sales would increase by a whopping 45% in 2018. Much of this growth probably stems from California's legalization of recreational weed in November 2016, and opening its doors to adult-use sales on Jan. 1.
Growth is also a function of favorability. Five separate national polls have been conducted since April of last year -- CBS News, Quinnipiac University, Gallup, Pew Research Center, and Fox News -- and all five have found support for legalization ranging from a low of 59% to a high of 64%. Quinnipiac University also found in its August poll that 94% are in favor of legalizing medical weed nationally, compared with just 4% who opposed the idea.
Marijuana's scheduling is a nightmare for businesses and medical patients
But in spite of this clear public support, and the rapid sales growth that has the potential to create jobs within the cannabis industry and in industries that help support the marijuana supply and distribution chain, it remains a Schedule I substance at the federal level. As a Schedule I substance, cannabis is wholly illegal, on par with LSD and heroin, is considered to be highly prone to abuse, and has no recognized medical benefits.
This Schedule I classification can be a nightmare for pot businesses , researchers, and medical patients. Businesses often have little or no access to basic banking services due to the fact that financial institutions report to the Federal Deposit Insurance Corporation, a federally created entity. Offering any financial services to a pot company could be viewed as a criminal and/or fineable offense.
Also, because of U.S. tax code 280E, weed companies also can't take normal income-tax deductions, leading to effective tax rates of as much as 90%.
Meanwhile, researchers have to deal with a mountain of red tape. With only one approved cannabis grow facility in the U.S., at the University of Mississippi, clinical tests to highlight the benefits or risks of marijuana are practically impossible to get off the ground.
The DEA and Jeff Sessions dig in their heels
Were this not enough, the U.S. Drug Enforcement Agency (DEA) and Attorney General Jeff Sessions have quashed any chance of reform in recent years.
The DEA, with the help of the Food and Drug Administration, examined the benefit and risk profile of cannabis back in 2016 at the behest of two petitions. Ultimately, the DEA chose not to reschedule marijuana . The DEA cited marijuana's high potential for abuse, the fact that it has no currently accepted medical use, and the lack of accepted safety under medical supervision as reasons it wasn't altering its stance. What's more, since it often takes years for the DEA to take up petitions, regulators are unlikely to review it again for a long time.
At the same time, Sessions is aiming to make life as difficult as possible for the cannabis industry. Last year, he sent a letter to a few of his congressional colleagues to see if the Rohrabacher-Farr Amendment (also known as Rohrabacher-Blumenauer) could be repealed. This is an annually approved budget amendment that protects medical marijuana businesses from federal prosecution. Thus far, Sessions has been unsuccessful.
However, Sessions was able to rescind the Cole memo on Jan. 4. The Cole memo was a loose set a "rules" that legalized states agreed to abide by to keep the federal government out of their business, so to speak. Things like ensuring that weed grown within a state stayed there, and keeping kids away from pot, were among the top priorities outlined in the Cole memo. Its rescinding will allow state-level prosecutors to use discretion when bringing cannabis charges against people and businesses, even those operating in legal states.
Sessions, who has previously suggested that "good people don't smoke marijuana," and is against the idea of using pot to fight opioid addiction, is certainly no friend of the weed industry.
Medical marijuana supporters are bringing the fight to Washington
But rather than sit idly by while Sessions targets an industry that's gaining support from the public, a group of medical cannabis supporters is fighting back.
Recently, a lawsuit was filed by five plaintiffs that targets the constitutionality of keeping cannabis as a Schedule I substance via the Controlled Substances Act. In particular, the lawsuit names both the DEA and Sessions as defendants. The plaintiffs include Army veteran Jose Belen; former NFL player Marvin Washington, a co-founder of a hemp-based performance products company; 12-year-old Alexis Bortell, who suffers from epilepsy; 7-year-old Jagger Cotte, who has a severe neurological disorder known as Leigh's syndrome; and the Cannabis Cultural Association, which focuses on helping minorities in legal states.
The 98-page suit dishes out a number of allegations, according to Newsweek , including:
That cannabis doesn't belong on the Controlled Substances list, considering that it has medical benefits.
That the Controlled Substances Act discriminates against persons of color, given that cannabis arrest records show disproportionate arrests based on race.
That the Controlled Substances Act limits patients' travels within the U.S.
The big question that needs to be answered
The real battleground here is whether medical cannabis offers benefits or not. Sessions has gone so far as to suggest that the opioid crisis began with marijuana and other drugs, and seems unwilling to explore the possibility that cannabis could be used medicine.
On the other hand, a number of early-stage university studies have demonstrated what look to be signs of a clinical benefit. Last year, the University of Bonn and Hebrew University found that giving tetrahydrocannabinol (THC), the psychoactive component of cannabis, to older mice helped improve their cognitive function . Specifically, when given THC, older mice were finishing a lab maze in a similar time as younger mice. That would imply that THC may have the potential to positively affect brain-related disease, such as Parkinson's or Alzheimer's disease.
Beyond just loose studies, cannabinoids from the cannabis plant have demonstrated positive benefits, too. GW Pharmaceuticals (NASDAQ: GWPH) , a clinical-stage drug developer focused on cannabinoids, recently filed a new drug approval application with the Food and Drug Administration for Epidiolex, a cannabidiol-based medicine for two rare types of childhood-onset epilepsy. In two separate late-stage trials for each indication, Dravet syndrome and Lennox-Gastaut syndrome, Epidiolex handily met statistical significance in terms of reducing seizure frequency relative to baseline compared to the placebo.
Is cannabis successful at treating all ailments? No. There have been plenty of studies that've fallen flat, including a late-stage cancer pain trial that involved GW Pharmaceuticals' Sativex in the United States. The key point, though, is that cannabis does appear to offer some sort of medical benefit to select groups of patients, at least according to the dozens of studies I've perused over the years.
This cannabis case will shape the industry for years to come
And don't think for a moment that anyone has a clue how this lawsuit will turn out. I recall that a lawsuit by Republicans in the House against the Affordable Care Act's cost-sharing reductions in 2014 wasn't given much of a chance of success. Two years later the GOP prevailed, and in 2017, President Trump dropped an ongoing appeal put in place by the Obama administration and did away with cost-sharing reductions .
In other words, any outcome is possible here, and this landmark cannabis case has the potential to shape, or should we say reshape, the intermediate and long-term outlook for the pot industry in the United States. In short, keep your eyes peeled, because the fireworks are about ready to fly.
10 stocks we like better than GW Pharmaceuticals
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and GW Pharmaceuticals wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of February 5, 2018
Sean Williams has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Sessions, who has previously suggested that "good people don't smoke marijuana," and is against the idea of using pot to fight opioid addiction, is certainly no friend of the weed industry. Quinnipiac University also found in its August poll that 94% are in favor of legalizing medical weed nationally, compared with just 4% who opposed the idea. Meanwhile, researchers have to deal with a mountain of red tape.
|
Quinnipiac University also found in its August poll that 94% are in favor of legalizing medical weed nationally, compared with just 4% who opposed the idea. Meanwhile, researchers have to deal with a mountain of red tape. The DEA and Jeff Sessions dig in their heels Were this not enough, the U.S. Drug Enforcement Agency (DEA) and Attorney General Jeff Sessions have quashed any chance of reform in recent years.
|
Quinnipiac University also found in its August poll that 94% are in favor of legalizing medical weed nationally, compared with just 4% who opposed the idea. Meanwhile, researchers have to deal with a mountain of red tape. The DEA and Jeff Sessions dig in their heels Were this not enough, the U.S. Drug Enforcement Agency (DEA) and Attorney General Jeff Sessions have quashed any chance of reform in recent years.
|
Quinnipiac University also found in its August poll that 94% are in favor of legalizing medical weed nationally, compared with just 4% who opposed the idea. Meanwhile, researchers have to deal with a mountain of red tape. The DEA and Jeff Sessions dig in their heels Were this not enough, the U.S. Drug Enforcement Agency (DEA) and Attorney General Jeff Sessions have quashed any chance of reform in recent years.
|
cd4deb40-1be6-4861-8597-05eff6d1decf
|
723501.0
|
2018-02-06 00:00:00 UTC
|
5 Things You'll Want to Know From the World's Biggest Marijuana Biotech
|
DEA
|
https://www.nasdaq.com/articles/5-things-youll-want-know-worlds-biggest-marijuana-biotech-2018-02-06
|
nan
|
nan
|
Anticipation is building for GW Pharmaceuticals (NASDAQ: GWPH) as the biotech prepares to hopefully launch its first product in the U.S. in 2018. The company announced its fiscal 2018 first-quarter results after the market closed on Monday. Frankly, most investors weren't too interested in the financial numbers. But there was definitely a desire to know more about what is going on with the potential launch of Epidiolex and GW's cannabinoid pipeline.
GW Pharmaceuticals executives fielded several questions on those very subjects in the company's quarterly conference call on Monday. Here are five things you'll want to know from what the world's biggest marijuana-focused biotech's management team said.
1. What are expectations for the FDA advisory committee meeting?
When GW Pharmaceuticals reported its fiscal 2017 Q4 results in early December , Chief Medical Officer Volker Knappertz stated that he thought there was "a 50-50 chance" of an advisory committee meeting to review Epidiolex. It took only a few weeks for those chances to shoot up to 100%. When the FDA accepted the New Drug Application (NDA) filing for Epidiolex, it also informed GW that it was planning to hold an advisory committee meeting.
During the company's call on Monday, Knappertz said that it was "very difficult to speculate" about what specific points the FDA advisory committee would address. He added that GW was preparing for a broad range of topics and has engaged an external consultant with significant experience in guiding drugmakers through the FDA regulatory process.
2. When could Epidiolex start generating revenue?
Julian Gangolli, GW Pharmaceuticals' president of North America, fielded what was perhaps the most important question asked during the company's conference call: When will Epidiolex make money? Of course, the premise of that question is that the FDA will approve the drug by the scheduled date of June 27, 2018. Assuming that approval is granted, Gangolli said that GW Pharmaceuticals should begin selling the drug in September. However, the quarter ending Dec. 31, 2018, will be when the company should have meaningful revenue from Epidiolex.
The gap from June to September stems from the time required for the U.S. Drug Enforcement Administration (DEA) to reschedule Epidiolex. Gangolli said that the DEA has up to 90 days to issue its interim final rule. That would put the U.S. launch of the drug in late September.
3. How are pre-launch activities going?
Obviously, GW plans to be ready to launch Epidiolex the minute both FDA approval and DEA rescheduling are completed. Gangolli said that the biotech is talking extensively with U.S. commercial, state, and federal payers that provide coverage to between 200 million and 220 million Americans. He added that GW is "not there yet on pricing," but is continuing to evaluate different pricing levels.
Gangolli stated that the U.S. sales leadership team is now fully in place. The company plans to hire around 70 sales representatives closer to the time of the Epidiolex launch. Gangolli said that there "was no shortage of interest" in these positions.
4. What's the scoop on CBDV?
While Epidiolex deservedly gets the most attention, GW Pharmaceuticals also has another intriguing cannabinoid in its pipeline -- cannabidivarin (CBDV). Data from a phase 2 study of CBDV in treating adults with partial-onset epilepsy is expected within the next couple of months. An investigator-led study of CBDV in treating autism spectrum disorders is scheduled to begin in the second quarter of 2018. GW also plans to conduct an open-label study of the drug in treating Rett syndrome in the second quarter, as well as a phase 2 study targeting the indication in the third quarter.
GW Pharmaceuticals CEO Justin Gover said that there has been considerable interest in the U.S. for CBDV following the successful clinical trials of Epidiolex. He noted that the biotech's efforts constitute a "logical response to investigator interest." Knappertz said, though, that statistical significance for some of these CBDV studies won't be as critical because they're smaller and the placebo response rate for patients in clinical studies has increased in recent years.
5. What has changed to make Sativex a more compelling asset?
The company announced on Dec. 13, 2017, that it had reacquired full rights to market Sativex in the U.S. GW currently markets the marijuana-based drug outside of the U.S. However, sales haven't been great. Gover was asked what has changed to make owning U.S. rights to Sativex more compelling now.
One reason why GW is excited about Sativex, according to Gover, stems from phase 2 study results announced in February 2017. That study evaluated the drug in treating recurrent glioblastoma multiforme, an aggressive form of brain cancer. Patients treated with Sativex had an 83% one-year survival rate compared to 53% for patients on placebo. Gover also noted that GW's position has changed dramatically from a decade ago when it licensed U.S. rights for Sativex to Otsuka Pharmaceutical.
Looking ahead
I recently stated that if I could buy only one marijuana stock , GW Pharmaceuticals would be it. I still feel that way.
While anything can happen with the FDA regulatory process, I fully expect that Epidiolex will gain approval. I also think that GW's launch of the drug will go reasonably well. My view is that 2019 will be a better indication for just how successful Epidiolex will be, though.
There are still plenty of risks, of course. Epidiolex could disappoint. CBDV might prove to be ineffective in clinical studies. However, I continue to view the risk-reward proposition for GW Pharmaceuticals favorably. 2018 will definitely be, as Justin Gover said on Monday, "an exciting and pivotal year" for the company.
10 stocks we like better than GW Pharmaceuticals
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now...and GW Pharmaceuticals wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of Feb. 5, 2018
Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
The gap from June to September stems from the time required for the U.S. Drug Enforcement Administration (DEA) to reschedule Epidiolex. Gangolli said that the DEA has up to 90 days to issue its interim final rule. Obviously, GW plans to be ready to launch Epidiolex the minute both FDA approval and DEA rescheduling are completed.
|
The gap from June to September stems from the time required for the U.S. Drug Enforcement Administration (DEA) to reschedule Epidiolex. Gangolli said that the DEA has up to 90 days to issue its interim final rule. Obviously, GW plans to be ready to launch Epidiolex the minute both FDA approval and DEA rescheduling are completed.
|
The gap from June to September stems from the time required for the U.S. Drug Enforcement Administration (DEA) to reschedule Epidiolex. Gangolli said that the DEA has up to 90 days to issue its interim final rule. Obviously, GW plans to be ready to launch Epidiolex the minute both FDA approval and DEA rescheduling are completed.
|
The gap from June to September stems from the time required for the U.S. Drug Enforcement Administration (DEA) to reschedule Epidiolex. Gangolli said that the DEA has up to 90 days to issue its interim final rule. Obviously, GW plans to be ready to launch Epidiolex the minute both FDA approval and DEA rescheduling are completed.
|
3f233e97-d2fa-4312-a79f-86f368b83bca
|
723502.0
|
2018-01-21 00:00:00 UTC
|
This Marijuana Stock Just Might Have 1 of the Biggest New Drug Launches of 2018
|
DEA
|
https://www.nasdaq.com/articles/marijuana-stock-just-might-have-1-biggest-new-drug-launches-2018-2018-01-21
|
nan
|
nan
|
I recently wrote about what could be the five biggest new drugs of 2018 . There wasn't a marijuana-related drug on the list. But that's just because I stopped at the top five. Had I gone further, it would be a different story.
Market research firm EvaluatePharma looked at all of the potential new drugs that could be launched in 2018 and ranked them by their projected sales in 2022. Coming in at No. 10 on the list was Epidiolex, a cannabidiol (CBD) drug developed by GW Pharmaceuticals (NASDAQ: GWPH) for treating two rare types of epilepsy. Could a marijuana-based drug really be one of the biggest success stories of the year? It just might.
The countdown is on
GW Pharmaceuticals completed its submission of a New Drug Application (NDA) for Epidiolex in October. The NDA was for two forms of childhood-onset epilepsy -- Lennox-Gastaut syndrome (LGS) and Dravet syndrome. In December, the FDA accepted the NDA. Even better, the agency granted priority review status to Epidiolex, which speeds up the review process.
The countdown is now on. An approval decision for GW's CBD drug is expected by June 27. It could even come more quickly than that, but I wouldn't count on it. As it stands now, the FDA will hold an advisory committee meeting to discuss the application for Epidiolex. This isn't an unusual step, though.
What are the chances for Epidiolex winning FDA approval? Pretty good. Around 90% of drugs for which an NDA is submitted gain approval. Many of those approvals rely on one late-stage clinical study. GW Pharmaceuticals, though, conducted three phase 3 safety and efficacy studies, all of which met their primary endpoints. The company also submitted safety data for close to 1,500 patients, with roughly 400 patients of them on continuous therapy for more than one year.
Assuming Epidiolex does get a thumbs-up from the FDA, there is another regulatory hurdle. Because CBD is a controlled substance under U.S. federal law, the Drug Enforcement Administration (DEA) will require Epidiolex to be scheduled.
GW Pharmaceuticals completed a human abuse liability study for CBD in 2017. The company hopes this data will convince the DEA to categorize Epidiolex as a Schedule IV drug, a classification reserved for drugs with low potential for abuse. Marijuana itself is a Schedule I drug, which means that it is deemed to "have no currently accepted medical use in the United States, a lack of accepted safety for use under medical supervision, and a high potential for abuse."
DEA scheduling should be completed within 90 days of FDA approval. GW has already discussed Epidiolex with the agency, and the company doesn't anticipate any problems with the process. If all goes according to plan, Epidiolex should be launched in the U.S. by October, if not sooner.
Commercial potential
Several factors play into how well a new drug performs. First, there must be a market need. GW Pharmaceuticals should be in good shape on that front. There are currently no FDA-approved treatments for Dravet syndrome. While there are approved treatments for LGS, many patients develop a resistance to initial medications.
The second factor is related to the first one. Sales for new drugs are higher when there isn't significant competition. Epidiolex will face competition from approved treatments and off-label use of drugs not approved for treating LGS and Dravet syndrome. However, because so many patients end up switching therapies, competition shouldn't be a big obstacle for Epidiolex's success -- at least not initially.
What about a new drug hitting the scene, though? Zogenix (NASDAQ: ZGNX) announced solid results in September from its late-stage study of ZX008 in treating Dravet syndrome. The biotech has another late-stage study to complete for the drug, which isn't a cannabinoid. At the earliest, Zogenix could file for FDA approval by late 2018. Still, though, because of the high percentage of patients who move from one treatment to another, there should be plenty of room for both Epidiolex and ZX008 to be successful commercially.
The third factor is convincing payers to cover a new drug and actually provide reimbursement for it. GW Pharmaceuticals has already hit the ground running in its efforts to convince the payer community. Julian Gangolli, GW Pharmaceuticals' president of North America, said in December that the company is meeting one-on-one with payers. The biotech's CEO, Justin Gover, also stated that the talks have gone well and that he didn't think payers will "impose any onerous prior authorization requirements" on Epidiolex.
Sales estimates for Epidiolex have ranged from $300 million to more than $2 billion. EvaluatePharma projected that the drug would generate sales of close to $1 billion by 2022. I think that's realistic. And it would certainly be enough to make Epidiolex one of the biggest new drug launches of this year.
Taking stock
What does all this mean for GW Pharmaceuticals stock? The biotech's market cap currently stands at close to $3.7 billion. If Epidiolex can hit the $1 billion sales mark or close to it, GW Pharmaceuticals should have some room to go higher.
And we've only talked about Epidiolex in treating LGS and Dravet syndrome so far. GW is targeting other indications for the drug and has additional pipeline candidates. The stock gained 18% in 2017. I think with the likely approval for Epidiolex and possible good news from the pipeline, GW Pharmaceuticals stock should enjoy a better year in 2018.
10 stocks we like better than GW Pharmaceuticals
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and GW Pharmaceuticals wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of January 2, 2018
Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Because CBD is a controlled substance under U.S. federal law, the Drug Enforcement Administration (DEA) will require Epidiolex to be scheduled. The company hopes this data will convince the DEA to categorize Epidiolex as a Schedule IV drug, a classification reserved for drugs with low potential for abuse. DEA scheduling should be completed within 90 days of FDA approval.
|
Because CBD is a controlled substance under U.S. federal law, the Drug Enforcement Administration (DEA) will require Epidiolex to be scheduled. The company hopes this data will convince the DEA to categorize Epidiolex as a Schedule IV drug, a classification reserved for drugs with low potential for abuse. DEA scheduling should be completed within 90 days of FDA approval.
|
Because CBD is a controlled substance under U.S. federal law, the Drug Enforcement Administration (DEA) will require Epidiolex to be scheduled. The company hopes this data will convince the DEA to categorize Epidiolex as a Schedule IV drug, a classification reserved for drugs with low potential for abuse. DEA scheduling should be completed within 90 days of FDA approval.
|
Because CBD is a controlled substance under U.S. federal law, the Drug Enforcement Administration (DEA) will require Epidiolex to be scheduled. The company hopes this data will convince the DEA to categorize Epidiolex as a Schedule IV drug, a classification reserved for drugs with low potential for abuse. DEA scheduling should be completed within 90 days of FDA approval.
|
2509bc3e-b900-4e7c-8190-9f4a365dbfa8
|
723503.0
|
2018-01-15 00:00:00 UTC
|
Piedmont Issues Fourth-Quarter Leasing Activities Updates
|
DEA
|
https://www.nasdaq.com/articles/piedmont-issues-fourth-quarter-leasing-activities-updates-2018-01-15
|
nan
|
nan
|
Piedmont Office Realty TrustPDM recently announced its leasing of approximately 2.1 million square feet in 2017, of which 900,000 square feet were rented out in the fourth quarter alone. Renewal of an existing lease deal and the renting of a new building were the major transactions undertaken by the company in the fourth quarter.
The above deals included, the renewal of Raytheon Company's 440,000-square foot lease through 2024, at 225 & 235 Presidential Way in the Boston office market and a new building deal with Gartner, Inc. covering roughly 152,000 square foot in the Dallas market at 6011 Connection Drive through 2034.
Other noteworthy deals included, 51,000-square foot expansion of US Bancorp's current space at US Bancorp Center in Minneapolis, MN, through 2024, Consilium Staffing, LLC's 5,000 square feet expansion and renewal of existing 15,000 square feet through 2021 at 161 Corporate Center in Irving, TX and Harvard University's renewal of 5,000 square feet and expansion of 15,000 square feet at One Brattle Square in Cambridge, MA to 2030.
Piedmont is engaged in acquisition, ownership, management and development of high-quality Class A office properties located across major U.S. markets. The continued transactional activity hints at its success in selling non-strategic assets and redeploying the proceeds into targeted submarkets.
Piedmont currently carries a Zacks Rank #4 (Sell). Over the past 30 days, the Zacks Consensus Estimate for 2017 funds from operations (FFO) per share remained unchanged at $1.75.
Shares of Piedmont lost 7.7% in the past six months, as against the decline of 5.4% recorded by the industry it belongs to.
Stocks That Warrant a Look
Rexford Industrial Realty REXR witnessed an upward earnings estimate revision of nearly 1% for 2018 in the last 60 days. Also, its shares gained 80.7% in the past 12 months. It carries a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
The Zacks Consensus Estimate for American Tower Corporation AMT for 2018 has been revised upward marginally over the last 60 days. Also, its shares have moved up 50.4% in 12 months' time. It carries a Zacks Rank #2.
Easterly Government Properties' DEA Zacks Consensus Estimate for 2018 has remained stable over the last 60 days. Its shares have gained 19.6% in the past 12 months. It carries a Zacks Rank #2.
Note: All EPS numbers presented in this write up represent FFO per share. FFO, a widely used metric to gauge the performance of REITs, is obtained after adding depreciation and amortization and other non-cash expenses to net income.
Wall Street's Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It's a once-in-a-generation opportunity to invest in pure genius.
Click for details >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
American Tower Corporation (REIT) (AMT): Free Stock Analysis Report
Piedmont Office Realty Trust, Inc. (PDM): Free Stock Analysis Report
Easterly Government Properties, Inc. (DEA): Free Stock Analysis Report
Rexford Industrial Realty, Inc. (REXR): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Renewal of an existing lease deal and the renting of a new building were the major transactions undertaken by the company in the fourth quarter. The above deals included, the renewal of Raytheon Company's 440,000-square foot lease through 2024, at 225 & 235 Presidential Way in the Boston office market and a new building deal with Gartner, Inc. covering roughly 152,000 square foot in the Dallas market at 6011 Connection Drive through 2034. Other noteworthy deals included, 51,000-square foot expansion of US Bancorp's current space at US Bancorp Center in Minneapolis, MN, through 2024, Consilium Staffing, LLC's 5,000 square feet expansion and renewal of existing 15,000 square feet through 2021 at 161 Corporate Center in Irving, TX and Harvard University's renewal of 5,000 square feet and expansion of 15,000 square feet at One Brattle Square in Cambridge, MA to 2030.
|
Other noteworthy deals included, 51,000-square foot expansion of US Bancorp's current space at US Bancorp Center in Minneapolis, MN, through 2024, Consilium Staffing, LLC's 5,000 square feet expansion and renewal of existing 15,000 square feet through 2021 at 161 Corporate Center in Irving, TX and Harvard University's renewal of 5,000 square feet and expansion of 15,000 square feet at One Brattle Square in Cambridge, MA to 2030. Easterly Government Properties' DEA Zacks Consensus Estimate for 2018 has remained stable over the last 60 days. Click to get this free report American Tower Corporation (REIT) (AMT): Free Stock Analysis Report Piedmont Office Realty Trust, Inc. (PDM): Free Stock Analysis Report Easterly Government Properties, Inc. (DEA): Free Stock Analysis Report Rexford Industrial Realty, Inc. (REXR): Free Stock Analysis Report To read this article on Zacks.com click here.
|
Other noteworthy deals included, 51,000-square foot expansion of US Bancorp's current space at US Bancorp Center in Minneapolis, MN, through 2024, Consilium Staffing, LLC's 5,000 square feet expansion and renewal of existing 15,000 square feet through 2021 at 161 Corporate Center in Irving, TX and Harvard University's renewal of 5,000 square feet and expansion of 15,000 square feet at One Brattle Square in Cambridge, MA to 2030. Click to get this free report American Tower Corporation (REIT) (AMT): Free Stock Analysis Report Piedmont Office Realty Trust, Inc. (PDM): Free Stock Analysis Report Easterly Government Properties, Inc. (DEA): Free Stock Analysis Report Rexford Industrial Realty, Inc. (REXR): Free Stock Analysis Report To read this article on Zacks.com click here. Renewal of an existing lease deal and the renting of a new building were the major transactions undertaken by the company in the fourth quarter.
|
The above deals included, the renewal of Raytheon Company's 440,000-square foot lease through 2024, at 225 & 235 Presidential Way in the Boston office market and a new building deal with Gartner, Inc. covering roughly 152,000 square foot in the Dallas market at 6011 Connection Drive through 2034. Renewal of an existing lease deal and the renting of a new building were the major transactions undertaken by the company in the fourth quarter. Other noteworthy deals included, 51,000-square foot expansion of US Bancorp's current space at US Bancorp Center in Minneapolis, MN, through 2024, Consilium Staffing, LLC's 5,000 square feet expansion and renewal of existing 15,000 square feet through 2021 at 161 Corporate Center in Irving, TX and Harvard University's renewal of 5,000 square feet and expansion of 15,000 square feet at One Brattle Square in Cambridge, MA to 2030.
|
7682aae3-55c5-4f81-9618-ba0695c85e17
|
723504.0
|
2018-01-08 00:00:00 UTC
|
Alexandria (ARE) Prices Public Offering of 6M Common Shares
|
DEA
|
https://www.nasdaq.com/articles/alexandria-are-prices-public-offering-of-6m-common-shares-2018-01-08
|
nan
|
nan
|
Alexandria Real Estate EquitiesARE recently priced its public offering of 6,000,000 shares of common stock at $123.50 per share. This share offering is related to a forward-sale deal signed by the company with Bank of America, N.A., JPMorgan Chase Bank, N.A., London Branch and Citibank, N.A.
The underwriters have been granted a 30-day option to purchase up to an additional 900,000 common shares. The offering, subject to customary closing conditions, is expected to close on or around Jan 8, 2018.
Per the forward-sale agreement, the forward purchasers will borrow and sell 6,000,000 shares of common stock (or 6,900,000 shares if the underwriters fully exercise their options) to the underwriters. The company is expected to settle the agreement through delivery of shares on or before Apr 8, 2019. Alexandria will receive cash proceeds amounting to the forward sale price after deducting underwriting discounts and commissions.
Issuing common stock through a forward-sale agreement offers certain benefits to the issuer and hence is a strategic fit for the company. While the company can set the price of the offering, the deal offers flexibility to delay the share issuance and receive the net proceeds, until a funding requirement has occurred.
The company does not expect to receive any proceeds from the share offering, initially. Nonetheless, upon settlement of the agreement, the net proceeds will be used as growth capital and to fund Alexandria's development pipeline. Specifically, funds will be invested in the pending near-term acquisitions and for the construction of its highly-leased projects.
Thereafter, the remaining proceeds will be held for general working expenses as well as corporate purposes. This may include shrinking unsecured senior debt obligations assumed by the company, if any.
Notably, sale of common share through this arrangement offer financial flexibility to the company as well as enables it to pursue its growth plans. These efforts will enhance the company's portfolio and boost occupancy levels, when development projects are delivered.
Encouragingly, over the past year, shares of this Zacks Rank #3 (Hold) company have outperformed the industry . While the stock has rallied 14.4%, the industry has recorded growth of 2% during this period.
Better-ranked stocks in the REIT space include Lamar Advertising Company LAMR , Outfront Media OUT and Easterly Government Properties DEA . All three carry a Zacks Rank of 2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
Lamar's funds from operations (FFO) per share estimates for 2017 remained unchanged at $4.96 over the past month. Its share price has increased 5.9% in three months' time.
Outfront Media's FFO per share estimates for the current year has remained unchanged at $1.98 in a month's time. Over the past three months, the stock has declined 5.4%.
Easterly Government Properties' Zacks Consensus Estimate for 2017 FFO has remained unchanged at $1.27 in a month's time. Also, its shares have gained 0.7% in three months' time.
Note: All EPS numbers presented in this write up represent funds from operations ("FFO") per share. FFO, a widely used metric to gauge the performance of REITs, is obtained after adding depreciation and amortization and other non-cash expenses to net income.
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Click here to see the 5 stocks >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Lamar Advertising Company (LAMR): Free Stock Analysis Report
Alexandria Real Estate Equities, Inc. (ARE): Free Stock Analysis Report
OUTFRONT Media Inc. (OUT): Free Stock Analysis Report
Easterly Government Properties, Inc. (DEA): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Better-ranked stocks in the REIT space include Lamar Advertising Company LAMR , Outfront Media OUT and Easterly Government Properties DEA . This share offering is related to a forward-sale deal signed by the company with Bank of America, N.A., JPMorgan Chase Bank, N.A., London Branch and Citibank, N.A. While the company can set the price of the offering, the deal offers flexibility to delay the share issuance and receive the net proceeds, until a funding requirement has occurred.
|
Better-ranked stocks in the REIT space include Lamar Advertising Company LAMR , Outfront Media OUT and Easterly Government Properties DEA . Click to get this free report Lamar Advertising Company (LAMR): Free Stock Analysis Report Alexandria Real Estate Equities, Inc. (ARE): Free Stock Analysis Report OUTFRONT Media Inc. (OUT): Free Stock Analysis Report Easterly Government Properties, Inc. (DEA): Free Stock Analysis Report To read this article on Zacks.com click here. This share offering is related to a forward-sale deal signed by the company with Bank of America, N.A., JPMorgan Chase Bank, N.A., London Branch and Citibank, N.A.
|
Click to get this free report Lamar Advertising Company (LAMR): Free Stock Analysis Report Alexandria Real Estate Equities, Inc. (ARE): Free Stock Analysis Report OUTFRONT Media Inc. (OUT): Free Stock Analysis Report Easterly Government Properties, Inc. (DEA): Free Stock Analysis Report To read this article on Zacks.com click here. This share offering is related to a forward-sale deal signed by the company with Bank of America, N.A., JPMorgan Chase Bank, N.A., London Branch and Citibank, N.A. While the company can set the price of the offering, the deal offers flexibility to delay the share issuance and receive the net proceeds, until a funding requirement has occurred.
|
While the company can set the price of the offering, the deal offers flexibility to delay the share issuance and receive the net proceeds, until a funding requirement has occurred. This share offering is related to a forward-sale deal signed by the company with Bank of America, N.A., JPMorgan Chase Bank, N.A., London Branch and Citibank, N.A. Better-ranked stocks in the REIT space include Lamar Advertising Company LAMR , Outfront Media OUT and Easterly Government Properties DEA .
|
46c4d7ea-e68d-4237-890b-b5bd56ad788a
|
723505.0
|
2018-01-05 00:00:00 UTC
|
LTC Clinches JV Deal to Develop Hamilton House for $23M
|
DEA
|
https://www.nasdaq.com/articles/ltc-clinches-jv-deal-to-develop-hamilton-house-for-%2423m-2018-01-05
|
nan
|
nan
|
LTC PropertiesLTC recently announced that it has entered into a joint-venture (JV) agreement with affiliates of Tealwood Senior Living and developer Tukka Properties to construct a private-pay assisted living and memory care community.
According to the JV deal, the companies will acquire a land parcel in Cedarburg, WI, to develop Hamilton House - a 110-unit healthcare campus - worth $23 million. The project is scheduled to break ground in 2018 and is expected to open in spring 2019.
While Tukka will develop the property, an affiliate of Tealwood will operate the property under a triple-net lease with the JV. In addition, LTC will act as a capital partner. The agreement is LTC's first initiative using this model.
Notably, this is also the first time that LTC and Tealwood have collaborated for a project. The venture has also enabled LTC to add Tealwood to its portfolio of operators. Tealwood has considerable experience in the management and operation of assisted living communities with responsibilities for more than 50 communities in the United States. Hence, the JV is a strategic fit for this healthcare real estate investment trust (REIT).
With the project, the company is making an attempt to offer more creative and flexible financing structures to regional operators. Per Tealwood's management, construction of Hamilton House will help the company expand its presence and offer assisted living for residence in "underserved markets."
Although LTC is focused to develop senior housing properties in partnership with regional operators, challenged operator performance and problems with tenants have hindered the growth of this company.
Shares of this Zacks Rank #3 (Hold) company have underperformed its industry , in the past year. In fact, the stock has declined 9.5% compared with the industry's gain of 2.9% during the same time period.
Better-ranked stocks in the REIT space include Lamar Advertising Company LAMR , Outfront Media OUT and Easterly Government Properties DEA . All three carry a Zacks Rank of 2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here
Lamar's funds from operations (FFO) per share estimates for 2017 remained unchanged at $4.96 over the past month. Its share price has increased 5.5% in three months' time.
Outfront Media's FFO per share estimates for the current year has remained unchanged at $1.98 in a month's time. Over the past three months, the stock has declined 5.4%.
Easterly Government Properties' Zacks Consensus Estimate for 2017 FFO has remained unchanged at $1.27 in a month's time. Also, its shares have gained 0.7% in three months' time.
Note: All EPS numbers presented in this write up represent funds from operations ("FFO") per share. FFO, a widely used metric to gauge the performance of REITs, is obtained after adding depreciation and amortization and other non-cash expenses to net income.
Zacks Editor-in-Chief Goes "All In" on This Stock
Full disclosure, Kevin Matras now has more of his own money in one particular stock than in any other. He believes in its short-term profit potential and also in its prospects to more than double by 2019. Today he reveals and explains his surprising move in a new Special Report.
Download it free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Lamar Advertising Company (LAMR): Free Stock Analysis Report
LTC Properties, Inc. (LTC): Free Stock Analysis Report
OUTFRONT Media Inc. (OUT): Free Stock Analysis Report
Easterly Government Properties, Inc. (DEA): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
According to the JV deal, the companies will acquire a land parcel in Cedarburg, WI, to develop Hamilton House - a 110-unit healthcare campus - worth $23 million. Better-ranked stocks in the REIT space include Lamar Advertising Company LAMR , Outfront Media OUT and Easterly Government Properties DEA . Click to get this free report Lamar Advertising Company (LAMR): Free Stock Analysis Report LTC Properties, Inc. (LTC): Free Stock Analysis Report OUTFRONT Media Inc. (OUT): Free Stock Analysis Report Easterly Government Properties, Inc. (DEA): Free Stock Analysis Report To read this article on Zacks.com click here.
|
Better-ranked stocks in the REIT space include Lamar Advertising Company LAMR , Outfront Media OUT and Easterly Government Properties DEA . Click to get this free report Lamar Advertising Company (LAMR): Free Stock Analysis Report LTC Properties, Inc. (LTC): Free Stock Analysis Report OUTFRONT Media Inc. (OUT): Free Stock Analysis Report Easterly Government Properties, Inc. (DEA): Free Stock Analysis Report To read this article on Zacks.com click here. According to the JV deal, the companies will acquire a land parcel in Cedarburg, WI, to develop Hamilton House - a 110-unit healthcare campus - worth $23 million.
|
Click to get this free report Lamar Advertising Company (LAMR): Free Stock Analysis Report LTC Properties, Inc. (LTC): Free Stock Analysis Report OUTFRONT Media Inc. (OUT): Free Stock Analysis Report Easterly Government Properties, Inc. (DEA): Free Stock Analysis Report To read this article on Zacks.com click here. According to the JV deal, the companies will acquire a land parcel in Cedarburg, WI, to develop Hamilton House - a 110-unit healthcare campus - worth $23 million. Better-ranked stocks in the REIT space include Lamar Advertising Company LAMR , Outfront Media OUT and Easterly Government Properties DEA .
|
According to the JV deal, the companies will acquire a land parcel in Cedarburg, WI, to develop Hamilton House - a 110-unit healthcare campus - worth $23 million. Better-ranked stocks in the REIT space include Lamar Advertising Company LAMR , Outfront Media OUT and Easterly Government Properties DEA . Click to get this free report Lamar Advertising Company (LAMR): Free Stock Analysis Report LTC Properties, Inc. (LTC): Free Stock Analysis Report OUTFRONT Media Inc. (OUT): Free Stock Analysis Report Easterly Government Properties, Inc. (DEA): Free Stock Analysis Report To read this article on Zacks.com click here.
|
c6bd22af-4e8b-4e91-b5be-10fcf11a8b11
|
723506.0
|
2018-01-04 00:00:00 UTC
|
Here's Why Marijuana Stocks Got Crushed Today
|
DEA
|
https://www.nasdaq.com/articles/heres-why-marijuana-stocks-got-crushed-today-2018-01-04
|
nan
|
nan
|
Attorney General Jeff Sessions is no friend to the pro-marijuana movement, and earlier today he solidified his opposition to the herb by rolling back Obama-era guidance to ease enforcement of federal marijuana laws in states where marijuana has been legalized.
Sessions decision sent shockwaves throughout the industry, causing a sharp sell-off in marijuana stocks. Among the stocks hit hardest were Aphria Inc. (NASDAQOTH: APHQF) , a Canadian marijuana company that's investing in medical marijuana in Florida . Its shares finished the trading day down more than 13%.
Marijuana companies that aren't even impacted directly by Sessions' decision fell, too. Canopy Growth (NASDAQOTH: TWMJF) , which is purposefully avoiding the U.S. market until federal marijuana laws are repealed, declined almost 10%, and Insys Therapeutics (NASDAQ: INSY) , which is working on marijuana drugs that it hopes will be FDA approved, tumbled more than 26%.
What's going on?
Pro-pot momentum has increased considerably over the past decade and according to Gallup polls, more Americans favor legalizing marijuana than ever before.
In response to shifting public opinions, 29 states have passed laws legalizing marijuana in one form or another, including eight states that have passed recreational marijuana laws. The biggest of those states, California, opened its recreational marijuana market on Jan. 1, clearing the way to what GreenWave Advisors estimates will become an $8 billion market .
Because legal marijuana markets are heavily taxed, states increasingly use marijuana legalization as an important source of new tax revenue. In Colorado, where recreational marijuana has been regulated since 2014, the government has already collected over $500 million in taxes. The tax revenue associated with legalizing marijuana in California could someday eclipse $1 billion.
Although many states are embracing marijuana, it remains illegal at the federal level and its classified by the Drug Enforcement Agency (DEA) as a Schedule 1 narcotic that's as risky as heroin.
Until now, federal law enforcement has turned a blind eye toward states passing recreational laws. That's in part because of an August 2013 memorandum from then Deputy Attorney General James Cole. In his memorandum, Cole shifted attention away from individuals and companies legally participating in pro-pot states, and toward prosecuting behaviors that remained illegal, such as interstate trafficking and distributing marijuana to children.
Cole's memorandum, which you can read in full , doesn't do away with the federal authority to prosecute marijuana violators in states that have legalized it, but it pretty clearly spells out that the view from the top was that enforcement within states should mostly be left up to state and local authorities, not the U.S. government.
On the surface, Sessions' decision to roll back Cole's guidance doesn't change anything materially. The federal government could always intervene under Cole's memorandum, however, it does increase uncertainty for emerging marijuana businesses that are already struggling to secure adequate financing and access to banking services governed under federal laws.
What's the takeaway?
In July 2017, Aphria announced it would be investing in a third-party company that would manage medical marijuana production and distribution in Florida. That investment, however, is tiny compared to the market opportunity that exists for Aphria in Canada, where medical marijuana is legal nationally and recreational laws are set to be in place in July 2018.
The Canadian market could double in the coming year, according to comments from Canopy Growth's CEO Bruce Linton, and his company is even more insulated than Aphria against Sessions. Rather than risk a U.S. federal crackdown, Canopy Growth -- the largest pure-play marijuana company in Canada -- has concentrated on markets elsewhere, including Germany.
Similarly, the impact of Sessions action on drug companies including GW Pharmaceuticals (NASDAQ: GWPH) and Insys Therapeutics is limited. Both GW Pharma and Insys Therapeutics are developing marijuana medicines based on marijuana cannabinoids. GW Pharmaceuticals, for example, is awaiting FDA approval of Epidiolex, a cannabidiol drug for use in specific and rare forms of epilepsy. Insys Therapeutics already has FDA approval and DEA scheduling for Syndros, its liquid formulation of the long-used THC-based drug, Marinol. Companies that secure FDA approval for marijuana drugs, and patients who use these drugs under the direction of a doctor, wouldn't be in federal cross-hairs.
The stocks that this shift in guidance does impact, however, are high-risk penny stocks that rely solely on U.S. marijuana markets for revenue. Penny stocks don't trade on the major market exchanges, and historically they're more prone to fraud . As a result, they're unsuitable investments for most investors anyway.
Overall, it remains to be seen whether any state attorney generals will crackdown on marijuana activity following Sessions decision, but it may not matter. For pro-marijuana advocates and marijuana investors, the hope has been for a friendlier federal government, and, it seems that remains unlikely, at least under this administration.
10 stocks we like better than Canopy Growth Corporation
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Canopy Growth Corporation wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of January 2, 2018
Todd Campbell has no position in any of the stocks mentioned. His clients may have positions in the companies mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Although many states are embracing marijuana, it remains illegal at the federal level and its classified by the Drug Enforcement Agency (DEA) as a Schedule 1 narcotic that's as risky as heroin. Insys Therapeutics already has FDA approval and DEA scheduling for Syndros, its liquid formulation of the long-used THC-based drug, Marinol. In his memorandum, Cole shifted attention away from individuals and companies legally participating in pro-pot states, and toward prosecuting behaviors that remained illegal, such as interstate trafficking and distributing marijuana to children.
|
Although many states are embracing marijuana, it remains illegal at the federal level and its classified by the Drug Enforcement Agency (DEA) as a Schedule 1 narcotic that's as risky as heroin. Insys Therapeutics already has FDA approval and DEA scheduling for Syndros, its liquid formulation of the long-used THC-based drug, Marinol. In response to shifting public opinions, 29 states have passed laws legalizing marijuana in one form or another, including eight states that have passed recreational marijuana laws.
|
Although many states are embracing marijuana, it remains illegal at the federal level and its classified by the Drug Enforcement Agency (DEA) as a Schedule 1 narcotic that's as risky as heroin. Insys Therapeutics already has FDA approval and DEA scheduling for Syndros, its liquid formulation of the long-used THC-based drug, Marinol. Canopy Growth (NASDAQOTH: TWMJF) , which is purposefully avoiding the U.S. market until federal marijuana laws are repealed, declined almost 10%, and Insys Therapeutics (NASDAQ: INSY) , which is working on marijuana drugs that it hopes will be FDA approved, tumbled more than 26%.
|
Although many states are embracing marijuana, it remains illegal at the federal level and its classified by the Drug Enforcement Agency (DEA) as a Schedule 1 narcotic that's as risky as heroin. Insys Therapeutics already has FDA approval and DEA scheduling for Syndros, its liquid formulation of the long-used THC-based drug, Marinol. In response to shifting public opinions, 29 states have passed laws legalizing marijuana in one form or another, including eight states that have passed recreational marijuana laws.
|
48ee88b7-81f0-4db3-9094-d14bfccda232
|
723507.0
|
2018-01-04 00:00:00 UTC
|
Agree Realty (ADC) Recaps 2017, Issues Guidance for 2018
|
DEA
|
https://www.nasdaq.com/articles/agree-realty-adc-recaps-2017-issues-guidance-for-2018-2018-01-04
|
nan
|
nan
|
Agree Realty CorporationADC provided an insight into the acquisitions and disposition activities that it plans to commence this year. The company also summed up the investment activities undertaken in 2017.
During 2017, total investment activity amounted to $399.7 million. It included acquisitions, development and the finished or presently under construction projects of Partner Capital Solutions.
Throughout 2017, the company's acquisition volume for retail net lease properties came in at $336.8 million which covered 79 properties. However, the company expects the volume to decline to the range of $250-$300 million in 2018. The capitalization rate for the acquisitions made in 2017 was 7.4% and the properties accounted for 47.2% of annualized base rents from investment grade retail tenants.
Disposition activity in 2017 included 15 assets, which totaled $45.8 million. Meanwhile, the company projects disposition for 2018 in the range of $25-$50 million. The capitalization rate for the dispositions made last year was 6.9%.
Joey Agree, president and chief executive officer at Agree Realty, is upbeat about the acquisitions executed last year and the bullish outlook for this year. He added, "Our unique capabilities and fortified balance sheet strongly position our growing Company to continue executing on our operating strategy in the upcoming year."
The company successfully raised roughly $87.1 million from the issuance of 1,776,766 shares of common stock at an average price of $49.03 per share. It issued the shares in the fourth quarter of 2017 through an at-the-market equity program.
Shares of Agree Realty have gained 12.5% in the past six months, underperforming the industry 's rally of 23.9%.
The company carries a Zacks Rank #3 (Hold).
Stocks That Warrant a Look
Arbor Realty Trust ABR witnessed an upward earnings estimate revision of 8.7% for 2017 in the last 60 days. Also, its shares have gained 1.9% in the past six months. It sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here .
One Liberty Properties OLP witnessed an upward earnings estimate revision of 7.1% for 2017 in the last 60 days. Also, its shares have gained 9.8% in the past six months. It also has a Zacks Rank #1.
Easterly Government Properties' DEA Zacks Consensus Estimate for 2017 has been revised nearly 1% upward over the last 60 days. Also, its shares have inched up 2.3% in six months' time. It carries a Zacks Rank #2 (Buy).
Note: All EPS numbers presented in this write up represent funds from operations ("FFO") per share. FFO, a widely used metric to gauge the performance of REITs, is obtained after adding depreciation and amortization and other non-cash expenses to net income.
Wall Street's Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It's a once-in-a-generation opportunity to invest in pure genius.
Click for details >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Arbor Realty Trust (ABR): Free Stock Analysis Report
Agree Realty Corporation (ADC): Free Stock Analysis Report
One Liberty Properties, Inc. (OLP): Free Stock Analysis Report
Easterly Government Properties, Inc. (DEA): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Easterly Government Properties' DEA Zacks Consensus Estimate for 2017 has been revised nearly 1% upward over the last 60 days. Click to get this free report Arbor Realty Trust (ABR): Free Stock Analysis Report Agree Realty Corporation (ADC): Free Stock Analysis Report One Liberty Properties, Inc. (OLP): Free Stock Analysis Report Easterly Government Properties, Inc. (DEA): Free Stock Analysis Report To read this article on Zacks.com click here. He added, "Our unique capabilities and fortified balance sheet strongly position our growing Company to continue executing on our operating strategy in the upcoming year."
|
Click to get this free report Arbor Realty Trust (ABR): Free Stock Analysis Report Agree Realty Corporation (ADC): Free Stock Analysis Report One Liberty Properties, Inc. (OLP): Free Stock Analysis Report Easterly Government Properties, Inc. (DEA): Free Stock Analysis Report To read this article on Zacks.com click here. Easterly Government Properties' DEA Zacks Consensus Estimate for 2017 has been revised nearly 1% upward over the last 60 days. Stocks That Warrant a Look Arbor Realty Trust ABR witnessed an upward earnings estimate revision of 8.7% for 2017 in the last 60 days.
|
Click to get this free report Arbor Realty Trust (ABR): Free Stock Analysis Report Agree Realty Corporation (ADC): Free Stock Analysis Report One Liberty Properties, Inc. (OLP): Free Stock Analysis Report Easterly Government Properties, Inc. (DEA): Free Stock Analysis Report To read this article on Zacks.com click here. Easterly Government Properties' DEA Zacks Consensus Estimate for 2017 has been revised nearly 1% upward over the last 60 days. The company successfully raised roughly $87.1 million from the issuance of 1,776,766 shares of common stock at an average price of $49.03 per share.
|
Easterly Government Properties' DEA Zacks Consensus Estimate for 2017 has been revised nearly 1% upward over the last 60 days. Click to get this free report Arbor Realty Trust (ABR): Free Stock Analysis Report Agree Realty Corporation (ADC): Free Stock Analysis Report One Liberty Properties, Inc. (OLP): Free Stock Analysis Report Easterly Government Properties, Inc. (DEA): Free Stock Analysis Report To read this article on Zacks.com click here. Meanwhile, the company projects disposition for 2018 in the range of $25-$50 million.
|
89c4493e-107c-44fd-8dd7-6e6761c76843
|
723508.0
|
2018-01-03 00:00:00 UTC
|
Washington REIT (WRE) to Acquire Arlington Tower for $250M
|
DEA
|
https://www.nasdaq.com/articles/washington-reit-wre-to-acquire-arlington-tower-for-%24250m-2018-01-03
|
nan
|
nan
|
Washington Real Estate Investment TrustWRE recently announced that it has decided to buy Arlington Tower, a 398,000-square foot, Class A office building for $250 million. The tower is located at Rosslyn submarket in Arlington, VA. The deal, which is subject to certain closing conditions, is expected to close in the first quarter of 2018.
Arlington Tower is situated at 1300 North 17th Street, which is two blocks from the Rosslyn Metro station. The tower also has a Walk Score® of 95 and offers direct traveler access to Route 50, Interstate 66 and the George Washington Parkway. In the past five years, this 19-story building, which enjoys panoramic river and monument views, has undergone significant renovation costing approximately $16 million.
A non-binding letter of intent to sell 2445 M Street NW - its 292,000-square foot DC office building - has also been initiated by Washington REIT with an institutional buyer. The property's sole tenant, the Advisory Board Company, is likely to vacate it on May 31, 2019. The proceed of the sale, which is subject to certain conditions, will be announced once it enters into a definitive contract with the buyer.
The company, which had earlier announced the sale of Braddock Metro Center, has entered into a definitive agreement and is likely to close the deal in this month, subject to certain conditions.
Paul T. McDermott, president and chief executive officer of Washington REIT, noted, "We are strategically allocating capital out of 2445 M Street and into Arlington Tower to improve our long-term growth prospects in a resurging Rosslyn, while de-risking the portfolio through increased cash flow stability and reduced exposure to single-tenant assets."
Shares of Washington REIT have lost 6.9% in the past six months, against the decline of 1% recorded by the industry it belongs to.
Currently, the stock carries a Zacks Rank #4 (Sell).
Stocks That Warrant a Look
Arbor Realty Trust ABR witnessed an upward earnings estimate revision of 8.7% for 2017, in the last 60 days. Also, its shares have gained 2.7%, in the past six months. It sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here .
Easterly Government Properties' DEA Zacks Consensus Estimate has been revised nearly 1% upward for 2017, over the last 60 days. Also, its shares have inched up 0.7%, in six months' time. It carries a Zacks Rank #2 (Buy).
One Liberty Properties OLP witnessed an upward earnings estimate revision of 7.1% for 2017, in the last 60 days. Also, its shares have gained 9.6%, in the past six months. It has a Zacks Rank #2.
Investor Alert: Breakthroughs Pending
A medical advance is now at the flashpoint between theory and realization. Billions of dollars in research have poured into it. Companies are already generating substantial revenue, and even more wondrous products are in the pipeline.
Cures for a variety of deadly diseases are in sight, and so are big potential profits for early investors. Zacks names 5 stocks to buy now.
Click here to see them >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Arbor Realty Trust (ABR): Free Stock Analysis Report
Washington Real Estate Investment Trust (WRE): Free Stock Analysis Report
One Liberty Properties, Inc. (OLP): Free Stock Analysis Report
Easterly Government Properties, Inc. (DEA): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
The deal, which is subject to certain closing conditions, is expected to close in the first quarter of 2018. The company, which had earlier announced the sale of Braddock Metro Center, has entered into a definitive agreement and is likely to close the deal in this month, subject to certain conditions. Easterly Government Properties' DEA Zacks Consensus Estimate has been revised nearly 1% upward for 2017, over the last 60 days.
|
Click to get this free report Arbor Realty Trust (ABR): Free Stock Analysis Report Washington Real Estate Investment Trust (WRE): Free Stock Analysis Report One Liberty Properties, Inc. (OLP): Free Stock Analysis Report Easterly Government Properties, Inc. (DEA): Free Stock Analysis Report To read this article on Zacks.com click here. The deal, which is subject to certain closing conditions, is expected to close in the first quarter of 2018. The company, which had earlier announced the sale of Braddock Metro Center, has entered into a definitive agreement and is likely to close the deal in this month, subject to certain conditions.
|
The company, which had earlier announced the sale of Braddock Metro Center, has entered into a definitive agreement and is likely to close the deal in this month, subject to certain conditions. Click to get this free report Arbor Realty Trust (ABR): Free Stock Analysis Report Washington Real Estate Investment Trust (WRE): Free Stock Analysis Report One Liberty Properties, Inc. (OLP): Free Stock Analysis Report Easterly Government Properties, Inc. (DEA): Free Stock Analysis Report To read this article on Zacks.com click here. The deal, which is subject to certain closing conditions, is expected to close in the first quarter of 2018.
|
The deal, which is subject to certain closing conditions, is expected to close in the first quarter of 2018. The company, which had earlier announced the sale of Braddock Metro Center, has entered into a definitive agreement and is likely to close the deal in this month, subject to certain conditions. Easterly Government Properties' DEA Zacks Consensus Estimate has been revised nearly 1% upward for 2017, over the last 60 days.
|
fedcac6a-48b8-4132-8ed1-e2ce0bd31347
|
723509.0
|
2017-12-18 00:00:00 UTC
|
Opioid Crisis: McKesson Corporation Stock Drops After 60 Minutes Report
|
DEA
|
https://www.nasdaq.com/articles/opioid-crisis-mckesson-corporation-stock-drops-after-60-minutes-report-2017-12-18
|
nan
|
nan
|
InvestorPlace - Stock Market News, Stock Advice & Trading Tips
McKesson Corporation (NYSE: MCK ) stock was down today following a 60 Minutes report on the company.
Source: Shutterstock
The new 60 Minutes report on McKesson Corporation has to do with the current opioid crisis in the U.S. The report includes an interview with former members of the Drug Enforcement Administration (DEA).
During the interview with the former DEA employees, they reveal that he organization was going to go after McKesson Corporation for its contribution to the opioid crisis. However, the organization backed down due to internal pressure and fear that its lawyers couldn't challenge McKesson Corporation's own legal team.
Some of the accusation made against McKesson Corporation by the former DEA employees include how it was distributing prescription pills . This includes claims that the company wouldnt reportsuspicious amounts of orders for opioids.
According to David Schiller, former leader of the DEA team investigating McKesson Corporation, the company would increase its order thresholds to avoid reporting suspicious activity. This resulted in the company allegedly sending massive amounts of the drug to small town pharmacies that had no need for that much.
10 Hot IPOs That You Could Buy in 2018
Schiller was hoping to take McKesson Corporation to court and hit it with a $1 billion fine. Instead, the company agreed to pay a $150 million fine in a settlement. Schiller says this isn't much of a punishment for a company that makes almost $200 billion a year in revenue. It's CEO has a yearly salary of $100 million, reports CBS News .
MCK stock was down 1% as of Monday afternoon.
More From InvestorPlace
The 10 Best Stocks for Your 401k
7 Stocks to Double Your Money
10 Super Safe Growth Stocks to Buy for Long-Lasting Dividends
As of this writing, William White did not hold a position in any of the aforementioned securities.
Compare Brokers
The post Opioid Crisis: McKesson Corporation Stock Drops After 60 Minutes Report appeared first on InvestorPlace .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
According to David Schiller, former leader of the DEA team investigating McKesson Corporation, the company would increase its order thresholds to avoid reporting suspicious activity. The report includes an interview with former members of the Drug Enforcement Administration (DEA). During the interview with the former DEA employees, they reveal that he organization was going to go after McKesson Corporation for its contribution to the opioid crisis.
|
The report includes an interview with former members of the Drug Enforcement Administration (DEA). During the interview with the former DEA employees, they reveal that he organization was going to go after McKesson Corporation for its contribution to the opioid crisis. Some of the accusation made against McKesson Corporation by the former DEA employees include how it was distributing prescription pills .
|
According to David Schiller, former leader of the DEA team investigating McKesson Corporation, the company would increase its order thresholds to avoid reporting suspicious activity. The report includes an interview with former members of the Drug Enforcement Administration (DEA). During the interview with the former DEA employees, they reveal that he organization was going to go after McKesson Corporation for its contribution to the opioid crisis.
|
During the interview with the former DEA employees, they reveal that he organization was going to go after McKesson Corporation for its contribution to the opioid crisis. The report includes an interview with former members of the Drug Enforcement Administration (DEA). Some of the accusation made against McKesson Corporation by the former DEA employees include how it was distributing prescription pills .
|
5c36e788-e681-4c31-b2a7-a964d27c89b9
|
723510.0
|
2017-12-06 00:00:00 UTC
|
5 Key Things to Know About This Leading Marijuana Stock's Future
|
DEA
|
https://www.nasdaq.com/articles/5-key-things-know-about-leading-marijuana-stocks-future-2017-12-06
|
nan
|
nan
|
You can count the number of pure-play marijuana stocks with a market cap of around $3 billion on one hand -- and have several fingers left over. GW Pharmaceuticals (NASDAQ: GWPH) ranks as one of the largest marijuana stocks on the market. But when the biotech reported its third-quarter results in August, investors were disappointed that the company was delaying its U.S. regulatory submission of cannabidiol (CBD) product Epidiolex. Over 10% of GW Pharma's market cap was wiped out in the days following the announcement.
Those concerns were a thing of the past when the company announced its fourth-quarter results on Monday. This time around, GW Pharmaceuticals' management team had nothing but good news to discuss. Here are five important things to know from their comments about the leading cannabinoid-focused biotech's future. (Quotes from S&P Global Market Intelligence .)
1. Timeline for Epidiolex
GW Pharmaceuticals completed its U.S. regulatory submission of Epidiolex in October. CEO Justin Gover said the company expects to hear from the FDA by the end of December on whether or not the filing will be accepted. Assuming it is, Gover stated that GW anticipates that it will receive confirmation of an expedited review, which should lead to an FDA approval decision on Epidiolex in mid-2018. Chief Medical Officer Volker Knappertz said he thinks there's "a 50-50 chance of an AdCom," referring to the FDA's process of sometimes convening an advisory committee to review filings before a final decision is made.
If the FDA approves Epidiolex, the next step will be for the U.S. Drug Enforcement Administration (DEA) to classify the drug into the appropriate schedule. Knappertz cited data from a human abuse liability study of CBD being presented at the American Epilepsy Society meeting this week. He said this data gave GW Pharma "confidence in reaffirming our expectation that Epidiolex will likely be placed into at least Schedule IV by the DEA" if it gains FDA approval. The DEA defines Schedule IV drugs as those "with a low potential for abuse and low risk of dependence."
Gover also said the company expects to submit its filing of Epidiolex for European approval by the end of 2017. He mentioned that GW Pharma's team has already met with European regulators. Gover expects the process to take a little over a year, with a decision on European approval for Epidiolex likely for the first quarter of 2019.
2. Encouraging data related to interaction with clobazam
One worry that some investors have had is the interaction between Epidiolex and clobazam, a currently approved anti-epilepsy drug Lundbeck markets under the brand name Onfi. GW Pharma's executives have mentioned in the past that they weren't concerned about any interactions preventing regulatory approval. In his comments during the company's fourth-quarter call, Knappertz highlighted why they were confident. He said three poster presentations at the American Epilepsy Society meeting "all suggest that patients on Epidiolex are able to achieve clinically meaningful responses both on and off clobazam." He stated that the studies found no interaction between a 10 mg dose of Epidiolex and clobozam.
With a 20 mg dose of Epidiolex, Knappertz acknowledged there there "seems to be a minor interaction, meaning that, on clobazam, there's a slightly higher reduction in seizure frequency." However, he stressed that any difference was only minor.
3. Commercialization plans
Of course, winning approval is only one step along the path. What about commercialization plans for Epidiolex? Julian Gangolli, GW Pharmaceuticals' president of North America, stated that the company expects to deploy "a dedicated sales force of approximately 70 sales professionals to target the approximate 4,000 to 5,000 physicians that treat the majority of patients within the expected indications for Epidiolex, if approved." These sales reps will operate under the banner of GW's U.S. operating company name, Greenwich Biosciences.
Gangolli said the company is establishing relationships with key opinion leaders in epilepsy, including with the major epilepsy centers of excellence in the U.S. He also stated that GW is meeting one-on-one with private and government payers. Gover added that in the conversations, payers "have indicated that they absolutely understand the need for this product" and that he doesn't think payers will "impose any onerous prior authorization requirements" on Epidiolex.
4. About potential competition
An analyst asked Gover about physician feedback related to use of Epidiolex in addition to Zogenix 's (NASDAQ: ZGNX) ZX008. In late September, Zogenix announced positive results from a late-stage study of ZX008 in treating Dravet syndrome, one of the indications Epidiolex also targets. Here's how Gover responded:
Is this just spin? I don't think so. Use of multiple drugs is a reality in the treatment of epilepsy patients. Even analysts bullish on GW project that Epidiolex will gain only a 33% market share.
5. Upcoming pipeline milestones
All the buzz right now is rightly focused on Epidiolex in treating Dravet syndrome and Lennox-Gastaut syndrome (LGS). However, GW Pharmaceuticals has several other promising pipeline programs.
Knappertz noted that results from a late-stage study of Epidiolex in treating tuberous sclerosis complex are expected in the second half of 2018. He also said results from the first part of a two-part phase 2/3 study in infantile spasms will come out in the first quarter of next year.
Beyond Epidiolex, Knappertz highlighted cannabidivarin. He said top-line results from a phase 2 study in adults with inadequately controlled focal seizures should be available in the first quarter of 2018. Knappertz also said GW hopes to regain full U.S. rights to Sativex, its cannabinoid oral spray approved in 30 countries outside the United States.
Looking ahead
In all, GW Pharmaceuticals' management team painted an attractive picture of the future for the biotech. I wouldn't be surprised if there are a few bumps along the way, but I think their view isn't too far off. Epidiolex appears to have a good shot at winning U.S. and European approval. I suspect payers won't present reimbursement hurdles that are too difficult to overcome. And I think GW's cannabinoid pipeline is quite promising. In my opinion, GW Pharmaceuticals continues to be one of the best marijuana stocks for investors to keep on their watch list.
10 stocks we like better than GW Pharmaceuticals
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and GW Pharmaceuticals wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of December 4, 2017
Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
If the FDA approves Epidiolex, the next step will be for the U.S. Drug Enforcement Administration (DEA) to classify the drug into the appropriate schedule. He said this data gave GW Pharma "confidence in reaffirming our expectation that Epidiolex will likely be placed into at least Schedule IV by the DEA" if it gains FDA approval. The DEA defines Schedule IV drugs as those "with a low potential for abuse and low risk of dependence."
|
If the FDA approves Epidiolex, the next step will be for the U.S. Drug Enforcement Administration (DEA) to classify the drug into the appropriate schedule. He said this data gave GW Pharma "confidence in reaffirming our expectation that Epidiolex will likely be placed into at least Schedule IV by the DEA" if it gains FDA approval. The DEA defines Schedule IV drugs as those "with a low potential for abuse and low risk of dependence."
|
He said this data gave GW Pharma "confidence in reaffirming our expectation that Epidiolex will likely be placed into at least Schedule IV by the DEA" if it gains FDA approval. If the FDA approves Epidiolex, the next step will be for the U.S. Drug Enforcement Administration (DEA) to classify the drug into the appropriate schedule. The DEA defines Schedule IV drugs as those "with a low potential for abuse and low risk of dependence."
|
He said this data gave GW Pharma "confidence in reaffirming our expectation that Epidiolex will likely be placed into at least Schedule IV by the DEA" if it gains FDA approval. If the FDA approves Epidiolex, the next step will be for the U.S. Drug Enforcement Administration (DEA) to classify the drug into the appropriate schedule. The DEA defines Schedule IV drugs as those "with a low potential for abuse and low risk of dependence."
|
ee1174cc-4b9e-46f3-b9eb-3cdbe519c245
|
723511.0
|
2017-12-05 00:00:00 UTC
|
The Power of New Analyst Coverage
|
DEA
|
https://www.nasdaq.com/articles/power-new-analyst-coverage-2017-12-05
|
nan
|
nan
|
Broker recommendations -- love them or hate them, they do have their place. And we all look at them eventually.
Whether you're a small individual investor or a large institutional portfolio manager (or somewhere in between), who doesn't like it when a stock gets an upgraded rating or sees a new analyst jumping in with coverage? We all do. (Although I should note that, in general, the change in the average broker recommendation is a better indicator than the actual recommendation itself.)
Anyway, today I want to talk about companies that receive new analyst coverage.
One of the things that generates analyst coverage is investor interest. How else can you explain the increased analyst coverage for Facebook (a company that's only been public for 2 1/2 yrs.) in comparison to a company like GE (public for more than 40 yrs.)?
And as new coverage is initiated, it becomes more visible, which in turn means potentially more demand (read higher prices).
This is often the case because analysts almost always initiate coverage with a positive recommendation. (Why write a research report on a company not widely followed only to say it stinks?)
And when it comes to companies with little to no analyst coverage, that one new recommendation can sometimes give portfolio managers the validation they need to build a position. (And the more money they can invest, the more they can potentially influence prices.)
The best way to use this information is to look for companies with analyst coverage that has increased over the last 4 weeks.
Simply look at the number of analyst recommendations now in comparison to the number of analyst recommendations 4 weeks ago. An increase in coverage is bullish whereas a decrease in coverage is bearish.
It's typically more bullish if the increase went from none to one or if the coverage was minimal to begin with. (Going from 25 to 26 isn't going to have the same impact because that 26th analyst isn't discovering something 'new'.) But increased coverage is better than decreased coverage -- assuming the coverage is positive of course.
Here's a screen to try:
• Number of Broker Ratings now greater than the Number of Broker Ratings four weeks ago
(This shows stocks where new coverage has recently been added.)
• Average Broker Rating less than Average Broker Rating four weeks ago
(By 'less than', I mean 'better than' four weeks ago.)
• And I'm applying all of the above parameters to stocks with Prices greater than or equal to 5 (most money managers won't even look at a stock under $5) and Average Daily Volume greater than or equal to 100,000 shares (if there's not enough volume, even individual investors won't want it).
Here are 5 stocks from this week's screen:
CHEF The Chef's Warehouse
(from 3 analysts four weeks ago to 5)
DEA Easterly Government Properties
(from 3 analysts four weeks ago to 4)
OPB Opus Bank
(from 3 analysts four weeks ago to 4)
TOWN TowneBank
(from 3 analysts four weeks ago to 4)
UGI UGI Corp.
(from 3 analysts four weeks ago to 4)
Many screeners won't let you search for the number of analysts covering a stock, let alone comparing the amount of coverage they had weeks or even months ago. But you can with the Research Wizard. And you can backtest it all. Find out how to pick the right stocks right now by taking a free trial to the Research Wizard stock picking and backtesting program.
Sign up for a free trial to the Research Wizard today.
Want more articles from this author? Scroll up to the top of this article and click the FOLLOW AUTHOR button to get an email each time a new article is published.
Disclosure: Officers, directors and/or employees of Zacks Investment Research may own or have sold short securities and/or hold long and/or short positions in options that are mentioned in this material. An affiliated investment advisory firm may own or have sold short securities and/or hold long and/or short positions in options that are mentioned in this material.
Disclosure: Performance information for Zacks' portfolios and strategies are available at: https://www.zacks.com/performance .
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
UGI Corporation (UGI): Free Stock Analysis Report
Towne Bank (TOWN): Free Stock Analysis Report
Opus Bank (OPB): Free Stock Analysis Report
Easterly Government Properties, Inc. (DEA): Free Stock Analysis Report
The Chefs' Warehouse, Inc. (CHEF): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Here are 5 stocks from this week's screen: CHEF The Chef's Warehouse (from 3 analysts four weeks ago to 5) DEA Easterly Government Properties (from 3 analysts four weeks ago to 4) OPB Opus Bank (from 3 analysts four weeks ago to 4) TOWN TowneBank (from 3 analysts four weeks ago to 4) UGI UGI Corp. (from 3 analysts four weeks ago to 4) Many screeners won't let you search for the number of analysts covering a stock, let alone comparing the amount of coverage they had weeks or even months ago. Click to get this free report UGI Corporation (UGI): Free Stock Analysis Report Towne Bank (TOWN): Free Stock Analysis Report Opus Bank (OPB): Free Stock Analysis Report Easterly Government Properties, Inc. (DEA): Free Stock Analysis Report The Chefs' Warehouse, Inc. (CHEF): Free Stock Analysis Report To read this article on Zacks.com click here. Whether you're a small individual investor or a large institutional portfolio manager (or somewhere in between), who doesn't like it when a stock gets an upgraded rating or sees a new analyst jumping in with coverage?
|
Here are 5 stocks from this week's screen: CHEF The Chef's Warehouse (from 3 analysts four weeks ago to 5) DEA Easterly Government Properties (from 3 analysts four weeks ago to 4) OPB Opus Bank (from 3 analysts four weeks ago to 4) TOWN TowneBank (from 3 analysts four weeks ago to 4) UGI UGI Corp. (from 3 analysts four weeks ago to 4) Many screeners won't let you search for the number of analysts covering a stock, let alone comparing the amount of coverage they had weeks or even months ago. Click to get this free report UGI Corporation (UGI): Free Stock Analysis Report Towne Bank (TOWN): Free Stock Analysis Report Opus Bank (OPB): Free Stock Analysis Report Easterly Government Properties, Inc. (DEA): Free Stock Analysis Report The Chefs' Warehouse, Inc. (CHEF): Free Stock Analysis Report To read this article on Zacks.com click here. Disclosure: Officers, directors and/or employees of Zacks Investment Research may own or have sold short securities and/or hold long and/or short positions in options that are mentioned in this material.
|
Here are 5 stocks from this week's screen: CHEF The Chef's Warehouse (from 3 analysts four weeks ago to 5) DEA Easterly Government Properties (from 3 analysts four weeks ago to 4) OPB Opus Bank (from 3 analysts four weeks ago to 4) TOWN TowneBank (from 3 analysts four weeks ago to 4) UGI UGI Corp. (from 3 analysts four weeks ago to 4) Many screeners won't let you search for the number of analysts covering a stock, let alone comparing the amount of coverage they had weeks or even months ago. Click to get this free report UGI Corporation (UGI): Free Stock Analysis Report Towne Bank (TOWN): Free Stock Analysis Report Opus Bank (OPB): Free Stock Analysis Report Easterly Government Properties, Inc. (DEA): Free Stock Analysis Report The Chefs' Warehouse, Inc. (CHEF): Free Stock Analysis Report To read this article on Zacks.com click here. Simply look at the number of analyst recommendations now in comparison to the number of analyst recommendations 4 weeks ago.
|
Here are 5 stocks from this week's screen: CHEF The Chef's Warehouse (from 3 analysts four weeks ago to 5) DEA Easterly Government Properties (from 3 analysts four weeks ago to 4) OPB Opus Bank (from 3 analysts four weeks ago to 4) TOWN TowneBank (from 3 analysts four weeks ago to 4) UGI UGI Corp. (from 3 analysts four weeks ago to 4) Many screeners won't let you search for the number of analysts covering a stock, let alone comparing the amount of coverage they had weeks or even months ago. Click to get this free report UGI Corporation (UGI): Free Stock Analysis Report Towne Bank (TOWN): Free Stock Analysis Report Opus Bank (OPB): Free Stock Analysis Report Easterly Government Properties, Inc. (DEA): Free Stock Analysis Report The Chefs' Warehouse, Inc. (CHEF): Free Stock Analysis Report To read this article on Zacks.com click here. The best way to use this information is to look for companies with analyst coverage that has increased over the last 4 weeks.
|
ebd5f128-1e62-4016-90cd-d6d1be701d95
|
723512.0
|
2017-12-04 00:00:00 UTC
|
Easterly Government Properties, Inc. (DEA) Ex-Dividend Date Scheduled for December 05, 2017
|
DEA
|
https://www.nasdaq.com/articles/easterly-government-properties-inc-dea-ex-dividend-date-scheduled-december-05-2017-2017-12
|
nan
|
nan
|
Easterly Government Properties, Inc. ( DEA ) will begin trading ex-dividend on December 05, 2017. A cash dividend payment of $0.26 per share is scheduled to be paid on December 21, 2017. Shareholders who purchased DEA prior to the ex-dividend date are eligible for the cash dividend payment. This represents an 4% increase over prior dividend payment. At the current stock price of $21.2, the dividend yield is 4.91%.
The previous trading day's last sale of DEA was $21.2, representing a -2.8% decrease from the 52 week high of $21.81 and a 11.58% increase over the 52 week low of $19.
DEA is a part of the Consumer Services sector, which includes companies such as American Tower Corporation (REIT) ( AMT ) and Simon Property Group, Inc. ( SPG ). DEA's current earnings per share, an indicator of a company's profitability, is $.1. Zacks Investment Research reports DEA's forecasted earnings growth in 2017 as 4.41%, compared to an industry average of -.3%.
For more information on the declaration, record and payment dates, visit the DEA Dividend History page. Our Dividend Calendar has the full list of stocks that have an ex-dividend today.
Interested in gaining exposure to DEA through an Exchange Traded Fund [ETF]?
The following ETF(s) have DEA as a top-10 holding:
IQ US Real Estate Small Cap ETF ( ROOF ).
The top-performing ETF of this group is ROOF with an increase of 0.24% over the last 100 days. It also has the highest percent weighting of DEA at 0.85%.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Shareholders who purchased DEA prior to the ex-dividend date are eligible for the cash dividend payment. DEA is a part of the Consumer Services sector, which includes companies such as American Tower Corporation (REIT) ( AMT ) and Simon Property Group, Inc. ( SPG ). Zacks Investment Research reports DEA's forecasted earnings growth in 2017 as 4.41%, compared to an industry average of -.3%.
|
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Easterly Government Properties, Inc. ( DEA ) will begin trading ex-dividend on December 05, 2017. Shareholders who purchased DEA prior to the ex-dividend date are eligible for the cash dividend payment.
|
Shareholders who purchased DEA prior to the ex-dividend date are eligible for the cash dividend payment. The previous trading day's last sale of DEA was $21.2, representing a -2.8% decrease from the 52 week high of $21.81 and a 11.58% increase over the 52 week low of $19. For more information on the declaration, record and payment dates, visit the DEA Dividend History page.
|
DEA's current earnings per share, an indicator of a company's profitability, is $.1. Easterly Government Properties, Inc. ( DEA ) will begin trading ex-dividend on December 05, 2017. Shareholders who purchased DEA prior to the ex-dividend date are eligible for the cash dividend payment.
|
c17b1df5-eb88-42d2-bbb3-7eb1782c55ec
|
723513.0
|
2017-12-04 00:00:00 UTC
|
SL Green's (SLG) Rating Upgraded by Fitch, Outlook Stable
|
DEA
|
https://www.nasdaq.com/articles/sl-greens-slg-rating-upgraded-by-fitch-outlook-stable-2017-12-04
|
nan
|
nan
|
SL Green Realty 's SLG whole lot of ratings has been upgraded by Fitch Ratings. Notably, SL Green's Issuer Default Rating (IDR) and senior unsecured notes have been bumped by a notch to "BBB" from "BBB-."
The rating agency also maintained its stable outlook.
The rating agency cited the company's adherence to tighter financial policies and efforts to attain a balanced capital structure by targeting leverage below 7.0x. The upgrade also reflects the shift in the company's borrowing strategy to an investment-grade, unsecured borrowing strategy.
Further, the company's recent refinancing activity to increase its unsecured corporate credit capacity by $217 million to $3 billion and stretch the maturities of debts highlights its favorable access to bond markets. (Read more: SL Green Refinances Loan to Upsize Credit Facility )
The rating acknowledges SL Green's premium New York office portfolio that enjoys decent demand for office space and has been able to deliver steady performance throughout the challenging real estate cycles. Additionally, the company's office portfolio enjoys long-term leases to well capitalized tenants. Notably, in third-quarter 2017, the mark-to-market on signed Manhattan office leases was 4% higher than the previous fully-escalated rents on the same spaces.
The rating agency also acknowledged SL Green's portfolio-repositioning efforts. The company resorts to non-core assets disposition, and reinvests the proceeds in strategic acquisitions and development efforts to reposition its portfolio. Such moves helped reap decent net operating income over the past years, according to Fitch Ratings. The company also enjoys a balanced lease maturity and a well-laddered debt maturity schedule.
Though geographic concentration and exposure to capital-intensive office assets serve as negative attributes, the high face rents stemming from the strong Manhattan portfolio would alleviate this risk.
Notably, this rating upgrade enhances the company's creditworthiness in the market and is likely to boost investors' confidence in the stock. In fact, such moves provide companies an opportunity to enjoy reduced costs on debts and better access to capital.
The company's shares have underperformed its industry , year to date. During the period, shares of the company have lost 5.1%, while the industry recorded growth of 6.9%.
SL Green currently carries a Zacks Rank #3 (Hold).
Better-ranked stocks in the real estate investment trust space include Franklin Street Properties FSP , Columbia Property Trust CXP and Easterly Government Properties DEA . All three carry a Zacks Rank of 2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
Franklin Street Properties' funds from operations (FFO) per share estimates for 2017 remained unchanged at $1.05 over the past month. Its share price has declined 7.9% in six months' time.
Columbia Property Trust's FFO per share estimates for the current year have moved up to $1.15 in a month's time. Over the past six months, the company's shares have gained 4.1%.
Easterly Government Properties' FFO per share estimates for 2017 remained unchanged at $1.26 over the last 60 days. Its shares have gained 3.4% in the past six months.
Note: All EPS numbers presented in this write up represent funds from operations ("FFO") per share. FFO, a widely used metric to gauge the performance of REITs, is obtained after adding depreciation and amortization and other non-cash expenses to net income.
Zacks' Best Private Investment Ideas
While we are happy to share many articles like this on the website, our best recommendations and most in-depth research are not available to the public.
Starting today, for the next month, you can follow all Zacks' private buys and sells in real time. Our experts cover all kinds of trades… from value to momentum . . . from stocks under $10 to ETF and option moves . . . from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises. You can even look inside exclusive portfolios that are normally closed to new investors.
Click here for Zacks' private trades >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
SL Green Realty Corporation (SLG): Free Stock Analysis Report
Franklin Street Properties Corp. (FSP): Free Stock Analysis Report
Easterly Government Properties, Inc. (DEA): Free Stock Analysis Report
Columbia Property Trust, Inc. (CXP): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Better-ranked stocks in the real estate investment trust space include Franklin Street Properties FSP , Columbia Property Trust CXP and Easterly Government Properties DEA . Zacks' Best Private Investment Ideas While we are happy to share many articles like this on the website, our best recommendations and most in-depth research are not available to the public. Click to get this free report SL Green Realty Corporation (SLG): Free Stock Analysis Report Franklin Street Properties Corp. (FSP): Free Stock Analysis Report Easterly Government Properties, Inc. (DEA): Free Stock Analysis Report Columbia Property Trust, Inc. (CXP): Free Stock Analysis Report To read this article on Zacks.com click here.
|
Better-ranked stocks in the real estate investment trust space include Franklin Street Properties FSP , Columbia Property Trust CXP and Easterly Government Properties DEA . Click to get this free report SL Green Realty Corporation (SLG): Free Stock Analysis Report Franklin Street Properties Corp. (FSP): Free Stock Analysis Report Easterly Government Properties, Inc. (DEA): Free Stock Analysis Report Columbia Property Trust, Inc. (CXP): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks' Best Private Investment Ideas While we are happy to share many articles like this on the website, our best recommendations and most in-depth research are not available to the public.
|
Better-ranked stocks in the real estate investment trust space include Franklin Street Properties FSP , Columbia Property Trust CXP and Easterly Government Properties DEA . Click to get this free report SL Green Realty Corporation (SLG): Free Stock Analysis Report Franklin Street Properties Corp. (FSP): Free Stock Analysis Report Easterly Government Properties, Inc. (DEA): Free Stock Analysis Report Columbia Property Trust, Inc. (CXP): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks' Best Private Investment Ideas While we are happy to share many articles like this on the website, our best recommendations and most in-depth research are not available to the public.
|
Better-ranked stocks in the real estate investment trust space include Franklin Street Properties FSP , Columbia Property Trust CXP and Easterly Government Properties DEA . Zacks' Best Private Investment Ideas While we are happy to share many articles like this on the website, our best recommendations and most in-depth research are not available to the public. Click to get this free report SL Green Realty Corporation (SLG): Free Stock Analysis Report Franklin Street Properties Corp. (FSP): Free Stock Analysis Report Easterly Government Properties, Inc. (DEA): Free Stock Analysis Report Columbia Property Trust, Inc. (CXP): Free Stock Analysis Report To read this article on Zacks.com click here.
|
c694f8e4-b520-49cf-8a8c-e8bf527ad3a7
|
723514.0
|
2017-12-04 00:00:00 UTC
|
Terreno (TRNO) Acquires $12.9M Industrial Asset in Carson
|
DEA
|
https://www.nasdaq.com/articles/terreno-trno-acquires-%2412.9m-industrial-asset-in-carson-2017-12-04
|
nan
|
nan
|
Terreno Realty CorporationTRNO is positioning itself to benefit from the improving fundamentals of the industrial markets by acquiring strategic assets in core markets. Recently, the company added another industrial property to its portfolio through the acquisition of an improved land parcel in Carson, CA.
Terreno purchased the 5.4-acre land parcel for approximately $12.9 million. The property is 100% leased on a short-term basis and its estimated stabilized cap rate is 5.2%.
Situated on the 2315 E Dominguez Street, this industrial space is just a mile away from the intersection of Interstates 405 and 710 in the South Bay submarket. It offers easy accessibility to the ports of Los Angeles and Long Beach, as well as the Los Angeles International Airport. This is likely to drive demand for the property, which makes it a strategic buyout for Terreno.
The company's investment-driven growth strategy is highlighted by its active acquisition activities. On Nov 1, 2017, it acquired another industrial asset buyout, consisting of an industrial distribution building, for approximately $8.4 million. In fact, during the third quarter Terreno added six industrial properties, spanning 258,000 square feet of space, and a 1.1-acre improved land parcel to its roster. It shelled out approximately $51.6 million for these buyouts.
Notably, the industrial asset category has grabbed attention on the back of elevated demand, recovering economy and job market, strengthening e-commerce market and a healthy manufacturing environment. Given Terreno's solid capacity to offer modern, bulk distribution properties, the company remains well poised to capitalize on robust industry fundamentals.
Encouragingly, year to date, shares of Terreno have outperformed the industry . While the company's shares have gained 31.3%, the industry has recorded growth of 6.9% during this period.
Better-ranked stocks in the real estate investment trust (REIT) space include Franklin Street Properties FSP , Columbia Property Trust CXP and Easterly Government Properties DEA . All three carry a Zacks Rank of 2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
Franklin Street Properties' funds from operations (FFO) per share estimates for 2017 remained unchanged at $1.05 over the past month. Its share price has declined 7.9% in six months' time.
Columbia Property Trust's FFO per share estimates for the current year have moved up to $1.15 in a month's time. Over the past six months, the company's shares have gained 4.1%.
Easterly Government Properties' FFO per share estimates for 2017 remained unchanged at $1.26 over the last 60 days. Its shares have gained 3.4% in the past six months.
Note: All EPS numbers presented in this write up represent funds from operations ("FFO") per share. FFO, a widely used metric to gauge the performance of REITs, is obtained after adding depreciation and amortization and other non-cash expenses to net income.
Zacks' Best Private Investment Ideas
While we are happy to share many articles like this on the website, our best recommendations and most in-depth research are not available to the public.
Starting today, for the next month, you can follow all Zacks' private buys and sells in real time. Our experts cover all kinds of trades… from value to momentum . . . from stocks under $10 to ETF and option moves . . . from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises. You can even look inside exclusive portfolios that are normally closed to new investors.
Click here for Zacks' private trades >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Terreno Realty Corporation (TRNO): Free Stock Analysis Report
Franklin Street Properties Corp. (FSP): Free Stock Analysis Report
Easterly Government Properties, Inc. (DEA): Free Stock Analysis Report
Columbia Property Trust, Inc. (CXP): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Better-ranked stocks in the real estate investment trust (REIT) space include Franklin Street Properties FSP , Columbia Property Trust CXP and Easterly Government Properties DEA . Zacks' Best Private Investment Ideas While we are happy to share many articles like this on the website, our best recommendations and most in-depth research are not available to the public. Click to get this free report Terreno Realty Corporation (TRNO): Free Stock Analysis Report Franklin Street Properties Corp. (FSP): Free Stock Analysis Report Easterly Government Properties, Inc. (DEA): Free Stock Analysis Report Columbia Property Trust, Inc. (CXP): Free Stock Analysis Report To read this article on Zacks.com click here.
|
Better-ranked stocks in the real estate investment trust (REIT) space include Franklin Street Properties FSP , Columbia Property Trust CXP and Easterly Government Properties DEA . Click to get this free report Terreno Realty Corporation (TRNO): Free Stock Analysis Report Franklin Street Properties Corp. (FSP): Free Stock Analysis Report Easterly Government Properties, Inc. (DEA): Free Stock Analysis Report Columbia Property Trust, Inc. (CXP): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks' Best Private Investment Ideas While we are happy to share many articles like this on the website, our best recommendations and most in-depth research are not available to the public.
|
Better-ranked stocks in the real estate investment trust (REIT) space include Franklin Street Properties FSP , Columbia Property Trust CXP and Easterly Government Properties DEA . Click to get this free report Terreno Realty Corporation (TRNO): Free Stock Analysis Report Franklin Street Properties Corp. (FSP): Free Stock Analysis Report Easterly Government Properties, Inc. (DEA): Free Stock Analysis Report Columbia Property Trust, Inc. (CXP): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks' Best Private Investment Ideas While we are happy to share many articles like this on the website, our best recommendations and most in-depth research are not available to the public.
|
Better-ranked stocks in the real estate investment trust (REIT) space include Franklin Street Properties FSP , Columbia Property Trust CXP and Easterly Government Properties DEA . Zacks' Best Private Investment Ideas While we are happy to share many articles like this on the website, our best recommendations and most in-depth research are not available to the public. Click to get this free report Terreno Realty Corporation (TRNO): Free Stock Analysis Report Franklin Street Properties Corp. (FSP): Free Stock Analysis Report Easterly Government Properties, Inc. (DEA): Free Stock Analysis Report Columbia Property Trust, Inc. (CXP): Free Stock Analysis Report To read this article on Zacks.com click here.
|
a15ade60-5376-408d-9437-1b720e42e382
|
723515.0
|
2017-12-01 00:00:00 UTC
|
Monmouth (MNR) Acquires Industrial Asset to Expand Pipeline
|
DEA
|
https://www.nasdaq.com/articles/monmouth-mnr-acquires-industrial-asset-to-expand-pipeline-2017-12-01
|
nan
|
nan
|
Monmouth Real Estate Investment CorporationMNR announced the acquisition of a new industrial building spanning 300,000 square feet, at 1414 South Council Road, Oklahoma City, OK. The company shelled out $30.3 million for this acquisition.
The property sits on approximately 123 acres of land and is well located near Interstate 40, with close proximity to the Will Rogers International Airport. Further, the property is anticipated to enjoy steady revenues as it is net-leased to a Delaware corporation - Amazon Fulfillment Services - for 10 years.
For Monmouth Real Estate, which specializes in single tenant, net-leased industrial properties, subject to long-term leases, mainly to investment-grade tenants, the buyout offers a good scope to enjoy steady cash flow from this property.
Per management, with the above-mentioned acquisition, the company adds the largest Internet-based retailer to its tenant roster and also positions itself to benefit from the e-retail boom.
Going by a report by Jones Lang LaSalle Incorporated JLL , in third-quarter 2017, the e-commerce sector accounted for nearly 25% of the total U.S. leasing demand as compared to 14.7% for the same period in the previous year. Hence, the company has been strategically repositioning its portfolio by investing heavily in industrial asset against the backdrop of the flourishing e-commerce, which is anticipated to drive demand for industrial space.
In fact, per the company's latest fiscal year earnings release, it acquired 10 properties, spanning 2.8 million square feet of industrial space, for $286.5 million during fiscal 2017. Year over year, the company has grown its gross leasable area by 17% through acquisitions and expansion activities.
Earlier this month, it acquired another 121,683-square-foot industrial property for $21,872,170. The company anticipates benefiting from the shift of supply chain toward the eastern seaboard and the region's strong economic growth prospects.
Year to date, shares of the company have outperformed the industry it belongs to. In fact, its shares have gained 17.2% compared with the industry's gain of 6.7% during the same time frame.
Better-ranked stocks in the real estate investment trust space include Columbia Property Trust CXP , Easterly Government Properties DEA and Franklin Street Properties FSP . All three stocks carry a Zacks Rank of 2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
Columbia Property Trust's FFO per share estimates for the current year have moved up to $1.15 in a week's time. Year to date, the company shares have gained 5.4%.
Easterly Government Properties' FFO per share estimates for the current year have remained unchanged at $1.26 in a month's time. Its shares have gained 5.8%, in the year so far.
Franklin Street Properties' FFO per share estimates for 2017 remained unchanged at $1.05 over the past month. Its share price has increased 9.2% in three months' time.
Note: All EPS numbers presented in this write up represent funds from operations ("FFO") per share. FFO, a widely used metric to gauge the performance of REITs, is obtained after adding depreciation and amortization and other non-cash expenses to net income.
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Click here to see the 5 stocks >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Jones Lang LaSalle Incorporated (JLL): Free Stock Analysis Report
Franklin Street Properties Corp. (FSP): Free Stock Analysis Report
Monmouth Real Estate Investment Corporation (MNR): Free Stock Analysis Report
Easterly Government Properties, Inc. (DEA): Free Stock Analysis Report
Columbia Property Trust, Inc. (CXP): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Better-ranked stocks in the real estate investment trust space include Columbia Property Trust CXP , Easterly Government Properties DEA and Franklin Street Properties FSP . Click to get this free report Jones Lang LaSalle Incorporated (JLL): Free Stock Analysis Report Franklin Street Properties Corp. (FSP): Free Stock Analysis Report Monmouth Real Estate Investment Corporation (MNR): Free Stock Analysis Report Easterly Government Properties, Inc. (DEA): Free Stock Analysis Report Columbia Property Trust, Inc. (CXP): Free Stock Analysis Report To read this article on Zacks.com click here. Monmouth Real Estate Investment CorporationMNR announced the acquisition of a new industrial building spanning 300,000 square feet, at 1414 South Council Road, Oklahoma City, OK.
|
Better-ranked stocks in the real estate investment trust space include Columbia Property Trust CXP , Easterly Government Properties DEA and Franklin Street Properties FSP . Click to get this free report Jones Lang LaSalle Incorporated (JLL): Free Stock Analysis Report Franklin Street Properties Corp. (FSP): Free Stock Analysis Report Monmouth Real Estate Investment Corporation (MNR): Free Stock Analysis Report Easterly Government Properties, Inc. (DEA): Free Stock Analysis Report Columbia Property Trust, Inc. (CXP): Free Stock Analysis Report To read this article on Zacks.com click here. In fact, per the company's latest fiscal year earnings release, it acquired 10 properties, spanning 2.8 million square feet of industrial space, for $286.5 million during fiscal 2017.
|
Better-ranked stocks in the real estate investment trust space include Columbia Property Trust CXP , Easterly Government Properties DEA and Franklin Street Properties FSP . Click to get this free report Jones Lang LaSalle Incorporated (JLL): Free Stock Analysis Report Franklin Street Properties Corp. (FSP): Free Stock Analysis Report Monmouth Real Estate Investment Corporation (MNR): Free Stock Analysis Report Easterly Government Properties, Inc. (DEA): Free Stock Analysis Report Columbia Property Trust, Inc. (CXP): Free Stock Analysis Report To read this article on Zacks.com click here. In fact, per the company's latest fiscal year earnings release, it acquired 10 properties, spanning 2.8 million square feet of industrial space, for $286.5 million during fiscal 2017.
|
Better-ranked stocks in the real estate investment trust space include Columbia Property Trust CXP , Easterly Government Properties DEA and Franklin Street Properties FSP . Click to get this free report Jones Lang LaSalle Incorporated (JLL): Free Stock Analysis Report Franklin Street Properties Corp. (FSP): Free Stock Analysis Report Monmouth Real Estate Investment Corporation (MNR): Free Stock Analysis Report Easterly Government Properties, Inc. (DEA): Free Stock Analysis Report Columbia Property Trust, Inc. (CXP): Free Stock Analysis Report To read this article on Zacks.com click here. For Monmouth Real Estate, which specializes in single tenant, net-leased industrial properties, subject to long-term leases, mainly to investment-grade tenants, the buyout offers a good scope to enjoy steady cash flow from this property.
|
a75754ad-e56d-4996-81d0-b4903052607a
|
723516.0
|
2017-11-27 00:00:00 UTC
|
4 Cheap Dividend Growers to Buy Now and Hold Forever
|
DEA
|
https://www.nasdaq.com/articles/4-cheap-dividend-growers-buy-now-and-hold-forever-2017-11-27
|
nan
|
nan
|
By Brett Owens
Today I'm going to reveal my personal strategy for outperforming the market over the long haul.
It's simple. All you have to do is buy dividend stocks --but not in the way most people think.
I'll also name 4 terrific dividend growers you can buy now and safely tuck away in your retirement portfolio forever. More on those in a moment. First, we need to talk about...
The Wrong Way to Buy Dividend Stocks
When picking stocks for the long haul, many folks put too much emphasis on the current dividend yield.
Trouble is, the high yielders that could really make a difference to your retirement--I'm talking payouts of 6%, 8% and up--are getting scarce as the S&P 500 grinds upward:
Few Trophies for Dividend Hunters
Worse, a high yield can easily lead you onto the rocks, something many people learned the hard way with telecom operator Frontier Communications ( FTR ).
A year ago (and many times since), I warned that its 12.9% yield was a house of cards. One number explained why: the payout ratio, or the percentage of earnings paid out as dividends.
Back then, this ratio was negative, so management was paying the dividend while losing money!
When the inevitable cut came, the reaction was swift and brutal:
FTR's Dividend Disaster
For one, the payout ratio is still negative, losses are widening, and FTR is carrying $17.6 billion in long-term debt. That's almost 32 times its $555.5-million market cap (or the value of all of its outstanding shares)!
A Better Way to Buy Dividend Stocks
Traps like Frontier are why we need to look past current yields and hone in on stocks with strong dividend growth backed by rising earnings and cash flows.
And when we find these gems, we need to hang on with both hands!
This is the safest and most reliable way to get rich in stocks . Because the longer you hold a top-flight dividend grower, the higher the yield on your initial buy gets.
This ignored number is a retirement game changer--as the first buy-and-hold "forever stock" I want to show you demonstrates.
"Forever" Stock No. 1: Life Storage
Let's say you invest $10,000 in Life Storage ( LSI ) a self-storage REIT I first flagged as a buy-and-hold "forever stock" on September 23 . Right now, LSI yields 4.5%, so you'd get $450 in annual dividends.
That's not bad!
But let's say its payouts rise to $600 a year--a 33% increase. Then you'd be effectively earning 6% on your original $10,000. As the trend continues, you could easily end up earning 10% or even 20% a year just from rising dividends.
That's easily attainable dividend growth for LSI, whose payout has more than doubled in the last five years.
There's more on the way: revenue and funds from operations (FFO)--a key REIT metric--are both surging, and the $4 annual dividend is easily covered by the trust's forecast 2017 FFO of $5.26 to $5.30.
Now let's move on to 3 more stocks perfect for generating these life-changing "hidden yields."
"Forever" Stock No. 2: Uncle Sam's Landlord
Easterly Government Properties ( DEA ): If there's one trend we can rely on, it's that government will keep growing.
The good news? Easterly is in the sweet spot. The REIT rents its 46 properties to 20 US government agencies, including the Department of Veterans Affairs and the FBI.
This truly is one of the most boring businesses I've ever seen, but it's delivering a steady rise in FFO. Management expects $1.26 to $1.29 a share for all of 2017, up smartly from $1.21 last year. And it's pegging another nice bump for 2018, to between $1.31 and $1.35.
No wonder Easterly has the confidence to raise the dividend twice a year , as it's been doing since its IPO in February 2015:
A Quiet Dividend Champion
The trust also boasts another stat you rarely see: its portfolio is 100% occupied.
That's because the bureaucrats adore its energy-efficient buildings (average age: 11.8 years), and the feds have long been moving from being owners to renters. That trend will only accelerate as budgets tighten:
Source: Easterly Government Properties November 2017 Investor Presentation
The kicker? Easterly is cheap at 16 times the midpoint of forecast 2018 FFO. So put this safe--and growing--payout on your shopping list now.
"Forever Stock" No. 3: A Fire Sale That Won't Last
Prudential Financial ( PRU ) just can't get any respect. Check out how the life-insurance giant has trailed its main rivals this year:
Snapshot of a Bargain
With numbers like these, you'd think the company is on death's door!
Far from it. Third-quarter earnings per share ( EPS ) hit $3.01 a share, up 13% from a year ago and smashing the Street's expectations. Revenue jumped more than 10%.
PRU's focus on retirement (its Retirement Solutions and Investment Management business chips in the bulk of its profit) sets it up to cash in nicely as the baby boomers retire--as they're doing, to the tune of 10,000 every day.
Here's something else I love: management knows how to bargain-hunt the company's own stock. Look at how PRU issued shares earlier this year, with the stock on the rise, then bought them back (resulting in fewer shares outstanding) as it dipped this fall:
Management Puts On a Buyback Clinic
A Shareholder-Return Machine
"Forever Stock" No. 4: Profit Alongside the CEO
I flagged Penske Automotive Group (PAG), owner of car and truck dealerships across the US, Canada and Western Europe, as a stock with huge upside in a September 25 article .
It's risen 1.5% since, but it's just getting started.
How do I know?
Because the CEO, famed automotive entrepreneur Roger Penske, snapped up a cool $50 million of shares just over a month ago, on October 20.
At times like these, it pays to remember the words of legendary investor Peter Lynch: "Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise."
Penske sees the same thing I do: a company firing on all cylinders. In the third quarter, record unit sales sent revenue up 7.2%, to $5.5 billion. EPS soared 6.8%, to $1.10.
This is one of the most diversified car stocks there is. PAG peddles a huge number of brands, without too much reliance on a single one:
If It Has a Hood Ornament, PAG Sells It
Source: Penske Automotive Q3 investor presentation
Yet first-level investors refuse to notice of the company's strengths. Not the least of those is its used-car business, which keeps the overall top line growing when new car sales flatten out. In Q3, PAG sold 25.4% more secondhand rides, offsetting a 2.5% decline in new-car sales.
But the first-level crowd's ignorance is fine by us--it gives us a chance to grab PAG cheap, at just 10.8 times forward earnings.
Finally, there's the dividend, which yields 2.7% and has risen every single quarter for six years running. With sales and profits surging and the payout taking up just 29% of PAG's last 12 months of profits, there's no chance of that slowing down, either.
Revealed: The 7 "Must Have" Dividend-Growth Stocks for 2018
My top 7 dividend-growth stocks for 2018just came out --and I've put them in a new Special Report I want to give you now .
These 3 sleeper picks are so boring they'd put Warren Buffett to sleep! But he'd still approve, because they have 3 advantages the competition can't match:
Soaring earnings and free cash flow backed by easily understandable businesses;
Microscopic payout ratios, to keep their double-digit dividend hikes coming; and
High barriers to entry, so they spend more time building their high-margin products--and less time fending off predators like Amazon.com (AMZN).
I consider these 3 stocks nothing less than the perfect businesses.
But you'll never hear about them in the financial media, obsessed as it is with shiny baubles like the Tesla (TSLA) self-driving truck and bitcoin, or speculating on whether tax reform will make its way through Congress.
So what stocks am I talking about here?
One of these companies makes hot water heaters for the Chinese market, which sounds pretty sleepy until you hear its CEO say he expects 15% annual sales growth for the foreseeable future.
It's easy to see why: Chinese demand for hot water is soaring along with the size of its middle class:
An Unstoppable Trend
This company's dividend has nearly tripled in the last 5 years,
Here are 3 other picks you'll discover in this must-have Special Report :
This stock has boosted its dividend payments more than 800% over the past 4 years and has at least another decade of double-digit growth left in the tank!
A "double threat" income-and-growth stock that rose more than 252% the last time it was anywhere near as cheap as it is now!
A 4.3% payer that raises its dividend more than once a year--and will double its payout by 2021 at its current pace!
Your special report is waiting for you now. Simply click here to get your copy and discover the names, tickers, buy prices and my complete analysis of these 7 dividend growers .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
4: Profit Alongside the CEO I flagged Penske Automotive Group (PAG), owner of car and truck dealerships across the US, Canada and Western Europe, as a stock with huge upside in a September 25 article . 2: Uncle Sam's Landlord Easterly Government Properties ( DEA ): If there's one trend we can rely on, it's that government will keep growing. Check out how the life-insurance giant has trailed its main rivals this year: Snapshot of a Bargain With numbers like these, you'd think the company is on death's door!
|
2: Uncle Sam's Landlord Easterly Government Properties ( DEA ): If there's one trend we can rely on, it's that government will keep growing. Check out how the life-insurance giant has trailed its main rivals this year: Snapshot of a Bargain With numbers like these, you'd think the company is on death's door! 4: Profit Alongside the CEO I flagged Penske Automotive Group (PAG), owner of car and truck dealerships across the US, Canada and Western Europe, as a stock with huge upside in a September 25 article .
|
2: Uncle Sam's Landlord Easterly Government Properties ( DEA ): If there's one trend we can rely on, it's that government will keep growing. Check out how the life-insurance giant has trailed its main rivals this year: Snapshot of a Bargain With numbers like these, you'd think the company is on death's door! 4: Profit Alongside the CEO I flagged Penske Automotive Group (PAG), owner of car and truck dealerships across the US, Canada and Western Europe, as a stock with huge upside in a September 25 article .
|
"Forever" Stock No. 2: Uncle Sam's Landlord Easterly Government Properties ( DEA ): If there's one trend we can rely on, it's that government will keep growing. Check out how the life-insurance giant has trailed its main rivals this year: Snapshot of a Bargain With numbers like these, you'd think the company is on death's door!
|
95da28b5-a7c7-4735-a96f-0db5a7c2868e
|
723517.0
|
2017-10-06 00:00:00 UTC
|
This Potential Billion-Dollar Marijuana-Based Drug Suddenly Finds Itself in Deep Trouble
|
DEA
|
https://www.nasdaq.com/articles/potential-billion-dollar-marijuana-based-drug-suddenly-finds-itself-deep-trouble-2017-10
|
nan
|
nan
|
Few, if any, industries can claim the breakneck growth pace that legal marijuana is currently producing. Last year, cannabis research firm ArcView pegged North American legal weed sales growth at 34% and opined that growth between 2017 and 2021 in North America could average 26% per year. That type of consistent high growth is tough to come by, which is why investors have been almost relentlessly piling into marijuana stocks. Over the past year, the market caps for a number of top pot stocks have jumped by more than 100%.
Leading the charge higher has been a rapid change in the way the American public views cannabis. In 1979, per a CBS News poll, just 29% of Americans were in favor of legalizing marijuana across the country. By April 2017, this had jumped to an all-time record of 61%. Also, a separate poll from Quinnipiac University in April of this year showed that 94% of Americans support the idea of federally legalizing medical cannabis compared to just 5% who oppose it.
A bright spot within the cannabis movement
With such broad-based support behind the legalization movement, especially when it comes to the medical side of the equation, investors are being led to believe that lawmakers in Congress will adjust the scheduling for pot sooner rather than later. But lawmakers have essentially dug in their heels and refused, thus far, to change their stance on weed despite clinical studies that have demonstrated possible benefits from cannabis or cannabinoids derived from the cannabis plant.
One of the more front-and-center, feel-good marijuana stocks is GW Pharmaceuticals (NASDAQ: GWPH) , the largest marijuana stock by market cap. GW Pharmaceuticals' leading drug candidate is Epidiolex, an oral cannabidiol (CBD) solution designed to treat patients with two rare types of childhood-onset epilepsy, Dravet syndrome and Lennox-Gastaut syndrome. CBD is the non-psychoactive component of cannabis.
In two late-stage trials for each indication, Epidiolex easily met its primary endpoint of a reduction in seizure frequency compared to the placebo, leading most investors and Wall Street to believe that GW's path to success would be a relative cakewalk. Assuming a strong launch and possible label expansion opportunities in the future, $1 billion in annual sales at its peak was not out of the question.
Well, folks, that cakewalk just became quicksand.
Enter Zogenix, stage right
Last week, small-cap biotech Zogenix (NASDAQ: ZGNX) shocked Wall Street and investors by unveiling phase 3 data on its investigational drug for Dravet syndrome, low-dose fenfluramine hydrochloride, which is referred to as fenfluramine for short. The study not only met its primary endpoint of a statistically significant reduction in seizure frequency relative to the placebo, but it would appear to have run circles around Epidiolex in a similar grouping of patients -- albeit the two drugs haven't gone head-to-head in a study.
Back in March 2016, GW Pharmaceuticals reported that Epidiolex had reduced seizure frequency by 39% in Dravet syndrome patients as compared to 13% for the placebo from baseline. The baseline was determined by following patients for four weeks prior to trial start, and the study lasted 14 weeks.
By comparison, Zogenix's fenfluramine delivered a superior 72.4% reduction in convulsive seizure frequency compared to 17.4% for placebo patients over the 14-week treatment period. One minor difference was that Zogenix took six weeks to establish its baseline instead of four. On the surface, and while doing a bit of an apples-to-oranges comparison, Zogenix's lead drug looks like a serious threat to GW's top experimental compound.
As noted by Janney analyst Ken Trbovich via Investor's Business Daily , "We believe investors previously ignored the threat from Zogenix because its program was only supported by a small (12 patients), open-label study conducted in Europe."
It's worth noting that Zogenix is also studying fenfluramine as a treatment for Lennox-Gastaut syndrome.
More issues for Epidiolex than meets the eye
That's not necessarily the only blow for GW Pharmaceuticals. In the company's third-quarter earnings release was an announcement that it had delayed its new drug application (NDA) filing in the U.S. for Epidiolex until October from mid-2017. A first-in-class drug would have an opportunity to gobble up market share with no approved indications, but Epidiolex's possible approval by the Food and Drug Administration (FDA) has now been pushed back a few months.
Also, there are no guarantees that Epidiolex can even beat fenfluramine, which is expected to have an NDA filed by Zogenix in the second half of 2018, to pharmacy shelves. Because Epidiolex is derived from cannabinoids, and there's no precedence for cannabinoid-based drugs on the market, it's likely the FDA will take its time with approving a marketing label, and that the U.S. Drug Enforcement Agency (DEA) will need to schedule Epidiolex before it makes it onto pharmacy shelves, assuming approval.
How do we know this? Because we just witnessed the same thing happen to Insys Therapeutics (NASDAQ: INSY) and its oral dronabinol solution -- essentially a synthetic version of tetrahydrocannabinol (THC) -- known as Syndros. Syndros was approved by the FDA in June 2016, but it didn't receive its scheduling from the DEA until earlier this year, and it wasn't given approval for its marketing label by the FDA until May 2017. The company finally launched Syndros as a treatment for chemotherapy-induced nausea and vomiting and anorexia associated with AIDS in August, 14 months post-approval. Epidiolex could suffer the same fate, losing most of its first-to-market advantage.
GW Pharmaceuticals' $2.6 billion valuation is predominantly derived from the expectation of success for Epidiolex. If it suddenly isn't the savior that shareholders and Wall Street expected, investors may need to reconsider what this stock is really worth. Sound the warning, folks, because GW Pharmaceuticals might be in deep trouble.
10 stocks we like better than GW Pharmaceuticals
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, the Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and GW Pharmaceuticals wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of September 5, 2017
The author(s) may have a position in any stocks mentioned.
Sean Williams has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Also, a separate poll from Quinnipiac University in April of this year showed that 94% of Americans support the idea of federally legalizing medical cannabis compared to just 5% who oppose it. Because Epidiolex is derived from cannabinoids, and there's no precedence for cannabinoid-based drugs on the market, it's likely the FDA will take its time with approving a marketing label, and that the U.S. Drug Enforcement Agency (DEA) will need to schedule Epidiolex before it makes it onto pharmacy shelves, assuming approval. Syndros was approved by the FDA in June 2016, but it didn't receive its scheduling from the DEA until earlier this year, and it wasn't given approval for its marketing label by the FDA until May 2017.
|
Also, a separate poll from Quinnipiac University in April of this year showed that 94% of Americans support the idea of federally legalizing medical cannabis compared to just 5% who oppose it. Because Epidiolex is derived from cannabinoids, and there's no precedence for cannabinoid-based drugs on the market, it's likely the FDA will take its time with approving a marketing label, and that the U.S. Drug Enforcement Agency (DEA) will need to schedule Epidiolex before it makes it onto pharmacy shelves, assuming approval. Syndros was approved by the FDA in June 2016, but it didn't receive its scheduling from the DEA until earlier this year, and it wasn't given approval for its marketing label by the FDA until May 2017.
|
Because Epidiolex is derived from cannabinoids, and there's no precedence for cannabinoid-based drugs on the market, it's likely the FDA will take its time with approving a marketing label, and that the U.S. Drug Enforcement Agency (DEA) will need to schedule Epidiolex before it makes it onto pharmacy shelves, assuming approval. Also, a separate poll from Quinnipiac University in April of this year showed that 94% of Americans support the idea of federally legalizing medical cannabis compared to just 5% who oppose it. Syndros was approved by the FDA in June 2016, but it didn't receive its scheduling from the DEA until earlier this year, and it wasn't given approval for its marketing label by the FDA until May 2017.
|
Also, a separate poll from Quinnipiac University in April of this year showed that 94% of Americans support the idea of federally legalizing medical cannabis compared to just 5% who oppose it. Because Epidiolex is derived from cannabinoids, and there's no precedence for cannabinoid-based drugs on the market, it's likely the FDA will take its time with approving a marketing label, and that the U.S. Drug Enforcement Agency (DEA) will need to schedule Epidiolex before it makes it onto pharmacy shelves, assuming approval. Syndros was approved by the FDA in June 2016, but it didn't receive its scheduling from the DEA until earlier this year, and it wasn't given approval for its marketing label by the FDA until May 2017.
|
9a4e973c-258c-49b2-8b6f-0a13372c7233
|
723518.0
|
2017-10-03 00:00:00 UTC
|
How Risky Is GW Pharmaceuticals Stock After Zogenix's Big News?
|
DEA
|
https://www.nasdaq.com/articles/how-risky-gw-pharmaceuticals-stock-after-zogenixs-big-news-2017-10-03
|
nan
|
nan
|
Call it the yin and yang of the biopharmaceutical industry. Good news for one company is nearly always bad news for another.
Zogenix (NASDAQ: ZGNX) announced very good news last week. Its experimental drug ZX008 proved to be very effective at reducing seizures in a late-stage study of patients with a rare form of epilepsy known as Dravet syndrome. As a result, Zogenix stock skyrocketed -- more than doubling in one day .
However, Zogenix's good news was bad news for GW Pharmaceuticals (NASDAQ: GWPH) . Like Zogenix, GW Pharma also has a drug targeting Dravet syndrome. That drug, Epidiolex, is expected to be submitted for U.S. regulatory approval this month for the Dravet syndrome indication, as well as for another type of epilepsy, Lennox-Gastaut syndrome (LGS). While Zogenix stock went up, GW Pharma stock sank, reflecting investors' fears about competition for Epidiolex. But just how risky is GW Pharmaceuticals stock after Zogenix's big news?
A natural tendency
What's the first thing many investors did when Zogenix announced its results? They compared them to the results for Epidiolex in treating Dravet syndrome. That's a natural tendency: Humans like to compare things. It's also problematic.
For example, Zogenix reported that patients taking a higher dose of ZX008 (0.8 mg/kg/day) achieved a 72.4% mean reduction in monthly convulsive seizure frequency, compared to 17.4% in placebo patients. In 2016, GW Pharma announced that patients taking Epidiolex achieved a median reduction in monthly seizures of 39%, compared to 13% for patients on placebo. ZX008 was better than Epidiolex, right? Not so fast.
The trials conducted by the two drugmakers involved different patients -- 119 patients for Zogenix and 120 for GW Pharma. There's no way to know for sure how ZX008 would have performed in GW Pharma's patient population or how Epidiolex would have performed in Zogenix's patient population.
Similarly, we can't conclude which drug is safer based on the clinical results. Zogenix reported that 95% of patients on the 0.8 mg/kg/day dose of ZX008 experienced adverse events, compared to 65% in the placebo group. GW Pharma said that 93% of patients taking Epidiolex experienced adverse events, versus 75% of patients on placebo. Again, though, because these were different patient populations, it would be incorrect to state that Epidiolex is a little safer than ZX008.
Just the facts
While comparing the two studies isn't a sound approach, there are some hard facts that we can evaluate. First, there now appear to be two experimental drugs with reasonable chances of winning FDA approval. That fact alone could hurt GW Pharmaceuticals. The company had hoped to be the sole player in the Dravet syndrome market, which currently has no FDA-approved treatment.
Second, GW Pharma still has a head start. Assuming the company completes its planned FDA submission for Epidiolex this month, the drug could be approved in the first half of 2018 if the FDA grants priority review. While the drug will also need to be scheduled by the U.S. Drug Enforcement Agency (DEA), a commercial launch in the second half of next year is possible.
Zogenix, meanwhile, has another late-stage study of ZX008 to complete. Assuming the company announces positive results from that study by mid-2018, it could file for U.S. approval by late 2018 -- roughly one year after GW Pharma.
The third fact to consider is that GW Pharma is applying for approval for Epidiolex in treating both Dravet syndrome and LGS. ZX008 hasn't been evaluated at all for the LGS indication, although Zogenix has announced plans to initiate a study.
Risk assessment
Is the risk for GW Pharmaceuticals now escalated? Yes, but probably less than some fear.
There's no question that the prospect of another Dravet syndrome drug potentially following hot on the heels of Epidiolex isn't what GW Pharmaceuticals wanted. However, analysts weren't expecting Epidiolex to capture the majority of the market anyway. Cantor Fitzgerald's Elemer Piros, for example, a definite bull on GW Pharma, only modeled for Epidiolex winning roughly 33% of the market at peak.
Also, many epilepsy patients require multiple drugs to treat their disease. One of the worries about Epidiolex was its interactions with some commonly used anti-epilepsy drugs. (GW Pharmaceuticals, by the way, thinks those worries are overblown and that drug-drug interactions could work to its benefit .) It's quite possible that should both Epidiolex and ZX008 win approval, there could be significant overlap, with patients using both drugs.
The reality is that the opportunities for Epidiolex are somewhat lower if ZX008 emerges as a rival, but the decrease in GW Pharmaceuticals' market cap largely reflects this. Zogenix stock is on better ground than GW Pharma stock is right now. The best way for GW Pharma to make a rebound is to get a green light from the FDA. That possibility is still months away.
10 stocks we like better than GW Pharmaceuticals
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and GW Pharmaceuticals wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of September 5, 2017
Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
While the drug will also need to be scheduled by the U.S. Drug Enforcement Agency (DEA), a commercial launch in the second half of next year is possible. Its experimental drug ZX008 proved to be very effective at reducing seizures in a late-stage study of patients with a rare form of epilepsy known as Dravet syndrome. Assuming the company announces positive results from that study by mid-2018, it could file for U.S. approval by late 2018 -- roughly one year after GW Pharma.
|
While the drug will also need to be scheduled by the U.S. Drug Enforcement Agency (DEA), a commercial launch in the second half of next year is possible. However, Zogenix's good news was bad news for GW Pharmaceuticals (NASDAQ: GWPH) . For example, Zogenix reported that patients taking a higher dose of ZX008 (0.8 mg/kg/day) achieved a 72.4% mean reduction in monthly convulsive seizure frequency, compared to 17.4% in placebo patients.
|
While the drug will also need to be scheduled by the U.S. Drug Enforcement Agency (DEA), a commercial launch in the second half of next year is possible. While Zogenix stock went up, GW Pharma stock sank, reflecting investors' fears about competition for Epidiolex. In 2016, GW Pharma announced that patients taking Epidiolex achieved a median reduction in monthly seizures of 39%, compared to 13% for patients on placebo.
|
While the drug will also need to be scheduled by the U.S. Drug Enforcement Agency (DEA), a commercial launch in the second half of next year is possible. While Zogenix stock went up, GW Pharma stock sank, reflecting investors' fears about competition for Epidiolex. They compared them to the results for Epidiolex in treating Dravet syndrome.
|
4e67cb0e-d2df-43dc-9b62-38d46c174c0f
|
723519.0
|
2017-09-25 00:00:00 UTC
|
This Marijuana Stock Is On an 8-Day Losing Streak -- Is It Time to Buy?
|
DEA
|
https://www.nasdaq.com/articles/marijuana-stock-8-day-losing-streak-it-time-buy-2017-09-25
|
nan
|
nan
|
Over the trailing year, there's arguably been no better-performing industry than marijuana and marijuana stocks. A majority of pot stocks have moved significantly higher over the past year, with a quick glance back in June showing that the average marijuana stock was up by better than 300% over the trailing year at that time.
Despite strong growth, volatility remains high
The most fundamentally sound reason for this bullishness derives from the growth in legal weed sales. ArcView, which is one of the leading cannabis research firms, found that legal weed sales grew in North America by 34% in 2016 to $6.9 billion. Moving forward, it sees a compound annual growth rate of 26% through 2021, which should lead to a nearly $22 billion market. It's certainly not out of the question that this could happen, either, with Mexico legalizing medical cannabis in June, Canada currently debating the legalization of recreational cannabis by July 2018, and more and more states legalizing weed in some form within the United States.
Underlying this incredible growth is also a marked shift in the way Americans think about pot. Prior to California becoming the first state to legalize medical pot in 1996, just a quarter of the population was in favor of marijuana being legal for adult use across the U.S. As of Oct. 2016, an all-time record high 60% of respondents want to see it legal across the country. With favorability improving, the pressure on lawmakers to push through scheduling changes for cannabis is growing.
But, of course, therein lies the rub: marijuana is still an illegal substance at the federal level. This bifurcation in legality between states and the federal government creates a lot of murkiness with regard to the future of the legal pot industry, and it also leads to a ton of volatility in marijuana stocks.
In fact, one pot stock, Insys Therapeutics (NASDAQ: INSY) , has seen its share price fall in eight consecutive trading sessions, through Friday, Sept. 22, 2017. Should this decline be chalked up to pot-stock industry volatility, or is there something deeper than investors should be concerned with? Let's have a look.
Subsys' subpar performance sacks Insys
Though shareholders would much prefer Insys' recent weakness be tied to long-term outlook murkiness for legal marijuana, its issues are primarily tied to the underperformance of Subsys , a sublingual synthetic opioid approved by the Food and Drug Administration (FDA) for the treatment breakthrough cancer pain.
Back in 2015, Insys and its lead drug, which has nothing to do with cannabis or cannabinoids derived from the cannabis plant, could do no wrong. Sales of the drug totaled nearly $331 million, up from $222 million in the previous year, and Insys reported almost $98 million in full-year EBITDA (earnings before interest, taxes, depreciation, and amortization). Then the wheels fell off the wagon. Allegations and lawsuits streamed in suggesting that up to 80% of Subsys sales were for off-label indications, and that its marketing team was purposely angling sales at these off-label indications. With increased regulatory scrutiny, sales of Subsys have since been halved from their peak, and Insys has been pushed from delivering healthy quarterly profits to notable losses each quarter.
What's next for Subsys? That's the problem: no one really knows. The company could be facing a slap on the wrist, a potentially hefty fine, or perhaps sales restrictions. There's also questions as to where Subsys' sales find a bottom and level off. We just don't know, and that's a big reason why Insys' stock continues to drift lower.
Syndros, your Insys' only hope
However, Insys Therapeutics' PR gaffe isn't necessarily a death sentence for the company's stock. In August, the company launched its long-awaited oral dronabinbol solution (essentially a synthetic version of tetrahydrocannabinol (THC)) known as Syndros as a treatment for chemotherapy-induced nausea and vomiting (CINV) and anorexia associated with AIDS. With peak sales potential of around $300 million, according to some Wall Street pundits, it could easily wind up replacing Subsys' lost sales.
The launch of Syndros was a long time coming for Insys given that it was actually approved by the FDA in July 2016. You're reading that correctly - it took 13 months from approval to bring the product to market. The issue is that as a synthetic version of THC it had to be scheduled by the U.S. Drug Enforcement Agency (DEA). The DEA didn't complete its scheduling until earlier this year, and the FDA didn't OK Syndros' marketing label until May. Being associated as a "marijuana" drug slowed the drugs' launch down to a crawl.
In the interim, Insys' hopes are very much reliant on a strong launch of Syndros. Not only will the company need to properly price the product so it sells, but its marketing team will need to compete against a host of established products in the CINV space. In other words, success is far from a guarantee.
To buy or not to buy, that is the question
However, if Insys does succeed, investors could be getting one heck of a bargain. Usually, drug developers are valued at around three times the peak sales of their lead drug, or higher, depending on growth metrics and portfolio diversity. Between Syndros and Subsys, $400 million to perhaps $450 million in combined annual sales by say 2022 or 2023 isn't out of the question. Right now, though, the company is valued at just $640 million, implying it may have the opportunity to double in value.
Make no mistake about it, Insys is riskier than your average investment. We don't know what penalties the company could incur from Subsys, and we also aren't sure how well the launch of Syndros will go in a very crowded indication. But if things go even modestly right for Insys, there could be significant value to be had here for investors. It's a marijuana stock that's certainly worth keeping your eyes on.
10 stocks we like better than Insys Therapeutics
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now… and Insys Therapeutics wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of September 5, 2017
Sean Williams has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Syndros, your Insys' only hope However, Insys Therapeutics' PR gaffe isn't necessarily a death sentence for the company's stock. The issue is that as a synthetic version of THC it had to be scheduled by the U.S. Drug Enforcement Agency (DEA). The DEA didn't complete its scheduling until earlier this year, and the FDA didn't OK Syndros' marketing label until May.
|
Syndros, your Insys' only hope However, Insys Therapeutics' PR gaffe isn't necessarily a death sentence for the company's stock. The issue is that as a synthetic version of THC it had to be scheduled by the U.S. Drug Enforcement Agency (DEA). The DEA didn't complete its scheduling until earlier this year, and the FDA didn't OK Syndros' marketing label until May.
|
Syndros, your Insys' only hope However, Insys Therapeutics' PR gaffe isn't necessarily a death sentence for the company's stock. The issue is that as a synthetic version of THC it had to be scheduled by the U.S. Drug Enforcement Agency (DEA). The DEA didn't complete its scheduling until earlier this year, and the FDA didn't OK Syndros' marketing label until May.
|
Syndros, your Insys' only hope However, Insys Therapeutics' PR gaffe isn't necessarily a death sentence for the company's stock. The issue is that as a synthetic version of THC it had to be scheduled by the U.S. Drug Enforcement Agency (DEA). The DEA didn't complete its scheduling until earlier this year, and the FDA didn't OK Syndros' marketing label until May.
|
3b424e12-1e9b-4f38-af55-11f1362e7246
|
723520.0
|
2017-09-16 00:00:00 UTC
|
Great News for Marijuana Proponents: National Teen Use Rates Are at a 15-Year Low
|
DEA
|
https://www.nasdaq.com/articles/great-news-marijuana-proponents-national-teen-use-rates-are-15-year-low-2017-09-16
|
nan
|
nan
|
Few industries have been able to put up growth numbers like the legal marijuana industry over the past couple of years. Though estimates vary, most analysts estimate the legal weed industry can grow by 25% to 35% annually between 2016 and 2021. GreenWave Advisors is calling for perhaps the highest growth rate, with $30 billion in U.S. sales and all 50 states legal to some degree (medical or recreational) by 2021.
The prospects of this consistent growth are what's fueled a ferocious rally in marijuana stocks over the past year. A number of cannabis producers and retailers have seen their share prices surge by 100% or more. It also hasn't hurt that more than half of all U.S. states have legalized to some degree, Mexico legalized medical cannabis in June, and Canada is considering legalizing recreational pot by next summer.
Two big reasons Congress hasn't changed its stance on weed
However, in spite of these clear positives for marijuana proponents and investors, the industry faces an almost insurmountable hurdle: the federal government. At the federal level, cannabis still holds a Schedule I designation, meaning it's on par with heroin and LSD, is entirely illegal, and has no perceived medical benefits.
Lawmakers' worries can essentially be boiled down to two primary concerns. First, they often claim that there isn't enough reliable clinical data on the benefits and risks of medical cannabis to consider altering its scheduling. Though you'll note that there are seemingly hundreds of university-sponsored research studies involving cannabis, there are very few Food and Drug Administration-approved studies involving cannabis and cannabinoids. It's the latter that Congress will want before deciding pot's fate on Capitol Hill. Perhaps the greatest irony here is that lawmakers want more clinical data, but the current scheduling of marijuana makes it extremely difficult to get the OK for researchers to run clinical studies.
The second issue many lawmakers have with the legal weed thesis is that it'll make it easier for adolescents to get their hands on pot. Some university studies have shown that adolescent minds can be adversely impacted by marijuana use while their brains are still developing, which makes lawmakers fear home-grow options that often accompany legalization efforts, as well as access to medical cannabis in a household, could ease access for teens.
But there may be good news on this latter objection.
Teen marijuana use rates hit a 15-year low
Recently, the Substance Abuse and Mental Health Services Administration (SAMHSA) released findings from its 2016 survey on drug use and health. The results showed that just 6.5% of teens aged 12 to 17 had used marijuana over the past month, which was down 0.5% from 2015, 1.7% from 2002, and is the lowest reading over the past 15 years. Mind you, eight states have voted to legalize adult-use weed since 2012, yet teen use rates have fallen by more than 1% between 2011 and 2016.
And this isn't the only data point that suggests teens aren't being lured by marijuana. Pro-legalization reform group Marijuana Policy Project (MPP) pointed out following the release of the SAMHSA report that teen pot use rates in both Colorado and Washington haven't materially changed since they began to sell adult-use weed in 2014.
Why the drop despite purportedly easier access to weed? MPP suggests that a tightly regulated industry, coupled with the clear notion that there's a line-in-the-sand legal age requirement for marijuana, has sunk in with adolescents. "Regulating marijuana for adults reinforces that message and creates effective mechanisms for making it more difficult for teens to obtain marijuana," said Morgan Fox, senior communications manager for Marijuana Policy Project.
Moving forward will be next to impossible under the Trump administration
For those who want to see medical cannabis, or even recreational weed, legalized across the United States, the data from the national SAMHSA report is great news. It wouldn't be surprising if the Canadian parliament looked to this data as well, as it's in the process of debating the legalization of adult-use weed throughout Canada in 2018. One of the biggest objections in Canada has been the home-grow option and the likelihood of adolescent getting their hands on marijuana.
Nevertheless, the excitement from this report can only extend so far. When all is said and done, it remains highly unlikely that marijuana has a path to rescheduling under the Trump administration. For starters, Congress is far too busy with healthcare and tax reform at present to consider marijuana legislation. Even if these two issues get tackled, President Trump will likely want to move onto passing an infrastructure bill next. There's next to no room on the docket for cannabis on Capitol Hill.
But this is far from the only issue. Attorney General Jeff Sessions will seemingly stop at nothing to ensure that marijuana's expansion is slowed or stopped completely. Sessions hasn't minced words in his views of marijuana, and in May, the attorney general sent a letter to congressional leaders asking them to repeal an amendment that protects medical cannabis businesses from federal prosecution. Sessions seems unwilling to let off the gas in his pursuit to prosecute pot businesses.
The Drug Enforcement Agency (DEA) is unlikely to be of help, either. It had an opportunity to review two petitions to reschedule marijuana last summer and chose to stand pat on its scheduling. The DEA determined that there wasn't enough clinical benefit-versus-risk data available to alter its scheduling, and noted concerns about abuse and oversight if its scheduling were to be changed. It can take a long time for petitions to work their way up to the DEA, so don't look for any chance of rescheduling anytime soon.
Despite industrywide momentum, the ceiling on the industry and marijuana stocks remains very much in place.
10 stocks we like better than Wal-Mart
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, the Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Wal-Mart wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of September 5, 2017
The author(s) may have a position in any stocks mentioned.
The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
The Drug Enforcement Agency (DEA) is unlikely to be of help, either. The DEA determined that there wasn't enough clinical benefit-versus-risk data available to alter its scheduling, and noted concerns about abuse and oversight if its scheduling were to be changed. It can take a long time for petitions to work their way up to the DEA, so don't look for any chance of rescheduling anytime soon.
|
The Drug Enforcement Agency (DEA) is unlikely to be of help, either. The DEA determined that there wasn't enough clinical benefit-versus-risk data available to alter its scheduling, and noted concerns about abuse and oversight if its scheduling were to be changed. It can take a long time for petitions to work their way up to the DEA, so don't look for any chance of rescheduling anytime soon.
|
The Drug Enforcement Agency (DEA) is unlikely to be of help, either. The DEA determined that there wasn't enough clinical benefit-versus-risk data available to alter its scheduling, and noted concerns about abuse and oversight if its scheduling were to be changed. It can take a long time for petitions to work their way up to the DEA, so don't look for any chance of rescheduling anytime soon.
|
The Drug Enforcement Agency (DEA) is unlikely to be of help, either. The DEA determined that there wasn't enough clinical benefit-versus-risk data available to alter its scheduling, and noted concerns about abuse and oversight if its scheduling were to be changed. It can take a long time for petitions to work their way up to the DEA, so don't look for any chance of rescheduling anytime soon.
|
a9805523-d979-4721-b2c9-c667fea85e1a
|
723521.0
|
2017-09-11 00:00:00 UTC
|
Easterly Government Properties, Inc. (DEA) Ex-Dividend Date Scheduled for September 12, 2017
|
DEA
|
https://www.nasdaq.com/articles/easterly-government-properties-inc-dea-ex-dividend-date-scheduled-september-12-2017-2017
|
nan
|
nan
|
Easterly Government Properties, Inc. ( DEA ) will begin trading ex-dividend on September 12, 2017. A cash dividend payment of $0.25 per share is scheduled to be paid on September 28, 2017. Shareholders who purchased DEA prior to the ex-dividend date are eligible for the cash dividend payment. This represents an 8.7% increase over prior dividend payment. At the current stock price of $20.04, the dividend yield is 4.99%.
The previous trading day's last sale of DEA was $20.04, representing a -8.12% decrease from the 52 week high of $21.81 and a 11.71% increase over the 52 week low of $17.94.
DEA is a part of the Consumer Services sector, which includes companies such as American Tower Corporation (REIT) ( AMT ) and Simon Property Group, Inc. ( SPG ). DEA's current earnings per share, an indicator of a company's profitability, is $.1. Zacks Investment Research reports DEA's forecasted earnings growth in 2017 as 4.13%, compared to an industry average of .4%.
For more information on the declaration, record and payment dates, visit the DEA Dividend History page. Our Dividend Calendar has the full list of stocks that have an ex-dividend today.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
DEA is a part of the Consumer Services sector, which includes companies such as American Tower Corporation (REIT) ( AMT ) and Simon Property Group, Inc. ( SPG ). Zacks Investment Research reports DEA's forecasted earnings growth in 2017 as 4.13%, compared to an industry average of .4%. For more information on the declaration, record and payment dates, visit the DEA Dividend History page.
|
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Easterly Government Properties, Inc. ( DEA ) will begin trading ex-dividend on September 12, 2017. Shareholders who purchased DEA prior to the ex-dividend date are eligible for the cash dividend payment.
|
Shareholders who purchased DEA prior to the ex-dividend date are eligible for the cash dividend payment. The previous trading day's last sale of DEA was $20.04, representing a -8.12% decrease from the 52 week high of $21.81 and a 11.71% increase over the 52 week low of $17.94. For more information on the declaration, record and payment dates, visit the DEA Dividend History page.
|
Shareholders who purchased DEA prior to the ex-dividend date are eligible for the cash dividend payment. DEA's current earnings per share, an indicator of a company's profitability, is $.1. Easterly Government Properties, Inc. ( DEA ) will begin trading ex-dividend on September 12, 2017.
|
c3cec528-6d9d-4121-9d6b-ba611dbb6196
|
723522.0
|
2017-09-08 00:00:00 UTC
|
Ex-Dividend Reminder: Easterly Government Properties, Hewlett Packard Enterprise and HP
|
DEA
|
https://www.nasdaq.com/articles/ex-dividend-reminder-easterly-government-properties-hewlett-packard-enterprise-and-hp-2017
|
nan
|
nan
|
Looking at the universe of stocks we cover at Dividend Channel , on 9/12/17, Easterly Government Properties Inc (Symbol: DEA), Hewlett Packard Enterprise Co (Symbol: HPE), and HP Inc (Symbol: HPQ) will all trade ex-dividend for their respective upcoming dividends. Easterly Government Properties Inc will pay its quarterly dividend of $0.25 on 9/28/17, Hewlett Packard Enterprise Co will pay its quarterly dividend of $0.065 on 10/4/17, and HP Inc will pay its quarterly dividend of $0.1327 on 10/4/17. As a percentage of DEA's recent stock price of $19.79, this dividend works out to approximately 1.26%, so look for shares of Easterly Government Properties Inc to trade 1.26% lower - all else being equal - when DEA shares open for trading on 9/12/17. Similarly, investors should look for HPE to open 0.49% lower in price and for HPQ to open 0.69% lower, all else being equal.
Below are dividend history charts for DEA, HPE, and HPQ, showing historical dividends prior to the most recent ones declared.
Easterly Government Properties Inc (Symbol: DEA) :
Hewlett Packard Enterprise Co (Symbol: HPE) :
HP Inc (Symbol: HPQ) :
In general, dividends are not always predictable, following the ups and downs of company profits over time. Therefore, a good first due diligence step in forming an expectation of annual yield going forward, is looking at the history above, for a sense of stability over time. This can help in judging whether the most recent dividends from these companies are likely to continue. If they do continue, the current estimated yields on annualized basis would be 5.05% for Easterly Government Properties Inc, 1.96% for Hewlett Packard Enterprise Co, and 2.77% for HP Inc.
In Friday trading, Easterly Government Properties Inc shares are currently off about 0.4%, Hewlett Packard Enterprise Co shares are up about 0.3%, and HP Inc shares are off about 0.5% on the day.
Click here to learn which 25 S.A.F.E. dividend stocks should be on your radar screen »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
As a percentage of DEA's recent stock price of $19.79, this dividend works out to approximately 1.26%, so look for shares of Easterly Government Properties Inc to trade 1.26% lower - all else being equal - when DEA shares open for trading on 9/12/17. Looking at the universe of stocks we cover at Dividend Channel , on 9/12/17, Easterly Government Properties Inc (Symbol: DEA), Hewlett Packard Enterprise Co (Symbol: HPE), and HP Inc (Symbol: HPQ) will all trade ex-dividend for their respective upcoming dividends. Below are dividend history charts for DEA, HPE, and HPQ, showing historical dividends prior to the most recent ones declared.
|
Looking at the universe of stocks we cover at Dividend Channel , on 9/12/17, Easterly Government Properties Inc (Symbol: DEA), Hewlett Packard Enterprise Co (Symbol: HPE), and HP Inc (Symbol: HPQ) will all trade ex-dividend for their respective upcoming dividends. Easterly Government Properties Inc (Symbol: DEA) : Hewlett Packard Enterprise Co (Symbol: HPE) : HP Inc (Symbol: HPQ) : In general, dividends are not always predictable, following the ups and downs of company profits over time. As a percentage of DEA's recent stock price of $19.79, this dividend works out to approximately 1.26%, so look for shares of Easterly Government Properties Inc to trade 1.26% lower - all else being equal - when DEA shares open for trading on 9/12/17.
|
Looking at the universe of stocks we cover at Dividend Channel , on 9/12/17, Easterly Government Properties Inc (Symbol: DEA), Hewlett Packard Enterprise Co (Symbol: HPE), and HP Inc (Symbol: HPQ) will all trade ex-dividend for their respective upcoming dividends. Easterly Government Properties Inc (Symbol: DEA) : Hewlett Packard Enterprise Co (Symbol: HPE) : HP Inc (Symbol: HPQ) : In general, dividends are not always predictable, following the ups and downs of company profits over time. As a percentage of DEA's recent stock price of $19.79, this dividend works out to approximately 1.26%, so look for shares of Easterly Government Properties Inc to trade 1.26% lower - all else being equal - when DEA shares open for trading on 9/12/17.
|
Looking at the universe of stocks we cover at Dividend Channel , on 9/12/17, Easterly Government Properties Inc (Symbol: DEA), Hewlett Packard Enterprise Co (Symbol: HPE), and HP Inc (Symbol: HPQ) will all trade ex-dividend for their respective upcoming dividends. As a percentage of DEA's recent stock price of $19.79, this dividend works out to approximately 1.26%, so look for shares of Easterly Government Properties Inc to trade 1.26% lower - all else being equal - when DEA shares open for trading on 9/12/17. Below are dividend history charts for DEA, HPE, and HPQ, showing historical dividends prior to the most recent ones declared.
|
a8e59447-6770-4709-b73f-d0829c251897
|
723523.0
|
2017-09-03 00:00:00 UTC
|
$1 Billion Cannabis Market by 2020 -- and Only 1 Small-Cap Marijuana Stock Is Set to Profit
|
DEA
|
https://www.nasdaq.com/articles/1-billion-cannabis-market-2020-and-only-1-small-cap-marijuana-stock-set-profit-2017-09-03
|
nan
|
nan
|
If you're familiar with the U.S. marijuana industry, you might think the headline of this article contains a mistake. Marijuana sales in the U.S. are estimated to have totaled $6.7 billion last year. So why would a cannabis market be worth only $1 billion by 2020? The answer is that there are multiple cannabis markets.
Marijuana and hemp both come from the cannabis sativa plant, but hemp is a variety of the plant that contains much lower levels of the psychotropic chemical tetrahydrocannabinol (THC) than marijuana does. Because of this, the Ninth Circuit Court of Appeals has ruled that the U.S. Drug Enforcement Agency (DEA) can't go after companies that sell hemp-based products as they can for marijuana growers.
While there are many industrial uses for hemp, one of the fastest-growing markets is hemp-based cannabidiol (CBD). Market research firm Brightfield Group estimates that this market totaled $170 million last year and could hit $1 billion within the next three years. And there's only one small-cap stock poised to profit from this tremendous growth -- Medical Marijuana Inc. (NASDAQOTH: MJNA) .
Ironic name
The ironic thing about Medical Marijuana, Inc.'s name is that the company doesn't sell marijuana at all -- for medical or other purposes. Medical Marijuana says that it's "not in the business of selling or dispensing either recreational or medical marijuana, directly or indirectly, so long as marijuana remains a federally controlled substance."
All of Medical Marijuana's products are hemp-based. The company's flagship product is Real Scientific Hemp Oil (RSHO). The CBD oil is available in three varieties. Medical Marijuana's subsidiary Red Dice Holdings also markets CBD products under the Dixie Botanicals brand in Colorado. In addition, the company's Kannaway multi-level marketing subsidiary sells several types of CBD products, including "energy chews," a skin-care line, and hemp vaporizers.
The company was founded in 2005 as Berkshire Collections. Four years (and two name changes) later, Medical Marijuana Inc. went public, becoming the first U.S. stock focused exclusively on the cannabis business.
Multiple players
Medical Marijuana's market cap now stands at more than $300 million. That's actually one of the larger market caps among cannabis stocks. And it's sizable enough to make Medical Marijuana the only small-cap stock focused on the hemp-based CBD market.
There are other contenders in that market, of course. CW Hemp, which markets hemp-based CBD oil under the Charlotte's Web brand, has around 7% of the market. CV Sciences claims a 5% market share with its Plus CBD Oil products. Elixinol and Hemp Life Today are tied with Medical Marijuana, at 2% of the market. The rest of the hemp CBD market is highly fragmented, with lots of tiny competitors.
One of these rivals to Medical Marijuana is publicly traded -- CV Sciences. However, CV Sciences' market cap is below $25 million, making it a nano-cap stock. Another company in the hemp CBD market, Isodiol International (formerly Laguna Blends), is traded on the Canadian Stock Exchange. Isodiol's market cap, though, is less than $200 million, a level that qualifies it as a microcap stock rather than a small-cap stock.
Growing market, good investment?
With the hemp CBD market potentially growing tremendously in the next few years, is Medical Marijuana stock a smart pick? I'd recommend caution.
Remember that this $1 billion market is only a projection. Many projections don't pan out. There's a clear and present danger that could make this projection fall apart: the increasing number of U.S. states that are legalizing marijuana , especially recreational marijuana. Brightfield Group suspects that hemp CBD markets will be threatened by recreational marijuana.
Medical Marijuana states that it's "poised" and "well-positioned for eventual cannabis legalization." However, all of its current products are already legal. Continued legalization of marijuana could potentially hurt the company's prospects.
Also, Medical Marijuana continues to lose money -- a lot of it. In 2016, the company reported revenue of just over $8 million, with a net loss totaling $25.9 million. The stock is priced at more than 38 times sales. That's an astronomically high valuation.
It's entirely possible that Brightfield Group's forecast of a $1 billion hemp CBD market by 2020 will prove to be accurate. If that happens, Medical Marijuana stock will likely benefit significantly. Buying the stock is probably the best bet for those wanting to profit from the growing CBD market. But in my view, it's a bet -- not an investment.
10 stocks we like better than Medical Marijuana, Inc.
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Medical Marijuana, Inc. wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of August 1, 2017
Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Because of this, the Ninth Circuit Court of Appeals has ruled that the U.S. Drug Enforcement Agency (DEA) can't go after companies that sell hemp-based products as they can for marijuana growers. Medical Marijuana's subsidiary Red Dice Holdings also markets CBD products under the Dixie Botanicals brand in Colorado. In addition, the company's Kannaway multi-level marketing subsidiary sells several types of CBD products, including "energy chews," a skin-care line, and hemp vaporizers.
|
Because of this, the Ninth Circuit Court of Appeals has ruled that the U.S. Drug Enforcement Agency (DEA) can't go after companies that sell hemp-based products as they can for marijuana growers. And it's sizable enough to make Medical Marijuana the only small-cap stock focused on the hemp-based CBD market. One of these rivals to Medical Marijuana is publicly traded -- CV Sciences.
|
Because of this, the Ninth Circuit Court of Appeals has ruled that the U.S. Drug Enforcement Agency (DEA) can't go after companies that sell hemp-based products as they can for marijuana growers. Medical Marijuana says that it's "not in the business of selling or dispensing either recreational or medical marijuana, directly or indirectly, so long as marijuana remains a federally controlled substance." And it's sizable enough to make Medical Marijuana the only small-cap stock focused on the hemp-based CBD market.
|
Because of this, the Ninth Circuit Court of Appeals has ruled that the U.S. Drug Enforcement Agency (DEA) can't go after companies that sell hemp-based products as they can for marijuana growers. All of Medical Marijuana's products are hemp-based. With the hemp CBD market potentially growing tremendously in the next few years, is Medical Marijuana stock a smart pick?
|
fbbdd422-7699-4052-9e67-70b1990f1f37
|
723524.0
|
2017-08-14 00:00:00 UTC
|
This Struggling Marijuana Stock Finally Launched Its Highly Anticipated Drug
|
DEA
|
https://www.nasdaq.com/articles/struggling-marijuana-stock-finally-launched-its-highly-anticipated-drug-2017-08-14
|
nan
|
nan
|
If you look around, chances are you won't find many marijuana stocks struggling. In fact, over the trailing one-year period, 12 out of 13 pot stocks with a market cap above $200 million had risen, with a majority up by at least 100% !
Marijuana stocks are mostly budding
A pretty steady change in market dynamics has caused this so-called "budding" of marijuana stocks. From the perspective of perception, more consumers than ever have either a positive view of the drug or want to see it legalized nationally. This all-time high in terms of favorability gives investors hope that Congress will indeed listen to the will of the people and alter its current scheduling at the federal level.
Select state governments have also pushed hard to get weed legalized. For example, residents in California wound up legalizing adult-use pot by a strong majority in the November 2016 elections, which is a delight to state legislators. California is known for running budget deficits, and the legalization of recreational marijuana should wind up generating $1 billion or more in tax revenue each year. That should help California make a dent in its budgetary needs.
Legal sales growth figures have been another major catalyst. Cannabis research firm ArcView is estimating that legal sales growth in North America could average 26% through 2021, leading to a nearly $22 billion market within five years.
The one bad apple among marijuana stocks
But there's always an outlier -- and for the marijuana industry that's drugmaker Insys Therapeutics (NASDAQ: INSY) . While a dozen of the largest pot stocks have rallied over the trailing year, it's the lone marijuana stock that's moved lower.
The source of most of Insys' issues can be traced to sublingual breakthrough cancer pain therapy Subsys. Lawsuits and allegations suggest that up to 80% of Subsys prescriptions written may have been for off-label uses. Last August, Illinois Attorney General Lisa Madigan filed a lawsuit against Insys claiming that the company was purposefully marketing Subsys to physicians that primarily prescribed opioid therapies (Subsys is a synthetic opioid), rather than oncologists, which is where Subsys' label indicates it should be used. This is one of numerous lawsuits thrown Insys' way.
In addition, federal prosecutors in Boston have charged six former Insys executives and managers, including former CEO Michael Babich, with a scheme to bribe doctors to prescribe Subsys. All six defendants have pleaded not guilty.
The result of these ongoing investigations into Subsys' usage has hammered sales of the drug, pushed Insys from healthy quarterly profits to growing losses, and crushed investors', physicians', and patients' confidence in the company.
On Aug. 3, Insys wound up reporting its second-quarter results, which showed a steep plunge in quarterly Subsys sales. Total revenue came in at $42.6 million, down from $69.2 million, and sales of the drug are now running at about half the pace they were on a quarterly basis from two years ago. It also lost $8.2 million after generating net income of $6 million in the year-ago quarter. Insys' press release also notes that it settled with the State of Illinois for $4.5 million over the aforementioned lawsuit.
"Yuck" pretty perfectly describes Insys' second-quarter report and performance over the past year and change.
This drug launch has game-changing potential
However, there was one tidbit of important info in the company's report that could soon give Insys' shareholders a reason to cheer : a new drug launch.
Just two weeks ago, the company launched Syndros, its second Food and Drug Administration (FDA)-approved product, for the treatment of chemotherapy-induced nausea and vomiting (CINV), as well as anorexia associated with AIDS. Syndros is a liquid, oral dronabinol solution, which is a fancy way of saying it's a synthetic version of tetrahydrocannabinol, or THC, the psychoactive component of cannabis.
Insys and its shareholders have been waiting a long time to bring Syndros to market. The FDA gave the thumbs-up to Syndros back on July 5, 2016. But because it's composed of synthetic THC, and cannabis is illegal at the federal level, it meant that Syndros' launch would be delayed while the U.S. Drug Enforcement Agency (DEA) scheduled the drug and the FDA approved its final marketing label. It took until earlier this year before the DEA placed a Schedule II categorization on Syndros, and only more recently did the FDA finally approve its label. All told, it took nearly 13 months from approval for Insys to finally launch its new marijuana drug.
Now here's where the excitement kicks in. Syndros is expected to bring in roughly $300 million to $400 million in peak annual sales, if the drug is effectively launched and priced. If Subsys sales merely stabilized where they're at now, and Syndros became a $150 million franchise within a few years, Insys would be back to generating $300 million to $350 million in annual sales once again. More importantly, it would be generating healthy cash flow and should be profitable. Let's not forget that this was a nearly $45 stock two summers ago and is now hovering around $10 per share.
Syndros won't necessarily have the red carpet rolled out, even if it is a synthetic THC solution. There are a number of already approved treatments for CINV on pharmacy shelves, meaning it could be tough for Syndros to initially capture market share. You can also probably count on seeing regulators keep a watchful eye on Insys with Syndros, given how many issues arose with Subsys.
Nevertheless, it gives Insys, and long-term shareholders who can stomach a lot of expected near-term volatility, the opportunity to benefit from a return to sales growth and bottom-line improvement. It may take a few quarters before we have a good bead on the success of Syndros' launch, but exciting things are happening, and investors should take note.
10 stocks we like better than Insys Therapeutics
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Insys Therapeutics wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of August 1, 2017
Sean Williams has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
But because it's composed of synthetic THC, and cannabis is illegal at the federal level, it meant that Syndros' launch would be delayed while the U.S. Drug Enforcement Agency (DEA) scheduled the drug and the FDA approved its final marketing label. It took until earlier this year before the DEA placed a Schedule II categorization on Syndros, and only more recently did the FDA finally approve its label. In addition, federal prosecutors in Boston have charged six former Insys executives and managers, including former CEO Michael Babich, with a scheme to bribe doctors to prescribe Subsys.
|
But because it's composed of synthetic THC, and cannabis is illegal at the federal level, it meant that Syndros' launch would be delayed while the U.S. Drug Enforcement Agency (DEA) scheduled the drug and the FDA approved its final marketing label. It took until earlier this year before the DEA placed a Schedule II categorization on Syndros, and only more recently did the FDA finally approve its label. Last August, Illinois Attorney General Lisa Madigan filed a lawsuit against Insys claiming that the company was purposefully marketing Subsys to physicians that primarily prescribed opioid therapies (Subsys is a synthetic opioid), rather than oncologists, which is where Subsys' label indicates it should be used.
|
But because it's composed of synthetic THC, and cannabis is illegal at the federal level, it meant that Syndros' launch would be delayed while the U.S. Drug Enforcement Agency (DEA) scheduled the drug and the FDA approved its final marketing label. It took until earlier this year before the DEA placed a Schedule II categorization on Syndros, and only more recently did the FDA finally approve its label. The one bad apple among marijuana stocks But there's always an outlier -- and for the marijuana industry that's drugmaker Insys Therapeutics (NASDAQ: INSY) .
|
But because it's composed of synthetic THC, and cannabis is illegal at the federal level, it meant that Syndros' launch would be delayed while the U.S. Drug Enforcement Agency (DEA) scheduled the drug and the FDA approved its final marketing label. It took until earlier this year before the DEA placed a Schedule II categorization on Syndros, and only more recently did the FDA finally approve its label. For example, residents in California wound up legalizing adult-use pot by a strong majority in the November 2016 elections, which is a delight to state legislators.
|
214cc1eb-06f4-4f5c-b8f9-246b0ac7a5e7
|
723525.0
|
2017-08-13 00:00:00 UTC
|
3 Marijuana Stocks That Could Make You the Most Money in the 2nd Half of 2017
|
DEA
|
https://www.nasdaq.com/articles/3-marijuana-stocks-could-make-you-most-money-2nd-half-2017-2017-08-13
|
nan
|
nan
|
For investors who enjoyed the huge run of marijuana stocks last year, the first half of 2017 probably hasn't been as exciting. Several of the largest marijuana stocks haven't performed all that great so far this year.
But how something begins doesn't necessarily dictate how it ends. I think that three marijuana stocks in particular could make you plenty of money in the second half of 2017. Here's why Aurora Cannabis (NASDAQOTH: ACBFF) , Canopy Growth Corporation (NASDAQOTH: TWMJF) , and Insys Therapeutics (NASDAQ: INSY) could be big winners by the time December winds down.
Aurora Cannabis
Aurora Cannabis soared more than 300% last year. So far in 2017, however, Aurora's share price has climbed only by a low double-digit percentage. I don't expect the stock to perform like it did in 2016 in the remainder of the year, but there are several reasons to anticipate a strong finish for Aurora in 2017.
The company ranks as one of the largest licensed providers of medical marijuana in Canada. This market continues to expand. As of late June, Aurora had 16,000 active registered patients less than 18 months after its first sale. The company added 3,000 of those patients in May and June alone. If this recent momentum continues (which I think will be the case), Aurora's revenue should increase tremendously in the next few months.
Aurora also stands to benefit from its expansion into the German market. Germany legalized medical marijuana earlier this year, but the country is importing the drug until it can establish a regulatory program for cultivation. That has opened a big market to Canadian marijuana growers in particular. Aurora has jumped on this opportunity by acquiring Pedanios GmbH, a leading German wholesale importer, exporter, and distributor of medical cannabis, a few months ago.
Then there's the potential for Canada to legalize recreational marijuana. Prime Minister Justin Trudeau appears to be committed to making that happen by July 2018. If that target date becomes more solidified over the next few months, expect Aurora Cannabis stock to rise in anticipation of a huge new market opening up in the near future.
Canopy Growth
Pretty much everything stated for Aurora Cannabis also applies for Canopy Growth -- except Canopy Growth is even bigger. Canopy Growth stock more than tripled in value last year but is only up a little so far in 2017. It could be poised for a fantastic finish, though.
Sales are soaring for the Canadian medical marijuana supplier. Canopy Growth reported its fiscal 2017 financial results on June 27. Revenue increased 214% year over year to nearly $40 million. Sales should keep on rocking throughout the rest of 2017.
Canopy Growth made a move into the German market even before the country officially legalized medical marijuana. It acquired Germany-based distributor MedCann GmbH Pharma and Nutraceuticals in November 2016. Canopy was also recognized by the German government as the first North American legal supply source of medical marijuana.
Like Aurora Cannabis, Canopy Growth appears poised to reap the rewards if Canada legalizes recreational marijuana. This legalization seems inevitable, even if it's delayed to give provinces more time to implement.
Insys Therapeutics
We probably could have included one of the other Canadian medical marijuana growers on the list for the exact same reasons Aurora Cannabis and Canopy Growth should be big winners in the second half of 2017. However, for variety's sake, I instead picked a biotech that develops cannabinoid drugs: Insys Therapeutics.
Unlike Aurora and Canopy Growth, Insys stock performed horribly last year -- plunging nearly 70%. Insys was up close to 60% year to date in May 2017, but gave up most of those gains. I think it could make a big comeback for two primary reasons.
First, in late July Insys finally launched Syndros, its cannabinoid treatment for anorexia associated with weight loss in AIDS patients and nausea and vomiting associated with chemotherapy in cancer patients. The company won regulatory approval for Syndros last year, but had to wait a long time for scheduling by the U.S. Drug Enforcement Agency (DEA). The drug should bolster Insys' financial performance in the second half of this year, particularly in the fourth quarter.
Second, there are some encouraging signs that sales for Insys' opioid painkiller Subsys could stabilize. The company announced recently that Subsys was being included on the formulary of a large pharmacy benefits manager (PBM) that had excluded the drug in the past. That change took effect in July. In addition, there are some other positive developments for Subsys that could impact sales in 2018. The drug will be the preferred TIRF (transmucosal immediate release Fentanyl) product on the formularies for two top PBMs and one large health insurer next year.
Half-baked predictions?
I'll be the first to admit that my predictions for these marijuana stocks' second-half performances could be way off if certain events happen. For Aurora Cannabis and Canopy Growth, any big bumps in the road for legalization of recreational marijuana in Canada would take a huge toll on the stocks.
Insys faces several risks that could derail a potential comeback. A massive fine from investigations into its past marketing practices could hurt. So could a weak launch for Syndros or a greater-than-expected loss of sales for Subsys.
Despite these real risks, though, I still think Aurora, Canopy Growth, and Insys could be the marijuana stocks that make investors the most money in the second half of 2017. And 2018 could be even better for all three stocks.
10 stocks we like better than Insys Therapeutics
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Insys Therapeutics wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of August 1, 2017
Keith Speights has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Prime Minister Justin Trudeau appears to be committed to making that happen by July 2018. The company won regulatory approval for Syndros last year, but had to wait a long time for scheduling by the U.S. Drug Enforcement Agency (DEA). Aurora has jumped on this opportunity by acquiring Pedanios GmbH, a leading German wholesale importer, exporter, and distributor of medical cannabis, a few months ago.
|
Prime Minister Justin Trudeau appears to be committed to making that happen by July 2018. The company won regulatory approval for Syndros last year, but had to wait a long time for scheduling by the U.S. Drug Enforcement Agency (DEA). Here's why Aurora Cannabis (NASDAQOTH: ACBFF) , Canopy Growth Corporation (NASDAQOTH: TWMJF) , and Insys Therapeutics (NASDAQ: INSY) could be big winners by the time December winds down.
|
Prime Minister Justin Trudeau appears to be committed to making that happen by July 2018. The company won regulatory approval for Syndros last year, but had to wait a long time for scheduling by the U.S. Drug Enforcement Agency (DEA). Insys Therapeutics We probably could have included one of the other Canadian medical marijuana growers on the list for the exact same reasons Aurora Cannabis and Canopy Growth should be big winners in the second half of 2017.
|
Prime Minister Justin Trudeau appears to be committed to making that happen by July 2018. The company won regulatory approval for Syndros last year, but had to wait a long time for scheduling by the U.S. Drug Enforcement Agency (DEA). Canopy Growth stock more than tripled in value last year but is only up a little so far in 2017.
|
a8de670e-5eb4-40ae-9071-12837291139f
|
723526.0
|
2017-08-04 00:00:00 UTC
|
Dow Jones Industrial Average Extends Streak of Record Highs After Jobs Report
|
DEA
|
https://www.nasdaq.com/articles/dow-jones-industrial-average-extends-streak-record-highs-after-jobs-report-2017-08-04
|
nan
|
nan
|
The Dow Jones Industrial Average (DJIA) ended higher for a ninth straight session, and notched an eighth straight record high , as stock traders applauded a strong July jobs report . It's the Dow's second-longest winning streak in just over a year. Meanwhile, the S&P 500 Index ( SPX ) and Nasdaq Composite (COMP) also managed to end the day higher, though the tech-rich Nasdaq failed to log a weekly win.
Continue reading for more on today's market, including:
Why 2017 could be the Dow's best year in 20.
3 stocks down more than 30% today.
How Toyota scored points with Trump .
Plus, the restaurant stock hit hard by analysts; a big move expected for NVIDIA; and 2 drug stocks bombarded by option bears.
The Dow Jones Industrial Average (DJIA- 22,092.81) closed at an all-time high, adding 66.7 points, or 0.3%. Nineteen of the Dow's 30 stocks ended higher, led by Goldman Sachs stock's 2.6% jump. Walt Disney stock paced the 11 decliners, giving up 1.3%. For the week, the Dow surged 1.2%.
The S&P 500 Index (SPX - 2,476.83) gained 4.7 points, or 0.2%. The tech-heavy Nasdaq Composite (COMP - 6,351.56) edged 11.2 points, or 0.2%, higher. For the week, the SPX gained 0.2%, while the COMP dropped 0.4%.
The CBOE Volatility Index (VIX - 10.03) slipped 0.4 point, or 3.9%. The "fear gauge" gave up 2.8% on the week.
5 Items on Our Radar Today
Google has reportedly been developing a program akin to Snapchat's Discover,. The new " Stamp " project -- which would provide real-time news from possible publishers like CNN or The New York Times -- could launch as early as next week. ( CNBC )
The U.S. Drug Enforcement Administration ( DEA ) has made a proposal to cut 20% of production on the most common opioids next year, to help battle the current opiate epidemic the U.S. The cut would be focused on reducing the number of overdose deaths, which kill more than 140 Americans a day. ( Reuters )
The restaurant stock hit hard by analysts.
Traders brace for another big move by NVIDIA stock .
2 drug stocks option bears are piling into.
Data courtesy of Trade-Alert
Commodities
oil prices
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
( CNBC ) The U.S. Drug Enforcement Administration ( DEA ) has made a proposal to cut 20% of production on the most common opioids next year, to help battle the current opiate epidemic the U.S. The cut would be focused on reducing the number of overdose deaths, which kill more than 140 Americans a day. The Dow Jones Industrial Average (DJIA- 22,092.81) closed at an all-time high, adding 66.7 points, or 0.3%.
|
( CNBC ) The U.S. Drug Enforcement Administration ( DEA ) has made a proposal to cut 20% of production on the most common opioids next year, to help battle the current opiate epidemic the U.S. The cut would be focused on reducing the number of overdose deaths, which kill more than 140 Americans a day. The Dow Jones Industrial Average (DJIA) ended higher for a ninth straight session, and notched an eighth straight record high , as stock traders applauded a strong July jobs report .
|
( CNBC ) The U.S. Drug Enforcement Administration ( DEA ) has made a proposal to cut 20% of production on the most common opioids next year, to help battle the current opiate epidemic the U.S. The cut would be focused on reducing the number of overdose deaths, which kill more than 140 Americans a day. The Dow Jones Industrial Average (DJIA) ended higher for a ninth straight session, and notched an eighth straight record high , as stock traders applauded a strong July jobs report .
|
( CNBC ) The U.S. Drug Enforcement Administration ( DEA ) has made a proposal to cut 20% of production on the most common opioids next year, to help battle the current opiate epidemic the U.S. The cut would be focused on reducing the number of overdose deaths, which kill more than 140 Americans a day. 3 stocks down more than 30% today.
|
41acee08-ebf3-4639-bc3c-5d25ee19e0b0
|
723527.0
|
2017-07-23 00:00:00 UTC
|
Marijuana Stock Investors, Take Note: The Weed Industry Could Create 283,422 Jobs by 2020
|
DEA
|
https://www.nasdaq.com/articles/marijuana-stock-investors-take-note-weed-industry-could-create-283422-jobs-2020-2017-07-23
|
nan
|
nan
|
Investors are always on the lookout for fast-growing industries, which means there's no surprise why marijuana stocks have been such strong performers over the past year. Far more pot stocks than not with a market cap of at least $200 million have doubled or tripled in value over the past year.
Optimistic growth figures for the industry are seemingly everywhere. Aside from the fact that a record number of Americans surveyed by Gallup and CBS News want to see cannabis legalized from both a recreational and medical perspective, the sales growth in the legal-weed industry has been phenomenal. Following 34% growth in legal weed sales in North America last year to $6.9 billion, total sales of recreational and medical marijuana are forecast to expand to $21.6 billion in North America by 2021, according to ArcView Market Research. This sustainable growth has been precisely why investors have latched on to marijuana stocks as possibly the greatest thing since sliced bread.
It's the economy, stupid!
But there's much more to the marijuana industry than just headline sales figures - even if these sales figures often steal the show. The marijuana industry is also about jobs growth and both the direct and indirect impact it could have on the U.S. economy.
According to a report issued earlier this year by New Frontier Data, titled "The Cannabis industry Annual Report: 2017 Legal Marijuana Outlook," the cannabis research firm is forecasting that the cannabis industry will have created a whopping 283,422 jobs by 2020. Amazingly enough, this assumes a slowdown in cannabis industry growth over the next couple of years. Nevertheless, New Frontier Data is projecting a compound annual growth rate (CAGR) in medical cannabis sales of 13% through 2025, and a CAGR of 25% for recreational sales over the same timeframe. By 2025, the U.S. recreational-weed industry is expected to be two and a half times the size of the medical-cannabis industry.
Comparatively, according to data from Forbes gathered from the Bureau of Labor Statistics (BLS), by 2024 the BLS expects manufacturing jobs, utility jobs, and government jobs to have declined by 814,000, 47,000, and 383,000, respectively. Imagine that: The marijuana industry offering a far better chance of job growth than the manufacturing industry.
Marijuana jobs aren't always "plant-touching"
And what investors need to realize is that these jobs aren't always what we would call "plant-touching," or hands-on with cannabis plants or its byproducts. Yes, there are plenty of jobs being created by growers, processors, distributors, retailers, and delivery services, but there's more to it than that. There are consultants to the industry, marketing strategists designed to boost sales, financial specialists who arrange loans and lines of credit for the pot industry, behind-the-scenes investors, and even suppliers, just to name a few of the jobs that have popped up over the years.
For example, Scotts Miracle-Gro (NYSE: SMG) , a company that for more than a century has made its living as a provider of products to make lawns and gardens thrive, has been using its expertise to get involved in hydroponics, which is a method of growing plants while using mineral nutrient solutions in water instead of soil, for the medical-cannabis industry. While Scotts' venture into the marijuana industry through hydroponics, soil, and lighting comprises only around 10% of its revenue, it's nonetheless a rapidly growing division for the company, and thus a major focus while growth in its traditional lawn and garden business slows.
Another good example would be Cree (NASDAQ: CREE) , which isn't often associated with the marijuana industry but soon might be . Cree is a developer of LED lighting and lighting systems, which are most traditionally used in homes and businesses. However, LED lighting may offer an intriguing alternative to commercial cannabis growers because of longer light lifespan, reduced heat output, and lower long-term costs. The question remains whether growers can get an optimal yield from LED lights compared with the high-pressure sodium lights that are currently used to grow cannabis. If LED light efficiency improves, and upfront costs drop, Cree could indirectly become a major industry player, yielding bigger profits for the company, and perhaps more jobs.
Image source: President Donald J. Trump's official Facebook page. Photo by Benjamin D. Applebaum.
Will Sessions and Trump put the kibosh on legal weed?
Yet in spite of this rapid growth and these bullish predictions from New Frontier Data, the federal government has done nothing more than dig in its heels and refuse to budge on its stance of marijuana as a Schedule I substance.
Last summer, the U.S. Drug Enforcement Agency (DEA) had an opportunity to review two petitions that requested cannabis be rescheduled or de-scheduled entirely. The DEA chose to stand pat and leave the drug's Schedule I categorization in place, given a lack of clinical trial data on weed's safety, benefits, and risks, as well as the potential lack of administration oversight should the drug be rescheduled. The DEA's ruling essentially leaves any hope for change up to Congress.
However, Congress' chance of getting anything done on the marijuana front seems even less likely. Attorney General Jeff Sessions is a noted opponent of pot's expansion. In fact, a note surfaced recently suggesting that he wanted permission to go after medical-cannabis dispensaries , a move that would encroach on states' rights. Meanwhile, President Trump hasn't exactly thrown his support behind recreational cannabis. During a February press briefing, White House press secretary Sean Spicer intimated that the current administration would not be so lax with federal marijuana regulations as the previous administration. That comment leaves the door open for a more restrictive federal stance at some point.
There's no denying that the marijuana industry has plenty of potential for both investors and job-seekers, but the federal government is simply too much of a wild card here. Those involved and investing in the industry have every reason to be a bit worried.
10 stocks we like better than Scotts Miracle-Gro
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Scotts Miracle-Gro wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of July 6, 2017
Sean Williams has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Last summer, the U.S. Drug Enforcement Agency (DEA) had an opportunity to review two petitions that requested cannabis be rescheduled or de-scheduled entirely. The DEA chose to stand pat and leave the drug's Schedule I categorization in place, given a lack of clinical trial data on weed's safety, benefits, and risks, as well as the potential lack of administration oversight should the drug be rescheduled. The DEA's ruling essentially leaves any hope for change up to Congress.
|
Last summer, the U.S. Drug Enforcement Agency (DEA) had an opportunity to review two petitions that requested cannabis be rescheduled or de-scheduled entirely. The DEA chose to stand pat and leave the drug's Schedule I categorization in place, given a lack of clinical trial data on weed's safety, benefits, and risks, as well as the potential lack of administration oversight should the drug be rescheduled. The DEA's ruling essentially leaves any hope for change up to Congress.
|
Last summer, the U.S. Drug Enforcement Agency (DEA) had an opportunity to review two petitions that requested cannabis be rescheduled or de-scheduled entirely. The DEA chose to stand pat and leave the drug's Schedule I categorization in place, given a lack of clinical trial data on weed's safety, benefits, and risks, as well as the potential lack of administration oversight should the drug be rescheduled. The DEA's ruling essentially leaves any hope for change up to Congress.
|
Last summer, the U.S. Drug Enforcement Agency (DEA) had an opportunity to review two petitions that requested cannabis be rescheduled or de-scheduled entirely. The DEA chose to stand pat and leave the drug's Schedule I categorization in place, given a lack of clinical trial data on weed's safety, benefits, and risks, as well as the potential lack of administration oversight should the drug be rescheduled. The DEA's ruling essentially leaves any hope for change up to Congress.
|
bee2e8a9-2cf7-4737-9929-7ddf70d1c079
|
723528.0
|
2017-07-23 00:00:00 UTC
|
3 Beaten-Up Biotechs Bouncing Back in 2017 (Hint: One Is a Marijuana Stock)
|
DEA
|
https://www.nasdaq.com/articles/3-beaten-biotechs-bouncing-back-2017-hint-one-marijuana-stock-2017-07-23
|
nan
|
nan
|
Not every stock that falls on tough times is worth buying in portfolios, but sometimes, catalysts can spark shareholder-friendly rallies, and in those situations, it can make sense. For example, risk-tolerant investors might want to consider picking up shares in the beaten-up biotech stocks Zogenix (NASDAQ: ZGNX) , Insys Therapeutics (NASDAQ: INSY) , and Keryx Pharmaceuticals (NASDAQ: KERX) . All three of these stocks are former highfliers, and each has catalysts that could help them regain some of their former glory.
Breathing new life into an old drug
Zogenix's share price has been more than cut in half from its peak in 2014, but a lot of those losses could be gained back if data that's expected this fall on its lead drug candidate is good.
In September, management expects to roll out results from a phase 3 trial evaluating ZX008 as a possible treatment for rare forms of childhood epilepsy.
ZX008 is a low dose of fenfluramine, the "fen" part of the failed obesity drug phen-fen. That drug was removed from the market in 1997 after it was discovered that it can increase cardiac risks.
While fenfluramine has a checkered past, there's reason to think it could find new life as an epilepsy treatment. Past studies have shown that in low doses, it can reduce the number of seizures experienced with tough-to-treat versions of the disease, including Dravet syndrome and Lennox-Gastaut syndrome.
For example, in one 10-patient study, 90% of participants taking it had an average seizure frequency of less than one per month, and 30% of patients were seizure-free over a five-year period. In a follow-up study, there was an average 76% reduction in monthly seizures from baseline in nine Dravet syndrome patients.
If phase 3 data in September confirms this drug's efficacy -- and it doesn't raise any safety concerns -- then Zogenix could soon have a commercial-stage epilepsy drug on the market that may help thousands of people.
Optimism has already sent shares soaring to nearly $14 from around $8 last November, but there could still be more room to run higher. After all, the company's market cap is only $350 million, and ZX-008's peak annual sales potential could exceed that.
Overcoming headwinds
When Insys Therapeutics CEO Saeed Motahari took the reins in April, he took on a big challenge. The company's shares had been throttled because of investigations into the improper off-labeling prescribing of its opioid spray Subsys that has doctors and former executives to be arrested on charges of kick-backs.
Previously, Subsys was a fast-growing pain drug generating sales north of $250 million. But as much as 80% of Subsys' prescription volume was for indications that it wasn't approved for. Scrutiny of kickbacks and a growing desire to curb opioid use in pain patients have caused Subsys' sales to crash below $40 million per quarter.
Investors have also been scared away from Insys Therapeutics by a slower-than-hoped-for launch of its marijuana medicine, Syndros. The drug is an oral reformulation of Marinol that can be used in AIDS and chemotherapy patients to boost appetite and reduce nausea.
Because doses of Syndros are more easily adjusted than Marinol, optimism was high that it could capture a big share of the $200 million Marinol market. However, it took a while for the Drug Enforcement Agency (DEA) to schedule Syndros, and management turnover probably didn't help the company execute on its launch strategy, either.
With so many stumbles, it's not surprising that Insys Therapeutics shares have taken a big hit.
INSY data by YCharts
Motahari, however, might have come on board at exactly the right time. While Subsys investigations continue, he seems open to settling them. Furthermore, Syndros has its DEA scheduling now, and he plans to launch it soon. He's also said he's going to jump-start the company's research programs, including work on developing medicine derived from the marijuana cannabinoid CBD for epilespy, pain, and addiction.
Undeniably, Motahari has got a lot of work to do, but his plans to get this company back on track are encouraging, and that could finally rekindle investors' interest in this stock. So far this year, shares are already up 34%.
Will patience (finally) pay off?
Keryx Pharmaceuticals' Auryxia won FDA approval in 2014, but so far, the drug has been more of a commercial dud than a stud.
Auryxia reduces phosphorous levels in chronic kidney disease patients on dialysis, and while Auryxia's oral dosing offers advantages to existing phosphate binders, it's struggled to gain a toehold in the indication. Auryxia's net product sales were just $27.2 million last year, which is less than 3% of what Sanofi 's Renagel and Renvela -- the most common phosphate binders -- hauled in during 2016.
Obviously, Auryxia's performance so far has been disappointing, but there's evidence that demand for the drug is picking up, and that sales could accelerate in the coming couple of years. Auryxia's sales were $10.5 million in Q1, and this year, management thinks sales will exceed $56 million.
Revenue could climb even higher in 2018 if the FDA decides to expand Auryxia's label in November. In trials, Auryxia boosted iron levels in non-dialysis patients with stage 3 to 5 chronic kidney disease (CKD). There are 1.6 million patients with CKD in these stages who have iron deficiency anemia, and thus, an approval would significantly increase Auryxia's addressable market.
Keryx Biopharmaceuticals shares have more than doubled from their lows, but a market cap of less than $900 million may not adequately reflect Auryxia's peak sales potential, if it gets an FDA green light later this year.
10 stocks we like better than Keryx Biopharmaceuticals
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Keryx Biopharmaceuticals wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of July 6, 2017
Todd Campbell has no position in any stocks mentioned. His clients may have positions in the companies mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
However, it took a while for the Drug Enforcement Agency (DEA) to schedule Syndros, and management turnover probably didn't help the company execute on its launch strategy, either. Furthermore, Syndros has its DEA scheduling now, and he plans to launch it soon. The company's shares had been throttled because of investigations into the improper off-labeling prescribing of its opioid spray Subsys that has doctors and former executives to be arrested on charges of kick-backs.
|
However, it took a while for the Drug Enforcement Agency (DEA) to schedule Syndros, and management turnover probably didn't help the company execute on its launch strategy, either. Furthermore, Syndros has its DEA scheduling now, and he plans to launch it soon. For example, risk-tolerant investors might want to consider picking up shares in the beaten-up biotech stocks Zogenix (NASDAQ: ZGNX) , Insys Therapeutics (NASDAQ: INSY) , and Keryx Pharmaceuticals (NASDAQ: KERX) .
|
However, it took a while for the Drug Enforcement Agency (DEA) to schedule Syndros, and management turnover probably didn't help the company execute on its launch strategy, either. Furthermore, Syndros has its DEA scheduling now, and he plans to launch it soon. For example, risk-tolerant investors might want to consider picking up shares in the beaten-up biotech stocks Zogenix (NASDAQ: ZGNX) , Insys Therapeutics (NASDAQ: INSY) , and Keryx Pharmaceuticals (NASDAQ: KERX) .
|
However, it took a while for the Drug Enforcement Agency (DEA) to schedule Syndros, and management turnover probably didn't help the company execute on its launch strategy, either. Furthermore, Syndros has its DEA scheduling now, and he plans to launch it soon. For example, risk-tolerant investors might want to consider picking up shares in the beaten-up biotech stocks Zogenix (NASDAQ: ZGNX) , Insys Therapeutics (NASDAQ: INSY) , and Keryx Pharmaceuticals (NASDAQ: KERX) .
|
a08c0647-341d-4e39-9c8c-7177755eb640
|
723529.0
|
2017-07-20 00:00:00 UTC
|
Hansa Market Taken Down in Global Law Enforcement Operation
|
DEA
|
https://www.nasdaq.com/articles/hansa-market-taken-down-in-global-law-enforcement-operation-2017-07-20
|
nan
|
nan
|
After darknet market AlphaBay went offline on July 4, many of its users migrated to Hansa Market - and played right into the hands of an "Operation Bayonet," a coordinated international law enforcement action. Today, both the U.S. Department of Justice and the Europol published press releases stating that Hansa Market has also been shut down.
According to the U.S. Department of Justice, the action was led by the Federal Bureau of Investigation (FBI) and the Drug Enforcement Administration ( DEA ), with law enforcement authorities in Thailand, the Netherlands, Lithuania, Canada, the United Kingdom, France and the Europol participating in the operation. Bayonet's focus was takedown of both Hansa Market and AlphaBay in the course of the same multi-agency investigation.
"This is an outstanding success by authorities in Europe and the U.S. The capability of drug traffickers and other serious criminals around the world has taken a serious hit today after a highly sophisticated joint action in multiple countries. By acting together on a global basis the law enforcement community has sent a clear message that we have the means to identify criminality and strike back, even in areas of the Dark Web. There are more of these operations to come," Rob Wainwright, the executive director of Europol, said today at a joint press conference with the U.S. Attorney General, the acting FBI director and the deputy director of the DEA in Washington, D.C.
According to Europol's press release, the European agency provided Dutch authorities with an investigation lead on the Hansa Market in 2016. Europol allegedly acquired the information with the help of Bitdefender, an internet security company advising Europol's European Cybercrime Centre (EC3). Investigators managed to locate the infrastructure of the darknet marketplace in the Netherlands, which resulted in the arrest of two administrators of the site in Germany. Hansa's servers were seized in the Netherlands, Germany and Lithuania.
Furthermore, Dutch law enforcement acquired information on "high value targets and delivery addresses for a large number of orders." With the help of Europol, the Dutch National Police collected information on approximately 10,000 foreign addresses of Hansa Market customers. In a covert action, Dutch law enforcement took control of Hansa a month ago, allowing investigators to monitor and gain information on the users of the marketplace without their knowledge.
Casting a Wider Net
It seems authorities planned their actions carefully since Hansa was already under their control when AlphaBay went offline on July 4. Europol stated that the Dutch National Police "could identify and disrupt the regular criminal activity on Hansa but then also sweep up all those new users displaced from AlphaBay who were looking for a new trading platform."
"The Dutch National Police have located Hansa Market and taken over control of this marketplace since June 20, 2017. We have modified the source code, which allowed us to capture passwords, PGP-encrypted order information, IP-Addresses, Bitcoins and other relevant information that may help law enforcement agencies worldwide to identify users of this marketplace. For more information about this operation, please consult our hidden service at http://politiepcvh42eav.onion ," Dutch authorities wrote on the seized Hansa website.
In total, 38,000 transactions were identified by Europol, who then alerted other agencies in 600 cases. Furthermore, Europol stated they have prepared "intelligence packages" to be sent out to "law enforcement partners across 37 countries, spawning many follow-up investigations across Europe and beyond."
AlphaBay went offline on July 4. At the time, many users suspected it was an exit scam. Authorities announced the arrest of the Alexandre Cazes, 26, the alleged administrator of the website, who was later found dead in his cell in Thailand. On the day of Cazes's arrest, law enforcement took down servers of the dark web marketplace in Canada, the Netherlands and Thailand.
Darknet marketplaces have generated massive police heat after dangerous synthetic drugs, such as fentanyl - the substance at the heart of drug epidemics in multiple countries, including Canada and the United States - were constantly offered for sale on the websites. The statements of U.S. Attorney General Jeff Sessions during the joint press release in Washington, D.C., confirm this assumption.
"Among other challenges, our great country is currently in the midst of the deadliest drug crisis in our history. One American now dies of a drug overdose every 11 minutes and more than 2 million Americans are addicted to prescription painkillers. Every day, as a result of drug abuse, American families are being bankrupted, friendships broken and promising lives cut short," he said.
"As of earlier this year, 122 vendors advertised fentanyl and 238 advertised heroin, and we know of several Americans who were killed by drugs sold on AlphaBay."
Sessions asserted that his department's work is not yet finished and issued a warning to people still ready to engage in illegal activity on the dark web. "We will continue to find, arrest, prosecute, convict and incarcerate criminals, drug traffickers and their enablers, wherever they are. The dark net is not a place to hide. We will use every tool we have to stop criminals from exploiting vulnerable people and sending so many Americans to an early grave."
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
According to the U.S. Department of Justice, the action was led by the Federal Bureau of Investigation (FBI) and the Drug Enforcement Administration ( DEA ), with law enforcement authorities in Thailand, the Netherlands, Lithuania, Canada, the United Kingdom, France and the Europol participating in the operation. There are more of these operations to come," Rob Wainwright, the executive director of Europol, said today at a joint press conference with the U.S. Attorney General, the acting FBI director and the deputy director of the DEA in Washington, D.C. Authorities announced the arrest of the Alexandre Cazes, 26, the alleged administrator of the website, who was later found dead in his cell in Thailand.
|
According to the U.S. Department of Justice, the action was led by the Federal Bureau of Investigation (FBI) and the Drug Enforcement Administration ( DEA ), with law enforcement authorities in Thailand, the Netherlands, Lithuania, Canada, the United Kingdom, France and the Europol participating in the operation. There are more of these operations to come," Rob Wainwright, the executive director of Europol, said today at a joint press conference with the U.S. Attorney General, the acting FBI director and the deputy director of the DEA in Washington, D.C. Authorities announced the arrest of the Alexandre Cazes, 26, the alleged administrator of the website, who was later found dead in his cell in Thailand.
|
According to the U.S. Department of Justice, the action was led by the Federal Bureau of Investigation (FBI) and the Drug Enforcement Administration ( DEA ), with law enforcement authorities in Thailand, the Netherlands, Lithuania, Canada, the United Kingdom, France and the Europol participating in the operation. There are more of these operations to come," Rob Wainwright, the executive director of Europol, said today at a joint press conference with the U.S. Attorney General, the acting FBI director and the deputy director of the DEA in Washington, D.C. Authorities announced the arrest of the Alexandre Cazes, 26, the alleged administrator of the website, who was later found dead in his cell in Thailand.
|
According to the U.S. Department of Justice, the action was led by the Federal Bureau of Investigation (FBI) and the Drug Enforcement Administration ( DEA ), with law enforcement authorities in Thailand, the Netherlands, Lithuania, Canada, the United Kingdom, France and the Europol participating in the operation. There are more of these operations to come," Rob Wainwright, the executive director of Europol, said today at a joint press conference with the U.S. Attorney General, the acting FBI director and the deputy director of the DEA in Washington, D.C. Authorities announced the arrest of the Alexandre Cazes, 26, the alleged administrator of the website, who was later found dead in his cell in Thailand.
|
7b65f796-9e29-469f-8c91-24178a4fe997
|
723530.0
|
2017-07-08 00:00:00 UTC
|
Wow! 92% of Patients Prefer Medical Marijuana to Opioids, New Survey Shows
|
DEA
|
https://www.nasdaq.com/articles/wow-92-patients-prefer-medical-marijuana-opioids-new-survey-shows-2017-07-08
|
nan
|
nan
|
The marijuana industry has been growing at a lightning-fast pace for years now, so it's not one bit surprising to see marijuana stock investors flocking to the "green rush."
Since 2012, voters in eight states have legalized recreational marijuana, while 28 states have legalized medical cannabis over the past 21 years. States like California are expected to see total cannabis sales (recreational and medical) approach $6 billion to $7 billion annually, leading to around $1 billion in annual tax revenue for the state. Colorado, which was one of the first two states to legalize adult-use pot back in 2012, tallied more than $1.3 billion in legal weed sales in 2016 and nearly $200 million in tax and licensing revenue.
All eyes on medical marijuana
While the focus for marijuana proponents has long been making it legal nationwide, it's the potential medical aspects of cannabis that have taken center stage in recent years. A Quinnipiac University poll from April found that 94% of respondents want to see medical marijuana legalized across the country, which is no coincidence given how encouraging cannabinoid- and CB receptor-based research has been for select drug developers.
For example, GW Pharmaceuticals (NASDAQ: GWPH) , the kingpin of all marijuana stocks based on market cap, has developed an oral cannabinoid-based drug known as Epidiolex that, in phase 3 trials, demonstrated a statistically significant reduction in seizure frequency for two rare types of childhood-onset epilepsy, Dravet syndrome and Lennox-Gastaut syndrome. While nothing is ever a given with the Food and Drug Administration, it's looking to have a better than 50-50 shot at approval given its strong clinical performance.
Insys Therapeutics (NASDAQ: INSY) is another drug developer that's making waves. In 2016, the FDA approved Syndros, an oral dronabinol solution that's essentially a synthetic version of tetrahydrocannbidiol, which you probably know best as THC. The drug was approved to treat chemotherapy-induced nausea and vomiting, as well as anorexia associated with AIDS. This new treatment option has the potential to generate $300 million annually in sales , according to Wall Street, but it's more importantly giving cancer patients a new antiemetic option during treatment.
Results like these are what give Americans hope that cannabis may offer medicinally positive benefits for certain ailments.
Can marijuana put an end to the opioid crisis in America?
Another aspect where medical cannabis could potentially make a massive impact is in fighting America's opioid crisis.
Opioids, which include drugs like hydrocodone, morphine, and fentanyl, work by interacting with opioid receptors on nerve cells in the brain and central nervous system to elicit pleasure and alleviate pain. Though these drugs do work to relieve pain, they unfortunately are also highly addictive, can have adverse impacts on the central nervous system, and led to 20,101 overdose-related deaths in 2015, per the American Society of Addiction Medicine. The issue is that there aren't many great alternatives to opioids in treating chronic pain, leaving physicians with little choice at times but to prescribe these addictive and potentially dangerous pain relievers.
Thus enters medical cannabis, which in 2015 and 2016 had no overdose-related deaths associated with the drug. Don't get me wrong: It is possible to overdose on marijuana. However, it's very difficult to die from an overdose of marijuana, based on statistical data, making it an intriguing option to replace opioids as a pain reliever.
It's also an option that the American public seems to prefer, when given the option. According to a recently published study entailing almost 2,900 medical cannabis patients, 92% preferred using medical marijuana to opioids to treat pain. It's worth pointing out that this wasn't a traditional scientific study. These were self-reporting patients, and no medical evaluation of drug efficacy was observed at any point. However, better than 9 in 10 patients preferred marijuana to opioids -- that's saying something.
The results of this somewhat-informal study give good reason for cannabinoid-based drug developers to take the time to develop alternatives to opioids. For instance, Zynerba Pharmaceuticals (NASDAQ: ZYNE) is readying ZYN001, a THC pro-drug patch that's absorbed through the skin, for early-stage testing in patients with fibromyalgia and peripheral neuropathic pain. The advantage of Zynerba's delivery system is that it bypasses the liver initially, possibly allowing for a lower dose to achieve the desired pain relief. This could represent one of many future paths to pain relief without opioids.
Don't bet on change anytime soon
But despite clear momentum for the weed industry, don't expect the federal government or U.S. Drug Enforcement Agency (DEA) to change its tune anytime soon.
For those who may not recall, the DEA had an opportunity to review medical cannabis last year as part of two petitions that requested it be removed as a Schedule 1 drug. Schedule 1 drugs, like LSD and heroin, are defined as having no medical benefits and are entirely illegal. After review, the DEA declined to reschedule marijuana, with the regulatory agency citing a lack of clinical benefit and risk data in its decision. The DEA also noted that a lack of marijuana use oversight steered it away from rescheduling the drug.
This brings up one of the great Catch-22s of medical marijuana: The DEA wants more clinical data from Food and Drug Administration-approved trials, but researchers can't get these studies off the ground because its Schedule 1 status is so restrictive.
The federal government is also unlikely to make things easier for drug developers. Even though President Trump threw his support behind medical marijuana during his campaign, his newly appointed attorney general, Jeff Sessions, is possibly the biggest opponent on Capitol Hill of its expansion (medically or recreationally). As long as Sessions sits on Trump's cabinet, any easing of federal restrictions seems very unlikely.
So, what does this mean for marijuana stocks and patients? Probably more of the same, I'm afraid. Patients could deal with delays in getting access to medical marijuana or cannabinoid-based drugs. Meanwhile, marijuana stocks may face tax disadvantages, since weed-based businesses can't take normal corporate income-tax deductions, and banking restrictions. Most pot businesses have no access to even something as simple as a checking account.
In short, companies like Zynerba Pharmaceuticals could get the short end of the stick despite the public seeming to overwhelmingly favor what medical pot brings to the table.
10 stocks we like better than Zynerba Pharmaceuticals
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Zynerba Pharmaceuticals wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of June 5, 2017
Sean Williams has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
This brings up one of the great Catch-22s of medical marijuana: The DEA wants more clinical data from Food and Drug Administration-approved trials, but researchers can't get these studies off the ground because its Schedule 1 status is so restrictive. Though these drugs do work to relieve pain, they unfortunately are also highly addictive, can have adverse impacts on the central nervous system, and led to 20,101 overdose-related deaths in 2015, per the American Society of Addiction Medicine. Thus enters medical cannabis, which in 2015 and 2016 had no overdose-related deaths associated with the drug.
|
This brings up one of the great Catch-22s of medical marijuana: The DEA wants more clinical data from Food and Drug Administration-approved trials, but researchers can't get these studies off the ground because its Schedule 1 status is so restrictive. Though these drugs do work to relieve pain, they unfortunately are also highly addictive, can have adverse impacts on the central nervous system, and led to 20,101 overdose-related deaths in 2015, per the American Society of Addiction Medicine. Thus enters medical cannabis, which in 2015 and 2016 had no overdose-related deaths associated with the drug.
|
This brings up one of the great Catch-22s of medical marijuana: The DEA wants more clinical data from Food and Drug Administration-approved trials, but researchers can't get these studies off the ground because its Schedule 1 status is so restrictive. Though these drugs do work to relieve pain, they unfortunately are also highly addictive, can have adverse impacts on the central nervous system, and led to 20,101 overdose-related deaths in 2015, per the American Society of Addiction Medicine. Thus enters medical cannabis, which in 2015 and 2016 had no overdose-related deaths associated with the drug.
|
This brings up one of the great Catch-22s of medical marijuana: The DEA wants more clinical data from Food and Drug Administration-approved trials, but researchers can't get these studies off the ground because its Schedule 1 status is so restrictive. Though these drugs do work to relieve pain, they unfortunately are also highly addictive, can have adverse impacts on the central nervous system, and led to 20,101 overdose-related deaths in 2015, per the American Society of Addiction Medicine. Thus enters medical cannabis, which in 2015 and 2016 had no overdose-related deaths associated with the drug.
|
690de6a7-5d20-4f5a-93fb-442b02551280
|
723531.0
|
2017-06-29 00:00:00 UTC
|
Bitcoin May Be Shooting Itself in the Foot by Acting as a Bridge Currency for the Marijuana Industry
|
DEA
|
https://www.nasdaq.com/articles/bitcoin-may-be-shooting-itself-foot-acting-bridge-currency-marijuana-industry-2017-06-29
|
nan
|
nan
|
On the surface it seems like a match made in heaven . Bringing together two of the fastest growing things on the planet -- the marijuana industry and bitcoin -- should allow bitcoin to gain new exposure and legitimacy as a digital currency, and gives the pot industry a means to get around its banking issues.
The marriage of bitcoin and marijuana
According to cannabis research firm ArcView, the North American legal weed industry could grow to more than $22 billion in sales by 2021, which would be triple what was sold legally in 2016. But, what's been keeping the industry from growing at an even quicker pace are a number of inherent disadvantages created by the U.S. federal government's scheduling of marijuana.
The U.S. government currently lists marijuana as a schedule I substance, meaning it has no medical benefits and is entirely illegal, just like LSD and heroin. This scheduling makes it very difficult to conduct the clinical studies lawmakers have requested on cannabis' benefits and risks.
Furthermore, there are tax disadvantages, with pot businesses being unable to take normal corporate-tax deductions. And finally, because banks report to the Federal Deposit Insurance Corporation (FDIC), a federally created entity, providing basic banking services to pot-based companies could be construed as money laundering under a strict interpretation of federal law. Thus, most deal only in cash, which is a security concern and growth inhibitor.
This is where cryptocurrency bitcoin enters. Some marijuana retailers have partnered with businesses that use the digital currency as a bridge between the consumers and the product (marijuana). A consumer has the option of paying a weed retailer in cash or using their credit card to purchase bitcoin that amounts to the value of their transaction in a weed-based store. The consumer then pays for the goods with their bitcoin, and the intermediary service then converts the bitcoin back to U.S. dollars for the pot-based retailer. This way consumers have a means of using their bank-issued credit card, retailers have a means to move beyond cash as their only option, and the intermediate service provider receives a transaction-based fee. Everyone wins -- especially bitcoin with the added publicity, and marijuana retailers since bitcoin customers who use their credits cards tend to spend more.
Bitcoin's "smart move" could wind up backfiring
However, investors who expect this marriage of bitcoin and marijuana to be successful could be sorely mistaken. While it's working in a select few states at the moment and helping to provide some legitimacy to bitcoin, it also gives bitcoin a pretty clear path to shooting itself in the foot.
The allure of bitcoin includes its relative anonymity, the fact that it's not backed by any global currency like the U.S. dollar, that it's a decentralized platform, and that it's essentially challenging monetary theory. But when introduced as a bridge currency between credit-holding consumers and marijuana, bitcoin becomes a prime target of U.S. regulators who still hold marijuana to be an illegal substance. Yes, the tide has turned substantially in the U.S. with regard to the percentage of consumers who want to see recreational and medical marijuana legalized, but that doesn't change the fact that it remains a schedule I substance in Washington, D.C.
Arguably the worst thing that could happen to bitcoin is that the U.S. federal government decides to put its foot down on the cryptocurrency. As we've seen, anonymity and security are already two of the biggest drawbacks of owning and investing in bitcoin, and acting as a bridge currency for a still federally illegal industry could only further prove the point of skeptics that bitcoin is a haven for criminals. The U.S. has previously used its banking might to financially starve criminals, foreign and domestic, but if there's a virtual currency system that's difficult to track, this route makes it difficult for the U.S. to cut off funding.
If the federal government were to implement regulations that made buying bitcoin more difficult, it could decimate a market that's still thinly traded compared to the daily share volumes you'd see exchanged on a reputable exchange like the NYSE. In other words, bitcoin's alliance with the marijuana industry is one gigantic gamble that could backfire.
Change is unlikely anytime soon
If the federal government changed its stance on marijuana at some point soon, this gamble might be worthwhile, but the chances of that happening are slim at best.
The U.S. Drug Enforcement Agency (DEA) had an opportunity to review two petitions for rescheduling last August and chose to keep everything as-is. The DEA determined that there was insufficient evidence of a benefit-versus-risk profile for cannabis, and also deemed it too dangerous to reclassify weed given a lack of proper patient oversight for administration of the drug. Since the DEA can take years to hear petitions, it's unlikely it'll review cannabis again anytime soon.
Additionally, the weed industry is unlikely to get any sympathy from the Trump administration. White House press secretary Sean Spicer commented in February that the administration would get tougher on federal marijuana regulations than the Obama administration, which is only reinforced by having Jeff Sessions, a clear-cut opponent of marijuana's expansion, as U.S. Attorney General.
The industry dynamics we've been accustomed to -- a long list of inherent disadvantages that often to lead to steep losses for marijuana stocks -- are likely to continue for at least the near-term, which bodes poorly for bitcoin's efforts to legitimize its currency through an alliance with marijuana companies.
10 stocks we like better than Wal-Mart
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, the Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Wal-Mart wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of June 5, 2017
The author(s) may have a position in any stocks mentioned.
The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
The DEA determined that there was insufficient evidence of a benefit-versus-risk profile for cannabis, and also deemed it too dangerous to reclassify weed given a lack of proper patient oversight for administration of the drug. Thus, most deal only in cash, which is a security concern and growth inhibitor. The U.S. Drug Enforcement Agency (DEA) had an opportunity to review two petitions for rescheduling last August and chose to keep everything as-is.
|
Thus, most deal only in cash, which is a security concern and growth inhibitor. The U.S. Drug Enforcement Agency (DEA) had an opportunity to review two petitions for rescheduling last August and chose to keep everything as-is. The DEA determined that there was insufficient evidence of a benefit-versus-risk profile for cannabis, and also deemed it too dangerous to reclassify weed given a lack of proper patient oversight for administration of the drug.
|
Thus, most deal only in cash, which is a security concern and growth inhibitor. The U.S. Drug Enforcement Agency (DEA) had an opportunity to review two petitions for rescheduling last August and chose to keep everything as-is. The DEA determined that there was insufficient evidence of a benefit-versus-risk profile for cannabis, and also deemed it too dangerous to reclassify weed given a lack of proper patient oversight for administration of the drug.
|
Thus, most deal only in cash, which is a security concern and growth inhibitor. The U.S. Drug Enforcement Agency (DEA) had an opportunity to review two petitions for rescheduling last August and chose to keep everything as-is. The DEA determined that there was insufficient evidence of a benefit-versus-risk profile for cannabis, and also deemed it too dangerous to reclassify weed given a lack of proper patient oversight for administration of the drug.
|
9dd7c14e-1e36-4b66-a328-51e3e246dae9
|
723532.0
|
2017-06-24 00:00:00 UTC
|
Surprise! Jeff Sessions Wants to Trample States' Rights and Prosecute Medical Marijuana Businesses
|
DEA
|
https://www.nasdaq.com/articles/surprise-jeff-sessions-wants-trample-states-rights-and-prosecute-medical-marijuana
|
nan
|
nan
|
The green rush is upon us. According to a recently released report from Marijuana Business Daily entitled "Marijuana Business Factbook 2017," legal marijuana sales -- this includes recreational and medical pot -- are slated to grow by 30% in 2017, about 45% next year, and catapult a total of 300% between 2016 and 2021 to north of $17 billion in the United States. This rapid growth has marijuana stock investors flocking into the industry, businesses scurrying to open up shop, and even has select governments scrambling to find ways to generate tax and licensing revenue off of cannabis.
For instance, Colorado, which was one of the first two states to legalize adult-use cannabis back in 2012, wound up selling slightly over $1.3 billion in legal weed in 2016. This more than 30% rise in year-over-year legal sales translated into almost $200 million in tax and licensing revenue for the state. Colorado has apportioned a good chunk of this tax revenue for its educational system, as well as law enforcement and in-state drug-abuse programs.
Federal law keeps the marijuana industry from thriving
Yet in spite of the pot industry growing like a weed, U.S. federal law provides a veritable glass ceiling that makes life exceptionally difficult for marijuana-based businesses. Keep in mind that, despite 28 states having legalized medical cannabis and eight states legalizing recreational pot, federal law still lists marijuana as a schedule I substance.
This means it's on par with heroin and LSD, has no medical benefits, and is entirely illegal. The only saving grace for the marijuana industry has been the Rohrabacher-Farr Amendment , which essentially prevents the use of federal funds to prosecute businesses that are abiding by their state's laws on medical and/or recreational weed.
But being listed as a schedule I substance means a world of additional disadvantages. For starters, running clinical trials involving cannabis is extremely challenging given its scheduling. Weed-based companies also face pretty sizable tax disadvantages because IRS tax code 280E disallows businesses that sell federally illegal substances from taking normal corporate-tax deductions. And finally, marijuana companies have a hard time obtaining basic banking services, since most financial institutions could be prosecuted for dealing with cannabis businesses under a strict interpretation of the law.
And don't expect this scheduling to change anytime soon. The U.S. Drug Enforcement Agency (DEA) in August of last year had the opportunity to review cannabis for rescheduling, but ultimately chose to keep its categorization the same.
Furthermore, the appointment of Jeff Sessions as Attorney General all but squashed any hope of federal change. Sessions, while in the Senate, was an ardent opponent of marijuana, and has made his feelings about the drug well known.
Sessions wants to go after medical marijuana businesses
Don't think for a moment that a little thing like not receiving any federal funding to go after marijuana businesses is going to stop Sessions. According to a letter that was first obtained by Massroots.com and verified by The Washington Post , Sessions sent a letter in May to Congressional leaders requesting the repeal of the Rohrabacher-Farrr Amendment so that he may lean on federal law to trample state's rights and prosecute businesses that deal with medical marijuana.
Here's what Sessions had to say about the Rohrabacher-Farr Amendment:
President Trump signing paperwork while flanked by Attorney General Jeff Sessions and his wife. Image source: President Donald J. Trump's official Facebook page. Photo by Benjamin D. Applebaum.
The request to undo Rohrabacher-Farr is one that Sessions is unlikely to win. A recent Quinnipiac poll found 93% of respondents supported the idea of legalizing medical marijuana nationwide, meaning rolling back the ability of states to grant access to medical cannabis could cause an uproar among voters.
Similarly, President Trump pledged support for the right of states to choose whether or not they want to allow their residents access to medical cannabis during his campaign. It seems unlikely that he'd allow Sessions the opportunity to prosecute medical weed businesses after publicly taking the position he did.
Another issue is that Sessions' argument regarding "an historic drug epidemic" doesn't entirely hold water. While there are still plenty of tests left to be run on the risks and benefits of marijuana, an interesting correlation noted by researchers in Health Affairs last year found that opioid prescriptions issued under Medicare dropped in states that had legalized medical cannabis. Considering there were 20,101 opioid-related overdose deaths in 2015 and zero weed-based overdose-related deaths in 2015, the arrow is pointing toward the possibility of marijuana offering some relief to the opioid epidemic, not an exacerbating factor as Sessions suggested in his letter to Congress.
Marijuana stocks can breathe a (partial) sigh of relief
Considering that there's bipartisan support for Rohrabacher-Farr in Congress, Sessions' request to go after the medical marijuana industry seems highly unlikely to be approved. That's good news for businesses focused on medical marijuana products, such as Southern California-based Medical Marijuana, Inc. (NASDAQOTH: MJNA) , which has investments in nutraceutical and medical cannabis businesses. Medical Marijuana, Inc.'s bread and butter are cannabidiol (CBD)-based products -- cannabidiol is the non-psychoactive component of marijuana -- which Sessions would have cracked down on.
It's also good news for drug developers focused on using cannabinoids from the cannabis plant. For example, GW Pharmaceuticals (NASDAQ: GWPH) has produced stellar results from multiple late-stage studies for CBD-based oral medication Epidiolex as a treatment for two rare types of childhood-onset epilepsy. Taking away Epidiolex from future patients, assuming it's approved by the Food and Drug Administration, would remove a drug that significantly reduced seizure frequency in Dravet syndrome and Lennox-Gastaut syndrome patients.
On the other hand, Sessions being unable to prosecute medical marijuana companies doesn't clear up the industry's primary issue of marijuana remaining as a schedule I substance. Tax and banking issues aren't going to suddenly disappear, and chances are that most marijuana stocks are going to continue losing money. For the time being, your best bet is to keep your money far away from marijuana stocks.
10 stocks we like better than GW Pharmaceuticals
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and GW Pharmaceuticals wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of June 5, 2017
Sean Williams has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
And finally, marijuana companies have a hard time obtaining basic banking services, since most financial institutions could be prosecuted for dealing with cannabis businesses under a strict interpretation of the law. The U.S. Drug Enforcement Agency (DEA) in August of last year had the opportunity to review cannabis for rescheduling, but ultimately chose to keep its categorization the same. According to a letter that was first obtained by Massroots.com and verified by The Washington Post , Sessions sent a letter in May to Congressional leaders requesting the repeal of the Rohrabacher-Farrr Amendment so that he may lean on federal law to trample state's rights and prosecute businesses that deal with medical marijuana.
|
And finally, marijuana companies have a hard time obtaining basic banking services, since most financial institutions could be prosecuted for dealing with cannabis businesses under a strict interpretation of the law. The U.S. Drug Enforcement Agency (DEA) in August of last year had the opportunity to review cannabis for rescheduling, but ultimately chose to keep its categorization the same. According to a letter that was first obtained by Massroots.com and verified by The Washington Post , Sessions sent a letter in May to Congressional leaders requesting the repeal of the Rohrabacher-Farrr Amendment so that he may lean on federal law to trample state's rights and prosecute businesses that deal with medical marijuana.
|
And finally, marijuana companies have a hard time obtaining basic banking services, since most financial institutions could be prosecuted for dealing with cannabis businesses under a strict interpretation of the law. The U.S. Drug Enforcement Agency (DEA) in August of last year had the opportunity to review cannabis for rescheduling, but ultimately chose to keep its categorization the same. According to a letter that was first obtained by Massroots.com and verified by The Washington Post , Sessions sent a letter in May to Congressional leaders requesting the repeal of the Rohrabacher-Farrr Amendment so that he may lean on federal law to trample state's rights and prosecute businesses that deal with medical marijuana.
|
And finally, marijuana companies have a hard time obtaining basic banking services, since most financial institutions could be prosecuted for dealing with cannabis businesses under a strict interpretation of the law. The U.S. Drug Enforcement Agency (DEA) in August of last year had the opportunity to review cannabis for rescheduling, but ultimately chose to keep its categorization the same. According to a letter that was first obtained by Massroots.com and verified by The Washington Post , Sessions sent a letter in May to Congressional leaders requesting the repeal of the Rohrabacher-Farrr Amendment so that he may lean on federal law to trample state's rights and prosecute businesses that deal with medical marijuana.
|
463f3d8b-5c25-4e03-af0a-f5c0defa8696
|
723533.0
|
2017-06-17 00:00:00 UTC
|
This Jeff Sessions Rumor Could Light a Fire Under Marijuana Stocks
|
DEA
|
https://www.nasdaq.com/articles/jeff-sessions-rumor-could-light-fire-under-marijuana-stocks-2017-06-17
|
nan
|
nan
|
The legal marijuana industry has been practically unstoppable recently. Legal sales of medical and recreational marijuana are expected to grow by roughly 30% in 2017, 45% in 2018, and peak at north of $17 billion in 2021, per the "Marijuana Business Factbook 2017," a newly released report from Marijuana Business Daily . And this growth has meant one thing to businesses and investors: dollar signs.
Over the past year, a number of marijuana stocks have doubled or tripled in value. Investors have been almost blindly buying into pot stocks with the expectation that state-level expansion will continue, and that recreational legalization in our neighbors to the north, Canada, could be a reality as early as next summer.
Jeff Sessions and the federal government hold the marijuana industry back
However, marijuana stocks and the industry have one big hurdle they've yet to overcome: restrictive U.S. federal laws.
Even though 28 states have legalized medical cannabis and residents in eight states have voted in favor of legalizing recreational weed, the federal government has been unwavering on its view of marijuana as a schedule I substance. A schedule I drug -- which places marijuana on par with heroin and LSD -- is entirely illegal and has no recognizable medical benefits. This scheduling also exempts pot-based businesses from taking normal corporate tax deductions, and it makes it incredibly tough for weed businesses to secure basic banking services, including something as simple as a checking account.
The U.S. Drug Enforcement Agency (DEA) had an opportunity to reschedule marijuana last summer, but chose to deny two petitions requesting it do so. The DEA cited a lack of safety and clinical benefit evidence, based on findings from the Food and Drug Administration, and signaled that a system of checks wasn't in place to regulate dispensing cannabis for medical purposes. Since the DEA can take years to review petitions, it seems unlikely that the regulatory body would review weed again anytime soon.
By a similar token, Congress isn't in any rush to consider rescheduling pot, despite the latest CBS News poll from April showing that support for marijuana's legalization reached an all-time high of 61%. Lawmakers have repeatedly suggested that they want more clinical evidence of the benefits and risks of marijuana use before they'd consider adjusting its scheduling. Yet, the irony is that the pot's current scheduling makes running clinical trials extremely difficult.
Image source: President Donald J. Trump's official Facebook page. Photo by Benjamin D. Applebaum.
And at the center of it all is newly appointed Attorney General Jeff Sessions. While in the Senate, Sessions made it very clear that he opposes any expansion of marijuana, and has gone on record numerous times suggesting that marijuana is not medicine, and that it leads to an increase in crime. Though Sessions received no money apportioned by the federal government to crack down on marijuana use and weed-based businesses in the 2018 budget proposal, Sessions' sway with President Trump could change that tune in the years to come.
Remember, White House press secretary Sean Spicer commented in February that the Trump administration would be markedly different in regulating marijuana than the Obama administration, meaning a crackdown could still be coming.
Add this all together, and we have a pretty encompassing view of why most marijuana stocks are still losing money, and why they may continue to do so for the immediate future.
This Jeff Sessions rumor could spark a rally in marijuana stocks
However, there could be a proverbial light at the end of the tunnel for marijuana stocks.
According to reports from multiple news agencies, the relationship between President Trump and Attorney General Sessions has become strained to the point that Sessions has suggested he might resign. The friction, per sources, stems from Sessions' decision this past March to recuse himself from anything related to the ongoing Russian investigation, which was a decision President Trump learned about just minutes before Sessions' announcement.
To be clear, this is just a rumor at this point, albeit it's a loud rumor with pressure from within Congress calling for Sessions to resign. If Sessions were to step down as Attorney General, it could be the spark that marijuana stocks are looking for.
Understandably, Sessions isn't the only issue on Capitol Hill . Without Sessions, the schedule I categorization of weed would still stand, as would the restrictive tax treatment of profits and inability to gain access to basic financial services. But, a key figure that had threatened to crack down on state's rights when it comes to marijuana would presumably be gone, which would reduce the chances of states like Colorado, Washington, Oregon, and soon California, having their recreational marijuana industries scaled back or closed entirely. It would be a big weight lifted off the shoulders of the industry.
Here's what it wouldn't do
Yet, as noted above, the restrictive nature of cannabis' scheduling wouldn't change, which means most marijuana stocks would, at the end of the day, still be unprofitable.
The marijuana stocks that demonstrate the most promise, but also those with the steepest losses at present, are those working toward creating cannabinoid-based medicines.
GW Pharmaceuticals (NASDAQ: GWPH) , the kingpin of the bunch in terms of market cap, successfully completed a handful of late-stage clinical studies involving its oral drug Epidiolex in patients with two rare types of childhood-onset epilepsy. Even though an approval from the FDA would seem to be in the cards, GW Pharmaceuticals is still on track to lose money through 2019, and its accumulated deficit (i.e., how much money it's lost since inception) has ballooned to nearly $279 million through the second quarter of 2017. Having Sessions out of office does nothing to improve these fundamentals. Even with a bright future for Epidiolex, it may be tough to extract any further value out of GW Pharmaceuticals -- and the case is the same with many other marijuana stocks.
This the dilemma for marijuana stocks: removing Sessions from the picture lightens the load of federal intervention in already legal states, but it does nothing to remove the murkiness of weed's schedule I status at the federal level. That still makes marijuana stocks worth avoiding in this Fool's opinion.
10 stocks we like better than GW Pharmaceuticals
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and GW Pharmaceuticals wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of June 5, 2017
Sean Williams has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
The DEA cited a lack of safety and clinical benefit evidence, based on findings from the Food and Drug Administration, and signaled that a system of checks wasn't in place to regulate dispensing cannabis for medical purposes. The U.S. Drug Enforcement Agency (DEA) had an opportunity to reschedule marijuana last summer, but chose to deny two petitions requesting it do so. Since the DEA can take years to review petitions, it seems unlikely that the regulatory body would review weed again anytime soon.
|
The U.S. Drug Enforcement Agency (DEA) had an opportunity to reschedule marijuana last summer, but chose to deny two petitions requesting it do so. The DEA cited a lack of safety and clinical benefit evidence, based on findings from the Food and Drug Administration, and signaled that a system of checks wasn't in place to regulate dispensing cannabis for medical purposes. Since the DEA can take years to review petitions, it seems unlikely that the regulatory body would review weed again anytime soon.
|
The U.S. Drug Enforcement Agency (DEA) had an opportunity to reschedule marijuana last summer, but chose to deny two petitions requesting it do so. The DEA cited a lack of safety and clinical benefit evidence, based on findings from the Food and Drug Administration, and signaled that a system of checks wasn't in place to regulate dispensing cannabis for medical purposes. Since the DEA can take years to review petitions, it seems unlikely that the regulatory body would review weed again anytime soon.
|
The U.S. Drug Enforcement Agency (DEA) had an opportunity to reschedule marijuana last summer, but chose to deny two petitions requesting it do so. The DEA cited a lack of safety and clinical benefit evidence, based on findings from the Food and Drug Administration, and signaled that a system of checks wasn't in place to regulate dispensing cannabis for medical purposes. Since the DEA can take years to review petitions, it seems unlikely that the regulatory body would review weed again anytime soon.
|
f18aa63d-ef64-4e65-9c16-04b6c00ebfa6
|
723534.0
|
2017-06-09 00:00:00 UTC
|
Easterly Government Properties, Inc. (DEA) Ex-Dividend Date Scheduled for June 12, 2017
|
DEA
|
https://www.nasdaq.com/articles/easterly-government-properties-inc-dea-ex-dividend-date-scheduled-june-12-2017-2017-06-09
|
nan
|
nan
|
Easterly Government Properties, Inc. ( DEA ) will begin trading ex-dividend on June 12, 2017. A cash dividend payment of $0.25 per share is scheduled to be paid on June 29, 2017. Shareholders who purchased DEA prior to the ex-dividend date are eligible for the cash dividend payment. This represents an 4.17% increase over prior dividend payment. At the current stock price of $20.8, the dividend yield is 4.81%.
The previous trading day's last sale of DEA was $20.8, representing a -2.71% decrease from the 52 week high of $21.38 and a 15.94% increase over the 52 week low of $17.94.
DEA is a part of the Consumer Services sector, which includes companies such as American Tower Corporation (REIT) ( AMT ) and Simon Property Group, Inc. ( SPG ). DEA's current earnings per share, an indicator of a company's profitability, is $.1. Zacks Investment Research reports DEA's forecasted earnings growth in 2017 as 4.68%, compared to an industry average of .4%.
For more information on the declaration, record and payment dates, visit the DEA Dividend History page. Our Dividend Calendar has the full list of stocks that have an ex-dividend today.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
DEA is a part of the Consumer Services sector, which includes companies such as American Tower Corporation (REIT) ( AMT ) and Simon Property Group, Inc. ( SPG ). Zacks Investment Research reports DEA's forecasted earnings growth in 2017 as 4.68%, compared to an industry average of .4%. For more information on the declaration, record and payment dates, visit the DEA Dividend History page.
|
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Easterly Government Properties, Inc. ( DEA ) will begin trading ex-dividend on June 12, 2017. Shareholders who purchased DEA prior to the ex-dividend date are eligible for the cash dividend payment.
|
Shareholders who purchased DEA prior to the ex-dividend date are eligible for the cash dividend payment. The previous trading day's last sale of DEA was $20.8, representing a -2.71% decrease from the 52 week high of $21.38 and a 15.94% increase over the 52 week low of $17.94. For more information on the declaration, record and payment dates, visit the DEA Dividend History page.
|
Shareholders who purchased DEA prior to the ex-dividend date are eligible for the cash dividend payment. DEA's current earnings per share, an indicator of a company's profitability, is $.1. Easterly Government Properties, Inc. ( DEA ) will begin trading ex-dividend on June 12, 2017.
|
be969c91-ed6c-4a6b-8c98-7ee11b080d2e
|
723535.0
|
2017-06-09 00:00:00 UTC
|
Ex-Dividend Reminders Incluse Prologis Inc (PLD) and and Hewlett Packard Enterprise Co (HPE)
|
DEA
|
https://www.nasdaq.com/articles/ex-dividend-reminders-incluse-prologis-inc-pld-and-and-hewlett-packard-enterprise-co-hpe
|
nan
|
nan
|
InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Looking at the universe of stocks we cover at Dividend Channel , Easterly Government Properties Inc (NYSE: DEA) , Prologis Inc (NYSE: PLD ), and Hewlett Packard Enterprise Co (NYSE: HPE ) will all trade ex-dividend for their respective upcoming dividends on 6/12/17.
Easterly Government Properties Inc will pay its quarterly dividend of 25 cents per share on 6/29/17, Prologis will pay its quarterly dividend of 44 cents per share on 6/30/17, and Hewlett Packard Enterprise will pay its quarterly dividend of 6.5 cents per share on 7/5/17.
START SLIDESHOW :
Click here to learn which 25 S.A.F.E. dividend stocks should be on your radar screen »
As a percentage of DEA's recent stock price of $20.78, this dividend works out to approximately 1.20%, so look for shares of Easterly Government Properties Inc to trade 1.20% lower - all else being equal - when DEA shares open for trading on 6/12/17.
10 Simply Safe Dividend Stocks to Buy for Retirement
Similarly, investors should look for PLD to open 0.78% lower in price and for HPE to open 0.38% lower, all else being equal.
Below are dividend history charts for DEA, PLD, and HPE, showing historical dividends prior to the most recent ones declared.
Easterly Government Properties Inc :
Prologis Inc :
Hewlett Packard Enterprise Co :
In general, dividends are not always predictable, following the ups and downs of company profits over time. Therefore, a good first due diligence step in forming an expectation of annual yield going forward, is looking at the history above, for a sense of stability over time.
This can help in judging whether the most recent dividends from these companies are likely to continue.
If they do continue, the current estimated yields on annualized basis would be 4.81% for Easterly Government Properties, 3.12% for Prologis, and 1.53% for Hewlett Packard Enterprise.
More From InvestorPlace
7 Dividend Stocks to Buy That Make The Grade
8 Dangerous Dividend Stocks That Could Cut or Kill Their Payouts
The Top 10 S&P 500 Dividend Stocks to Buy Now
The post Ex-Dividend Reminders Incluse Prologis Inc (PLD) and and Hewlett Packard Enterprise Co (HPE) appeared first on InvestorPlace .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Looking at the universe of stocks we cover at Dividend Channel , Easterly Government Properties Inc (NYSE: DEA) , Prologis Inc (NYSE: PLD ), and Hewlett Packard Enterprise Co (NYSE: HPE ) will all trade ex-dividend for their respective upcoming dividends on 6/12/17. dividend stocks should be on your radar screen » As a percentage of DEA's recent stock price of $20.78, this dividend works out to approximately 1.20%, so look for shares of Easterly Government Properties Inc to trade 1.20% lower - all else being equal - when DEA shares open for trading on 6/12/17. Below are dividend history charts for DEA, PLD, and HPE, showing historical dividends prior to the most recent ones declared.
|
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Looking at the universe of stocks we cover at Dividend Channel , Easterly Government Properties Inc (NYSE: DEA) , Prologis Inc (NYSE: PLD ), and Hewlett Packard Enterprise Co (NYSE: HPE ) will all trade ex-dividend for their respective upcoming dividends on 6/12/17. dividend stocks should be on your radar screen » As a percentage of DEA's recent stock price of $20.78, this dividend works out to approximately 1.20%, so look for shares of Easterly Government Properties Inc to trade 1.20% lower - all else being equal - when DEA shares open for trading on 6/12/17. Below are dividend history charts for DEA, PLD, and HPE, showing historical dividends prior to the most recent ones declared.
|
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Looking at the universe of stocks we cover at Dividend Channel , Easterly Government Properties Inc (NYSE: DEA) , Prologis Inc (NYSE: PLD ), and Hewlett Packard Enterprise Co (NYSE: HPE ) will all trade ex-dividend for their respective upcoming dividends on 6/12/17. dividend stocks should be on your radar screen » As a percentage of DEA's recent stock price of $20.78, this dividend works out to approximately 1.20%, so look for shares of Easterly Government Properties Inc to trade 1.20% lower - all else being equal - when DEA shares open for trading on 6/12/17. Below are dividend history charts for DEA, PLD, and HPE, showing historical dividends prior to the most recent ones declared.
|
dividend stocks should be on your radar screen » As a percentage of DEA's recent stock price of $20.78, this dividend works out to approximately 1.20%, so look for shares of Easterly Government Properties Inc to trade 1.20% lower - all else being equal - when DEA shares open for trading on 6/12/17. InvestorPlace - Stock Market News, Stock Advice & Trading Tips Looking at the universe of stocks we cover at Dividend Channel , Easterly Government Properties Inc (NYSE: DEA) , Prologis Inc (NYSE: PLD ), and Hewlett Packard Enterprise Co (NYSE: HPE ) will all trade ex-dividend for their respective upcoming dividends on 6/12/17. Below are dividend history charts for DEA, PLD, and HPE, showing historical dividends prior to the most recent ones declared.
|
f21528d6-93d8-4a11-a00a-980cc53c2828
|
723536.0
|
2017-06-06 00:00:00 UTC
|
Why I Will (Probably) Never Invest in Marijuana Stocks
|
DEA
|
https://www.nasdaq.com/articles/why-i-will-probably-never-invest-marijuana-stocks-2017-06-06
|
nan
|
nan
|
Chances are that you'd struggle to find an industry with faster, more consistent growth than the marijuana industry -- and that's a big reason why investors have flocked to marijuana stocks.
Legal pot sales are expected to skyrocket over the next five to 10 years. According to cannabis research firm ArcView, legal weed sales could top $22 billion in North America by 2021, while the Marijuana Business Factbook 2017, published by Marijuana Business Daily , calls for approximately $17 billion in legal U.S. sales by 2021. Investment firm Cowen & Co. went even further and is calling for $50 billion in legal U.S. sales by 2026.
Rapidly changing public opinion has also fueled these bullish projections. According to Gallup and CBS News, the number of respondents who want to see recreational weed legalized nationally jumped to all-time highs of 60% and 61%, respectively.
The result has been triple-digit gains in a number of marijuana stocks.
However, this Fool has absolutely no desire at the moment to invest in marijuana, nor will I probably ever invest in marijuana stocks. Why? These six reasons sum it up pretty well.
1. Weed stocks face major financial disadvantages
The first issue I have with pot stocks is that businesses involved in the marijuana industry are set to face two notable disadvantages .
To begin with, weed-based businesses have a very difficult time gaining access to basic banking services, ranging from loans and lines of credit to something as simple as a bank account. Since most financial institutions report to the Federal Deposit Insurance Corporation (FDIC), and the FDIC is a federally created entity, providing banking services to marijuana businesses could be construed as money laundering and result in pretty hefty fines for participating banks. This leaves pot companies to deal in cash, which is a security concern and a growth inhibitor.
The second problem is that the Internal Revenue Service (IRS) puts the kibosh on what marijuana-based companies can deduct from their taxes. U.S. tax code 280E disallows businesses that sell a federally illegal substance from taking normal corporate income-tax deductions. This means cannabis businesses are stuck paying tax on their gross profits instead of net profits.
2. Most are penny stocks (and thus should be avoided)
Another issue to consider is that most marijuana stocks trade on the over-the-counter exchanges, and are in many cases penny stocks.
The concern with over-the-counter stocks is financial reporting. Even though the OTC exchanges have done a better job of improving reporting standards in recent years, it can still be difficult for investors to get accurate and up-to-date financial information. And if you can't get accurate cash flow, cash balance, and debt figures, it's not a smart investment idea.
As for penny stocks (those with share prices of $5 or less), they tend to be highly volatile and potentially thinly traded. Avoiding penny stocks is almost always a good idea.
3. A majority of cannabis stocks are losing money, yet valuations are astronomical
A prime concern that's bound to scare away fundamentals-focused investors is that nearly all marijuana stocks are losing money. This is a function of the industry being highly fragmented (i.e., there are a lot of smaller mom-and-pop dispensaries, which means lots of competition), and the U.S. government holding firm on its stance of weed as an illicit substance.
There are a small handful of exceptions. For instance, Canadian grower and retailer for the medical cannabis industry Aphria (NASDAQOTH: APHQF) has generated a profit in five consecutive quarters . The company also has a fully funded $100 million project known as its Phase IV expansion that's more than tripling its growing capacity to 1 million square feet. Realistically, Aphria's profits could further expand.
However, Aphria is also valued at what could be a P/E of more than 100. Aprhia, along with its peers and other marijuana stocks, is trading at astronomical valuations. Investors appear to be succumbing to emotional investing, which could come back to haunt them if pot stocks continue to produce quarterly loss after quarterly loss.
Image source: President Donald J. Trump's official Facebook page. Photo by Benjamin D. Applebaum.
4. The DEA and federal government are unlikely to support change
A common sense reason to avoid investing in marijuana stocks is that it's illegal at the federal level, and that doesn't look as if it'll change anytime soon. Marijuana's schedule I categorization means it has no recognized medical benefits and is an illicit substance.
Last August, the U.S. Drug Enforcement Agency (DEA) had an opportunity to review two petitions to change cannabis from its schedule I status, but the DEA declined to change its scheduling. The regulatory agency found insufficient evidence that marijuana was safe or effective in the clinical setting, and believed that inadequate safety checks were in place for doctors to oversee administration of the drug. Since the DEA often takes years to tackle petitions, it could be years before it reviews pot again for rescheduling.
Furthermore, the Trump administration is unlikely to give the green light to the weed industry. Newly appointed Attorney General Jeff Sessions could accurately be described as marijuana's most ardent opponent in the Senate prior to this new role in the Trump administration. If Sessions had his way, he'd probably roll back marijuana's expansion in its entirety and reinstitute federal law.
5. Expansion may be more limited than you realize
Something you should also keep in mind is that the state-level expansions the industry has thrived on over the past couple of years may soon slow.
As of the end of 2016, 28 states had legalized medical cannabis and eight had approved recreational weed for adult use. There aren't too many states left where the legislature and/or governor supports legalizing medical marijuana.
Meanwhile, attempts to legalize recreational weed could be stymied by Sessions and other opponents in the Republican Party. With the federal government looking unlikely to legalize marijuana, the industry is reliant on state-level expansion for growth. If that growth slows, investors could be in for a world of hurt.
6. Rescheduling may actually make things worse
Finally, marijuana stock investors have to understand that even rescheduling marijuana won't necessarily fix the industry's problems.
If marijuana were to be rescheduled by the DEA to schedule II (making it legal for physicians to prescribe), it would put cannabis under the strict oversight of the Food and Drug Administration (FDA). The FDA would have the power to control marketing and labeling of medical cannabis products, and it would almost certainly oversee the manufacturing of pot and pot-based products. Most notably, it could require that clinical trials be run to confirm the medically beneficial qualities that companies currently tout for cannabis products. Clinical trials could cost marijuana companies millions upon millions of dollars.
The only factor that could possibly change my view on pot stocks is the level to which the federal government changes its stance on marijuana, should that ever happen. Given the right amount of industry consolidation and a lessening of regulations surrounding marijuana businesses, they could be worth investing in many years down the road. In the meantime, this Fool would strongly recommend that investors keep their distance from marijuana stocks.
10 stocks we like better than Aphira Inc.
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Aphira wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of May 1, 2017
Sean Williams has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
If marijuana were to be rescheduled by the DEA to schedule II (making it legal for physicians to prescribe), it would put cannabis under the strict oversight of the Food and Drug Administration (FDA). This leaves pot companies to deal in cash, which is a security concern and a growth inhibitor. And if you can't get accurate cash flow, cash balance, and debt figures, it's not a smart investment idea.
|
The DEA and federal government are unlikely to support change A common sense reason to avoid investing in marijuana stocks is that it's illegal at the federal level, and that doesn't look as if it'll change anytime soon. This leaves pot companies to deal in cash, which is a security concern and a growth inhibitor. And if you can't get accurate cash flow, cash balance, and debt figures, it's not a smart investment idea.
|
This leaves pot companies to deal in cash, which is a security concern and a growth inhibitor. And if you can't get accurate cash flow, cash balance, and debt figures, it's not a smart investment idea. Avoiding penny stocks is almost always a good idea.
|
The DEA and federal government are unlikely to support change A common sense reason to avoid investing in marijuana stocks is that it's illegal at the federal level, and that doesn't look as if it'll change anytime soon. Since the DEA often takes years to tackle petitions, it could be years before it reviews pot again for rescheduling. This leaves pot companies to deal in cash, which is a security concern and a growth inhibitor.
|
50d18519-00e6-42ae-81fa-9f4284ba38c2
|
723537.0
|
2017-06-04 00:00:00 UTC
|
With These 4 Words, the DEA Head Shut Down Any Hope of Legalizing Marijuana Anytime Soon
|
DEA
|
https://www.nasdaq.com/articles/these-4-words-dea-head-shut-down-any-hope-legalizing-marijuana-anytime-soon-2017-06-04
|
nan
|
nan
|
In recent years, growth in the marijuana industry has been phenomenal. In fact, you'd struggle to find an industry that could deliver comparable growth over an extended period of time, which is a prime reason why investors have flocked to marijuana stocks.
Last year in North America, according to cannabis research firm ArcView, net sales of cannabis were an estimated $53.3 billion. Of this amount, just $6.9 billion was conducted through legal channels. The remaining $46.4 billion stands as a pie-in-the-sky opportunity for the pot industry to attract new customers through legal means. This, along with record-high approval ratings for marijuana in Gallup's and CBS News' most recent polls, is what's pushed many marijuana stocks higher by at least 100% over the trailing 12-month period.
Also noteworthy is the fact that our neighbors to the north and south could be readying to expand the use of legal marijuana. In Canada, where medical cannabis has been legal since 2001, Prime Minister Justin Trudeau introduced legislation that would make recreational weed legal for adult use by next summer. Meanwhile, legislation made it through Mexico's Congress that would legalize medical marijuana throughout the country.
Where's the U.S. while this is going on, you ask? Mostly stuck in neutral.
Federal scheduling of marijuana is holding the industry back
In terms of state-level legalizations, the U.S. has made marked progress in recent years. As of the end of 2016, more than half of all states (28) had legalized medical cannabis, and residents in eight states have voted to legalize recreational marijuana since Nov. 2012.
However, and this is the big "however," the federal stance on marijuana remains the same today as it's been for decades. Namely, cannabis is a schedule I substance, meaning it has no medical benefits and is entirely illegal -- the same as heroin or LSD. This stance was considered acceptable to many back in the 1990s when, according to Gallup, just a quarter of respondents wanted weed legalized nationally. With approximately three out of five survey-takers wanting to see pot legalized nationally today, Congress' view on marijuana isn't all that popular.
In fact, categorizing marijuana as a schedule I substance has some pretty adverse impacts on companies that operate legally within the industry.
For example, most weed-based business have little to no access to basic banking services, ranging from obtaining a loan or line of credit to something as simple as getting a checking account. Since most financial institutions report to the Federal Deposit Insurance Corporation, a federally created entity, and the federal government lists cannabis as schedule I, any banking institutions that offers services to pot-based businesses could, under a strict interpretation of the law, be guilty of money laundering.
Furthermore, businesses involved in the marijuana industry face some pretty stiff tax disadvantages. IRS tax code 280E disallows businesses that sell federally illegal substances, like marijuana, from taking normal corporate tax deductions. The result is pot-based businesses get stuck paying tax on their gross profits (should they be profitable), as opposed to net profits like normal businesses.
You can essentially kiss any chance of legalization goodbye under the Trump administration
Though the public is holding out hope that lawmakers on Capitol Hill will take notice of the shifting tide toward marijuana, the chances of that happening are slim-to-none, and commentary from the chief of the U.S. Drug Enforcement Agency (DEA) last week supported that view.
DEA Chief Chuck Rosenberg reinforced his previous view on weed in just four words last week, saying that "marijuana is not medicine" while speaking at the Cleveland Clinic in Ohio.
Despite acknowledging that medical marijuana has demonstrated some positive benefits in terms of treating childhood epilepsy, Rosenburg said, "If it turns out that there is something in smoked marijuana that helps people, that's awesome. I will be the last person to stand in the way of that. But let's run it through the Food and Drug Administration process, and let's stick to the science on it."
Rosenburg's commentary may refer to GW Pharmaceuticals ' (NASDAQ: GWPH) Epidiolex, an oral cannabidiol solution that wowed during multiple phase 3 trials in two rare forms of childhood-onset epilepsy, Dravet syndrome and Lennox-Gastaut syndrome. With statistically significant reductions seen in seizure frequency, Epidiolex is on track to potentially gain FDA approval, partially debunking Rosenburg's thesis on medical marijuana (i.e., it's cannabinoid-based, not smokable marijuana).
The DEA's scheduling of cannabis, however, makes FDA-approved clinical trials of medical marijuana very difficult to run. It's the ultimate Catch-22: the DEA needs more clinical evidence to consider altering marijuana's scheduling, but the FDA keeps a tight lid on the number of clinical trials that can be run on medical cannabis.
Marijuana stocks could struggle
With the DEA's chief having a negative view of marijuana, and the federal government unlikely to suggest a rescheduling with ardent opponent Jeff Sessions as attorney general, legal sales growth could all be for naught for marijuana stocks .
The big factor that investors have to take into account is that marijuana stocks are regularly losing money. With the rare exception of Canadian medical marijuana producers and growers, such as Canopy Growth Corp. , most pot stocks are deeply in the red.
For instance, cannabinoid-based drug developer Corbus Pharmaceuticals (NASDAQ: CRBP) is still in the clinical-stage of the drug development process, and it could be years before it's generating recurring revenue and has any shot at reducing its annual losses. Corbus' pipeline is reliant on a single developing drug, anabasum, and the company's $48.9 million in cash and cash equivalents will only last the company through 2018. In other words, marijuana stock investors are likely playing with fire by investing in Corbus, or practically any cannabinoid-based drug developer at this point.
My suggestion would be to not let your emotions get the better of you, and to stay away from marijuana stocks until we see some concrete policy changes from Washington, D.C.
10 stocks we like better than Corbus Pharmaceuticals Holdings
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Corbus Pharmaceuticals Holdings wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of May 1, 2017
Sean Williams has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
DEA Chief Chuck Rosenberg reinforced his previous view on weed in just four words last week, saying that "marijuana is not medicine" while speaking at the Cleveland Clinic in Ohio. In Canada, where medical cannabis has been legal since 2001, Prime Minister Justin Trudeau introduced legislation that would make recreational weed legal for adult use by next summer. You can essentially kiss any chance of legalization goodbye under the Trump administration Though the public is holding out hope that lawmakers on Capitol Hill will take notice of the shifting tide toward marijuana, the chances of that happening are slim-to-none, and commentary from the chief of the U.S. Drug Enforcement Agency (DEA) last week supported that view.
|
In Canada, where medical cannabis has been legal since 2001, Prime Minister Justin Trudeau introduced legislation that would make recreational weed legal for adult use by next summer. You can essentially kiss any chance of legalization goodbye under the Trump administration Though the public is holding out hope that lawmakers on Capitol Hill will take notice of the shifting tide toward marijuana, the chances of that happening are slim-to-none, and commentary from the chief of the U.S. Drug Enforcement Agency (DEA) last week supported that view. DEA Chief Chuck Rosenberg reinforced his previous view on weed in just four words last week, saying that "marijuana is not medicine" while speaking at the Cleveland Clinic in Ohio.
|
Marijuana stocks could struggle With the DEA's chief having a negative view of marijuana, and the federal government unlikely to suggest a rescheduling with ardent opponent Jeff Sessions as attorney general, legal sales growth could all be for naught for marijuana stocks . In Canada, where medical cannabis has been legal since 2001, Prime Minister Justin Trudeau introduced legislation that would make recreational weed legal for adult use by next summer. You can essentially kiss any chance of legalization goodbye under the Trump administration Though the public is holding out hope that lawmakers on Capitol Hill will take notice of the shifting tide toward marijuana, the chances of that happening are slim-to-none, and commentary from the chief of the U.S. Drug Enforcement Agency (DEA) last week supported that view.
|
In Canada, where medical cannabis has been legal since 2001, Prime Minister Justin Trudeau introduced legislation that would make recreational weed legal for adult use by next summer. You can essentially kiss any chance of legalization goodbye under the Trump administration Though the public is holding out hope that lawmakers on Capitol Hill will take notice of the shifting tide toward marijuana, the chances of that happening are slim-to-none, and commentary from the chief of the U.S. Drug Enforcement Agency (DEA) last week supported that view. DEA Chief Chuck Rosenberg reinforced his previous view on weed in just four words last week, saying that "marijuana is not medicine" while speaking at the Cleveland Clinic in Ohio.
|
14ae4082-c413-4adb-b72e-0d6be5cdac3f
|
723538.0
|
2017-06-01 00:00:00 UTC
|
This Is the Only Marijuana Stock to Rocket Higher by a Double-Digit Percentage Last Week
|
DEA
|
https://www.nasdaq.com/articles/only-marijuana-stock-rocket-higher-double-digit-percentage-last-week-2017-06-01
|
nan
|
nan
|
Chances are that if investors took a good look around, they'd struggle to find an industry growing as fast as the legal weed industry, which is what makes marijuana stocks such an attractive lure.
According to the "Marijuana Business Factbook 2017," a recently released report from Marijuana Business Daily , legal pot sales are expected to grow by 45% in 2018 from a range of $5.1 billion to $6.1 billion in 2017, and they're projected to triple as a whole in the U.S. between 2017 and 2021 to more than $17 billion. This rapid legal sales growth, combined with a major shift in the public's opinion toward cannabis, has some investors confident that marijuana stocks could be the greatest thing since sliced bread.
This budding marijuana stock skyrocketed last week
Of course, this has also led to some degree of emotional investing when it comes to marijuana stocks, which has a tendency of boosting volatility. Last week, one marijuana stock made waves by scorching higher by 12%, making it the only pot stock to have moved by a double-digit percentage in that time period. The company? None other than Insys Therapeutics (NASDAQ: INSY) .
The lone press release that appears to have influenced Insys' move last week affirmed that the Food and Drug Administration (FDA) had approved the final product label for Syndros, an oral dronabinol solution designed to treat chemotherapy-induced nausea and vomiting (CINV), as well as anorexia associated with AIDS. Syndros was approved by the FDA last summer, but it had to wait until the Drug Enforcement Agency (DEA) scheduled the drug, which occurred earlier this year (it was classed as schedule II).
According to the press release, which came out Wednesday, May 24, the FDA approval of its label was the last step needed prior to Syndros' launch, which is now expected in August 2017. Said CEO Saeed Motahari:
"The finalization of the approved product label for Syndros by the FDA marks a milestone for Insys and the last regulatory step required prior to the product's launch. ... We maintain our commitment to bringing novel therapeutic solutions to patients in need and are excited to launch Syndros in August."
Though Wall Street estimates vary widely, Syndros is expected to generate peak annual sales of as much as $300 million to $400 million .
Here's why Insys can't wait to launch Syndros
But there's another big reason why Insys is eager to launch Syndros: It's still dealing with fallout from Subsys, its only other FDA-approved drug, which is designed to treat breakthrough cancer pain.
Allegations and lawsuits suggest that up to 80% of Subsys prescriptions were being written for off-label indications. These suits, along with the bad PR, have hammered sales of Subsys, which generated approximately $330 million in sales in 2015. This year, Wall Street is forecasting that sales of Subsys could be half of what they were in 2015. In the process, Insys and its shareholders have witnessed healthy quarterly profits turn into modest quarterly losses.
The launch of Syndros may very well help take the spotlight off of Subsys, which could still take a couple of quarters for Insys to sort out. More importantly, Syndros should push Insys back to profitability, and it'll generate much-needed cash flow to continue expanding its pipeline. If Insys can indeed return to healthy profitability, it could be quite inexpensive at its current level.
Something marijuana stock investors should keep in mind
However, marijuana stock investors who may have considered adding Insys Therapeutics to their portfolios on the expected launch of Syndros in a few months' time should also take into consideration just how competitive the CINV market can be. There are dopamine agonists, NK-1 inhibitors, serotonin agonists, anti-anxiety drugs, and stomach-acid blockers already on pharmacy shelves and being used to treat CINV. These established medicines could be difficult for Syndros to unseat, and the drug's peak annual sales range forecast by Wall Street may be utopian.
Don't forget about the big picture when dealing with marijuana stocks.
Let's not also forget the disadvantages that marijuana-based drug developers regularly face. For instance, Insys will have had to wait more than a year prior to launching Syndros because of the need for scheduling from the DEA and label approval from the FDA. This wait may have allowed existing CINV medicines to further entrench themselves.
On a broader basis, marijuana companies face a mountain of disadvantages caused by the federal government's schedule I categorization. These disadvantages, which have the potential to extend to drug developers, can include an inability to secure basic banking services, as well as unfair tax treatment relative to normal businesses. U.S. tax code Section 280E disallows weed-based businesses from taking corporate tax deductions, thus forcing them to pay tax on their gross profits instead of net profits.
In short, even though marijuana stocks like Insys continue to dazzle with big gains, the macroeconomic outlook for the industry could easily go up in smoke. While Insys could arguably be among the most intriguing marijuana stocks given the fact that it has two FDA-approved products (one of which is cannabinoid-based), much of the industry is probably worth avoiding for the time being.
10 stocks we like better than Insys Therapeutics
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Insys Therapeutics wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of May 1, 2017
Sean Williams has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Syndros was approved by the FDA last summer, but it had to wait until the Drug Enforcement Agency (DEA) scheduled the drug, which occurred earlier this year (it was classed as schedule II). Here's why Insys can't wait to launch Syndros But there's another big reason why Insys is eager to launch Syndros: It's still dealing with fallout from Subsys, its only other FDA-approved drug, which is designed to treat breakthrough cancer pain. Don't forget about the big picture when dealing with marijuana stocks.
|
Here's why Insys can't wait to launch Syndros But there's another big reason why Insys is eager to launch Syndros: It's still dealing with fallout from Subsys, its only other FDA-approved drug, which is designed to treat breakthrough cancer pain. Syndros was approved by the FDA last summer, but it had to wait until the Drug Enforcement Agency (DEA) scheduled the drug, which occurred earlier this year (it was classed as schedule II). Don't forget about the big picture when dealing with marijuana stocks.
|
Here's why Insys can't wait to launch Syndros But there's another big reason why Insys is eager to launch Syndros: It's still dealing with fallout from Subsys, its only other FDA-approved drug, which is designed to treat breakthrough cancer pain. Syndros was approved by the FDA last summer, but it had to wait until the Drug Enforcement Agency (DEA) scheduled the drug, which occurred earlier this year (it was classed as schedule II). Don't forget about the big picture when dealing with marijuana stocks.
|
For instance, Insys will have had to wait more than a year prior to launching Syndros because of the need for scheduling from the DEA and label approval from the FDA. Syndros was approved by the FDA last summer, but it had to wait until the Drug Enforcement Agency (DEA) scheduled the drug, which occurred earlier this year (it was classed as schedule II). Here's why Insys can't wait to launch Syndros But there's another big reason why Insys is eager to launch Syndros: It's still dealing with fallout from Subsys, its only other FDA-approved drug, which is designed to treat breakthrough cancer pain.
|
f1535916-6232-496e-9f2a-4717f92c6bb3
|
723539.0
|
2017-05-31 00:00:00 UTC
|
EastGroup Properties (EGP) Shares Recent Business Activities
|
DEA
|
https://www.nasdaq.com/articles/eastgroup-properties-egp-shares-recent-business-activities-2017-05-31
|
nan
|
nan
|
EastGroup Properties, Inc.EGP recently announced its business activities. This includes shift in top management positions, transaction activities and sale of common shares.
The Jackson, MS-based real estate investment trust recruited two new executive officers as Senior Vice Presidents for the Texas and Western regions. Also, the company promoted several other people in various positions.
In April, the company acquired the fully-leased Broadmoor Commerce Park in Atlanta for $6.3 million. This multi-tenant business distribution building, comprising 84,000 square feet, is built on 17 acres of land. EastGroup Properties plans to develop another 107,000-square-foot distribution building on the site.
In the same month, the company purchased 30 acres of land in the Round Rock submarket of Austin for $5.3 million. In May, EastGroup Properties acquired Southpark Corporate Center 5-7 in Austin for $10.2 million.
In May, EastGroup Properties sold Stemmons Circle, a 99,000-square-foot building in Dallas for $5.1 million.
Shares of EastGroup Properties have outperformed the Zacks categorized REIT and Equity Trust - Other industry in the last six months. Shares of the company increased 18.5%, whereas the industry gained 9%. In the last thirty days, both its second-quarter and full-year 2017 FFO per share estimates remained unchanged.
Currently, EastGroup Properties carries a Zacks Rank #3 (Hold).
Investors interested in the REIT space, may consider better-ranked stocks like Easterly Government Properties, Inc. DEA , Gaming and Leisure Properties, Inc. GLPI and American Tower Corporation AMT , each carrying a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
In the last 30 days, Easterly Government Properties' FFO per share for second-quarter 2017 declined 3.2% to 30 cents.
In the last 30 days, Gaming and Leisure Properties' FFO per share for second-quarter 2017 increased 1.3% to 77 cents.
In the last 30 days, American Tower Corporation's FFO per share for second-quarter 2017 remained unchanged at $1.55.
Note: FFO, a widely used metric to gauge the performance of REITs, is obtained after adding depreciation and amortization and other non-cash expenses to net income. All EPS numbers presented in this write up represent FFO per share .
More Stock News: 8 Companies Verge on Apple-Like Run
Did you miss Apple's 9X stock explosion after they launched their iPhone in 2007? Now 2017 looks to be a pivotal year to get in on another emerging technology expected to rock the market. Demand could soar from almost nothing to $42 billion by 2025. Reports suggest it could save 10 million lives per decade which could in turn save $200 billion in U.S. healthcare costs.
A bonus Zacks Special Report names this breakthrough and the 8 best stocks to exploit it. Like Apple in 2007, these companies are already strong and coiling for potential mega-gains. Click to see them right now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
American Tower Corporation (REIT) (AMT): Free Stock Analysis Report
EastGroup Properties, Inc. (EGP): Free Stock Analysis Report
Gaming and Leisure Properties, Inc. (GLPI): Free Stock Analysis Report
Easterly Government Properties, Inc. (DEA): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Investors interested in the REIT space, may consider better-ranked stocks like Easterly Government Properties, Inc. DEA , Gaming and Leisure Properties, Inc. GLPI and American Tower Corporation AMT , each carrying a Zacks Rank #2 (Buy). Click to get this free report American Tower Corporation (REIT) (AMT): Free Stock Analysis Report EastGroup Properties, Inc. (EGP): Free Stock Analysis Report Gaming and Leisure Properties, Inc. (GLPI): Free Stock Analysis Report Easterly Government Properties, Inc. (DEA): Free Stock Analysis Report To read this article on Zacks.com click here. The Jackson, MS-based real estate investment trust recruited two new executive officers as Senior Vice Presidents for the Texas and Western regions.
|
Investors interested in the REIT space, may consider better-ranked stocks like Easterly Government Properties, Inc. DEA , Gaming and Leisure Properties, Inc. GLPI and American Tower Corporation AMT , each carrying a Zacks Rank #2 (Buy). Click to get this free report American Tower Corporation (REIT) (AMT): Free Stock Analysis Report EastGroup Properties, Inc. (EGP): Free Stock Analysis Report Gaming and Leisure Properties, Inc. (GLPI): Free Stock Analysis Report Easterly Government Properties, Inc. (DEA): Free Stock Analysis Report To read this article on Zacks.com click here. In the last 30 days, American Tower Corporation's FFO per share for second-quarter 2017 remained unchanged at $1.55.
|
Investors interested in the REIT space, may consider better-ranked stocks like Easterly Government Properties, Inc. DEA , Gaming and Leisure Properties, Inc. GLPI and American Tower Corporation AMT , each carrying a Zacks Rank #2 (Buy). Click to get this free report American Tower Corporation (REIT) (AMT): Free Stock Analysis Report EastGroup Properties, Inc. (EGP): Free Stock Analysis Report Gaming and Leisure Properties, Inc. (GLPI): Free Stock Analysis Report Easterly Government Properties, Inc. (DEA): Free Stock Analysis Report To read this article on Zacks.com click here. Shares of EastGroup Properties have outperformed the Zacks categorized REIT and Equity Trust - Other industry in the last six months.
|
Investors interested in the REIT space, may consider better-ranked stocks like Easterly Government Properties, Inc. DEA , Gaming and Leisure Properties, Inc. GLPI and American Tower Corporation AMT , each carrying a Zacks Rank #2 (Buy). Click to get this free report American Tower Corporation (REIT) (AMT): Free Stock Analysis Report EastGroup Properties, Inc. (EGP): Free Stock Analysis Report Gaming and Leisure Properties, Inc. (GLPI): Free Stock Analysis Report Easterly Government Properties, Inc. (DEA): Free Stock Analysis Report To read this article on Zacks.com click here. Currently, EastGroup Properties carries a Zacks Rank #3 (Hold).
|
e3c580e5-a3b9-491b-9114-2cdb71ff267b
|
723540.0
|
2017-05-31 00:00:00 UTC
|
Outfront Collaborates with Indonesian Ministry of Tourism
|
DEA
|
https://www.nasdaq.com/articles/outfront-collaborates-with-indonesian-ministry-of-tourism-2017-05-31
|
nan
|
nan
|
Outfront Media Inc.OUT , a leading provider of out-of-home advertising space, has expanded partnership with Indonesian Ministry of Tourism, Wonderful Indonesia. Out-front has deployed the Indonesian Ministry of Tourism's first-ever U.S. out-of-home campaign in the dynamic Times Square.
The Indonesian Ministry of Tourism aims to promote Indonesia and reach the target goal of 20 million visitors by 2019. Times Square is an extraordinary location, which gives promotional opportunities in the most dynamic atmosphere. Also, it gives a chance to reach out to more than 300,000 people who visit Times Square regularly.
The advertising campaigns showcase the picturesque landscape and culture of the country. Three billboards will be on display throughout the month of June, which coincides with the summer travel season. Three prime locations have been chosen for the deployment of the billboards - 7th Avenue & 48th Street, 5 Times Square & 41st Street and 727 Seventh Avenue between 48th & 49th Street.
Notably, in early May, Outfront reported first-quarter 2017 adjusted funds from operations (FFO) per share of 28 cents, in line with the Zacks Consensus Estimate. The figure, however, came lower than the year-ago quarter tally of 34 cents.
Shares of Outfront have underperformed the Zacks categorized REIT and Equity Trust - Other industry in the last six months. Shares of the company decreased 8.9%, whereas the industry gained 8.9%. In the last thirty days, both its second-quarter and full-year 2017 FFO per share estimates moved south.
Currently, Outfront carries a Zacks Rank #4 (Sell).
Investors interested in the REIT space, may consider better-ranked stocks like Easterly Government Properties, Inc. DEA , Gaming and Leisure Properties, Inc. GLPI and American Tower Corporation AMT , each carrying a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
In the last 30 days, Easterly Government Properties' FFO per share for second-quarter 2017 declined 3.2% to 30 cents.
In the last 30 days, Gaming and Leisure Properties' FFO per share for second-quarter 2017 increased 1.3% to 77 cents.
In the last 30 days, American Tower Corporation's FFO per share for second-quarter 2017 remained unchanged at $1.55.
Note: FFO, a widely used metric to gauge the performance of REITs, is obtained after adding depreciation and amortization and other non-cash expenses to net income. All EPS numbers presented in this write up represent FFO per share.
More Stock News: 8 Companies Verge on Apple-Like Run
Did you miss Apple's 9X stock explosion after they launched their iPhone in 2007? Now 2017 looks to be a pivotal year to get in on another emerging technology expected to rock the market. Demand could soar from almost nothing to $42 billion by 2025. Reports suggest it could save 10 million lives per decade which could in turn save $200 billion in U.S. healthcare costs.
A bonus Zacks Special Report names this breakthrough and the 8 best stocks to exploit it. Like Apple in 2007, these companies are already strong and coiling for potential mega-gains. Click to see them right now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
American Tower Corporation (REIT) (AMT): Free Stock Analysis Report
OUTFRONT Media Inc. (OUT): Free Stock Analysis Report
Gaming and Leisure Properties, Inc. (GLPI): Free Stock Analysis Report
Easterly Government Properties, Inc. (DEA): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Investors interested in the REIT space, may consider better-ranked stocks like Easterly Government Properties, Inc. DEA , Gaming and Leisure Properties, Inc. GLPI and American Tower Corporation AMT , each carrying a Zacks Rank #2 (Buy). Click to get this free report American Tower Corporation (REIT) (AMT): Free Stock Analysis Report OUTFRONT Media Inc. (OUT): Free Stock Analysis Report Gaming and Leisure Properties, Inc. (GLPI): Free Stock Analysis Report Easterly Government Properties, Inc. (DEA): Free Stock Analysis Report To read this article on Zacks.com click here. Outfront Media Inc.OUT , a leading provider of out-of-home advertising space, has expanded partnership with Indonesian Ministry of Tourism, Wonderful Indonesia.
|
Investors interested in the REIT space, may consider better-ranked stocks like Easterly Government Properties, Inc. DEA , Gaming and Leisure Properties, Inc. GLPI and American Tower Corporation AMT , each carrying a Zacks Rank #2 (Buy). Click to get this free report American Tower Corporation (REIT) (AMT): Free Stock Analysis Report OUTFRONT Media Inc. (OUT): Free Stock Analysis Report Gaming and Leisure Properties, Inc. (GLPI): Free Stock Analysis Report Easterly Government Properties, Inc. (DEA): Free Stock Analysis Report To read this article on Zacks.com click here. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
|
Investors interested in the REIT space, may consider better-ranked stocks like Easterly Government Properties, Inc. DEA , Gaming and Leisure Properties, Inc. GLPI and American Tower Corporation AMT , each carrying a Zacks Rank #2 (Buy). Click to get this free report American Tower Corporation (REIT) (AMT): Free Stock Analysis Report OUTFRONT Media Inc. (OUT): Free Stock Analysis Report Gaming and Leisure Properties, Inc. (GLPI): Free Stock Analysis Report Easterly Government Properties, Inc. (DEA): Free Stock Analysis Report To read this article on Zacks.com click here. Notably, in early May, Outfront reported first-quarter 2017 adjusted funds from operations (FFO) per share of 28 cents, in line with the Zacks Consensus Estimate.
|
Investors interested in the REIT space, may consider better-ranked stocks like Easterly Government Properties, Inc. DEA , Gaming and Leisure Properties, Inc. GLPI and American Tower Corporation AMT , each carrying a Zacks Rank #2 (Buy). Click to get this free report American Tower Corporation (REIT) (AMT): Free Stock Analysis Report OUTFRONT Media Inc. (OUT): Free Stock Analysis Report Gaming and Leisure Properties, Inc. (GLPI): Free Stock Analysis Report Easterly Government Properties, Inc. (DEA): Free Stock Analysis Report To read this article on Zacks.com click here. Out-front has deployed the Indonesian Ministry of Tourism's first-ever U.S. out-of-home campaign in the dynamic Times Square.
|
85fa984f-6271-4301-9852-6ce6ade95292
|
723541.0
|
2017-05-28 00:00:00 UTC
|
A First-of-Its-Kind Recreational Marijuana Bill Was Just Introduced in New Jersey
|
DEA
|
https://www.nasdaq.com/articles/first-its-kind-recreational-marijuana-bill-was-just-introduced-new-jersey-2017-05-28
|
nan
|
nan
|
Considering how unpopular marijuana was with the public during the mid-1990s, it's phenomenal to take a step back and witness just how rapidly pot's presence has grown in the United States over the past 21 years.
Marveling marijuana's expansion
In 1996, California became the first state to legalize the use of medical cannabis for compassionate use. Since California, 27 additional states and Washington, D.C., have followed. Five new states legalized medical weed last year alone, including Pennsylvania and Ohio, which chose to do so entirely through the legislative process.
In 2012, Washington and Colorado became the first two states to legalize recreational marijuana for adult use. Since then, six additional states have legalized recreational pot, too. If not for Arizona's recreational weed initiative falling 2% short of passing in November, it would have been a clean sweep for pot initiatives this past election.
This expansion is founded upon a fundamental shift of opinion from the public (and to some degree legislators) on marijuana. According to a Gallup poll in 2016, 60% of respondents want to see cannabis legalized nationally, which compares to just 25% in 1995. This shift also allowed North American sales of legal weed (which includes Mexico and Canada, as well as recreational and medical sales) to jump 34% last year to $6.9 billion, per ArcView Market Research.
And this expansion could be far from done in North America. Our neighbors to the north are contemplating a bill to legalize recreational weed by the summer of 2018, while Mexico's legislature recently passed a bill to legalize medical marijuana.
A first-of-its-kind recreational marijuana bill was just introduced
Within the U.S., a number of states could be readying for a run at recreational legalization in 2017 or 2018. However, one of the unlikeliest of candidates, New Jersey, just entered the picture in a big way.
Last week, Sen. Nicholas Scutari (D-NJ) introduced a bill that would legalize recreational marijuana in The Garden State. Said Scutari, "It's time to end the detrimental effect these archaic laws are having on our residents and our state."
The move to introduce a recreational weed bill is a bit surprising given that Gov. Chris Christie (R-NJ) is one of the most ardent opponents of marijuana's expansion. In fact, during his presidential campaign Christie alluded that federal law would have been reinstated had he won the Republican ticket and national election over the Democratic candidate. In other words, Christie would almost certainly reject a legalization initiative that gets to his desk, assuming approval in the state's legislature.
But, Scutari also notes that he's looking toward the future. New Jersey has a gubernatorial election this November, and plenty of Democrats are lined up in an attempt to unseat Christie. A majority of these leading candidates have voiced their willingness to legalize recreational pot if a measure were brought to their desk.
However, it's not Scutari's forward-thinking bill that makes it so unique -- it's what would (and wouldn't) be legalized.
According to the bill, marijuana products would face a tax for five years ranging from 7% to 25%, and a special regulatory division known as the Division of Marijuana Enforcement would be created to oversee the industry. Adults ages 21 and over would be allowed to possess up to one ounce of cannabis, along with 16 ounces of cannabis-infused edibles, 72 ounces of marijuana tinctures, drinks, and oils, and seven grams of concentrates.
Now here's the interesting component of this bill: home cultivation would not be allowed ! If passed, it would make New Jersey the first state to legalize recreational marijuana without allowing at least some legal home cultivation.
But with Christie as governor, the chances of this bill passing into law in its current form are slim-to-none.
A mountain of hurdles crush businesses and marijuana stock investors
Admittedly, New Jersey introducing a recreational pot bill was a huge surprise. However, it doesn't overshadow the fact that the weed industry is facing a number of major hurdles that aren't likely to go away or dissipate anytime soon.
Plain and simple, marijuana remains a schedule I substance at the federal level. This means it has no recognized medical benefits, and it's illegal. This illegal status makes it very difficult for research companies to run clinical trials involving cannabis, and it makes life tough for companies that operate in the weed business.
For example, marijuana-based businesses have little or no access to basic banking services, which forces many to deal solely in cash. This can be a major security concern, and it's also quite the detriment to growth given a lack of access to lines of credit or traditional loans.
Pot companies also get the short end of the stick come tax time. Unlike normal businesses that are able to take corporate income-tax deductions, businesses that sell a federally illicit substance aren't allowed to take corporate tax deductions. This result in weed companies paying an exceptionally higher tax rate than normal businesses.
These disadvantages, along with a White House that doesn't seem keen on the idea of marijuana's expansion, are what make investing in marijuana stocks so dangerous.
Take a drug developer like Insys Therapeutics (NASDAQ: INSY) as an example. Its Food and Drug Administration-approved drug Syndros, an oral dronabinol solution that's essentially the pharmaceutical version of tetrahydrocannabinol, the psychoactive component of cannabis, was approved last year but won't hit pharmacy shelves until the second-half of 2017. The nearly one-year wait between approval and eventual launch for this drug to treat chemotherapy-induced nausea and vomiting and anorexia associated with AIDS is because of the need for scheduling from the Drug Enforcement Agency (DEA). As a schedule II substance, which is what the DEA labeled it earlier this year, it'll face tight regulatory oversight, which will make sales growth challenging for Insys.
Other pot stocks within the U.S., both big and small, will face similar challenges from either the Food and Drug Administration or federal law. Even with public opinion changing rapidly and legal sales of weed growing by a double-digit percentage, your best bet is to stay away from marijuana stocks for the time being and cross your fingers for change at the federal level.
10 stocks we like better than Insys Therapeutics
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Insys Therapeutics wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of May 1, 2017
Sean Williams has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
As a schedule II substance, which is what the DEA labeled it earlier this year, it'll face tight regulatory oversight, which will make sales growth challenging for Insys. For example, marijuana-based businesses have little or no access to basic banking services, which forces many to deal solely in cash. These disadvantages, along with a White House that doesn't seem keen on the idea of marijuana's expansion, are what make investing in marijuana stocks so dangerous.
|
For example, marijuana-based businesses have little or no access to basic banking services, which forces many to deal solely in cash. These disadvantages, along with a White House that doesn't seem keen on the idea of marijuana's expansion, are what make investing in marijuana stocks so dangerous. The nearly one-year wait between approval and eventual launch for this drug to treat chemotherapy-induced nausea and vomiting and anorexia associated with AIDS is because of the need for scheduling from the Drug Enforcement Agency (DEA).
|
For example, marijuana-based businesses have little or no access to basic banking services, which forces many to deal solely in cash. These disadvantages, along with a White House that doesn't seem keen on the idea of marijuana's expansion, are what make investing in marijuana stocks so dangerous. The nearly one-year wait between approval and eventual launch for this drug to treat chemotherapy-induced nausea and vomiting and anorexia associated with AIDS is because of the need for scheduling from the Drug Enforcement Agency (DEA).
|
For example, marijuana-based businesses have little or no access to basic banking services, which forces many to deal solely in cash. These disadvantages, along with a White House that doesn't seem keen on the idea of marijuana's expansion, are what make investing in marijuana stocks so dangerous. The nearly one-year wait between approval and eventual launch for this drug to treat chemotherapy-induced nausea and vomiting and anorexia associated with AIDS is because of the need for scheduling from the Drug Enforcement Agency (DEA).
|
a62d57c0-fe65-42c6-ac16-d50dd163ad6d
|
723542.0
|
2017-05-26 00:00:00 UTC
|
Will it be Wise to Hold Cousins (CUZ) in Your Portfolio?
|
DEA
|
https://www.nasdaq.com/articles/will-it-be-wise-to-hold-cousins-cuz-in-your-portfolio-2017-05-26
|
nan
|
nan
|
We updated our research report on Cousins Properties IncorporatedCUZ on May 25.
This Atlanta, GA-based real estate investment trust (REIT) is engaged in the acquisition, ownership, development and management of upscale office and mixed-use properties throughout the Sunbelt markets of the U.S., with special focus on Arizona, Florida, Georgia, North Carolina, and Texas. In first-quarter 2017, the company reported better-than-expected funds from operations (FFO) per share. The quarter witnessed solid leasing activity and strong net operating income (NOI) growth.
Cousins Properties enjoys an unmatched portfolio of Class A office assets, concentrated over the high-growth Sun Belt market. Importantly, the Sun Belt market exhibits above-average job growth due to long-term demographic trends. Also, assets in these markets command higher rents compared to the broader market. In fact, around 83% of the company's office portfolio is situated in the best urban sub markets in each city, offering the company ample scope for growth.
However, intense competition, high dependence on office portfolio and any rise in interest rate are concerns before Cousins Properties.
In the last 30 days, the company's second-quarter and full-year 2017 FFO per share estimates remained unchanged. Shares of Cousins Properties have outperformed the Zacks categorized REIT and Equity Trust - Other industry in the last three months. While the stock increased 0.4%, the industry lost 0.3%.
Currently, Cousins Properties carries a Zacks Rank #3 (Hold).
Investors interested in the REIT space, may consider better-ranked stocks like Easterly Government Properties, Inc. DEA , Gaming and Leisure Properties, Inc. GLPI and Equity LifeStyle Properties, Inc. ELS , each carrying a Zacks Rank #2. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
In the last 30 days, Easterly Government Properties' FFO per share for second-quarter 2017 remained unchanged at 31 cents.
In the last 30 days, Gaming and Leisure Properties' FFO per share for second-quarter 2017 increased 1.3% to 77 cents.
In the last 30 days, Equity LifeStyle Properties' FFO per share for second-quarter 2017 remained unchanged at 81 cents.
Note: FFO, a widely used metric to gauge the performance of REITs, is obtained after adding depreciation and amortization and other non-cash expenses to net income. All EPS numbers presented in this write up represent FFO per share .
Looking for Ideas with Even Greater Upside?
Today's investment ideas are short-term, directly based on our proven 1 to 3 month indicator. In addition, I invite you to consider our long-term opportunities. These rare trades look to start fast with strong Zacks Ranks, but carry through with double and triple-digit profit potential. Starting now, you can look inside our home run, value, and stocks under $10 portfolios, plus more. Click here for a peek at this private information >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Equity Lifestyle Properties, Inc. (ELS): Free Stock Analysis Report
Cousins Properties Incorporated (CUZ): Free Stock Analysis Report
Gaming and Leisure Properties, Inc. (GLPI): Free Stock Analysis Report
Easterly Government Properties, Inc. (DEA): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Investors interested in the REIT space, may consider better-ranked stocks like Easterly Government Properties, Inc. DEA , Gaming and Leisure Properties, Inc. GLPI and Equity LifeStyle Properties, Inc. ELS , each carrying a Zacks Rank #2. Looking for Ideas with Even Greater Upside? Today's investment ideas are short-term, directly based on our proven 1 to 3 month indicator.
|
Investors interested in the REIT space, may consider better-ranked stocks like Easterly Government Properties, Inc. DEA , Gaming and Leisure Properties, Inc. GLPI and Equity LifeStyle Properties, Inc. ELS , each carrying a Zacks Rank #2. Click to get this free report Equity Lifestyle Properties, Inc. (ELS): Free Stock Analysis Report Cousins Properties Incorporated (CUZ): Free Stock Analysis Report Gaming and Leisure Properties, Inc. (GLPI): Free Stock Analysis Report Easterly Government Properties, Inc. (DEA): Free Stock Analysis Report To read this article on Zacks.com click here. Looking for Ideas with Even Greater Upside?
|
Investors interested in the REIT space, may consider better-ranked stocks like Easterly Government Properties, Inc. DEA , Gaming and Leisure Properties, Inc. GLPI and Equity LifeStyle Properties, Inc. ELS , each carrying a Zacks Rank #2. Click to get this free report Equity Lifestyle Properties, Inc. (ELS): Free Stock Analysis Report Cousins Properties Incorporated (CUZ): Free Stock Analysis Report Gaming and Leisure Properties, Inc. (GLPI): Free Stock Analysis Report Easterly Government Properties, Inc. (DEA): Free Stock Analysis Report To read this article on Zacks.com click here. Looking for Ideas with Even Greater Upside?
|
Investors interested in the REIT space, may consider better-ranked stocks like Easterly Government Properties, Inc. DEA , Gaming and Leisure Properties, Inc. GLPI and Equity LifeStyle Properties, Inc. ELS , each carrying a Zacks Rank #2. Looking for Ideas with Even Greater Upside? Today's investment ideas are short-term, directly based on our proven 1 to 3 month indicator.
|
06da6dd1-d5e0-4e94-89e2-3a02dfcb2c96
|
723543.0
|
2017-05-25 00:00:00 UTC
|
Sun Communities (SUI) Begins Offering 3.5M Common Shares
|
DEA
|
https://www.nasdaq.com/articles/sun-communities-sui-begins-offering-3.5m-common-shares-2017-05-25
|
nan
|
nan
|
Sun Communities, Inc.SUI announced the commencement of a public offering of 3.5 million common shares. The move is likely to add to the financial flexibility of this Southfield, MI-based residential real estate investment trust (REIT).
Sun Communities is engaged in owning, operating & financing manufactured housing communities concentrated in the mid-western & southeastern US. As of Mar 31, 2017, the company owned or had an interest in 342 communities comprising around 118,000 developed sites, located in 29 states and Ontario, Canada.
The company plans to utilize the net proceeds generated from the offering for repayment of outstanding borrowings under the revolving loan under its senior credit facility. Also, the company intends to use the proceeds for funding future acquisitions, meeting working capital requirements and general corporate purposes.
Shares of Sun Communities have outperformed the Zacks categorized REIT and Equity Trust - Residential industry in the last three months. Shares of the company have increased 5.1%, whereas the industry has edged up 0.6%. In the last seven days, both its second-quarter and full-year 2017 funds from operations (FFO) per share estimates moved south.
Currently, Sun Communities carries a Zacks Rank #2 (Buy).
Investors interested in the REIT space, may consider better-ranked stocks like Easterly Government Properties, Inc. DEA , Gaming and Leisure Properties, Inc. GLPI and DiamondRock Hospitality Company DRH , each carrying a Zacks Rank #2. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
In the last 30 days, Easterly Government Properties' FFO per share for second-quarter 2017 remained unchanged at 31 cents.
In the last 30 days, Gaming and Leisure Properties' FFO per share for second-quarter 2017 increased 1.3% to 77 cents.
In the last 30 days, DiamondRock Hospitality Company' FFO per share for second-quarter 2017 remained unchanged at 31 cents.
Note: FFO, a widely used metric to gauge the performance of REITs, is obtained after adding depreciation and amortization and other non-cash expenses to net income. All EPS numbers presented in this write up represent FFO per share .
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look. See the pot trades we're targeting>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Sun Communities, Inc. (SUI): Free Stock Analysis Report
Diamondrock Hospitality Company (DRH): Free Stock Analysis Report
Gaming and Leisure Properties, Inc. (GLPI): Free Stock Analysis Report
Easterly Government Properties, Inc. (DEA): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Investors interested in the REIT space, may consider better-ranked stocks like Easterly Government Properties, Inc. DEA , Gaming and Leisure Properties, Inc. GLPI and DiamondRock Hospitality Company DRH , each carrying a Zacks Rank #2. Click to get this free report Sun Communities, Inc. (SUI): Free Stock Analysis Report Diamondrock Hospitality Company (DRH): Free Stock Analysis Report Gaming and Leisure Properties, Inc. (GLPI): Free Stock Analysis Report Easterly Government Properties, Inc. (DEA): Free Stock Analysis Report To read this article on Zacks.com click here. The company plans to utilize the net proceeds generated from the offering for repayment of outstanding borrowings under the revolving loan under its senior credit facility.
|
Investors interested in the REIT space, may consider better-ranked stocks like Easterly Government Properties, Inc. DEA , Gaming and Leisure Properties, Inc. GLPI and DiamondRock Hospitality Company DRH , each carrying a Zacks Rank #2. Click to get this free report Sun Communities, Inc. (SUI): Free Stock Analysis Report Diamondrock Hospitality Company (DRH): Free Stock Analysis Report Gaming and Leisure Properties, Inc. (GLPI): Free Stock Analysis Report Easterly Government Properties, Inc. (DEA): Free Stock Analysis Report To read this article on Zacks.com click here. In the last 30 days, Easterly Government Properties' FFO per share for second-quarter 2017 remained unchanged at 31 cents.
|
Investors interested in the REIT space, may consider better-ranked stocks like Easterly Government Properties, Inc. DEA , Gaming and Leisure Properties, Inc. GLPI and DiamondRock Hospitality Company DRH , each carrying a Zacks Rank #2. Click to get this free report Sun Communities, Inc. (SUI): Free Stock Analysis Report Diamondrock Hospitality Company (DRH): Free Stock Analysis Report Gaming and Leisure Properties, Inc. (GLPI): Free Stock Analysis Report Easterly Government Properties, Inc. (DEA): Free Stock Analysis Report To read this article on Zacks.com click here. In the last 30 days, DiamondRock Hospitality Company' FFO per share for second-quarter 2017 remained unchanged at 31 cents.
|
Investors interested in the REIT space, may consider better-ranked stocks like Easterly Government Properties, Inc. DEA , Gaming and Leisure Properties, Inc. GLPI and DiamondRock Hospitality Company DRH , each carrying a Zacks Rank #2. Click to get this free report Sun Communities, Inc. (SUI): Free Stock Analysis Report Diamondrock Hospitality Company (DRH): Free Stock Analysis Report Gaming and Leisure Properties, Inc. (GLPI): Free Stock Analysis Report Easterly Government Properties, Inc. (DEA): Free Stock Analysis Report To read this article on Zacks.com click here. Shares of Sun Communities have outperformed the Zacks categorized REIT and Equity Trust - Residential industry in the last three months.
|
88cebe53-b0bd-445e-b62e-730f429f7bd2
|
723544.0
|
2017-05-24 00:00:00 UTC
|
DDR Prices $450 Million Senior Unsecured Notes Offering
|
DEA
|
https://www.nasdaq.com/articles/ddr-prices-%24450-million-senior-unsecured-notes-offering-2017-05-24
|
nan
|
nan
|
DDR Corp.DDR announced that it has priced an offering of $450 million worth senior unsecured notes. This pricing of offering of notes is likely to add to the financial flexibility of the Beachwood, OH-based retail real estate investment trust (REIT).
The offering, which is slated to be due on 2027, bears a rate of interest of 4.7%. Interest payment on the notes will be made on a semi-annual basis on Jun 1 and Dec 1. The first payment will be made on Dec 1, 2017. Subject to the satisfaction of certain customary closing conditions, the offering is likely to close on or around May 26, 2017.
DDR is engaged in owning, acquiring, developing, redeveloping, leasing and managing shopping centers, especially in the high-growth areas of the country. In first-quarter 2017, the company reported funds from operations (FFO) of 30 cents per share, beating the Zacks Consensus Estimate by a penny. The company plans to utilize the net proceeds generated from the offering for repayment of debts under its $750 million unsecured revolving credit facility and for general corporate purposes. The general corporate purposes may include repayment of secured and unsecured debt.
Shares of DDR have underperformed the Zacks categorized REIT and Equity Trust - Retail industry in the last three months. Shares of the company decreased 38.9%, whereas the industry lost 10.6%. In the last 30 days, its second quarter and full-year 2017 funds from operations (FFO) per share estimates remained unchanged.
Currently, DDR carries a Zacks Rank #3 (Hold).
Investors interested in the REIT space, may consider better-ranked stocks like Easterly Government Properties, Inc. DEA , Gaming and Leisure Properties, Inc. GLPI and DiamondRock Hospitality Company DRH , each carrying a Zacks Rank #2. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
In the last 30 days, Easterly Government Properties' FFO per share for second-quarter 2017 remained unchanged at 31 cents.
In the last 30 days, Gaming and Leisure Properties' FFO per share for second-quarter 2017 increased 1.3% to 77 cents.
In the last 30 days, DiamondRock Hospitality Company' FFO per share for second-quarter 2017 remained unchanged at 31 cents.
Note: FFO, a widely used metric to gauge the performance of REITs, is obtained after adding depreciation and amortization and other non-cash expenses to net income. All EPS numbers presented in this write up represent FFO per share .
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look. See the pot trades we're targeting>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
DDR Corp. (DDR): Free Stock Analysis Report
Diamondrock Hospitality Company (DRH): Free Stock Analysis Report
Gaming and Leisure Properties, Inc. (GLPI): Free Stock Analysis Report
Easterly Government Properties, Inc. (DEA): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Investors interested in the REIT space, may consider better-ranked stocks like Easterly Government Properties, Inc. DEA , Gaming and Leisure Properties, Inc. GLPI and DiamondRock Hospitality Company DRH , each carrying a Zacks Rank #2. Click to get this free report DDR Corp. (DDR): Free Stock Analysis Report Diamondrock Hospitality Company (DRH): Free Stock Analysis Report Gaming and Leisure Properties, Inc. (GLPI): Free Stock Analysis Report Easterly Government Properties, Inc. (DEA): Free Stock Analysis Report To read this article on Zacks.com click here. This pricing of offering of notes is likely to add to the financial flexibility of the Beachwood, OH-based retail real estate investment trust (REIT).
|
Investors interested in the REIT space, may consider better-ranked stocks like Easterly Government Properties, Inc. DEA , Gaming and Leisure Properties, Inc. GLPI and DiamondRock Hospitality Company DRH , each carrying a Zacks Rank #2. Click to get this free report DDR Corp. (DDR): Free Stock Analysis Report Diamondrock Hospitality Company (DRH): Free Stock Analysis Report Gaming and Leisure Properties, Inc. (GLPI): Free Stock Analysis Report Easterly Government Properties, Inc. (DEA): Free Stock Analysis Report To read this article on Zacks.com click here. In the last 30 days, Easterly Government Properties' FFO per share for second-quarter 2017 remained unchanged at 31 cents.
|
Investors interested in the REIT space, may consider better-ranked stocks like Easterly Government Properties, Inc. DEA , Gaming and Leisure Properties, Inc. GLPI and DiamondRock Hospitality Company DRH , each carrying a Zacks Rank #2. Click to get this free report DDR Corp. (DDR): Free Stock Analysis Report Diamondrock Hospitality Company (DRH): Free Stock Analysis Report Gaming and Leisure Properties, Inc. (GLPI): Free Stock Analysis Report Easterly Government Properties, Inc. (DEA): Free Stock Analysis Report To read this article on Zacks.com click here. In first-quarter 2017, the company reported funds from operations (FFO) of 30 cents per share, beating the Zacks Consensus Estimate by a penny.
|
Click to get this free report DDR Corp. (DDR): Free Stock Analysis Report Diamondrock Hospitality Company (DRH): Free Stock Analysis Report Gaming and Leisure Properties, Inc. (GLPI): Free Stock Analysis Report Easterly Government Properties, Inc. (DEA): Free Stock Analysis Report To read this article on Zacks.com click here. Investors interested in the REIT space, may consider better-ranked stocks like Easterly Government Properties, Inc. DEA , Gaming and Leisure Properties, Inc. GLPI and DiamondRock Hospitality Company DRH , each carrying a Zacks Rank #2. Interest payment on the notes will be made on a semi-annual basis on Jun 1 and Dec 1.
|
861d44ba-6975-4ec8-bfef-c9057a6ac279
|
723545.0
|
2017-05-23 00:00:00 UTC
|
Highwoods to Develop MetLife's Office Building in Weston
|
DEA
|
https://www.nasdaq.com/articles/highwoods-to-develop-metlifes-office-building-in-weston-2017-05-23
|
nan
|
nan
|
Highwoods Properties, Inc.HIW announced that it has been selected by MetLife, Inc. MET to develop a third office building for its global technology campus in Cary's mixed-use Weston planned unit development (PUD). The Raleigh, NC-based real estate investment trust (REIT) will invest $63 million for this 219,000 square feet, fully pre-leased building. Construction on this build-to-suit project is slated to begin this summer and is likely to be complete in first-quarter 2019.
Notably, Highwoods developed the first two buildings for MetLife in 2015. The addition of the third building in the 655,000-square-foot campus took the REIT's total investment to around $172 million. Also, with this project, the development pipeline of Highwoods has risen to 2 million square feet. This amounts to an expected investment of around $612 million, which is 85% pre-leased on a dollar-weighted basis.
Headquartered in NY, MetLife is a leading provider of insurance and financial services to a broad spectrum of individual and institutional customers and is a trusted and highly regarded customer of Highwoods. The successful growth of MetLife in Weston indicates the availability of strong technology-oriented employment pool that attracts companies to this area.
Shares of Highwoods underperformed the Zacks categorized REIT and Equity Trust - Other industry in the last three months. Shares of the company decreased 3.5%, whereas the industry lost 0.8%. However, in the last 30 days, its full-year 2017 FFO per share estimates moved up.
Currently, both Highwoods and MetLife carry a Zacks Rank #3 (Hold).
Investors interested in the REIT space, may consider better-ranked stocks like Easterly Government Properties, Inc. DEA and Gaming and Leisure Properties, Inc. GLPI , each carrying a Zacks Rank #2. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
In the last 30 days, Easterly Government Properties' FFO per share for second-quarter 2017 remained unchanged at 31 cents.
In the last 30 days, Gaming and Leisure Properties' FFO per share for second-quarter 2017 increased 1.3% to 77 cents.
Note: FFO, a widely used metric to gauge the performance of REITs, is obtained after adding depreciation and amortization and other non-cash expenses to net income. All EPS numbers presented in this write up represent FFO per share .
Zacks' 2017 IPO Watch List
Before looking into the stocks mentioned above, you may want to get a head start on potential tech IPOs that are popping up on Zacks' radar. Imagine being in the first wave of investors to jump on a company with almost unlimited growth potential? This Special Report gives you the current scoop on 5 that may go public at any time.
One has driven from 0 to a $68 billion valuation in 8 years. Four others are a little less obvious but already show jaw-dropping growth. Download this IPO Watch List today for free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
MetLife, Inc. (MET): Free Stock Analysis Report
Highwoods Properties, Inc. (HIW): Free Stock Analysis Report
Gaming and Leisure Properties, Inc. (GLPI): Free Stock Analysis Report
Easterly Government Properties, Inc. (DEA): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Investors interested in the REIT space, may consider better-ranked stocks like Easterly Government Properties, Inc. DEA and Gaming and Leisure Properties, Inc. GLPI , each carrying a Zacks Rank #2. Click to get this free report MetLife, Inc. (MET): Free Stock Analysis Report Highwoods Properties, Inc. (HIW): Free Stock Analysis Report Gaming and Leisure Properties, Inc. (GLPI): Free Stock Analysis Report Easterly Government Properties, Inc. (DEA): Free Stock Analysis Report To read this article on Zacks.com click here. The successful growth of MetLife in Weston indicates the availability of strong technology-oriented employment pool that attracts companies to this area.
|
Investors interested in the REIT space, may consider better-ranked stocks like Easterly Government Properties, Inc. DEA and Gaming and Leisure Properties, Inc. GLPI , each carrying a Zacks Rank #2. Click to get this free report MetLife, Inc. (MET): Free Stock Analysis Report Highwoods Properties, Inc. (HIW): Free Stock Analysis Report Gaming and Leisure Properties, Inc. (GLPI): Free Stock Analysis Report Easterly Government Properties, Inc. (DEA): Free Stock Analysis Report To read this article on Zacks.com click here. The Raleigh, NC-based real estate investment trust (REIT) will invest $63 million for this 219,000 square feet, fully pre-leased building.
|
Investors interested in the REIT space, may consider better-ranked stocks like Easterly Government Properties, Inc. DEA and Gaming and Leisure Properties, Inc. GLPI , each carrying a Zacks Rank #2. Click to get this free report MetLife, Inc. (MET): Free Stock Analysis Report Highwoods Properties, Inc. (HIW): Free Stock Analysis Report Gaming and Leisure Properties, Inc. (GLPI): Free Stock Analysis Report Easterly Government Properties, Inc. (DEA): Free Stock Analysis Report To read this article on Zacks.com click here. Highwoods Properties, Inc.HIW announced that it has been selected by MetLife, Inc. MET to develop a third office building for its global technology campus in Cary's mixed-use Weston planned unit development (PUD).
|
Click to get this free report MetLife, Inc. (MET): Free Stock Analysis Report Highwoods Properties, Inc. (HIW): Free Stock Analysis Report Gaming and Leisure Properties, Inc. (GLPI): Free Stock Analysis Report Easterly Government Properties, Inc. (DEA): Free Stock Analysis Report To read this article on Zacks.com click here. Investors interested in the REIT space, may consider better-ranked stocks like Easterly Government Properties, Inc. DEA and Gaming and Leisure Properties, Inc. GLPI , each carrying a Zacks Rank #2. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
|
438342e2-ee17-4bcd-abc2-16b26b1a5299
|
723546.0
|
2017-05-23 00:00:00 UTC
|
Simon Property (SPG) Plans to Invest $1B in its Portfolio
|
DEA
|
https://www.nasdaq.com/articles/simon-property-spg-plans-to-invest-%241b-in-its-portfolio-2017-05-23
|
nan
|
nan
|
Simon Property Group, Inc.SPG , the Indianapolis, IN-based retail real estate investment trust (REIT), is continuing with its strategy to invest in its portfolio. The underlying idea is to augment the number of visitors and enhance their experience.
Simon Property is engaged in acquiring, owning and leasing a diverse portfolio of shopping malls. The company reported first-quarter 2017 funds from operations (FFO) of $2.74 per share, missing the Zacks Consensus Estimate by 2 cents. Despite choppy retail environment during the quarter, the company reaffirmed its earlier outlook.
Importantly, increasing consumer purchases through the Internet has emerged as a pressing concern for retail REITs, including Simon Property, which is striving to counter the pressure through various initiatives. Given this backdrop, the latest initiatives to lift the shopping experience of the customers is very significant.
In fact, in the last five years, the retail REIT invested over $5 billion in development projects and intends to spend around $1 billion each in 2017 and 2018. Several initiatives are likely to be taken by the company to enhance the premier shopping, dining and entertainment destinations across the U.S. These include investing in various physical projects, renovation, interior enhancements, redevelopment, redevelopment, addition of new restaurants and eateries, mixed-use developments etc.
Shares of Simon Property have underperformed the Zacks categorized REIT and Equity Trust - Retail industry in the last three months. Shares of the company have decreased 14.5%, whereas the industry has lost 10%. Moreover, in the last 30 days, both its second quarter and full-year 2017 FFO per share estimates moved down.
Currently, Simon Property carries a Zacks Rank #3 (Hold).
Investors interested in the REIT space, may consider better-ranked stocks like Easterly Government Properties, Inc. DEA , Gaming and Leisure Properties, Inc. GLPI and DiamondRock Hospitality Company DRH , each carrying a Zacks Rank #2. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
In the last 30 days, Easterly Government Properties' FFO per share for second-quarter 2017 remained unchanged at 31 cents.
In the last 30 days, Gaming and Leisure Properties' FFO per share for second-quarter 2017 increased 1.3% to 77 cents.
In the last 30 days, DiamondRock Hospitality Company' FFO per share for second-quarter 2017 remained unchanged at 31 cents.
Note: FFO, a widely used metric to gauge the performance of REITs, is obtained after adding depreciation and amortization and other non-cash expenses to net income. All EPS numbers presented in this write up represent FFO per share .
Zacks' 2017 IPO Watch List
Before looking into the stocks mentioned above, you may want to get a head start on potential tech IPOs that are popping up on Zacks' radar. Imagine being in the first wave of investors to jump on a company with almost unlimited growth potential? This Special Report gives you the current scoop on 5 that may go public at any time.
One has driven from 0 to a $68 billion valuation in 8 years. Four others are a little less obvious but already show jaw-dropping growth. Download this IPO Watch List today for free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Simon Property Group, Inc. (SPG): Free Stock Analysis Report
Diamondrock Hospitality Company (DRH): Free Stock Analysis Report
Gaming and Leisure Properties, Inc. (GLPI): Free Stock Analysis Report
Easterly Government Properties, Inc. (DEA): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
The underlying idea is to augment the number of visitors and enhance their experience. Investors interested in the REIT space, may consider better-ranked stocks like Easterly Government Properties, Inc. DEA , Gaming and Leisure Properties, Inc. GLPI and DiamondRock Hospitality Company DRH , each carrying a Zacks Rank #2. Click to get this free report Simon Property Group, Inc. (SPG): Free Stock Analysis Report Diamondrock Hospitality Company (DRH): Free Stock Analysis Report Gaming and Leisure Properties, Inc. (GLPI): Free Stock Analysis Report Easterly Government Properties, Inc. (DEA): Free Stock Analysis Report To read this article on Zacks.com click here.
|
Investors interested in the REIT space, may consider better-ranked stocks like Easterly Government Properties, Inc. DEA , Gaming and Leisure Properties, Inc. GLPI and DiamondRock Hospitality Company DRH , each carrying a Zacks Rank #2. Click to get this free report Simon Property Group, Inc. (SPG): Free Stock Analysis Report Diamondrock Hospitality Company (DRH): Free Stock Analysis Report Gaming and Leisure Properties, Inc. (GLPI): Free Stock Analysis Report Easterly Government Properties, Inc. (DEA): Free Stock Analysis Report To read this article on Zacks.com click here. The underlying idea is to augment the number of visitors and enhance their experience.
|
Investors interested in the REIT space, may consider better-ranked stocks like Easterly Government Properties, Inc. DEA , Gaming and Leisure Properties, Inc. GLPI and DiamondRock Hospitality Company DRH , each carrying a Zacks Rank #2. Click to get this free report Simon Property Group, Inc. (SPG): Free Stock Analysis Report Diamondrock Hospitality Company (DRH): Free Stock Analysis Report Gaming and Leisure Properties, Inc. (GLPI): Free Stock Analysis Report Easterly Government Properties, Inc. (DEA): Free Stock Analysis Report To read this article on Zacks.com click here. The underlying idea is to augment the number of visitors and enhance their experience.
|
The underlying idea is to augment the number of visitors and enhance their experience. Investors interested in the REIT space, may consider better-ranked stocks like Easterly Government Properties, Inc. DEA , Gaming and Leisure Properties, Inc. GLPI and DiamondRock Hospitality Company DRH , each carrying a Zacks Rank #2. Click to get this free report Simon Property Group, Inc. (SPG): Free Stock Analysis Report Diamondrock Hospitality Company (DRH): Free Stock Analysis Report Gaming and Leisure Properties, Inc. (GLPI): Free Stock Analysis Report Easterly Government Properties, Inc. (DEA): Free Stock Analysis Report To read this article on Zacks.com click here.
|
15b5ed1f-bbbf-4c31-809c-4a460b6d06af
|
723547.0
|
2017-05-22 00:00:00 UTC
|
Liberty Property (LPT) Rides on Growing Industrial Market
|
DEA
|
https://www.nasdaq.com/articles/liberty-property-lpt-rides-on-growing-industrial-market-2017-05-22
|
nan
|
nan
|
We updated our research report on Liberty Property TrustLPT on May 19.
This Malvern, PA-based real estate investment trust (REIT) is engaged in leasing, property management, development, construction management, design management and related services for a portfolio of industrial and office properties. In first-quarter 2017, the company reported funds from operations (FFO) of 60 cents per share, surpassing the Zacks Consensus Estimate of 58 cents.
In the last 30 days, the company's full-year 2017 FFO per share estimates moved up. In fact, the fundamentals of the industrial market is strong, backed by growing demand for industrial properties amid manageable supply, which has led to strong rent growth, increased occupancy and development opportunities. Therefore, given its premium quality industrial portfolio located in upscale locations, pro-business environment and continued e-commerce demand, Liberty Property is poised to gain.
The company is enhancing its portfolio mix through continued divestitures of office properties. However, the near-term dilution effect of such moves on earnings is unavoidable. Also, operational risks associated with huge construction pipeline and rise in interest rates are concerns before Liberty Property.
Shares of Liberty Property outperformed the Zacks categorized REIT and Equity Trust - Other industry in the last three months. Shares of the company increased 4.8%, whereas the industry lost 0.1%.
Currently, Liberty Property carries a Zacks Rank #3 (Hold).
Investors interested in the REIT space, may consider stocks like Easterly Government Properties, Inc. DEA , Gaming and Leisure Properties, Inc. GLPI and DiamondRock Hospitality Company DRH , each carrying a Zacks Rank #2. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
In the last 30 days, Easterly Government Properties' FFO per share for second-quarter 2017 remained unchanged at 31 cents.
In the last 30 days, Gaming and Leisure Properties' FFO per share for second-quarter 2017 increased 1.3% to 77 cents.
In the last 30 days, DiamondRock Hospitality Company' FFO per share for second-quarter 2017 remained unchanged at 31 cents.
Note: FFO, a widely used metric to gauge the performance of REITs, is obtained after adding depreciation and amortization and other non-cash expenses to net income. All EPS numbers presented in this write up represent FFO per share .
Zacks' 2017 IPO Watch List
Before looking into the stocks mentioned above, you may want to get a head start on potential tech IPOs that are popping up on Zacks' radar. Imagine being in the first wave of investors to jump on a company with almost unlimited growth potential? This Special Report gives you the current scoop on 5 that may go public at any time.
One has driven from 0 to a $68 billion valuation in 8 years. Four others are a little less obvious but already show jaw-dropping growth. Download this IPO Watch List today for free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Diamondrock Hospitality Company (DRH): Free Stock Analysis Report
Gaming and Leisure Properties, Inc. (GLPI): Free Stock Analysis Report
Easterly Government Properties, Inc. (DEA): Free Stock Analysis Report
Liberty Property Trust (LPT): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Investors interested in the REIT space, may consider stocks like Easterly Government Properties, Inc. DEA , Gaming and Leisure Properties, Inc. GLPI and DiamondRock Hospitality Company DRH , each carrying a Zacks Rank #2. Click to get this free report Diamondrock Hospitality Company (DRH): Free Stock Analysis Report Gaming and Leisure Properties, Inc. (GLPI): Free Stock Analysis Report Easterly Government Properties, Inc. (DEA): Free Stock Analysis Report Liberty Property Trust (LPT): Free Stock Analysis Report To read this article on Zacks.com click here. Also, operational risks associated with huge construction pipeline and rise in interest rates are concerns before Liberty Property.
|
Investors interested in the REIT space, may consider stocks like Easterly Government Properties, Inc. DEA , Gaming and Leisure Properties, Inc. GLPI and DiamondRock Hospitality Company DRH , each carrying a Zacks Rank #2. Click to get this free report Diamondrock Hospitality Company (DRH): Free Stock Analysis Report Gaming and Leisure Properties, Inc. (GLPI): Free Stock Analysis Report Easterly Government Properties, Inc. (DEA): Free Stock Analysis Report Liberty Property Trust (LPT): Free Stock Analysis Report To read this article on Zacks.com click here. In the last 30 days, Easterly Government Properties' FFO per share for second-quarter 2017 remained unchanged at 31 cents.
|
Investors interested in the REIT space, may consider stocks like Easterly Government Properties, Inc. DEA , Gaming and Leisure Properties, Inc. GLPI and DiamondRock Hospitality Company DRH , each carrying a Zacks Rank #2. Click to get this free report Diamondrock Hospitality Company (DRH): Free Stock Analysis Report Gaming and Leisure Properties, Inc. (GLPI): Free Stock Analysis Report Easterly Government Properties, Inc. (DEA): Free Stock Analysis Report Liberty Property Trust (LPT): Free Stock Analysis Report To read this article on Zacks.com click here. This Malvern, PA-based real estate investment trust (REIT) is engaged in leasing, property management, development, construction management, design management and related services for a portfolio of industrial and office properties.
|
Investors interested in the REIT space, may consider stocks like Easterly Government Properties, Inc. DEA , Gaming and Leisure Properties, Inc. GLPI and DiamondRock Hospitality Company DRH , each carrying a Zacks Rank #2. Click to get this free report Diamondrock Hospitality Company (DRH): Free Stock Analysis Report Gaming and Leisure Properties, Inc. (GLPI): Free Stock Analysis Report Easterly Government Properties, Inc. (DEA): Free Stock Analysis Report Liberty Property Trust (LPT): Free Stock Analysis Report To read this article on Zacks.com click here. In the last 30 days, the company's full-year 2017 FFO per share estimates moved up.
|
fd3b2511-7f3d-4f80-a11e-133466a2841b
|
723548.0
|
2017-05-22 00:00:00 UTC
|
661 Million Reasons to Like These 3 Marijuana Stocks
|
DEA
|
https://www.nasdaq.com/articles/661-million-reasons-these-3-marijuana-stocks-2017-05-22
|
nan
|
nan
|
Why should investors like marijuana stocks? For some, the rationale might be the enormous market potential. For others, it could be simply that many marijuana stocks have soared over the last year or so.
There are plenty of reasons for investors to like three marijuana stocks in particular -- GW Pharmaceuticals (NASDAQ: GWPH) , Insys Therapeutics (NASDAQ: INSY) , and Aphria (NASDAQOTH: APHQF) . In fact, there are at least 661 million reasons. That's the amount of cash in U.S. dollars that the three companies have combined. Here's why the cash stockpiles held by GW, Insys, and Apria are important.
GW Pharmaceuticals: Enough money to launch Epidiolex
At the end of the first quarter, GW Pharmaceuticals reported cash and cash equivalents totaling $383.9 million. A large chunk of that amount (roughly $290 million) was raised in July 2016 through a public stock offering.
This cash position is critical for GW Pharmaceuticals, because the biotech remains unprofitable. GW posted a loss in the first quarter of more than $43 million. That means the company must continue to pull from its cash to fund operations. The good news is that GW Pharmaceuticals should be in good shape to make it at least through 2018 without having to raise more money.
Even better news is that the company could have significantly more revenue coming in by the time it needs more cash. GW Pharmaceuticals expects to file for U.S. regulatory approval of cannabinoid epilepsy drug Epidiolex in the second half of this year. Estimates are all over the map for how much revenue Epidiolex might make, with bears projecting peak sales of $300 million and bulls projecting peak sales of $3 billion.
Insys Therapeutics: Cash to get past Subsys woes
Insys Therapeutics enjoyed a nice cash stockpile of $155.3 million at the end of the first quarter, including cash, cash equivalents, and short-term investments. The company's cash position has deteriorated, though, due to falling sales of opioid pain drug Subsys.
Like GW, though, Insys could have help on the way with a new product. Insys' new product is Syndros, a cannabinoid drug for treating chemically induced nausea and vomiting (CINV) and anorexia associated with weight loss in patients with AIDS. The company won approval from the U.S. Food and Drug Administration (FDA) in July 2016, but had to wait for scheduling by the U.S. Drug Enforcement Agency (DEA). The DEA announced in March 2017 that Syndros would be a schedule II controlled substance. Insys now awaits final labeling from the FDA before it can market the drug.
Insys has great expectations for Syndros. It will be the first liquid form of dronabinol on the market. That gives it several competitive advantages, including ease of adjusting of doses by physicians and faster onset of action. Piper Jaffray thinks Syndros could reach peak annual sales of $300 million to $400 million. Insys' solid cash position should allow the company to plow on despite problems with Subsys to see if Syndros becomes as successful as hoped -- and prove short-sellers wrong about the stock.
Aphria: Cash to expand
Aphria reported $122 million in cash, cash equivalents, and short-term investments at the end of its most-recent quarter. Unlike GW Pharmaceuticals and Insys Therapeutics, Aphria is profitable. The marijuana grower posted earnings of $4.95 million on revenue of $5.12 million last quarter.
So why is Aphria's cash position still important? Aphria is one of less than 40 authorized providers of medical marijuana in Canada. The country is on track to allow legalized use of recreational marijuana by the summer of 2018. That means the potential market for Aphria is about to explode. The company's cash position puts it in great shape to expand.
It wouldn't be surprising to see larger marijuana growers in Canada scoop up smaller players. Aphria acquired CannWay Pharmaceuticals last year in an all-stock transaction. The company probably wishes it could have used cash instead: Aphria's share price is up more than 400% since it bought CannWay. Now, Aphria has plenty of cash and could very well use some of it in anticipation of reaching a much larger market next year.
Put your cash on the line?
Should investors buy these three marijuana stocks just because they have plenty of cash? No. There are lots of other factors to consider, including probable earnings growth, valuation, and competitive dynamics.
Still, though, the fact that GW Pharmaceuticals, Insys Therapeutics, and Aphria have strong cash positions makes them more desirable than they'd otherwise be. Thanks to their cash stockpiles, these three are in better shape for the future than many other marijuana stocks.
10 stocks we like better than GW Pharmaceuticals
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and GW Pharmaceuticals wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of May 1, 2017
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
The company won approval from the U.S. Food and Drug Administration (FDA) in July 2016, but had to wait for scheduling by the U.S. Drug Enforcement Agency (DEA). The DEA announced in March 2017 that Syndros would be a schedule II controlled substance. GW Pharmaceuticals expects to file for U.S. regulatory approval of cannabinoid epilepsy drug Epidiolex in the second half of this year.
|
The company won approval from the U.S. Food and Drug Administration (FDA) in July 2016, but had to wait for scheduling by the U.S. Drug Enforcement Agency (DEA). The DEA announced in March 2017 that Syndros would be a schedule II controlled substance. There are plenty of reasons for investors to like three marijuana stocks in particular -- GW Pharmaceuticals (NASDAQ: GWPH) , Insys Therapeutics (NASDAQ: INSY) , and Aphria (NASDAQOTH: APHQF) .
|
The company won approval from the U.S. Food and Drug Administration (FDA) in July 2016, but had to wait for scheduling by the U.S. Drug Enforcement Agency (DEA). The DEA announced in March 2017 that Syndros would be a schedule II controlled substance. GW Pharmaceuticals: Enough money to launch Epidiolex At the end of the first quarter, GW Pharmaceuticals reported cash and cash equivalents totaling $383.9 million.
|
The company won approval from the U.S. Food and Drug Administration (FDA) in July 2016, but had to wait for scheduling by the U.S. Drug Enforcement Agency (DEA). The DEA announced in March 2017 that Syndros would be a schedule II controlled substance. Why should investors like marijuana stocks?
|
eae42544-36f1-469a-b461-95cf1bafa951
|
723549.0
|
2017-05-19 00:00:00 UTC
|
Could Amazon Steamroller These Pharmacy Stocks?
|
DEA
|
https://www.nasdaq.com/articles/could-amazon-steamroller-these-pharmacy-stocks-2017-05-19
|
nan
|
nan
|
First, the big bookstores. Then, major retailers. Are pharmacy chains the next to be steamrollered by Amazon (NASDAQ: AMZN) ?
CNBC reported that the giant e-commerce company is exploring the possibility of expanding into the pharmacy market. According to the report, Amazon plans to hire a team and is in "deep discussion with industry experts." Could the stocks of major pharmacy retailers CVS Health (NYSE: CVS) and Walgreens Boots Alliance (NASDAQ: WBA) be in trouble in the not-too-distant future from a disruptive competitor with deep pockets?
A huge opportunity
It makes sense that Amazon would eye the pharmacy market. A whopping $425 billion was spent on prescription drugs in 2015 -- a record high. QuintilesIMS projects that prescription drug spending could reach $640 million by 2020.
The rapid rise of high-deductible health insurance plans is another key reason Amazon would be interested in the pharmacy market. According to a Kaiser Family Foundation survey, only 4% of covered workers in the U.S. had high-deductible plans in 2006. The number had soared to 29% by last year.
High deductibles cause Americans to pay much more attention to the costs of healthcare. And that presents an opportunity for Amazon. The company's current e-commerce strategy should enable Amazon to have lower-cost operations than brick-and-mortar pharmacies like CVS and Walgreens. Americans are already used to finding good deals on Amazon for other products. If the company offered prescription drugs also, there would likely be an immediate (and sizable) market.
Should CVS and Walgreens be worried?
CVS and Walgreens don't have reason to worry just yet, though. Amazon hasn't committed to moving forward into the pharmacy market at this point.
There are significantly more regulatory hurdles to clear with filling prescriptions than there are for selling books and other retail products. The Centers for Medicare and Medicaid Services (CMS) established standards for e-prescribing that must be followed. The U.S. Drug Enforcement Administration (DEA) has even more stringent requirements for electronically filling prescriptions for controlled substances, including many current pain medications on the market.
With Amazon's resources, though, regulatory hurdles shouldn't be a big factor in keeping the e-tailer from entering the pharmacy market. Actually, there don't appear to be any obstacles Amazon couldn't overcome if it chooses to move forward. The biggest prerequisite is acquiring the necessary industry expertise, and Amazon appears to already be taking steps to address this by recruiting a team of pharmacy industry experts.
Over the long run, though, CVS and Walgreens probably should be worried. Over 43% of CVS Health's total revenue in the first quarter of 2017 came from its retail/long-term care segment. More important, almost 79% of the company's gross profit stemmed from the segment. Nearly 85% of Walgreens Boots Alliance's first-quarter revenue and 93% of its adjusted operating income were generated by its U.S. and international retail pharmacies.
At least some of that revenue and earnings could be at risk if Amazon jumps into the pharmacy market. Of course, how successful Amazon might be depends on how much lower its prescription drug costs are compared to CVS and Walgreens. Unless costs are significantly lower, Americans might prefer to stay with their traditional pharmacies.
An especially vulnerable area
One area in which Amazon could potentially make significant inroads is in competing with mail-order pharmacies. CVS Health has 13 specialty mail-order pharmacies and four mail service dispensing pharmacies. Walgreens and Prime Therapeutics recently combined their mail-order pharmacy operations as part of a strategic alliance announced last year.
Here's the kicker with CVS Health's and Walgreens' mail-order pharmacy businesses, though: The operations are part of the two companies' pharmacy benefits management (PBM) units, and not their retail units. It's possible that Amazon could decide to not only compete in the retail prescription drug market, but also go after the PBM market.
Amazon hired Mark Lyons away from Premera Blue Cross earlier this year to build an internal PBM. It wouldn't be too huge of a stretch to expand into offering PBM services to external customers. Such a move wouldn't just affect CVS Health and Walgreens; large PBM Express Scripts could also be hurt if Amazon successfully launched a PBM.
Steamroller blues
I don't think CVS Health and Walgreens investors should be singing James Taylor's "Steamroller Blues" -- at least not yet. Even if Amazon decides to move into the pharmacy market, it could take a while for it to get its operations fully up to speed.
It's also possible Amazon's efforts could flop. Another e-commerce player, Drugstore.com, gave the online pharmacy business a shot, beginning operations when the dot-com craze of the late 90s was in full fever. Walgreens bought the small company in 2011 but shut it down last year.
However, I predict Amazon will enter the pharmacy market and will be very successful. That will hurt CVS Health and Walgreens. Whether or not Amazon will be, as James Taylor sang, a "hefty hunk of steaming junk" that rolls over the big pharmacy retailers remains to be seen.
10 stocks we like better than Amazon
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now...and Amazon wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of May 1, 2017.
Keith Speights owns shares of Express Scripts. The Motley Fool owns shares of and recommends Amazon. The Motley Fool owns shares of Express Scripts. The Motley Fool recommends CVS Health and Quintiles IMS Holdings. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
The U.S. Drug Enforcement Administration (DEA) has even more stringent requirements for electronically filling prescriptions for controlled substances, including many current pain medications on the market. Americans are already used to finding good deals on Amazon for other products. Another e-commerce player, Drugstore.com, gave the online pharmacy business a shot, beginning operations when the dot-com craze of the late 90s was in full fever.
|
Americans are already used to finding good deals on Amazon for other products. The U.S. Drug Enforcement Administration (DEA) has even more stringent requirements for electronically filling prescriptions for controlled substances, including many current pain medications on the market. Could the stocks of major pharmacy retailers CVS Health (NYSE: CVS) and Walgreens Boots Alliance (NASDAQ: WBA) be in trouble in the not-too-distant future from a disruptive competitor with deep pockets?
|
Americans are already used to finding good deals on Amazon for other products. The U.S. Drug Enforcement Administration (DEA) has even more stringent requirements for electronically filling prescriptions for controlled substances, including many current pain medications on the market. Could the stocks of major pharmacy retailers CVS Health (NYSE: CVS) and Walgreens Boots Alliance (NASDAQ: WBA) be in trouble in the not-too-distant future from a disruptive competitor with deep pockets?
|
Americans are already used to finding good deals on Amazon for other products. The U.S. Drug Enforcement Administration (DEA) has even more stringent requirements for electronically filling prescriptions for controlled substances, including many current pain medications on the market. It's possible that Amazon could decide to not only compete in the retail prescription drug market, but also go after the PBM market.
|
fb112008-95aa-41a1-bd6d-9bdc74201de4
|
723550.0
|
2017-05-18 00:00:00 UTC
|
Retail Properties of America Inks Lease With Ulta Beauty
|
DEA
|
https://www.nasdaq.com/articles/retail-properties-of-america-inks-lease-with-ulta-beauty-2017-05-18
|
nan
|
nan
|
Oak Brook, IL-based retail real estate investment trust (REIT), Retail Properties of America, Inc.RPAI , announced that Ulta Beauty, Inc. ULTA , has inked a new lease at Huebner Oaks. Slated to open in fall 2017, the Bolingbrook, IL-based beauty retailer will occupy 8,000 square feet of retail space in the 287,000 square feet Huebner Oaks.
With the opening of the center, Ulta Beauty, the premier beauty destination for cosmetics, fragrance, skin, hair care products and salon services, will be joining top retailers like Bath & Body Works, Victoria's Secret, Gap Chico's, Old Navy and REI, along with other national retailers.
Huebner Oaks, which is 99% leased, can be easily accessed from I-10 and boasts a strong retail and restaurant lineup. The addition of Ulta Beauty to this center is likely to benefit Retail Properties of America going forward.
Shares of Retail Properties of America underperformed the Zacks categorized REIT and Equity Trust - Retail industry in the last three months. Shares of the company decreased 16.1%, whereas the industry lost 11%.
Currently, Retail Properties of America carries a Zacks Rank #3 (Hold), whereas Ulta Beauty has a Zacks Rank #2 (Buy).
Investors interested in the REIT space, may consider stocks like Easterly Government Properties, Inc. DEA and Gaming and Leisure Properties, Inc. GLPI , each carrying a Zacks Rank #2. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
In the last 30 days, Easterly Government Properties' funds from operations (FFO) per share for second-quarter 2017 remained unchanged at 31 cents.
In the last 30 days, Gaming and Leisure Properties' FFO per share for second-quarter 2017 moved up 1.3% to 77 cents.
Note: FFO, a widely used metric to gauge the performance of REITs, is obtained after adding depreciation and amortization and other non-cash expenses to net income. All EPS numbers presented in this write up represent FFO per share .
Will You Make a Fortune on the Shift to Electric Cars?
Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.
With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.
It's not the one you think.
See This Ticker Free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Ulta Beauty Inc. (ULTA): Free Stock Analysis Report
Retail Properties of America, Inc. (RPAI): Free Stock Analysis Report
Gaming and Leisure Properties, Inc. (GLPI): Free Stock Analysis Report
Easterly Government Properties, Inc. (DEA): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Investors interested in the REIT space, may consider stocks like Easterly Government Properties, Inc. DEA and Gaming and Leisure Properties, Inc. GLPI , each carrying a Zacks Rank #2. Here's another stock idea to consider. Click to get this free report Ulta Beauty Inc. (ULTA): Free Stock Analysis Report Retail Properties of America, Inc. (RPAI): Free Stock Analysis Report Gaming and Leisure Properties, Inc. (GLPI): Free Stock Analysis Report Easterly Government Properties, Inc. (DEA): Free Stock Analysis Report To read this article on Zacks.com click here.
|
Investors interested in the REIT space, may consider stocks like Easterly Government Properties, Inc. DEA and Gaming and Leisure Properties, Inc. GLPI , each carrying a Zacks Rank #2. Click to get this free report Ulta Beauty Inc. (ULTA): Free Stock Analysis Report Retail Properties of America, Inc. (RPAI): Free Stock Analysis Report Gaming and Leisure Properties, Inc. (GLPI): Free Stock Analysis Report Easterly Government Properties, Inc. (DEA): Free Stock Analysis Report To read this article on Zacks.com click here. Here's another stock idea to consider.
|
Click to get this free report Ulta Beauty Inc. (ULTA): Free Stock Analysis Report Retail Properties of America, Inc. (RPAI): Free Stock Analysis Report Gaming and Leisure Properties, Inc. (GLPI): Free Stock Analysis Report Easterly Government Properties, Inc. (DEA): Free Stock Analysis Report To read this article on Zacks.com click here. Investors interested in the REIT space, may consider stocks like Easterly Government Properties, Inc. DEA and Gaming and Leisure Properties, Inc. GLPI , each carrying a Zacks Rank #2. Here's another stock idea to consider.
|
Investors interested in the REIT space, may consider stocks like Easterly Government Properties, Inc. DEA and Gaming and Leisure Properties, Inc. GLPI , each carrying a Zacks Rank #2. Here's another stock idea to consider. Click to get this free report Ulta Beauty Inc. (ULTA): Free Stock Analysis Report Retail Properties of America, Inc. (RPAI): Free Stock Analysis Report Gaming and Leisure Properties, Inc. (GLPI): Free Stock Analysis Report Easterly Government Properties, Inc. (DEA): Free Stock Analysis Report To read this article on Zacks.com click here.
|
01ec8695-966f-4042-a394-2d0df7164d42
|
723551.0
|
2017-05-16 00:00:00 UTC
|
Should You Get Rid of FARMLAND PARTNERS (FPI) Now?
|
DEA
|
https://www.nasdaq.com/articles/should-you-get-rid-of-farmland-partners-fpi-now-2017-05-16
|
nan
|
nan
|
Similar to wise buying decisions, exiting certain underperformers at the right time helps maximize portfolio returns. Selling off losers can be difficult, but if both the share price and estimates are falling, it could be time to get rid of the security before more losses hit your portfolio.
One such stock that you may want to consider dropping is FARMLAND PARTNERS INC.FPI , which has witnessed a significant price decline in the past four weeks, and it has seen negative earnings estimate revisions for the current quarter and the current year. A Zacks Rank #4 (Sell) further confirms weakness in FPI.
A key reason for this move has been the negative trend in earnings estimate revisions. For the full year, we have seen 1 estimate moving down in the past 30 days, compared with no upward revisions. This trend has caused the consensus estimate to trend lower, going from 50 cents a share a month ago to its current level of 44 cents.
Also, for the current quarter, FARMLAND PARTNERS has seen 1 downward estimate revision versus no revisions in the opposite direction, dragging the consensus estimate down to 9 cents a share from 11 cents over the past 30 days.
The stock also has seen some pretty dismal trading lately, as the share price has dropped 7.6% in the past month.
Farmland Partners Inc. Price and Consensus
Farmland Partners Inc. Price and Consensus | Farmland Partners Inc. Quote
So it may not be a good decision to keep this stock in your portfolio anymore, at least if you don't have a long time horizon to wait.
If you are still interested in the REIT and Equity Trust - Other industry, you may instead consider a better-ranked stock - EASTERLY GOVERNMENT PROPERTIES, INC. DEA . The stock currently holds a Zacks Rank #1 (Strong Buy) and may be a better selection at this time.
5 Trades Could Profit "Big-League" from Trump Policies
If the stocks above spark your interest, wait until you look into companies primed to make substantial gains from Washington's changing course.
Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals, tariffs, lower taxes, higher interest rates, and spending surges in defense and infrastructure.
See these buy recommendations now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Easterly Government Properties, Inc. (DEA): Free Stock Analysis Report
Farmland Partners Inc. (FPI): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
If you are still interested in the REIT and Equity Trust - Other industry, you may instead consider a better-ranked stock - EASTERLY GOVERNMENT PROPERTIES, INC. DEA . Click to get this free report Easterly Government Properties, Inc. (DEA): Free Stock Analysis Report Farmland Partners Inc. (FPI): Free Stock Analysis Report To read this article on Zacks.com click here. Selling off losers can be difficult, but if both the share price and estimates are falling, it could be time to get rid of the security before more losses hit your portfolio.
|
Click to get this free report Easterly Government Properties, Inc. (DEA): Free Stock Analysis Report Farmland Partners Inc. (FPI): Free Stock Analysis Report To read this article on Zacks.com click here. If you are still interested in the REIT and Equity Trust - Other industry, you may instead consider a better-ranked stock - EASTERLY GOVERNMENT PROPERTIES, INC. DEA . One such stock that you may want to consider dropping is FARMLAND PARTNERS INC.FPI , which has witnessed a significant price decline in the past four weeks, and it has seen negative earnings estimate revisions for the current quarter and the current year.
|
Click to get this free report Easterly Government Properties, Inc. (DEA): Free Stock Analysis Report Farmland Partners Inc. (FPI): Free Stock Analysis Report To read this article on Zacks.com click here. If you are still interested in the REIT and Equity Trust - Other industry, you may instead consider a better-ranked stock - EASTERLY GOVERNMENT PROPERTIES, INC. DEA . Also, for the current quarter, FARMLAND PARTNERS has seen 1 downward estimate revision versus no revisions in the opposite direction, dragging the consensus estimate down to 9 cents a share from 11 cents over the past 30 days.
|
If you are still interested in the REIT and Equity Trust - Other industry, you may instead consider a better-ranked stock - EASTERLY GOVERNMENT PROPERTIES, INC. DEA . Click to get this free report Easterly Government Properties, Inc. (DEA): Free Stock Analysis Report Farmland Partners Inc. (FPI): Free Stock Analysis Report To read this article on Zacks.com click here. One such stock that you may want to consider dropping is FARMLAND PARTNERS INC.FPI , which has witnessed a significant price decline in the past four weeks, and it has seen negative earnings estimate revisions for the current quarter and the current year.
|
898fbc8f-1ea2-4893-bb08-1eb02055122c
|
723552.0
|
2017-05-10 00:00:00 UTC
|
Here's Why Marijuana Stock Insys Therapeutics Briefly Plunged As Much As 11%
|
DEA
|
https://www.nasdaq.com/articles/heres-why-marijuana-stock-insys-therapeutics-briefly-plunged-much-11-2017-05-10
|
nan
|
nan
|
What happened
Shares of Insys Therapeutics (NASDAQ: INSY) , a biopharmaceutical company that develops medicines to treat pain and other supportive-care products, tumbled by as much as 11% during Wednesdays trading session before recovering to finish lower by less than 2%. The reason for the volatile trading can probably be traced to carryover from the company's first-quarter earnings release before the opening bell on Tuesday.
So what
For the quarter, Insys wound up reporting $36 million in sales, which was down by more than 40% from the $60.4 million recorded in Q1 2016. Insys has been struggling as allegations and lawsuits surrounding Subsys, its sublingual breakthrough cancer-pain medication, have mounted. These suits suggest that the bulk of Subsys' sales were being made for off-label indications. In response, Subsys' sales have taken a big hit in recent quarters. In fact, the company took a $2.1 million charge in Q1 2017 for "excess and obsolete Subsys inventory." Comparatively, Wall Street had been looking for $37.8 million in sales.
As Subsys sales have dropped, so has Insys' bottom line. The company wound up reporting a net loss of $6.5 million, or $0.09 per share, which reversed a year-ago profit of $2.3 million, or $0.03 per share. The $0.09-per-share loss was actually $0.01 better than expected.
The reason we're seeing such concern from investors is there's no clear indication when Insys' Subsys issues will be resolved. The company has already reduced its research-and-development expenses, but when Subsys' sales are tracking nearly 50% lower than they were less than two years ago, no amount of cost cuts has been able to return Insys back to profitability.
Now what
The potential saving grace and wild card for Insys is going to be Syndros, an oral dronabinol solution that was approved by the Food and Drug Administration to treat chemotherapy-induced nausea and vomiting and anorexia associated with AIDS last summer. This drug is essentially a pharmaceutical version of tetrahydrocannabinol (THC), the psychoactive component of cannabis.
The hold-up for Syndros' launch had been its need for scheduling from the U.S. Drug Enforcement Agency (DEA). Earlier this year, the DEA categorized Syndros as a Schedule II product, clearing the way for a second-half-of-2017 launch. Some estimates suggest this marijuana-based drug could yield $300 million or more in peak annual sales, which would be a near-complete replacement of Subsys sales at their peak.
If Insys can stabilize Subsys' sales, put litigation surrounding Subsys in the past, and successfully launch Syndros later this year, it could become an intriguing turnaround candidate. What investors have to realize, though, is this will be a multi-year turnaround, and not something that'll happen overnight. This Fool would encourage biotech investors and those interested in marijuana stocks to add Insys Therapeutics to their watchlist.
10 stocks we like better than Insys Therapeutics
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Insys Therapeutics wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of May 1, 2017
Sean Williams has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
The hold-up for Syndros' launch had been its need for scheduling from the U.S. Drug Enforcement Agency (DEA). Earlier this year, the DEA categorized Syndros as a Schedule II product, clearing the way for a second-half-of-2017 launch. The reason for the volatile trading can probably be traced to carryover from the company's first-quarter earnings release before the opening bell on Tuesday.
|
The hold-up for Syndros' launch had been its need for scheduling from the U.S. Drug Enforcement Agency (DEA). Earlier this year, the DEA categorized Syndros as a Schedule II product, clearing the way for a second-half-of-2017 launch. What happened Shares of Insys Therapeutics (NASDAQ: INSY) , a biopharmaceutical company that develops medicines to treat pain and other supportive-care products, tumbled by as much as 11% during Wednesdays trading session before recovering to finish lower by less than 2%.
|
The hold-up for Syndros' launch had been its need for scheduling from the U.S. Drug Enforcement Agency (DEA). Earlier this year, the DEA categorized Syndros as a Schedule II product, clearing the way for a second-half-of-2017 launch. What happened Shares of Insys Therapeutics (NASDAQ: INSY) , a biopharmaceutical company that develops medicines to treat pain and other supportive-care products, tumbled by as much as 11% during Wednesdays trading session before recovering to finish lower by less than 2%.
|
The hold-up for Syndros' launch had been its need for scheduling from the U.S. Drug Enforcement Agency (DEA). Earlier this year, the DEA categorized Syndros as a Schedule II product, clearing the way for a second-half-of-2017 launch. So what For the quarter, Insys wound up reporting $36 million in sales, which was down by more than 40% from the $60.4 million recorded in Q1 2016.
|
391f91cb-a352-4e52-acd1-bc1b2c864d9b
|
723553.0
|
2017-05-07 00:00:00 UTC
|
Neutral Zone Infraction: NFL Commissioner Roger Goodell Weighs in on Marijuana
|
DEA
|
https://www.nasdaq.com/articles/neutral-zone-infraction-nfl-commissioner-roger-goodell-weighs-marijuana-2017-05-07
|
nan
|
nan
|
While there have been bumps in the road for the legal marijuana industry, the past two decades have mostly been marked by progress. In 1996, California became the first state to legalize medical cannabis for compassionate-use patients. Since then, 27 other states and Washington, D.C. have followed. We've also witnessed residents in eight states legalize recreational pot since 2012.
This steady state-level expansion has led to the recent rapid growth in legal weed sales. In North America last year, legal pot sales jumped 34%, to $6.9 billion, according to ArcView Market Research, with Colorado seeing a very clear surge in legal marijuana sales. After generating $135 million in tax and licensing fee revenue on $996 million in legal sales in 2015, the Centennial State generated nearly $200 million in tax and licensing revenue last year as legal sales surged past $1.3 billion.
At the heart of this expansion, and beyond just the desire of select state governments to boost tax revenue, is a softening stance on pot from the American public. National pollster Gallup, which has conducted marijuana polls for nearly 50 years, reported that support for nationwide legalization rose to 60% in 2016, an all-time high.
Similar figures were found in a recent CBS News poll, where 61% supported the nationwide legalization of pot compared to only 33% who opposed it. That's up 10% since April 2014, and 21% since Oct. 2011.
An NFL figurehead weighs in on marijuana (and you won't like what he said)
However, not everyone is happy to see marijuana gaining steam. On Capitol Hill, U.S. Attorney General Jeff Sessions could arguably be described as cannabis' most ardent opponent. In February, White House press secretary Sean Spicer warned of tougher federal recreational weed enforcement in the months to come, though it's still debatable how much tougher the federal government will get.
Even more recently, NFL Commissioner Roger Goodell, who is himself no stranger to scrutiny in the public's eye, weighed in on the possibility of medical and/or recreational marijuana use in the NFL. As you probably correctly surmised, Goodell tore down any hope that the NFL would become the first major sport -- and by far the most popular sport in the U.S. -- to allow its players to use marijuana without facing drug-testing repercussions.
In a recent radio interview on ESPN's Mike & Mike , Goodell had this to say about medical marijuana use (quotes courtesy of Sports Illustrated ):
If this sounds eerily familiar, it's because the U.S. Drug Enforcement Agency (DEA) passed on the opportunity to reschedule, or de-schedule, marijuana this past summer. Two petitions had asked the regulatory agency to re-examine cannabis, but the DEA found that there wasn't sufficient clinical evidence to suggest that marijuana had medical benefits that outweighed its risks.
Goodell also weighed in on recreational weed use, saying:
Why Goodell's comments matter
Some of you might be wondering why Goodell even deserves the time of day when it comes to the debate on marijuana. The answer is simple: It's all about ambassadors and impressions.
Think about it this way: Nearly all major retail brands tend to lean on well-known ambassadors to help improve customer engagement with a brand. Under Armour leans on the NBA's Steph Curry and other big names, whereas Nike has LeBron James and a cadre of other leading athletes across a variety of sports representing its brand. The opinions of these celebrities and athletes help shape the public's opinion and drive engagement.
Even though Roger Goodell is the antithesis of the word "popular," he still represents the most popular sport/brand in this country - a sport that had an average of 16.5 million viewers per game during the 2016 season. That's a lot of eyeballs and opinions that could be influenced by Goodell's commentary, including lawmakers on Capitol Hill.
What we're left with is a growing bifurcation between the American public and those who make laws. Increasingly, the public would like to see the federal government softening its stance on pot, or legalizing marijuana altogether. Lawmakers, on the other hand, want more clinical evidence that marijuana is safe. Mind you, the Catch-22 is that this evidence is almost impossible to come by because of pot's strict schedule I status, which makes getting clearance to run scientific studies involving marijuana difficult.
The end result here is that Goodell's commentary is just another blow to marijuana stock investors who remain hopeful that the recreational weed industry will flourish in the United States. The U.S. marijuana industry already struggles to obtain basic banking services and is disallowed from taking normal business deductions. Goodell's comments simply reinforce that the highly popular NFL won't be a staging ground in support of change, at least for the time being, leaving investors to wonder where their white knight catalyst for change is going to come from.
10 stocks we like better than Wal-Mart
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, the Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Wal-Mart wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of April 3, 2017
The author(s) may have a position in any stocks mentioned.
Sean Williams has no position in any stocks mentioned. The Motley Fool owns shares of and recommends Nike, Under Armour (A Shares), and Under Armour (C Shares). The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Two petitions had asked the regulatory agency to re-examine cannabis, but the DEA found that there wasn't sufficient clinical evidence to suggest that marijuana had medical benefits that outweighed its risks. In a recent radio interview on ESPN's Mike & Mike , Goodell had this to say about medical marijuana use (quotes courtesy of Sports Illustrated ): If this sounds eerily familiar, it's because the U.S. Drug Enforcement Agency (DEA) passed on the opportunity to reschedule, or de-schedule, marijuana this past summer. Under Armour leans on the NBA's Steph Curry and other big names, whereas Nike has LeBron James and a cadre of other leading athletes across a variety of sports representing its brand.
|
In a recent radio interview on ESPN's Mike & Mike , Goodell had this to say about medical marijuana use (quotes courtesy of Sports Illustrated ): If this sounds eerily familiar, it's because the U.S. Drug Enforcement Agency (DEA) passed on the opportunity to reschedule, or de-schedule, marijuana this past summer. Two petitions had asked the regulatory agency to re-examine cannabis, but the DEA found that there wasn't sufficient clinical evidence to suggest that marijuana had medical benefits that outweighed its risks. After generating $135 million in tax and licensing fee revenue on $996 million in legal sales in 2015, the Centennial State generated nearly $200 million in tax and licensing revenue last year as legal sales surged past $1.3 billion.
|
In a recent radio interview on ESPN's Mike & Mike , Goodell had this to say about medical marijuana use (quotes courtesy of Sports Illustrated ): If this sounds eerily familiar, it's because the U.S. Drug Enforcement Agency (DEA) passed on the opportunity to reschedule, or de-schedule, marijuana this past summer. Two petitions had asked the regulatory agency to re-examine cannabis, but the DEA found that there wasn't sufficient clinical evidence to suggest that marijuana had medical benefits that outweighed its risks. After generating $135 million in tax and licensing fee revenue on $996 million in legal sales in 2015, the Centennial State generated nearly $200 million in tax and licensing revenue last year as legal sales surged past $1.3 billion.
|
In a recent radio interview on ESPN's Mike & Mike , Goodell had this to say about medical marijuana use (quotes courtesy of Sports Illustrated ): If this sounds eerily familiar, it's because the U.S. Drug Enforcement Agency (DEA) passed on the opportunity to reschedule, or de-schedule, marijuana this past summer. Two petitions had asked the regulatory agency to re-examine cannabis, but the DEA found that there wasn't sufficient clinical evidence to suggest that marijuana had medical benefits that outweighed its risks. We've also witnessed residents in eight states legalize recreational pot since 2012.
|
8626ee58-5397-474e-9676-da1abd869c7e
|
723554.0
|
2017-04-29 00:00:00 UTC
|
Study: A National Medical Marijuana Program Would Save Medicaid $1 Billion a Year
|
DEA
|
https://www.nasdaq.com/articles/study-national-medical-marijuana-program-would-save-medicaid-1-billion-year-2017-04-29
|
nan
|
nan
|
The marijuana industry is growing like a weed. Last year, legal weed sales grew by 34%, according to cannabis research firm ArcView, and by 2021, legal sales (which includes medical and recreational pot) are expected to exceed $22 billion. Investment firm Cowen & Co. has an even more bullish forecast on legal weed, calling for $50 billion in sales by 2026. These estimates are what have revenue-hungry state governments, as well as investors, drooling with excitement.
Take Colorado as a good example. Residents in Colorado legalized recreational cannabis in 2012 along with Washington, becoming the first two states to do so. Last year, Colorado generated more than $1.3 billion in legal weed sales, two-thirds of which came from the recreational side of the equation, leading to almost $200 million in tax and licensing-fee revenue.
Investors have relished in the growth as well. Most marijuana stocks have doubled or tripled in value over the past year, if not more. We've even seen a few Canadian medical marijuana producers and retailers turning a quarterly profit, which is a nice departure from the years of losses investors have been accustomed to with pot stocks.
The federal government constrains pot's potential
But the major hurdle the marijuana industry has yet to overcome is escaping its restrictive Schedule 1 status from the U.S. federal government. As a Schedule 1 drug, marijuana is recognized as having no medically beneficial qualities, and is illegal. This leaves cannabis companies to face a number of disadvantages that include having little to no access to basic banking services, and having to pay tax on their gross profits instead of net profits since they can't take normal business deductions.
Most lawmakers and investors look at the marijuana industry from a profit-loss standpoint, but there's also a human factor involved. Medical marijuana is currently approved in 28 states and Washington, D.C., and it's often prescribed to treat a host of ailments including glaucoma, epilepsy, and pain associated with cancer, to name a few. Because the U.S. doesn't have a nationwide medical marijuana program (which is something 93% of survey takers in the latest Quinnipiac poll would like to see happen), tens of millions of Americans are denied access to medical cannabis.
A national medical marijuana program could save a lot of money
Yet, a recent study suggests that if a medical marijuana program existed, it would not only save lives but a sizable amount of money in the process.
As background, in July 2016, father-daughter duo David and Ashley Bradford of the University of Georgia published a study in the journal Health Affairs that examined the effect of medical cannabis on Medicare in states that had legalized medical pot. What they found was a $165.2 million reduction in prescription drug expenses for Medicare in states that had legal medical weed. Across the U.S., they estimated that nearly $500 million could be saved for Medicare if medical marijuana were legalized nationally.
In particular, the July 2016 study notes that there were 1,826 fewer doses of pain pills issued under Medicare in legal medical weed states, 562 fewer doses of anxiety meds, and 541 fewer doses of nausea pills, all based on 2013 data. The lower doses of pain pills is of particular interest because opioid overdose-related deaths totaled 20,101 in 2015, according to the American Society of Addiction Medicine. Though it's possible to overdose on marijuana, too, no one has died from a pot overdose. Thus, some pundits have suggested that access to medical marijuana is a way to fight the opioid epidemic in order to save lives and reduce costs.
This month, the Bradfords were at it again, releasing a brand-new study in Health Affairs that examined the impact a national medical marijuana program would have on Medicaid. The researchers examined quarterly data on all fee-for-service Medicaid prescriptions between 2007 and 2014, paying particular attention to states where medical marijuana was legal. They estimated that if a national medical marijuana law were in place in 2014, it would have resulted in $1.01 billion in savings for Medicaid.
They noted that in legal medical marijuana states under Medicaid, there was a 17% reduction in nausea prescriptions filled, a 13% decrease in depression prescriptions, and once again an 11% drop in pain medications filled.
Long story short, medical pot would save the federal government about $1.5 billion annually, based on the Bradfords' findings, if it were legalized nationally.
Two major issues with the Bradfords' thesis
While the Bradfords' study paints a pretty encouraging picture for medical pot, there are two major issues with it.
First and foremost, the $1 billion "saved" in Medicaid and the nearly $500 million "saved" from Medicare aren't going into anyone's pockets in particular. The difference is that instead of the federal government footing the bill for prescription medicines, consumers will be on the hook for the out-of-pocket costs associated with medical marijuana. As a Schedule 1 drug, no insurer is going to cover cannabis as an approved therapy, and even if it were legalized, there's no guarantee that insurers would cover the drug. This means a national marijuana program would save the federal government money by transferring about $1.5 billion in costs to consumers who choose to buy pot instead of prescription medicines.
President Trump flanked by Jeff Sessions and his wife, Mary Blackshears. Image source: President Donald J. Trump official Facebook page. Photo by Benjamin D. Applebaum.
The other issue is that the Trump administration is in seemingly no rush to consider legalizing medical marijuana. Even though Donald Trump has been in favor of patients having access to medical cannabis, having ardent weed opponent Jeff Sessions as U.S. attorney general means there's very little likelihood of a medical legalization happening anytime soon.
What's more, the U.S. Drug Enforcement Agency (DEA) had its opportunity to reschedule or deschedule cannabis this past summer but chose to keep its current Schedule 1 categorization intact. The DEA suggested that a lack of adequate clinical benefit and risk data on pot, along with inadequate safety checks on an addictive drug, made altering its scheduling a bad idea. Petitions to reschedule a drug can take years to reach the DEA, meaning medical cannabis' chances of a rescheduling are slim at best.
Even though legal pot sales are heating up, marijuana stock investors might be wise to keep their expectations in check given the uncertain future of weed in Washington.
10 stocks we like better than Wal-Mart
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, the Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Wal-Mart wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of April 3, 2017
The author(s) may have a position in any stocks mentioned.
The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
The DEA suggested that a lack of adequate clinical benefit and risk data on pot, along with inadequate safety checks on an addictive drug, made altering its scheduling a bad idea. The lower doses of pain pills is of particular interest because opioid overdose-related deaths totaled 20,101 in 2015, according to the American Society of Addiction Medicine. What's more, the U.S. Drug Enforcement Agency (DEA) had its opportunity to reschedule or deschedule cannabis this past summer but chose to keep its current Schedule 1 categorization intact.
|
The lower doses of pain pills is of particular interest because opioid overdose-related deaths totaled 20,101 in 2015, according to the American Society of Addiction Medicine. What's more, the U.S. Drug Enforcement Agency (DEA) had its opportunity to reschedule or deschedule cannabis this past summer but chose to keep its current Schedule 1 categorization intact. The DEA suggested that a lack of adequate clinical benefit and risk data on pot, along with inadequate safety checks on an addictive drug, made altering its scheduling a bad idea.
|
The lower doses of pain pills is of particular interest because opioid overdose-related deaths totaled 20,101 in 2015, according to the American Society of Addiction Medicine. What's more, the U.S. Drug Enforcement Agency (DEA) had its opportunity to reschedule or deschedule cannabis this past summer but chose to keep its current Schedule 1 categorization intact. The DEA suggested that a lack of adequate clinical benefit and risk data on pot, along with inadequate safety checks on an addictive drug, made altering its scheduling a bad idea.
|
What's more, the U.S. Drug Enforcement Agency (DEA) had its opportunity to reschedule or deschedule cannabis this past summer but chose to keep its current Schedule 1 categorization intact. The lower doses of pain pills is of particular interest because opioid overdose-related deaths totaled 20,101 in 2015, according to the American Society of Addiction Medicine. The DEA suggested that a lack of adequate clinical benefit and risk data on pot, along with inadequate safety checks on an addictive drug, made altering its scheduling a bad idea.
|
e132920c-d3ae-41bd-ab39-67e88603d412
|
723555.0
|
2017-04-23 00:00:00 UTC
|
This Landmark Cannabis Bill Is Great News for Marijuana Stocks
|
DEA
|
https://www.nasdaq.com/articles/landmark-cannabis-bill-great-news-marijuana-stocks-2017-04-23
|
nan
|
nan
|
Investors would probably struggle to find an industry that's growing at a faster and more consistent pace than legal marijuana.
Last year alone, according to cannabis research firm ArcView, North American legal pot sales jumped 34% to $6.9 billion. ArcView estimates that legal sales could top $22 billion by 2021, with investment firm Cowen & Co. expecting legal sales to hit $50 billion by 2026. Regardless of what estimate you choose to believe, the legal marijuana industry is growing by between 20% and 30% a year. That type of consistent long-term growth is certainly appealing to investors.
The sky could be the limit -- if not for these issues
Of course, the marijuana industry continues to face a laundry list of risks.
For instance, the U.S. federal government continues to categorize cannabis as a Schedule I substance, thus denying marijuana companies the ability to take normal corporate tax deductions, and in many cases ensuring they have little to no access to basic banking services. Since financial institutions report to the Federal Deposit Insurance Corporation (FDIC), and the FDIC is a federally created entity, dealing with cannabis businesses could be construed as money laundering.
There are also a number of political risks. In February, White House press secretary Sean Spicer announced that the Trump administration would depart from the lax policies of the preceding administration and step up enforcement on federal laws on recreational pot. It's unclear just how rigorous this federal enforcement might be, but newly appointed Attorney General Jeff Sessions might arguably be the most ardent opponent of marijuana's expansion in the country, so you can imagine the concern within the industry.
The lack of a clear line in the sand between federal and state laws, and even legal cannabis laws within some states, can also create issues and lead to business uncertainty. While the sky could be the limit for marijuana stocks, they've been largely held back by a number of adverse factors.
This landmark Colorado bill could be big for marijuana stocks
However, a benchmark bill that was passed in the Colorado Senate last week by a landslide 35-0 vote looks to put an end to one of the industry's greatest recreational pot uncertainties (at least within Colorado).
The bill ( HB17-1221 ), known as the Grey and Black Market Marijuana Enforcement Efforts, will make it illegal for marijuana growing cooperatives to exist in Colorado. In co-ops, one individual is designated as the farmer while users share in the costs of electricity, water, and fertilizer needed to grow marijuana. This is allowed in Colorado, as the law's language allows adults over the age of 21 to assist someone else in growing pot.
Growing recreational cannabis as a cooperative makes it far less costly since only the individual farmer designated to grow pays tax, allowing some Coloradans to avoid up to a 30% retail tax on pot, depending on the jurisdiction. Lawmakers viewed this loophole as just another way for the black market to thrive, and believe this bill to outlaw co-ops will close that loophole.
This bill also provides nearly $6 million a year of marijuana tax revenue to law enforcement agencies, which will be used to investigate illegal growing operations within the state.
Additionally, Gov. John Hickenlooper has plans to pass a separate bill limiting the number of medical cannabis plants that can be grown in a resident's home to 12. This would require medical users who are authorized to grow more than 12 plants to do so in a commercial or agricultural setting, or to buy from a medical marijuana dispensary. In other words, the tax-free ride is ending at 12 plants for medical patients.
Though a tougher regulatory environment might not seem like a good thing for the industry, it's actually great news for legal businesses and marijuana stocks. By more precisely defining the legality of who can grow recreational pot, Colorado is laying the groundwork for its legal businesses to thrive. Since Colorado is such a marijuana pioneer, other states may soon follow its lead.
U.S. pot stocks still need a federal "push"
While Colorado's bill is a great step in the right direction for marijuana stocks in the U.S., they still need some help from the federal government to be a viable investment opportunity, and it's unclear when that might happen.
Last summer, the U.S. Drug Enforcement Agency (DEA) had the opportunity to consider rescheduling or descheduling pot and it chose to do neither despite two petitions. The DEA claimed that there wasn't enough benefit-versus-risk data available to change its scheduling, nor the proper oversight to allow a drug like cannabis to be prescribed by physicians. Given how long it takes for petitions of this nature to make their way to the DEA, we could be looking at years before the U.S. government considers rescheduling once again.
On the other hand, our neighbors to the north (Canada) could be on the precipice of legalizing recreational cannabis. If new legislation is passed and Canada does indeed allow adults to purchase pot legally, then some of its largest grow farms could become instant winners. A few names that come to mind are Canopy Growth Corp. (NASDAQOTH: TWMJF) , Aphria (NASDAQOTH: APHQF) , and Aurora Cannabis (NASDAQOTH: ACBFF) .
Perhaps what's most interesting is that if the U.S. government ever did change its tune on marijuana, these three Canadian pot stocks would likely be the biggest beneficiaries of all, since they're all busy expanding their grow operations to meet heightened demand.
For example, Aurora Cannabis is currently in the process of constructing its Aurora Sky project, which is a technologically advanced 800,000-square-foot growing space that could easily be used meet recreational weed demand for Canada and/or the United States. Inclusive of a recent acquisition of a 40,000-square-foot facility, Aurora's grow capacity will soon jump from less than 100,000 square feet to nearly 900,000!
Aphria has also been expanding organically, while Canopy Growth's acquisition of Mettrum has allowed its growing capacity to expand quickly.
As U.S. states work out the kinks with their marijuana laws, we may begin to see these more developed and centralized Canadian marijuana stocks benefit. Of course, we really need to see a change of heart on Capitol Hill if real progress is to be made within the pot industry and with marijuana stocks as a whole.
10 stocks we like better than AURORA CANNABIS IN COM NPV
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now… and AURORA CANNABIS IN COM NPV wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of April 3, 2017
Sean Williams has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Since financial institutions report to the Federal Deposit Insurance Corporation (FDIC), and the FDIC is a federally created entity, dealing with cannabis businesses could be construed as money laundering. Last summer, the U.S. Drug Enforcement Agency (DEA) had the opportunity to consider rescheduling or descheduling pot and it chose to do neither despite two petitions. The DEA claimed that there wasn't enough benefit-versus-risk data available to change its scheduling, nor the proper oversight to allow a drug like cannabis to be prescribed by physicians.
|
Since financial institutions report to the Federal Deposit Insurance Corporation (FDIC), and the FDIC is a federally created entity, dealing with cannabis businesses could be construed as money laundering. Last summer, the U.S. Drug Enforcement Agency (DEA) had the opportunity to consider rescheduling or descheduling pot and it chose to do neither despite two petitions. The DEA claimed that there wasn't enough benefit-versus-risk data available to change its scheduling, nor the proper oversight to allow a drug like cannabis to be prescribed by physicians.
|
Since financial institutions report to the Federal Deposit Insurance Corporation (FDIC), and the FDIC is a federally created entity, dealing with cannabis businesses could be construed as money laundering. Last summer, the U.S. Drug Enforcement Agency (DEA) had the opportunity to consider rescheduling or descheduling pot and it chose to do neither despite two petitions. The DEA claimed that there wasn't enough benefit-versus-risk data available to change its scheduling, nor the proper oversight to allow a drug like cannabis to be prescribed by physicians.
|
Since financial institutions report to the Federal Deposit Insurance Corporation (FDIC), and the FDIC is a federally created entity, dealing with cannabis businesses could be construed as money laundering. Last summer, the U.S. Drug Enforcement Agency (DEA) had the opportunity to consider rescheduling or descheduling pot and it chose to do neither despite two petitions. The DEA claimed that there wasn't enough benefit-versus-risk data available to change its scheduling, nor the proper oversight to allow a drug like cannabis to be prescribed by physicians.
|
212673c3-4efa-4208-8325-896eb78fb1ec
|
723556.0
|
2017-04-21 00:00:00 UTC
|
Better Know a Marijuana Stock: Insys Therapeutics
|
DEA
|
https://www.nasdaq.com/articles/better-know-marijuana-stock-insys-therapeutics-2017-04-21
|
nan
|
nan
|
Marijuana stocks seem like the Holy Grail for investors.
According to cannabis research firm ArcView, legal pot sales (which include medical and recreational) grew by a scorching 34% in North America to $6.9 billion last year -- albeit $46.4 billion in sales were still conducted on the black market, meaning there's a very significant opportunity for legal businesses to attract under-the-table consumers in the years to come. This shouldn't be too difficult with more and more U.S. states and countries considering legalization.
If investment firm Cowen & Co. is right, and legal marijuana sales can grow to $50 billion by 2026, then the rally in marijuana stocks could be just the beginning.
But there are dozens of marijuana stocks to choose from, and with emotions running high, investors may be jumping into these stocks for all the wrong reasons, or worse yet, without understanding the benefits and risks offered by each company.
With this in mind, we'll take the time to highlight and dissect one marijuana stock each week until we've covered the bigger players (those with market caps above $200 million). Last week, we took a closer look at the largest publicly traded pot stock, GW Pharmaceuticals (NASDAQ: GWPH) . Today, we're going to more closely examine Insys Therapeutics (NASDAQ: INSY) .
What Insys Therapeutics does
Insys Therapeutics, like GW Pharmaceuticals, is a drug developer, but it's also not your traditional marijuana stock. For instance, Insys doesn't have its entire pipeline devoted to cannabinoid-based drugs, although the cannabinoid-based drugs it has developed or that are in the works could one day provide a majority of its sales and profits.
Currently, Insys has two drugs approved by the Food and Drug Administration (FDA): Subsys and Syndros. It also has about a half-dozen other drugs in development.
Subsys is the company's sublingual spray offered to adult cancer patients dealing with constant pain. Subsys has absolutely nothing to do with cannabis, but it is responsible for nearly every cent of Insys' sales at this point. It's also the reason Insys has been profitable on a recurring full-year basis since 2013.
Syndros, on the other hand, is an oral dronabinol solution, which is a pharmaceutical version of tetrahydrocannabinol, the psychoactive component of cannabis. It was approved by the FDA in July as a treatment for chemotherapy-induced nausea and vomiting (CINV) as well as a treatment for anorexia in patients with AIDS.
Promise and opportunities
One clear intrigue of a company like Insys is that it's already been profitable on a recurring basis in each of the past four years, with an aggregate of $181 million in free cash flow generated over that time span. Insys ended 2016 with $236.7 million in cash and cash equivalents, which suggests that it has more than enough capital to continue its research and market its therapies if they're approved by the FDA. Even with a recent hiccup in Subsys sales (which we'll get to a bit later), there's plenty of wiggle room with its cash on hand.
Question marks surrounding Syndros are also beginning to lift. Its launch had been delayed while awaiting scheduling from the U.S. Drug Enforcement Agency (DEA). With Insys announcing that the DEA listed Syndros as a Schedule 2 substance, its pathway to pharmacy shelves is now clear. The company is targeting a release of Syndros during the second half of 2017. According to analysts at Piper Jaffray, Syndros has peak annual sales potential of $300 million to $400 million. Considering that Insys generated $87 million in free cash flow (FCF) in 2015 from around $330 million in Subsys sales, this means Insys' FCF could double with the introduction of Syndros.
Insys' pipeline offers plenty of intrigue, too. The company anticipates filing a new drug application for its buprenorphine sublingual spray by the end of this year, and it's advancing a cannabidiol (CBD)-based formulation that's designed to treat a number of severe pediatric epilepsies. In fact, Insys' CBD formulation -- currently in midstage studies for Dravet syndrome and Lennox-Gastaut syndrome -- is going to pit it directly against GW Pharmaceuticals' Epidiolex, which shone in phase 3 studies by demonstrating a statistically significant reduction in seizure frequency for both indications.
Risks and concerns
However, no marijuana stock is perfect.
One of the biggest risks of investing in Insys is the uncertain future for Subsys. A number of lawsuits have alleged improper marketing tactics for Subsys, which has subsequently reduced sales of the drug. During Q4, Insys' total sales fell to $54.9 million from $93.9 million in the year-ago quarter, and it reported a $3.7 million net loss after generating net income of $18.2 million in Q4 2015. According to one lawsuit, more than 80% of the prescriptions written for Subsys were for off-label indications by the end of 2015. Until Insys clears up these lawsuits, a gray cloud and quarterly losses could follow.
There's also concern about the impending launch of Syndros. While most Wall Street pundits see the drug generating in the neighborhood of $300 million in peak annual sales as an alternative chemotherapy-induced nausea and vomiting (CINV) and anorexia treatment for people with AIDS, it's going to face a lot of competition, as well as have the Subsys PR debacle hanging over its head. For instance, there are dopamine antagonists, NK-1 inhibitors, serotonin antagonists, anti-anxiety drugs, and stomach-acid blockers, already being used to treat CINV. If Syndros isn't priced properly or Insys' marketing team does a poor job of getting insurers to cover the drug, Syndros could get lost in a sea of competition.
Insys is also faced with a group of lawmakers on Capitol Hill who aren't receptive to the idea of freeing up regulations for marijuana companies. Though the American public overwhelmingly supports the legalization of medical cannabis, lawmakers demand more evidence on its risks and benefits be presented from FDA-approved clinical trials. However, with the drug currently labeled as Schedule 1, running these studies is practically impossible. This means the continuation of inherent disadvantages for companies involved with cannabis.
Should you buy Insys Therapeutics?
Of course, the big question is whether you should buy this profitable marijuana stock. The answer is more complicated than you'd realize.
On the one hand, Insys offers a number of compelling reasons to buy. For one, it's on the precipice of launching its dronabinol solution Syndros in a matter of months, and it may have its buprenorphine sublingual spray approved for patients before 2018 is up. We're talking about the real potential for Insys to see its sales double from $242 million in 2016 to perhaps close to $500 million by 2021.
The stock is also exceptionally cheap, assuming Insys can meet the peak annual sales expectations of Wall Street. By 2020, the consensus is that it'll earn $1.73 per share. Based on its current share price of $11, that'd be incredibly inexpensive given the rate of sales growth that it's offering with Syndros readying to launch and other pipeline products advancing.
The reason Insys is such a complicated stock is tied to its Subsys overhang. Sales of the drug continue to be impacted by ongoing litigation, with Wall Street expecting revenue to fall by about a third this year. Since Subsys is responsible for essentially every cent of sales, that's bad news for Insys, and it could actually push the company well into the red this year. It's also possible Insys winds up facing hefty fines as a result of these ongoing lawsuits.
Without question, Insys is a risky marijuana stock. However, for patient investors who aren't opposed to volatile investments, dipping your toes into the water might be worthwhile.
10 stocks we like better than Insys Therapeutics
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Insys Therapeutics wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of April 3, 2017
Sean Williams has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Subsys is the company's sublingual spray offered to adult cancer patients dealing with constant pain. Its launch had been delayed while awaiting scheduling from the U.S. Drug Enforcement Agency (DEA). With Insys announcing that the DEA listed Syndros as a Schedule 2 substance, its pathway to pharmacy shelves is now clear.
|
Subsys is the company's sublingual spray offered to adult cancer patients dealing with constant pain. Its launch had been delayed while awaiting scheduling from the U.S. Drug Enforcement Agency (DEA). With Insys announcing that the DEA listed Syndros as a Schedule 2 substance, its pathway to pharmacy shelves is now clear.
|
Subsys is the company's sublingual spray offered to adult cancer patients dealing with constant pain. Its launch had been delayed while awaiting scheduling from the U.S. Drug Enforcement Agency (DEA). With Insys announcing that the DEA listed Syndros as a Schedule 2 substance, its pathway to pharmacy shelves is now clear.
|
Subsys is the company's sublingual spray offered to adult cancer patients dealing with constant pain. Its launch had been delayed while awaiting scheduling from the U.S. Drug Enforcement Agency (DEA). With Insys announcing that the DEA listed Syndros as a Schedule 2 substance, its pathway to pharmacy shelves is now clear.
|
6157bd33-bf0b-4d6d-96e1-247cfadf1eca
|
723557.0
|
2017-04-16 00:00:00 UTC
|
This Landmark Marijuana Bill Would Move Cannabis to Schedule III
|
DEA
|
https://www.nasdaq.com/articles/landmark-marijuana-bill-would-move-cannabis-schedule-iii-2017-04-16
|
nan
|
nan
|
The Marijuana industry is growing rapidly, and at the moment it seems as if nearly everyone wants in.
According to cannabis research firm ArcView, legal cannabis sales in North America surged by 34% last year to $6.9 billion, and by 2021, sales of legal weed are expected to top $22 billion. Investment firm Cowen & Co. is arguably even more bullish, calling for $50 billion in legal pot sales by 2026, which works out to a compounded annual growth rate of more than 23%.
This growth rate is all thanks to the rapidly changing opinion of the public and a number of legislators in select states. National pollster Gallup, which has been keeping tabs on the public's opinion of marijuana for nearly 50 years, notes that 60% of respondents were in favor of a national legalization in its 2016 poll, an all-time high. Comparatively, just 25% felt the same way back in 1995.
Select states have also been eager to legalize pot given the opportunity to collect tax revenue and licensing fees. For instance, Colorado wound up generating nearly $200 million in tax and licensing revenue last year after bringing in around $135 million in 2015. This revenue helps support the state's school system, as well as law enforcement and drug abuse and education programs.
Marijuana's federal "glass ceiling"
Yet, no matter how far marijuana seems to reach at the state level, it always has a glass ceiling hanging over its head in the form of the federal government. On Capitol Hill, cannabis remains a schedule I drug, meaning it's illegal and is deemed to have no medical benefits. Being listed as a schedule I substance comes with a number of inherent disadvantages.
For starters, weed businesses have very little or no access to basic banking services. Since financial institutions normally report to the Federal Deposit Insurance Corporation (FDIC), and the FDIC is a federally created entity, loaning money to pot businesses or even opening a checking account for them could be construed as money laundering. If the federal government wanted to strictly enforce federal law at some point down the road, financial institutions that were caught offering basic banking services to cannabis businesses could face fines and/or criminal charges.
Companies that sell federally illegal substances like marijuana also get shafted come tax time. U.S. tax code 280E disallows businesses that sell federally illegal substances from taking normal business deductions, which ultimately leaves these companies to pay far more in taxes than any normal business would.
Research is constrained as well. Lawmakers on Capitol Hill have often suggested that they'd be more willing to consider rescheduling marijuana if there were more clinical evidence of its benefits and risks available. However, the Catch-22 is that this data isn't easy to obtain because of the strict scheduling of cannabis as a schedule I substance.
However, there may be a middle ground to be found.
This landmark marijuana bill would change the game
Last week, two members of the House, Rep. Matt Gaetz (R-Fl.) and Rep. Darren Soto (D-Fl.), proposed new legislation that would remove marijuana as a schedule I substance and reinstitute it as a schedule III substance. Bypassing schedule II and going straight to schedule III would remove a number of key restrictions on the industry.
For instance, manufacturers of schedule III substances can indeed obtain basic banking services, which means access to loans to grow their business, as well as checking accounts. Having to deal in cash is a major security concern for pot businesses today.
Schedule III substances also don't fall under the control of U.S. tax code 280E. This would mean that medical cannabis businesses would be able to take normal tax deductions, thus paying tax on their net profits as opposed to gross profits. Being able to hang onto more of their income could help with expansion and hiring.
As a schedule III drug, it would also be considerably easier for researchers to examine the benefits and risks of the drug without first gaining federal approval to run studies. Select clinical trials pertaining to various forms of epilepsy, glaucoma, cancer, pain, and diabetes, have shown promise, and this new bill would make it significantly easier for additional research to be conducted.
Most importantly, it would put the onus of responsibility back on the states since it would effectively be decriminalizing medical marijuana across the U.S. Though consumers would probably prefer to see a complete descheduling of pot, allowing states to regulate their own medical weed industry is a consolation prize that marijuana proponents would probably gladly accept.
A gesture that'll fall on deaf ears
This isn't the first marijuana reform bill that's been proposed in Congress, and it's unlikely to be the last. However, like all marijuana reforms proposed before it, Gaetz's and Soto's bill is likely to fall on deaf ears in Washington.
In February, White House press secretary Sean Spicer signaled a change in the way the Trump administration will handle the enforcement of cannabis at the federal level. While it's looking unlikely that the administration will step up enforcement on medical marijuana, which is good news for the 28 states that have legalized the substance, it's disconcerting news for the eight states that have legalized recreational pot, and the other states that have considered doing so.
No one is entirely sure what sort of enforcement the Trump administration has in store for the pot industry, but with Attorney General Jeff Sessions at the reins of the Justice Department, one can only assume the worst. While in the Senate, Sessions was arguably the most ardent opponent of marijuana's expansion.
The industry also missed out on an opportunity to have the Drug Enforcement Agency (DEA) reschedule marijuana this past summer. Despite two petitions to do so, the DEA decided that there wasn't sufficient existing benefits data to merit a change from schedule I. The DEA often takes years to hear petitions of this nature, so it'll likely be years before cannabis has a shot at another DEA review.
Considering that President Trump has a laundry list of objectives still to tackle (healthcare, tax reform, and infrastructure), marijuana simply isn't anywhere on his list.
For current and prospective marijuana stock investors, this isn't good news. It means the perpetuation of inherent disadvantages that make profitability seem like a pipedream for most marijuana stocks. For the time being, the safest place for investors remains firmly planted on the sidelines.
10 stocks we like better than Wal-Mart
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, the Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Wal-Mart wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of April 3, 2017
The author(s) may have a position in any stocks mentioned.
The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Having to deal in cash is a major security concern for pot businesses today. A gesture that'll fall on deaf ears This isn't the first marijuana reform bill that's been proposed in Congress, and it's unlikely to be the last. However, like all marijuana reforms proposed before it, Gaetz's and Soto's bill is likely to fall on deaf ears in Washington.
|
Having to deal in cash is a major security concern for pot businesses today. A gesture that'll fall on deaf ears This isn't the first marijuana reform bill that's been proposed in Congress, and it's unlikely to be the last. However, like all marijuana reforms proposed before it, Gaetz's and Soto's bill is likely to fall on deaf ears in Washington.
|
Having to deal in cash is a major security concern for pot businesses today. A gesture that'll fall on deaf ears This isn't the first marijuana reform bill that's been proposed in Congress, and it's unlikely to be the last. However, like all marijuana reforms proposed before it, Gaetz's and Soto's bill is likely to fall on deaf ears in Washington.
|
Having to deal in cash is a major security concern for pot businesses today. A gesture that'll fall on deaf ears This isn't the first marijuana reform bill that's been proposed in Congress, and it's unlikely to be the last. However, like all marijuana reforms proposed before it, Gaetz's and Soto's bill is likely to fall on deaf ears in Washington.
|
c72988c8-8bef-4416-9fe3-55eabf0d4ce0
|
723558.0
|
2017-04-02 00:00:00 UTC
|
Colorado Has a Radical Plan to Save Its Billion-Dollar Marijuana Industry From a Federal Crackdown
|
DEA
|
https://www.nasdaq.com/articles/colorado-has-radical-plan-save-its-billion-dollar-marijuana-industry-federal-crackdown
|
nan
|
nan
|
The marijuana industry has been on a roll lately. Just last year, five states legalized medical cannabis (two of which did so entirely through the legislative process and without putting a measure on a ballot), while the number of recreational marijuana states doubled to eight. In fact, had a recreational marijuana measure not been defeated in Arizona by just 2 percentage points, it would have been a clean sweep for cannabis in the November elections.
The success of the pot industry is directly correlated with the rapidly changing perceptions surrounding it. Gallup, which has conducted surveys on how many respondents would like to see cannabis legalized nationwide for almost 50 years, found that only 25% favored its nationwide legalization in 1995. As of 2016, this approval rating had jumped to 60%, representing an all-time high.
A separate and more recent survey from the independent Quinnipiac University found 59% national support for recreational marijuana and only 36% opposition. When it came to just medical marijuana, an overwhelming 93% of respondents would like to see it legalized.
The federal government digs in its heels
Standing in the way of this popular opinion are the U.S. Drug Enforcement Agency (DEA) and Congress. In August, the DEA denied two petitions that requested it reschedule or de-schedule marijuana from its current Schedule 1 status. The DEA declined with the reasoning that there was inadequate safety and benefits data available, as well as improper oversight for a drug that can be easily abused. As a Schedule 1 drug, marijuana is labeled illegal and having no medical benefits.
Congress, on the other hand, is caught in something of a catch-22. Lawmakers want lots of additional benefits and risk data that can only be found through running clinical trials, yet these trials are nearly impossible to run since obtaining marijuana for medical research is exceptionally difficult with the drug bearing a Schedule 1 designation.
But this may not be the worst of it for the marijuana industry.
In February, White House press secretary Sean Spicer said that the Trump administration would not remain as lax in the federal regulation of cannabis as the Obama administration had been. The good news is President Trump has been unwavering in his support of medical cannabis, meaning the 28 states that've legalized medicinal pot are likely safe.
Recreational cannabis is a different story. Spicer intimated that a federal crackdown should be expected on the recreational marijuana industry, though what's not known at this time is to what degree. Spicer's comments could simply imply tougher regulations that ensure legal weed stays out of the hands of minors. Then again, it could involve a full-scale reversal of the hands-off approach under the Obama administration, leading to enforcement of federal laws against recreational cannabis. With ardent marijuana opponent Jeff Sessions recently appointed the U.S. attorney general, the chances for pot's growth to come to a crashing halt are seeming more likely by the day.
Recreational-marijuana states scramble to protect their cash cow
If (and this is a big "if") the federal government does choose to completely roll back the freedoms of state-level recreational pot, it puts more than just the cannabis industry in a bind. States like Colorado, Washington, and Oregon have come to rely on the tax and licensing revenue generated from the recreational marijuana industry to fill gaps in their budgets.
For instance, Colorado wound up selling more than $1.3 billion in legal marijuana in 2016, a more-than-30% increase from the prior-year period, when legal cannabis sales fell just shy of the $1 billion mark. Overall, $875 million in Colorado's sales came from recreational marijuana, with the remainder coming from the medical side of the equation.
However, there's a major difference in taxation between the two. Medical pot is only taxed at 2.9% in Colorado whereas recreational marijuana bears a 17.9% tax. Having its recreational weed business banned would cost Colorado well over $100 million in annual tax revenue, at least $40 million of which goes to fund its schools.
Colorado's legislature is therefore developing a plan that could help protect its marijuana crops from being seized should the federal government present it with a worst-case scenario.
A bill that was proposed last week and passed in the state's Republican Senate by a 4-1 vote would allow Colorado's approximately 500 licensed recreational marijuana growers to immediately reclassify their cannabis as medical instead of recreational. The bill would allow this change to be "based on a business need due to a change in local, state or federal law or enforcement policy."
The upside of such a bill is that it would protect from seizure the more than 800,000 marijuana plants that were being grown in Colorado's retail system as of this past summer. The downside, though, is that it would still strip Colorado of highly valuable taxable income because the tax rates on medicinal pot are substantially lower than recreational. In other words, it would be a victory in name only for Colorado.
Other states are discussing similar methods to protect their marijuana industries against a potential federal crackdown.
The waiting game continues
For now, the uncomfortable waiting game continues for the marijuana industry and investors who are eager to get in on an industry expected to grow by more than 23% per year over the next decade, according to investment firm Cowen & Co. Though cannabis represents an incredible growth opportunity, two factors should keep investors away from marijuana stocks for the time being.
For starters, most marijuana stocks are losing money, and they'll probably continue to do so for the near future. The seven-largest companies combined hardly generate any revenue, and just one is profitable over the trailing year, and by a small amount at that. The marijuana industry is far from established, and businesses that continue to bleed red will eventually succumb to the pressure from fundamentals-focused investors.
More importantly, no one's exactly sure what the Trump administration might do to the recreational pot industry. There's obvious concern with Sessions as attorney general that a worst-case scenario could come true, which would be devastating to a lot of marijuana stocks.
Simply put, until we have more answers, your money should stay far away from marijuana stocks.
10 stocks we like better than Wal-Mart
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, the Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Wal-Mart wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of March 6, 2017
The author(s) may have a position in any stocks mentioned.
The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
The federal government digs in its heels Standing in the way of this popular opinion are the U.S. Drug Enforcement Agency (DEA) and Congress. In August, the DEA denied two petitions that requested it reschedule or de-schedule marijuana from its current Schedule 1 status. The DEA declined with the reasoning that there was inadequate safety and benefits data available, as well as improper oversight for a drug that can be easily abused.
|
The federal government digs in its heels Standing in the way of this popular opinion are the U.S. Drug Enforcement Agency (DEA) and Congress. In August, the DEA denied two petitions that requested it reschedule or de-schedule marijuana from its current Schedule 1 status. The DEA declined with the reasoning that there was inadequate safety and benefits data available, as well as improper oversight for a drug that can be easily abused.
|
The federal government digs in its heels Standing in the way of this popular opinion are the U.S. Drug Enforcement Agency (DEA) and Congress. In August, the DEA denied two petitions that requested it reschedule or de-schedule marijuana from its current Schedule 1 status. The DEA declined with the reasoning that there was inadequate safety and benefits data available, as well as improper oversight for a drug that can be easily abused.
|
The federal government digs in its heels Standing in the way of this popular opinion are the U.S. Drug Enforcement Agency (DEA) and Congress. In August, the DEA denied two petitions that requested it reschedule or de-schedule marijuana from its current Schedule 1 status. The DEA declined with the reasoning that there was inadequate safety and benefits data available, as well as improper oversight for a drug that can be easily abused.
|
1c21b7c8-03aa-4351-a63f-a990d21eeb38
|
723559.0
|
2017-03-24 00:00:00 UTC
|
Why Wasn't Insys Therapeutics' Bounce Bigger?
|
DEA
|
https://www.nasdaq.com/articles/why-wasnt-insys-therapeutics-bounce-bigger-2017-03-24
|
nan
|
nan
|
Insys Therapeutics (NASDAQ: INSY) finally got the news it has been waiting on for a long time. The company announced on Thursday that the U.S. Drug Enforcement Agency (DEA) completed its scheduling of Syndros after the cannabinoid drug won approval by the Food and Drug Administration (FDA) nearly nine months ago.
At the market open, Insys stock soared by double-digit percentages. However, that spike quickly fizzled out, with the biotech's shares ultimately gaining less than 4%. Why wasn't Insys' bounce bigger?
Process of elimination
Let's first rule out the reasons that didn't cause Insys' jump to be relatively low. Was there a surprise in the DEA's scheduling decision? Nope. Insys had prepared to receive a Schedule II classification for Syndros -- and that's exactly what it got.
Neither was there any other bad news hidden in the announcement. Insys interim CEO Santosh Vetticaden said that the company will work with the FDA to finalize labeling and launch Syndros in the second half of this year. That time frame shouldn't be a shock to anyone.
What about something else going on in the world that could impact Insys? Again, there was nothing obvious that should hold back the stock. The U.S. House of Representatives was initially scheduled to vote on a potential replacement plan for Obamacare, the American Health Care Act, on Thursday. However, it would be a stretch to speculate that uncertainty about the outcome of the vote had even a minimal impact on Insys.
Most likely culprits
One possible reason why Insys didn't enjoy a bigger bounce could be concerns about the company's delay in reporting its fourth-quarter and full-year 2016 results. On March 15, Insys announced that it would push back on filing its 10-K with the Securities and Exchange Commission while an internal review by its board of directors' audit committee wrapped up.
That internal review focused on the company's processes for estimating and increasing sales allowances and on extended payment terms granted to some customers in the third quarter of 2016. Insys stated, however, that it expected to submit its 10-K filing by the end of March and that the financial impact of changes resulting from the review shouldn't exceed $5 million.
Another potential reason why Insys' share price increase was relatively small could be that many remain skeptical about the potential for Syndros. Insys thinks the drug could generate sales of more than $200 million. If that estimate becomes reality, the stock should be valued much more highly than it is right now.
Insys' market cap currently stands near $750 million. Even though sales of the company's sole drug on the market, Subsys, are declining, Insys still should be on track to post revenue of around $235 million for 2016.
If you assumed that the company could continue making roughly this amount going forward and that Syndros achieves its potential, Insys could be looking at annual revenue topping $500 million in the not-too-distant future. Based on this, the stock could easily trade at double its current price -- even allowing for the fact that Syndros won't hit the market until later this year.
A prediction
My hunch is that the reason Insys' initial spike faded was a combination of both of the aforementioned factors -- uncertainty about its internal review and some degree of skepticism over Syndros. I predict that both issues will be gone by the end of 2017.
The internal review question will probably be answered very quickly. It will take a few months for Insys to launch Syndros, but I won't be surprised if the drug gets a fast start out of the gate.
Even before the DEA scheduling for Syndros was announced, I argued that Insys Therapeutics was the best marijuana stock on the market right now . Despite the stock's somewhat lackluster response to the recent news, I still think Insys is destined to head higher. Potentially much higher.
10 stocks we like better than Insys Therapeutics
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Insys Therapeutics wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of February 6, 2017
Keith Speights has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
The company announced on Thursday that the U.S. Drug Enforcement Agency (DEA) completed its scheduling of Syndros after the cannabinoid drug won approval by the Food and Drug Administration (FDA) nearly nine months ago. Was there a surprise in the DEA's scheduling decision? Even before the DEA scheduling for Syndros was announced, I argued that Insys Therapeutics was the best marijuana stock on the market right now .
|
The company announced on Thursday that the U.S. Drug Enforcement Agency (DEA) completed its scheduling of Syndros after the cannabinoid drug won approval by the Food and Drug Administration (FDA) nearly nine months ago. Was there a surprise in the DEA's scheduling decision? Even before the DEA scheduling for Syndros was announced, I argued that Insys Therapeutics was the best marijuana stock on the market right now .
|
Even before the DEA scheduling for Syndros was announced, I argued that Insys Therapeutics was the best marijuana stock on the market right now . The company announced on Thursday that the U.S. Drug Enforcement Agency (DEA) completed its scheduling of Syndros after the cannabinoid drug won approval by the Food and Drug Administration (FDA) nearly nine months ago. Was there a surprise in the DEA's scheduling decision?
|
Even before the DEA scheduling for Syndros was announced, I argued that Insys Therapeutics was the best marijuana stock on the market right now . The company announced on Thursday that the U.S. Drug Enforcement Agency (DEA) completed its scheduling of Syndros after the cannabinoid drug won approval by the Food and Drug Administration (FDA) nearly nine months ago. Was there a surprise in the DEA's scheduling decision?
|
797e976a-defa-48d7-a87a-3db55e1ac18a
|
723560.0
|
2017-03-21 00:00:00 UTC
|
Is This the Best Marijuana Stock to Buy Right Now?
|
DEA
|
https://www.nasdaq.com/articles/best-marijuana-stock-buy-right-now-2017-03-21
|
nan
|
nan
|
There certainly are a few reasons to be pessimistic about Insys Therapeutics (NASDAQ: INSY) .
Its cannabidiol drug, Syndros, still hasn't been scheduled by the U.S. Drug Enforcement Agency (DEA). The company recently announced a delay in the release of its fourth-quarter and full 2016 results. And Insys Therapeutics stock has dropped more than 30% over the last few weeks.
Despite all of that, could Insys actually be the best marijuana stock to buy right now? I think so. Here's why.
This too shall pass
The issues that are currently hurting Insys Therapeutics stock are only temporary. Although the DEA still hasn't scheduled Syndros under the Controlled Substances Act nearly nine months after the drug won approval from the Food and Drug Administration (FDA), that slow pace isn't unusual. It sometimes takes the DEA more than a year to schedule a product.
And, while it's never a good thing when a company has to delay reporting its results, Insys is unlikely to make the market wait much longer. The board of directors' audit committee said it found some issues in an internal review, and those caused the company to submit a notification of late filing with the Securities and Exchange Commission. This submission gave Insys an automatic 15-day extension on filing its 10-K for 2016. The company said it doesn't anticipate needing additional time beyond that.
What about the impact of the internal review? The audit committee is looking at the company's processes "related to estimation of, and increases to, certain sales allowances recorded during 2016" plus "extended payment terms offered to certain customers during the third quarter of 2016." Insys stated that its figures for 2015 net revenue and pre-tax income could be reduced by no more than $5 million. Assuming that's the extent of the impact, this issue should blow over quickly.
Not a happy time for marijuana stocks
Many marijuana stocks are languishing due to uncertainty about what actions the Trump administration plans to take to enforce federal laws against the sale and use of marijuana. For example, shares for Medical Marijuana Inc. (NASDAQOTH: MJNA) , one of the largest U.S. marijuana distributors, have fallen more than 20% year-to-date.
Medical Marijuana Inc. and other marijuana stocks could be headed for a long roller coaster ride. Every comment made by the White House and every tweet from President Trump about marijuana holds the potential to cause shares to rise or fall. This could go on for another four years -- and potentially longer.
However, this uncertainty doesn't affect developers of cannabinoid drugs like Insys and GW Pharmaceuticals (NASDAQ: GWPH) . Those companies are on the right side of federal laws and regulations. Admittedly, GW Pharmaceuticals does face some unknowns: It must still gain FDA approval for Epidiolex, its l cannabidiol drug . However, Epidiolex's chances appear to be pretty good based on late-stage study results.
Best marijuana stock?
I have argued in the past that GW Pharmaceuticals was the best marijuana stock on the market -- and I still think it should do very well. However, for now, at least, I suspect that Insys has taken over the top spot.
Syndros could generate annual sales of more than $200 million. Dronabinol is already frequently prescribed as a treatment for anorexia in patients with AIDS, and for nausea and vomiting associated with chemotherapy. As the first oral form of dronabinol, Syndros' ease of use should allow Insys to grab a significant chunk of the market.
Three things need to happen in order for Insys Therapeutics stock to soar. First, the company needs to report its fourth-quarter and full 2016 results soon. That should occur. Second, Insys needs to reassure investors that its internal review didn't uncover more serious issues. I think the company will likely put those fears to rest in its discussion of the fourth-quarter results. Third, the DEA needs to complete its scheduling of Syndros. That might take a few more months, but investors can anticipate this item will also be checked off relatively soon.
I see no reason why Insys' share price can't regain its levels from a few weeks ago, and go even higher. The recent pullback presents a solid buying opportunity. Insys Therapeutics looks like the best marijuana stock to buy right now.
10 stocks we like better than Insys Therapeutics
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Insys Therapeutics wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of February 6, 2017
Keith Speights has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Its cannabidiol drug, Syndros, still hasn't been scheduled by the U.S. Drug Enforcement Agency (DEA). Although the DEA still hasn't scheduled Syndros under the Controlled Substances Act nearly nine months after the drug won approval from the Food and Drug Administration (FDA), that slow pace isn't unusual. It sometimes takes the DEA more than a year to schedule a product.
|
Its cannabidiol drug, Syndros, still hasn't been scheduled by the U.S. Drug Enforcement Agency (DEA). Although the DEA still hasn't scheduled Syndros under the Controlled Substances Act nearly nine months after the drug won approval from the Food and Drug Administration (FDA), that slow pace isn't unusual. It sometimes takes the DEA more than a year to schedule a product.
|
Its cannabidiol drug, Syndros, still hasn't been scheduled by the U.S. Drug Enforcement Agency (DEA). Although the DEA still hasn't scheduled Syndros under the Controlled Substances Act nearly nine months after the drug won approval from the Food and Drug Administration (FDA), that slow pace isn't unusual. It sometimes takes the DEA more than a year to schedule a product.
|
Its cannabidiol drug, Syndros, still hasn't been scheduled by the U.S. Drug Enforcement Agency (DEA). Although the DEA still hasn't scheduled Syndros under the Controlled Substances Act nearly nine months after the drug won approval from the Food and Drug Administration (FDA), that slow pace isn't unusual. It sometimes takes the DEA more than a year to schedule a product.
|
dcf350cc-7f98-45d9-968a-51c985da914b
|
723561.0
|
2017-03-20 00:00:00 UTC
|
15 Things You Need to Know Before Investing in Marijuana Stocks
|
DEA
|
https://www.nasdaq.com/articles/15-things-you-need-know-investing-marijuana-stocks-2017-03-20
|
nan
|
nan
|
In terms of growth, you'd struggle to find an industry that's been piling on the dollars on a year-over-year basis faster than marijuana -- and it's rightly getting the attention of investors. In less than four years, cannabinoid-based drugmaker GW Pharmaceuticals (NASDAQ: GWPH) is up nearly 1,300%, while Medical Marijuana on the over-the-counter exchanges has had three separate instances since 2012 where its stock has rallied between 300% and 1,000%.
Huge moves like these are known for attracting investors, both big and small. However, blindly investing in an industry, even the marijuana industry, is rarely ever a good move. Before you invest in marijuana stocks, there are a few things -- 15 to be precise -- that you need to know.
1. Marijuana's growth rate is top notch
Investors really will struggle to find an industry with a more consistent long-term growth rate than marijuana. Cannabis research firm ArcView estimated North American legal sales growth at 34%, to $6.9 billion in 2016, and investment firm Cowen & Co. is forecasting up to $50 billion in legal pot sales by 2026. Between 2016 and 2026, this works out to a growth rate of more than 23% annually. Those are growth figures that make investors drool with anticipation.
2. The public strongly supports its legalization
As a whole, Americans want to see marijuana legalized across the country, or at worst, decriminalized. Gallup, which has been conducting polls on pot with some regularity for nearly 50 years, found that 60% of respondents in 2016 wanted to see weed legalized nationally, up from 25% back in 1995. A separate study from the independent Quinnipiac University found overwhelming support (93%) for the national legalization of medical marijuana.
3. Two groups still oppose legalizing marijuana
Though the general public wants to see marijuana legalized, two groups still oppose cannabis . According to Gallup's 2016 survey, just 42% of respondents who identify as Republican favored the idea of legalizing pot nationally. The second group is seniors aged 55 and up. Just 45% of seniors supported the idea of legalizing weed nationwide. It should be noted that both groups have softened their views on marijuana and increased their support over the past decade, but with Republicans in charge of Congress, it could slow pot's progress on Capitol Hill.
4. There's no shortage of marijuana stocks to choose from
If investing in marijuana stocks is on your agenda, you'll certainly have no shortage of companies to choose from. There are dozens of publicly traded marijuana stocks (albeit no marijuana electronic-traded funds for the time being), though most of the publicly traded companies tend to be pretty small in terms of market cap. The largest pot stock is the aforementioned GW Pharmaceuticals, with a valuation that's north of $3 billion.
5. Most pot stocks trade on the OTC exchanges
Because reputable exchanges like the New York Stock Exchange (NYSE) and Nasdaq have market-cap and share-price requirements, the vast majority of marijuana stocks trade on the over-the-counter boards or pink sheets. The good news for investors is that the over-the-counter (OTC) exchanges have done a good job of ratcheting up listing and reporting standards over the past couple of years. However, they're still no NYSE or Nasdaq. This can make it quite difficult for investors to get up-to-date and accurate information on the marijuana stocks they're considering for their portfolios.
6. Nearly all marijuana stocks are losing money
Another issue that investors should strongly consider is that practically all marijuana stocks are currently losing money. Back in the late 1990s and early 2000s, losses were overlooked for internet-based companies with the thinking that their top-line growth would save the day. This soon led to the dot-com bubble. Fundamentals always matter. The big question to consider is whether these cannabis companies have the capital to survive the early years and development of the legal pot industry.
7. Monopolies are beginning to gain hold
The marijuana industry is primarily segmented, with many smaller businesses operating in the retail, growing, and processing side of the equation at the state level. However, states like Colorado have begun to see a larger infiltration of big businesses. A moratorium on recreational pot licenses has allowed big business in Colorado to scoop up many of the available licenses, while in Washington, bigger businesses are flooding the market with product. While these moves in Colorado and Washington state could pave the way for a big business takeover of the industry, it also means lower margins in the meantime.
8. Cannabis businesses have little access to banking
As has long been the case, pot stocks don't have much in the way of access to financial institutions. Banks ultimately report to the federal government, and since the federal government deems marijuana to be a schedule 1 substance, providing a checking account or a loan to a marijuana business could be viewed as money laundering. With so few basic banking options, most cannabis businesses are forced to deal solely in cash, which is a major security concern and an inhibitor of growth.
9. U.S. tax code 280E is a nuisance
Weed stocks also face a major tax code disadvantage known as 280E. The Internal Revenue Service disallows businesses from taking normal business tax deductions if they're selling a substance that the federal government deems is illegal -- and marijuana most definitely is illegal. This means marijuana businesses are likely paying tax on their gross profits instead of net profits, leaving them less money to reinvest, hire, and buy new product.
10. The Trump administration may crack down on recreational pot
The Obama administration maintained a very hands-off approach to marijuana, allowing states to handle the regulation of their medical and/or recreational pot industries. White House press secretary Sean Spicer recently suggested that the Trump administration won't be as lax. While Trump has pledged to allow states to legalize access to medical marijuana, Spicer signaled that the federal government could be more stringent with its enforcement of recreational weed laws. Exactly how stringent remains to be seen.
11. Attorney General Jeff Sessions is no fan
Along those same lines, new Attorney General Jeff Sessions is a major opponent of the marijuana industry. Sessions doesn't believe marijuana is a drug that good people use, nor does he believe that it can make a difference in reducing the opioid epidemic in America. While Sessions commented during his confirmation hearing that he would abide by the president's policy on pot, he would probably like nothing more than to stamp out any opportunity for marijuana's expansion.
12. The DEA is no fan, either
The U.S. Drug Enforcement Agency (DEA) had an opportunity this past summer to consider rescheduling or de-scheduling marijuana, but chose not to. The DEA pointed to a lack of clinical benefits and safety data, as well as insufficient oversight, as its reasoning why it was keeping cannabis as a schedule 1 substance. Because petitions can take so long to work their way up to the DEA, it's unlikely that it'll give cannabis another look for years to come.
13. A congressional Catch-22
Aside from Congress being made up of a majority of Republicans who, as was noted earlier, tend to have an unfavorable view on marijuana, Congress's staunch stance on keeping pot as a schedule 1 substance creates an annoying Catch-22 for the industry. Lawmakers on Capitol Hill want more clinical data to pore over, but those trials can't be run as long as cannabis remains in the restrictive schedule 1 status. Even promising clinical products, such as GW Pharmaceuticals' Epidiolex, which met its primary endpoints in late-stage studies to treat two types of childhood-onset epilepsy, are no sure thing to be approved by the Food and Drug Administration (FDA).
14. State expansion may slow
The marijuana industry has numerous expansionary channels, but the industry may soon have to rely on organic growth if it wants to move the needle. Between Trump, Sessions, and the DEA on Capitol Hill, and the fact that many of the remaining medical marijuana states that haven't legalized are under Republican control, state-level expansion may wind up slowing in the years to come.
15. Rescheduling could be a nightmare
Finally, it's important for investors to realize that a rescheduling of marijuana at the federal level isn't necessarily a solution. Even if Congress or the DEA moves marijuana down a notch to schedule 2, it could make things even worse for the pot industry.
While a schedule 2 status would recognize cannabis as having medically beneficial qualities, it would also give the FDA the power to tightly regulate pot as a drug. This means regulating marketing and packaging of medical cannabis, overseeing its manufacturing, and possibly even requiring companies to run costly and time-consuming clinical studies on the benefits and safety of marijuana.
As you can see, investing in marijuana stocks is probably a lot more complicated than you may have realized at first. In many ways, they could prove to be more trouble that they're worth, in spite of their superior growth rates.
10 stocks we like better than GW Pharmaceuticals
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and GW Pharmaceuticals wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of February 6, 2017
Sean Williams has no position in any stocks mentioned. The Motley Fool recommends Nasdaq. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Between Trump, Sessions, and the DEA on Capitol Hill, and the fact that many of the remaining medical marijuana states that haven't legalized are under Republican control, state-level expansion may wind up slowing in the years to come. According to Gallup's 2016 survey, just 42% of respondents who identify as Republican favored the idea of legalizing pot nationally. Just 45% of seniors supported the idea of legalizing weed nationwide.
|
According to Gallup's 2016 survey, just 42% of respondents who identify as Republican favored the idea of legalizing pot nationally. Just 45% of seniors supported the idea of legalizing weed nationwide. With so few basic banking options, most cannabis businesses are forced to deal solely in cash, which is a major security concern and an inhibitor of growth.
|
According to Gallup's 2016 survey, just 42% of respondents who identify as Republican favored the idea of legalizing pot nationally. Just 45% of seniors supported the idea of legalizing weed nationwide. With so few basic banking options, most cannabis businesses are forced to deal solely in cash, which is a major security concern and an inhibitor of growth.
|
Even if Congress or the DEA moves marijuana down a notch to schedule 2, it could make things even worse for the pot industry. According to Gallup's 2016 survey, just 42% of respondents who identify as Republican favored the idea of legalizing pot nationally. Just 45% of seniors supported the idea of legalizing weed nationwide.
|
2d2860e0-71f7-429d-aa99-377a299781d3
|
723562.0
|
2017-03-19 00:00:00 UTC
|
Here's the Scoop on a Recently Introduced Marijuana Bill That Would Protect States' Rights
|
DEA
|
https://www.nasdaq.com/articles/heres-scoop-recently-introduced-marijuana-bill-would-protect-states-rights-2017-03-19
|
nan
|
nan
|
The marijuana industry has been practically unstoppable for the better part of four years.
Since 2012, eight states (along with Washington, D.C.) have legalized recreational, adult-use pot, including residents in four states who voted in favor of doing so in the November 2016 election. In fact, if not for Arizona, which had its adult-use proposition fail in the November elections, marijuana would have had a clean sweep.
Just as impressive, since 1996 -- which is when California became the first state to legalize medical cannabis for compassionate use in select ailments -- 28 states have legalized medical marijuana. Two states (Ohio and Pennsylvania) did so in 2016 entirely through the legislative process.
Marijuana's momentum can partially be traced to the rapidly changing perception of the drug. A recently conducted survey from the independent Quinnipiac University found that 59% of respondents would like to see pot legalized nationally compared to just 36% of respondents who oppose such legalization. A more robust 93% favored the legalization of medical cannabis compared to just 6% who opposed it.
The other half of the formula is the money behind the marijuana industry. Cannabis research firm ArcView Market Research recently reported that North American legal pot sales totaled $6.9 billion in 2016, up 34% from the previous year. Yet, $46.4 billion in sales last year still came from the black market, implying that the industry has plenty of work -- and opportunity -- ahead.
Capitol Hill is a major impediment
Despite what may have seemed like a near-perfect 2016, the marijuana industry was dealt a blow in August when the U.S. Drug Enforcement Agency (DEA) chose to deny two petitions to reschedule (or de-schedule) cannabis from its current status as Schedule 1. The DEA justified its decision by claiming that there wasn't enough clinical and safety evidence to support a scheduling change, and there wasn't adequate oversight for what's deemed to be a highly addictive and illegal substance with no medical benefits. It'll probably be many years before the DEA considers rescheduling cannabis again.
A more recent cause for concern came directly from White House press secretary Sean Spicer. Spicer commented last month that the Trump administration wouldn't be as lax on marijuana enforcement as the Obama administration, which had a hands-off approach to pot regulation. Though Trump has strongly supported medical cannabis in the past, and will likely allow states to continue setting their own medical marijuana laws, it's becoming more likely that the federal government could crack down on recreational marijuana at the state level.
This clearly has the industry worried.
This new pot bill would protect states' rights
But a recently introduced bill in Congress could help protect existing consumers and businesses in states that have passed marijuana initiatives or amendments.
On Feb. 7, 2017, Rep. Dana Rohrabacher (D-Ca.) introduced House Bill 975 (link opens PDF), which is more affably known as the "Respect State Marijuana Laws Act of 2017." The bill, which has bipartisan support from seven Democrats and seven Republicans, would seek to protect the rights of states that have chosen to legalize medical and/or recreational pot.
Officially, as written in H.R. 975:
In other words, if H.R. 975 were to pass, the federal government couldn't enforce federal law on consumers and businesses that are operating within their legal rights in medical and recreational marijuana states.
Additionally, H.R. 975 would provide significant clarity when it comes to providing basic banking services to the cannabis industry. Somewhere around half of all pot businesses aren't even receiving banking services, meaning many are forced to deal entirely in cash, which is a major security concern. Because marijuana is illegal, and most banks are regulated by the Federal Deposit Insurance Corporation, offering banking services to the marijuana industry could be construed as money laundering.
The timing of this bill is also intriguing given that Rohrabacher and three of his colleagues -- Rep. Don Young (R-Ak.), Rep. Earl Blumenauer (D-Or.), and Rep. Jared Polis (D-Co.) -- formed the Congressional Cannabis Caucus to attempt to facilitate change in Washington that would bridge the currently wide gap between federal law and state laws on marijuana.
Will it work?
The formation of a Cannabis Caucus is a bold move on Capitol Hill that signals just how far the public opinion of marijuana has come in a relatively short period of time. Realistically, though, Rohrabacher's bill is probably dead in the water.
The legislative branch of the U.S. government is entirely Republican-leaning for the time being, and the polling has demonstrated that just two groups are opposed to cannabis' expansion: seniors and Republicans. Though Gallup's polling has shown that both groups have significantly softened their views toward marijuana over the past decade, it's still unlikely that the current Congress is going to be open to the idea of decriminalizing or rescheduling the drug.
So, what does that mean for marijuana stocks and pot businesses as a whole? Likely more of the same.
If Rohrabacher's bill fails to gain momentum, it'll mean that most marijuana companies will be forced to continue dealing in cash. It also means that pot businesses will be unable to get around U.S. tax code 280E, which disallows businesses that are selling an illegal substance from taking normal tax deductions.
In short, the deck will remain stacked against marijuana stocks and the industry in general. Investors would be wise to keep their dollars safely on the sidelines.
10 stocks we like better than Wal-Mart
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, the Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Wal-Mart wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of March 6, 2017
The author(s) may have a position in any stocks mentioned.
The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Capitol Hill is a major impediment Despite what may have seemed like a near-perfect 2016, the marijuana industry was dealt a blow in August when the U.S. Drug Enforcement Agency (DEA) chose to deny two petitions to reschedule (or de-schedule) cannabis from its current status as Schedule 1. Though Gallup's polling has shown that both groups have significantly softened their views toward marijuana over the past decade, it's still unlikely that the current Congress is going to be open to the idea of decriminalizing or rescheduling the drug. The DEA justified its decision by claiming that there wasn't enough clinical and safety evidence to support a scheduling change, and there wasn't adequate oversight for what's deemed to be a highly addictive and illegal substance with no medical benefits.
|
Somewhere around half of all pot businesses aren't even receiving banking services, meaning many are forced to deal entirely in cash, which is a major security concern. Capitol Hill is a major impediment Despite what may have seemed like a near-perfect 2016, the marijuana industry was dealt a blow in August when the U.S. Drug Enforcement Agency (DEA) chose to deny two petitions to reschedule (or de-schedule) cannabis from its current status as Schedule 1. The DEA justified its decision by claiming that there wasn't enough clinical and safety evidence to support a scheduling change, and there wasn't adequate oversight for what's deemed to be a highly addictive and illegal substance with no medical benefits.
|
Capitol Hill is a major impediment Despite what may have seemed like a near-perfect 2016, the marijuana industry was dealt a blow in August when the U.S. Drug Enforcement Agency (DEA) chose to deny two petitions to reschedule (or de-schedule) cannabis from its current status as Schedule 1. The DEA justified its decision by claiming that there wasn't enough clinical and safety evidence to support a scheduling change, and there wasn't adequate oversight for what's deemed to be a highly addictive and illegal substance with no medical benefits. It'll probably be many years before the DEA considers rescheduling cannabis again.
|
If Rohrabacher's bill fails to gain momentum, it'll mean that most marijuana companies will be forced to continue dealing in cash. Capitol Hill is a major impediment Despite what may have seemed like a near-perfect 2016, the marijuana industry was dealt a blow in August when the U.S. Drug Enforcement Agency (DEA) chose to deny two petitions to reschedule (or de-schedule) cannabis from its current status as Schedule 1. The DEA justified its decision by claiming that there wasn't enough clinical and safety evidence to support a scheduling change, and there wasn't adequate oversight for what's deemed to be a highly addictive and illegal substance with no medical benefits.
|
a106bf5a-f12f-4aa2-abba-16c5bfbffe49
|
723563.0
|
2017-03-12 00:00:00 UTC
|
If President Trump Wants Jobs, This Report Says He Should Leave Marijuana Alone
|
DEA
|
https://www.nasdaq.com/articles/if-president-trump-wants-jobs-report-says-he-should-leave-marijuana-alone-2017-03-12
|
nan
|
nan
|
President Trump promised in his inauguration speech to create 25 million new jobs for Americans in the next decade. A new report indicates one way to help get to that goal is to allow states that have legalized marijuana to move forward uninterrupted.
New Frontier Data, which specializes in data analysis for the cannabis industry, recently published a report projecting that legalized marijuana will create close to 300,000 jobs over the next three years. But is this projection realistic?
Calculating from Colorado
Colorado was the first state to legalize recreational marijuana, changing its laws in 2013 with legalization taking effect in 2014. At the end of 2015, over 2,500 businesses were licensed in Colorado to sell marijuana, according to research performed by the state's Department of Public Safety.
These new businesses are estimated to have created 20,000 new jobs in Colorado. There has also been a positive but unmeasured impact on jobs with ancillary businesses. But that's just in one state.
Since Colorado legalized recreational marijuana, another seven states plus the District of Columbia have followed suit. The total population of these seven states and one district is more than 11 times the size of Colorado's population. (California's population alone is seven times larger than that of Colorado.)
Based on population, it makes sense that at least 220,000 jobs could be created due to legalized recreational marijuana in these states. But what about the remaining jobs needed to arrive at New Frontier Data's estimated total?
Twenty other states have legalized medical marijuana. That figure doesn't count 16 states that allow limited use of medical marijuana. It's not too much of a stretch to estimate that close to 80,000 jobs could be created to meet the demand for medical marijuana in these states.
What kind of jobs
Many of the jobs created by marijuana growers pay quite nicely. A "grow master" with primary responsibilities for cultivating strains of marijuana can make $100,000 in some cases. Marijuana dispensaries need store managers just like other retailers; salaries for these store managers can be up to $75,000.
As with any industry, though, there are more lower-paying jobs than high-paying jobs. Employees who cut marijuana flowers from stems, called "bud trimmers," typically make around $13 per hour. Marijuana growers also need workers for jobs similar to those at other companies, including packaging staff, delivery drivers, receptionists, and retail sales staff.
Most marijuana companies won't generate a large number of jobs. If we look at Colorado, for example, dividing 20,000 jobs by roughly 2,500 businesses gives an average of eight jobs per business.
One of the largest publicly traded marijuana companies, Medical Marijuana, Inc. (NASDAQOTH: MJNA) , has only 18 employees. That number includes the company's CEO, corporate secretary, and vice president of operations. It also includes Medical Marijuana's eight subsidiaries.
Medical Marijuana's employee count hints at something that the job estimates from New Frontier Data don't mention: Many of the jobs created by the industry are contract or part-time positions. A quick look at one of the jobs sites that focus on the marijuana industry, like 420careers.com, shows quite a few part-time and freelance jobs listed.
The bigger picture
The White House has indicated that it plans to enforce federal laws related to recreational use of marijuana, but views medical marijuana differently. A crackdown by the U.S. Drug Enforcement Administration (DEA) could make the marijuana jobs projections disappear like a puff of smoke.
However, if the Trump administration looks at estimates from the U.S. Bureau of Labor Statistics, perhaps it could change its tune. The federal agency projects that only 13 industries will create more jobs by 2024 than the marijuana industry could in just three years. Twenty major industries will lose a combined 1.2 million jobs.
Will the jobs outlook for the marijuana industry help influence federal policies? Perhaps not. However, for the president to reach his goal of creating 25 million jobs over the next decade, he'll need all the help he can get. There could be at least a sliver of hope, for marijuana companies and their investors, that the Trump administration will leave marijuana alone.
10 stocks we like better than Wal-Mart
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, the Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Wal-Mart wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of March 6, 2017
The author(s) may have a position in any stocks mentioned.
Keith Speights has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
A crackdown by the U.S. Drug Enforcement Administration (DEA) could make the marijuana jobs projections disappear like a puff of smoke. At the end of 2015, over 2,500 businesses were licensed in Colorado to sell marijuana, according to research performed by the state's Department of Public Safety. Based on population, it makes sense that at least 220,000 jobs could be created due to legalized recreational marijuana in these states.
|
A crackdown by the U.S. Drug Enforcement Administration (DEA) could make the marijuana jobs projections disappear like a puff of smoke. Calculating from Colorado Colorado was the first state to legalize recreational marijuana, changing its laws in 2013 with legalization taking effect in 2014. Medical Marijuana's employee count hints at something that the job estimates from New Frontier Data don't mention: Many of the jobs created by the industry are contract or part-time positions.
|
A crackdown by the U.S. Drug Enforcement Administration (DEA) could make the marijuana jobs projections disappear like a puff of smoke. Based on population, it makes sense that at least 220,000 jobs could be created due to legalized recreational marijuana in these states. What kind of jobs Many of the jobs created by marijuana growers pay quite nicely.
|
A crackdown by the U.S. Drug Enforcement Administration (DEA) could make the marijuana jobs projections disappear like a puff of smoke. These new businesses are estimated to have created 20,000 new jobs in Colorado. Medical Marijuana's employee count hints at something that the job estimates from New Frontier Data don't mention: Many of the jobs created by the industry are contract or part-time positions.
|
03b62f01-10f2-4c25-8fa0-7586d2105eb1
|
723564.0
|
2017-03-02 00:00:00 UTC
|
Easterly Government Properties, Inc. (DEA) Ex-Dividend Date Scheduled for March 03, 2017
|
DEA
|
https://www.nasdaq.com/articles/easterly-government-properties-inc-dea-ex-dividend-date-scheduled-march-03-2017-2017-03-02
|
nan
|
nan
|
Easterly Government Properties, Inc. ( DEA ) will begin trading ex-dividend on March 03, 2017. A cash dividend payment of $0.24 per share is scheduled to be paid on March 22, 2017. Shareholders who purchased DEA prior to the ex-dividend date are eligible for the cash dividend payment. This represents an 9.09% increase over prior dividend payment.
The previous trading day's last sale of DEA was $20.8, representing a -1.28% decrease from the 52 week high of $21.07 and a 23% increase over the 52 week low of $16.91.
DEA is a part of the Consumer Services sector, which includes companies such as Simon Property Group, Inc. ( SPG ) and American Tower Corporation (REIT) ( AMT ). DEA's current earnings per share, an indicator of a company's profitability, is $.07. Zacks Investment Research reports DEA's forecasted earnings growth in 2016 as 16.03%, compared to an industry average of .7%.
For more information on the declaration, record and payment dates, visit the DEA Dividend History page. Our Dividend Calendar has the full list of stocks that have an ex-dividend today.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
DEA is a part of the Consumer Services sector, which includes companies such as Simon Property Group, Inc. ( SPG ) and American Tower Corporation (REIT) ( AMT ). Zacks Investment Research reports DEA's forecasted earnings growth in 2016 as 16.03%, compared to an industry average of .7%. For more information on the declaration, record and payment dates, visit the DEA Dividend History page.
|
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Easterly Government Properties, Inc. ( DEA ) will begin trading ex-dividend on March 03, 2017. Shareholders who purchased DEA prior to the ex-dividend date are eligible for the cash dividend payment.
|
Shareholders who purchased DEA prior to the ex-dividend date are eligible for the cash dividend payment. The previous trading day's last sale of DEA was $20.8, representing a -1.28% decrease from the 52 week high of $21.07 and a 23% increase over the 52 week low of $16.91. For more information on the declaration, record and payment dates, visit the DEA Dividend History page.
|
Shareholders who purchased DEA prior to the ex-dividend date are eligible for the cash dividend payment. Easterly Government Properties, Inc. ( DEA ) will begin trading ex-dividend on March 03, 2017. The previous trading day's last sale of DEA was $20.8, representing a -1.28% decrease from the 52 week high of $21.07 and a 23% increase over the 52 week low of $16.91.
|
b74b7f03-1cc3-4814-971b-f137703ff6c8
|
723565.0
|
2017-03-01 00:00:00 UTC
|
Pre-Market Earnings Report for March 2, 2017 : CNQ, KR, BUD, BURL, JOY, ACIW, MEI, ANF, DEA, BKS, ANIP, SUP
|
DEA
|
https://www.nasdaq.com/articles/pre-market-earnings-report-march-2-2017-cnq-kr-bud-burl-joy-aciw-mei-anf-dea-bks-anip-sup
|
nan
|
nan
|
The following companies are expected to report earnings prior to market open on 03/02/2017. Visit our Earnings Calendar for a full list of expected earnings releases.
Canadian Natural Resources Limited ( CNQ ) is reporting for the quarter ending December 31, 2016. The oil company's consensus earnings per share forecast from the 1 analyst that follows the stock is $0.07. This value represents a 22.22% decrease compared to the same quarter last year. Zacks Investment Research reports that the 2016 Price to Earnings ratio for CNQ is -63.80 vs. an industry ratio of -26.40.
Kroger Company ( KR ) is reporting for the quarter ending January 31, 2017. The supermarket company's consensus earnings per share forecast from the 10 analysts that follow the stock is $0.53. This value represents a 7.02% decrease compared to the same quarter last year. KR missed the consensus earnings per share in the 4th calendar quarter of 2016 by -2.38%. Zacks Investment Research reports that the 2017 Price to Earnings ratio for KR is 15.07 vs. an industry ratio of 21.30.
Anheuser-Busch Inbev SA ( BUD ) is reporting for the quarter ending December 31, 2016. The alcohol company's consensus earnings per share forecast from the 2 analysts that follow the stock is $1.03. This value represents a 33.97% decrease compared to the same quarter last year. Zacks Investment Research reports that the 2016 Price to Earnings ratio for BUD is 30.00 vs. an industry ratio of 36.80.
Burlington Stores, Inc. ( BURL ) is reporting for the quarter ending January 31, 2017. The discount retail company's consensus earnings per share forecast from the 8 analysts that follow the stock is $1.70. This value represents a 14.09% increase compared to the same quarter last year. In the past year BURL has beat the expectations every quarter. The highest one was in the 4th calendar quarter where they beat the consensus by 51.52%. Zacks Investment Research reports that the 2017 Price to Earnings ratio for BURL is 28.08 vs. an industry ratio of 15.10, implying that they will have a higher earnings growth than their competitors in the same industry.
Joy Global Inc. ( JOY ) is reporting for the quarter ending January 31, 2017. The machinery company's consensus earnings per share forecast from the 3 analysts that follow the stock is $-0.04. This value represents a 82.61% increase compared to the same quarter last year. Zacks Investment Research reports that the 2017 Price to Earnings ratio for JOY is 67.12 vs. an industry ratio of 25.30, implying that they will have a higher earnings growth than their competitors in the same industry.
ACI Worldwide, Inc. ( ACIW ) is reporting for the quarter ending December 31, 2016. The computer software company's consensus earnings per share forecast from the 4 analysts that follow the stock is $0.54. This value represents a 35.00% increase compared to the same quarter last year. The "days to cover" for this stock exceeds 20 days. Zacks Investment Research reports that the 2016 Price to Earnings ratio for ACIW is 51.50 vs. an industry ratio of 58.60.
Methode Electronics, Inc. ( MEI ) is reporting for the quarter ending January 31, 2017. The electrical connectors company's consensus earnings per share forecast from the 4 analysts that follow the stock is $0.52. This value represents a 15.56% increase compared to the same quarter last year. In the past year MEI and beat the expectations the other three quarters. Zacks Investment Research reports that the 2017 Price to Earnings ratio for MEI is 17.36 vs. an industry ratio of 13.20, implying that they will have a higher earnings growth than their competitors in the same industry.
Abercrombie & Fitch Company ( ANF ) is reporting for the quarter ending January 31, 2017. The retail (shoe) company's consensus earnings per share forecast from the 13 analysts that follow the stock is $0.76. This value represents a 29.63% decrease compared to the same quarter last year. Zacks Investment Research reports that the 2017 Price to Earnings ratio for ANF is -239.20 vs. an industry ratio of 6.70.
Easterly Government Properties, Inc. ( DEA ) is reporting for the quarter ending December 31, 2016. The reit company's consensus earnings per share forecast from the 3 analysts that follow the stock is $0.31. This value represents a 19.23% increase compared to the same quarter last year. In the past year DEA has met analyst expectations four times Zacks Investment Research reports that the 2016 Price to Earnings ratio for DEA is 17.08 vs. an industry ratio of 20.20.
Barnes & Noble, Inc. ( BKS ) is reporting for the quarter ending January 31, 2017. The retail company's consensus earnings per share forecast from the 1 analyst that follows the stock is $1.13. This value represents a 8.65% increase compared to the same quarter last year. BKS missed the consensus earnings per share in the 4th calendar quarter of 2016 by -7.41%. Zacks Investment Research reports that the 2017 Price to Earnings ratio for BKS is 17.50 vs. an industry ratio of 20.30.
ANI Pharmaceuticals, Inc. ( ANIP ) is reporting for the quarter ending December 31, 2016. The biomedical (gene) company's consensus earnings per share forecast from the 2 analysts that follow the stock is $1.02. This value represents a 137.21% increase compared to the same quarter last year. ANIP missed the consensus earnings per share in the 4th calendar quarter of 2015 by -6.52%. Zacks Investment Research reports that the 2016 Price to Earnings ratio for ANIP is 16.27 vs. an industry ratio of -2.70, implying that they will have a higher earnings growth than their competitors in the same industry.
Superior Industries International, Inc. ( SUP ) is reporting for the quarter ending December 31, 2016. The auto (truck) company's consensus earnings per share forecast from the 1 analyst that follows the stock is $0.24. This value represents a 36.84% decrease compared to the same quarter last year. In the past year SUP has beat the expectations every quarter. The highest one was in the 3rd calendar quarter where they beat the consensus by 31.58%. Zacks Investment Research reports that the Price to Earnings ratio for SUP is 0.00 vs. an industry ratio of 12.20.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Easterly Government Properties, Inc. ( DEA ) is reporting for the quarter ending December 31, 2016. In the past year DEA has met analyst expectations four times Zacks Investment Research reports that the 2016 Price to Earnings ratio for DEA is 17.08 vs. an industry ratio of 20.20. The discount retail company's consensus earnings per share forecast from the 8 analysts that follow the stock is $1.70.
|
In the past year DEA has met analyst expectations four times Zacks Investment Research reports that the 2016 Price to Earnings ratio for DEA is 17.08 vs. an industry ratio of 20.20. Easterly Government Properties, Inc. ( DEA ) is reporting for the quarter ending December 31, 2016. Zacks Investment Research reports that the 2017 Price to Earnings ratio for BURL is 28.08 vs. an industry ratio of 15.10, implying that they will have a higher earnings growth than their competitors in the same industry.
|
Easterly Government Properties, Inc. ( DEA ) is reporting for the quarter ending December 31, 2016. In the past year DEA has met analyst expectations four times Zacks Investment Research reports that the 2016 Price to Earnings ratio for DEA is 17.08 vs. an industry ratio of 20.20. Zacks Investment Research reports that the 2017 Price to Earnings ratio for BURL is 28.08 vs. an industry ratio of 15.10, implying that they will have a higher earnings growth than their competitors in the same industry.
|
Easterly Government Properties, Inc. ( DEA ) is reporting for the quarter ending December 31, 2016. In the past year DEA has met analyst expectations four times Zacks Investment Research reports that the 2016 Price to Earnings ratio for DEA is 17.08 vs. an industry ratio of 20.20. In the past year BURL has beat the expectations every quarter.
|
6881e834-be2c-4ea3-9287-fd8fa796528f
|
723566.0
|
2017-02-19 00:00:00 UTC
|
3 Reasons Not to Worry (Too Much) About Marijuana Stocks With Trump's New Attorney General
|
DEA
|
https://www.nasdaq.com/articles/3-reasons-not-worry-too-much-about-marijuana-stocks-trumps-new-attorney-general-2017-02-19
|
nan
|
nan
|
President Trump selected a U.S. senator known for his opposition to marijuana legalization to become the new attorney general for the country. Jeff Sessions raised concerns among marijuana legalization proponents during his confirmation hearings with comments such as this one: "The U.S. Congress has made the possession of marijuana in every state, and distribution of it, an illegal act. So if that's not desired any longer, Congress should pass a law to change the rule."
Now, Sessions isn't just a nominee anymore. He is the U.S. attorney general, with broad powers to enforce federal laws. What will change for the expanding medical marijuana industry? Possibly very little. Here are three reasons not to worry (too much) about marijuana stocks being negatively impacted by Jeff Sessions.
1. Trump's previous statements
Remember that the attorney general reports to the president. Sessions' views on marijuana legalization aren't nearly as important as Trump's views on it.
Trump has indicated that he is personally opposed to legalizing marijuana. However, during the presidential campaign, he said, "In terms of marijuana and legalization, I think that should be a state issue, state-by-state." He has also expressed support for legal use of medical marijuana.
During Sessions' confirmation hearings, a spokesman for the Trump administration stated that the attorney general would implement the president's agenda. It seems unlikely that Sessions would go against Trump's policies.
2. Different priorities
Even if Sessions personally wanted to pursue targeting marijuana suppliers operating in states that have legalized marijuana, he's going to have many more critical things on his plate. For one, there's defending President Trump's immigration-related executive orders in court.
Prior to Sessions being sworn in, Trump announced several other executive orders that should keep his new attorney general quite busy. He wants to intensify efforts against international drug cartels. A new national task force charged with reducing violent crime will be created. Trump also wants measures enacted to address violence directed at law enforcement.
It seems pretty clear that Trump's law enforcement priorities will take plenty of time to implement. He hasn't mentioned anything related to cracking down on individuals and businesses that are violating federal laws in states that have legalized marijuana.
3. The other governmental branches
What if Sessions does direct the Drug Enforcement Administration (DEA) to go after marijuana businesses? Even though federal laws clearly prohibit the sale of marijuana, there is legal uncertainty about the U.S. government's rights to shut down state markets. Expect states where marijuana is legal to fight in the federal court system.
Then there's Congress. Two congressmen from California, Rep. Dana Rohrabacher and Rep. Sam Farr, have successfully pushed for inclusion of an amendment into federal spending packages over the past three years that prohibits the federal government from using funds to enforce marijuana laws in states that have legalized medical marijuana. Rep. Rohrabacher and Rep. Farr are trying to keep that amendment in place.
Rep. Rohrabacher and 12 co-sponsors from both major political parties also introduced legislation titled the "Respect States Marijuana Laws Act of 2017." This bill would change the Controlled Substances Act to prioritize state law above federal laws.
There's no guarantee that these efforts by congressional representatives will gain traction, of course. However, any actions by Sessions to crack down in states where marijuana is now legalized could allow Rep. Rohrabacher and the other co-sponsors to win more support for their bill.
A reason to worry
I don't think there's much reason to worry about marijuana stocks being hurt by Jeff Sessions or the Trump administration in general. There is one reason for concern, though.
Falling cannabis prices will eventually make it more difficult for some marijuana companies to succeed. Marijuana could become just like any other commodity. Only the biggest and most differentiated companies will survive if that happens. The biggest risk for marijuana stocks probably isn't enforcement of federal anti-marijuana laws but another more universal law: the law of supply and demand.
10 stocks we like better than Wal-Mart
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, the Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Wal-Mart wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as ofDecember 12 , 2016
The author(s) may have a position in any stocks mentioned.
The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
The other governmental branches What if Sessions does direct the Drug Enforcement Administration (DEA) to go after marijuana businesses? During Sessions' confirmation hearings, a spokesman for the Trump administration stated that the attorney general would implement the president's agenda. Even though federal laws clearly prohibit the sale of marijuana, there is legal uncertainty about the U.S. government's rights to shut down state markets.
|
The other governmental branches What if Sessions does direct the Drug Enforcement Administration (DEA) to go after marijuana businesses? During Sessions' confirmation hearings, a spokesman for the Trump administration stated that the attorney general would implement the president's agenda. Two congressmen from California, Rep. Dana Rohrabacher and Rep. Sam Farr, have successfully pushed for inclusion of an amendment into federal spending packages over the past three years that prohibits the federal government from using funds to enforce marijuana laws in states that have legalized medical marijuana.
|
The other governmental branches What if Sessions does direct the Drug Enforcement Administration (DEA) to go after marijuana businesses? Jeff Sessions raised concerns among marijuana legalization proponents during his confirmation hearings with comments such as this one: "The U.S. Congress has made the possession of marijuana in every state, and distribution of it, an illegal act. Two congressmen from California, Rep. Dana Rohrabacher and Rep. Sam Farr, have successfully pushed for inclusion of an amendment into federal spending packages over the past three years that prohibits the federal government from using funds to enforce marijuana laws in states that have legalized medical marijuana.
|
The other governmental branches What if Sessions does direct the Drug Enforcement Administration (DEA) to go after marijuana businesses? He is the U.S. attorney general, with broad powers to enforce federal laws. During Sessions' confirmation hearings, a spokesman for the Trump administration stated that the attorney general would implement the president's agenda.
|
29ddd94c-085e-4a18-9a10-e60ab390c0ff
|
723567.0
|
2017-01-29 00:00:00 UTC
|
3 Marijuana Stocks Ready to Soar in 2017
|
DEA
|
https://www.nasdaq.com/articles/3-marijuana-stocks-ready-soar-2017-2017-01-29
|
nan
|
nan
|
Marijuana stocks enjoyed a terrific year in 2016. Barring increased enforcement of federal laws prohibiting the sale of marijuana, many of these stocks should continue to do well this year. Put GW Pharmaceuticals (NASDAQ: GWPH) , Insys Therapeutics (NASDAQ: INSY) , and Scotts Miracle-Gro (NYSE: SMG) near the top of the list of marijuana stocks ready to soar in 2017. Here's why.
Image source: Getty Images.
GW Pharmaceuticals: Coming to America?
GW Pharmaceuticals claims to be "the world leader in cannabinoid science." Whether or not the company deserves that mantle, GW is certainly one of the top developers of cannabinoid drugs. GW's Sativex is marketed in 16 countries for treating multiple sclerosis spasticity and has won regulatory approval in a dozen other countries. However, Sativex isn't approved in the U.S.
It's quite possible, though, that GW Pharmaceuticals will crack the U.S. market before long -- but with another drug. The company expects to submit Epidiolex for approval by the U.S. Food and Drug Administration (FDA) in the first half of 2017 for the treatment of two rare forms of epilepsy, Dravet syndrome and Lennox-Gastaut syndrome.
GW reported positive results last year from three late-stage clinical studies of Epidiolex. The drug, which is a liquid formulation of pure plant-derived cannabidiol, was found to significantly reduce seizure frequency compared to placebo, and it was generally well-tolerated by patients.
GW Pharmaceuticals' stock shot up more than 60% in 2016. I think its shares will continue to climb this year in anticipation of the FDA submissions for Epidiolex and ultimate approval in 2018.
Insys Therapeutics: A bounce on the schedule?
Unlike GW Pharmaceuticals, Insys Therapeutics had a rotten year in 2016. Insys' stock dropped more than 65% last year thanks to plunging sales of Subsys, the company's sublingual fentanyl spray for breakthrough cancer pain.
If Insys' fortunes were entirely dependent on Subsys, I wouldn't hold much hope that 2017 will be better than last year. However, Insys won regulatory approval for another drug last July: its first cannabinoid product, Syndros.
Syndros gained approval from the FDA for treating anorexia associated with weight loss in patients with AIDS, as well as nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional treatments. Because the drug contains a marijuana-based ingredient, it must be scheduled as a controlled substance by the U.S. Drug Enforcement Administration (DEA).
I suspect that Insys will see a big bounce when the DEA completes the scheduling for Syndros. The company projects peak sales of $200 million or more for the drug. I suspect that could be on the low end of Syndros' potential. Considering that Insys probably will make less than $250 million in total revenue for 2016, good news from the DEA should translate to nice gains for the stock this year.
Scotts Miracle-Gro: The marijuana stock that isn't a marijuana stock
You won't find any products sold by Scotts Miracle-Gro that contain even a trace of marijuana. So why is the stock included on a list of marijuana stocks? Because many marijuana growers depend heavily on the company's products.
Scotts has been scooping up leading hydroponics companies over the past few years. In 2014, the company gained control of AeroGrow International. In 2015, it bought General Hydroponics and Vermicrop. Last year, Scotts acquired American Agritech and Gavita, which markets indoor lighting systems for greenhouses and hydroponic gardening. These moves have helped make Scotts Miracle-Gro a go-to provider for marijuana growers.
While Scotts doesn't talk much about its dominant position in the marijuana market, it's clear the company knows exactly what it's doing. Scotts' latest 10-K annual report filing to the U.S. Securities and Exchange Commission states that the company's hydroponic gardening products "may be purchased for use in industries or segments that are subject to inconsistent and rapidly changing laws and regulations with evolving consumer perceptions." That's a pretty good description of the U.S. marijuana industry.
Scotts Miracle-Gro's share price jumped nearly 50% in 2016. Can it go even higher? I think so. The stock trades at 20 times forward earnings, which is a bit pricey. However, the relaxation of marijuana laws in more states in the November elections has opened up a much bigger market for Scotts for 2017 and beyond.
10 stocks we like better than Wal-Mart
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, the Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Wal-Mart wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as ofDecember 12 , 2016
The author(s) may have a position in any stocks mentioned.
Keith Speights has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Because the drug contains a marijuana-based ingredient, it must be scheduled as a controlled substance by the U.S. Drug Enforcement Administration (DEA). I suspect that Insys will see a big bounce when the DEA completes the scheduling for Syndros. Considering that Insys probably will make less than $250 million in total revenue for 2016, good news from the DEA should translate to nice gains for the stock this year.
|
Because the drug contains a marijuana-based ingredient, it must be scheduled as a controlled substance by the U.S. Drug Enforcement Administration (DEA). I suspect that Insys will see a big bounce when the DEA completes the scheduling for Syndros. Considering that Insys probably will make less than $250 million in total revenue for 2016, good news from the DEA should translate to nice gains for the stock this year.
|
Because the drug contains a marijuana-based ingredient, it must be scheduled as a controlled substance by the U.S. Drug Enforcement Administration (DEA). I suspect that Insys will see a big bounce when the DEA completes the scheduling for Syndros. Considering that Insys probably will make less than $250 million in total revenue for 2016, good news from the DEA should translate to nice gains for the stock this year.
|
Because the drug contains a marijuana-based ingredient, it must be scheduled as a controlled substance by the U.S. Drug Enforcement Administration (DEA). I suspect that Insys will see a big bounce when the DEA completes the scheduling for Syndros. Considering that Insys probably will make less than $250 million in total revenue for 2016, good news from the DEA should translate to nice gains for the stock this year.
|
91e60a7a-6468-4c9b-b55d-8accfff7c866
|
723568.0
|
2016-11-22 00:00:00 UTC
|
The 3 Best REITs to Buy Under the Trump Presidency
|
DEA
|
https://www.nasdaq.com/articles/the-3-best-reits-to-buy-under-the-trump-presidency-2016-11-22
|
nan
|
nan
|
InvestorPlace InvestorPlace - Stock Market News, Stock Advice & Trading Tips
With the presidential election decided, it's time to take a look at some sectors to see which stocks might offer opportunities to profit. Certainly, one has to look at real estate investment trusts. There are many types of REITs, but one thing they all have in common is that their underlying real estate must generate revenue on an ongoing basis.
There is a general perception that a Trump presidency will be good for the overall economy, and so REITs should benefit in general, as well.There is concern that rates will rise, but the economy has to improve before that happens.
Nevertheless, finding which REITs to buy means that the REITs need to have pricing power incorporated into their rental schemes to offset potential interest rate increases, or have rock-solid ongoing tenancies.
The 10 Best S&P 500 Blue-Chip Dividend Stocks to Buy Now
With that as a backdrop, here are three suggestions for REITs to buy in a Trump presidency.
REITs to Buy in a Trump Presidency: Easterly Government Properties Inc (DEA)
Dividend Yield:
Easterly Government Properties Inc (NYSE: DEA ) invests primarily in government-leased buildings. Who better to lease to than a client with infinite resources that will never go bankrupt? DEA properties are all handled through the General Services Administration which has been leasing up a storm for the last twenty years.
Now, within the federal government, which agencies would REITs like DEA most love to lease to? Those offering essential services, like the FBI and ICE. These two agencies alone account for about 21% of total lease income.
Thus, even if Trump pulls way back on government spending (which isn't at all guaranteed), these two divisions won't be cut back. If anything, ICE will see increased budgets.
Sure enough, DEA has 100% of its properties leased out with an average term of 7 years. The idea that DEA is insulted from interest rate increases comes from the fact that, because these agencies are pretty central to the nation, DEA can raise rents as needed to offset rate risk.
REITs to Buy in a Trump Presidency: Corporate Office Properties Trust (OFC)
Dividend Yield:
Sticking with this same theme, I've come across Corporate Office Properties Trust (NYSE: OFC ) which, despite its name, is actually another REIT to buy that leases a lot of property to the feds. It is super-focused on companies involved in defense and national security.
That means about 30% of the portfolio is leased to the government itself, and another 57% are leased to defense firms like Boeing Co (NYSE: BA ). The remaining 13% are leased to big, urban office buildings.
This has led to some great revenue charts for OFC because, despite the sequester (remember that?), there has been a 40% growth in revenue since 2011. It is leasing close to a million square feet per year. Debt is mostly unsecured and first maturity isn't until 2020.
The 10 Best Growth Stocks to Buy for 2017
Sentiment regarding OFC has improved, with stock at $28.80. It hit $19.50 just in the past year.
REITs to Buy in a Trump Presidency: Ladder Capital Corp (LADR)
Dividend Yield:
Still, shouldn't we be prepared for rising interest rates when we consider REITs to buy? Sure, so have a look at Ladder Capital Corp (NYSE: LADR ). This is a commercial mREIT, which I generally avoided because anything with the word "mortgage" involved still scares me.
However, LADR is a different beast. LADR drops its capital into the equity and debt of commercial real estate. This sector is doing quite well, there's a lot of activity and that translates to a need for capital.
I'm not crazy about holding actual mortgage debt, so what I love about LADR is that it will either purchase loans or originate them and either sells them off or holds some with laddered maturities. Best of all, it sticks primarily to senior secured loans.
Lawrence Meyers is the CEO of PDL Capital, and manager of the forthcoming Liberty Portfolio stock newsletter . As of this writing, he has no position in any stock mentioned. He has 22 years' experience in the stock market, and has written more than 1,600 articles on investing. Lawrence Meyers can be reached at TheLibertyPortfolio@gmail.com .
The post The 3 Best REITs to Buy Under the Trump Presidency appeared first on InvestorPlace .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
DEA properties are all handled through the General Services Administration which has been leasing up a storm for the last twenty years. REITs to Buy in a Trump Presidency: Easterly Government Properties Inc (DEA) Dividend Yield: Easterly Government Properties Inc (NYSE: DEA ) invests primarily in government-leased buildings. Now, within the federal government, which agencies would REITs like DEA most love to lease to?
|
REITs to Buy in a Trump Presidency: Easterly Government Properties Inc (DEA) Dividend Yield: Easterly Government Properties Inc (NYSE: DEA ) invests primarily in government-leased buildings. DEA properties are all handled through the General Services Administration which has been leasing up a storm for the last twenty years. Now, within the federal government, which agencies would REITs like DEA most love to lease to?
|
REITs to Buy in a Trump Presidency: Easterly Government Properties Inc (DEA) Dividend Yield: Easterly Government Properties Inc (NYSE: DEA ) invests primarily in government-leased buildings. DEA properties are all handled through the General Services Administration which has been leasing up a storm for the last twenty years. Now, within the federal government, which agencies would REITs like DEA most love to lease to?
|
REITs to Buy in a Trump Presidency: Easterly Government Properties Inc (DEA) Dividend Yield: Easterly Government Properties Inc (NYSE: DEA ) invests primarily in government-leased buildings. DEA properties are all handled through the General Services Administration which has been leasing up a storm for the last twenty years. Now, within the federal government, which agencies would REITs like DEA most love to lease to?
|
1a0fa4e2-356a-4042-8829-58743268bce5
|
723569.0
|
2016-10-05 00:00:00 UTC
|
5 REIT Stocks to Avoid as Chances of Rate Hike Increase
|
DEA
|
https://www.nasdaq.com/articles/5-reit-stocks-to-avoid-as-chances-of-rate-hike-increase-2016-10-05
|
nan
|
nan
|
Speculation regarding the timing of the next rate hike has kept the real estate investment trust ("REIT") sector on tenterhooks. However, the possibility of another hike has been doing the rounds since the last rate hike in Dec 2015. And any further hike in rates will adversely affect the REIT industry. (Read: REIT Stocks in Free Fall, Thanks to Rate Hike Speculation )
Now, the chances of a hike have increased. Currently the job market is robust and near to the full employment level. Further, the rate of inflation is close to the target level and is likely to gather pace. The global economy and the financial markets, are now better placed, raising the possibility of a rate hike.
Currently, the target range of a hike is between 0.25% and 0.50% and majority of the policymakers expect a rise in rates by 0.25% before the end of 2016.
Notably, there is an inverse relationship between rate of interest and the REIT sector. An increase in interest rate raises borrowing costs for REITs, which in turn, negatively impacts their profitability. Moreover, REITs are viewed as dividend-yielding investments. A rise in interest rate puts pressure on dividend yields, thereby making REIT stocks less attractive.
REITs to Avoid
Given such a situation, when the odds of a rate hike are quite high, it is time to be extra cautious about keeping REIT stocks in your portfolio. Here we have selected few potentially risky REIT stocks by using the Zacks Screener . Among the sell rated (Zacks rank # 4 or 5) REITs, stocks with negative three to five year earnings growth have been taken. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
We have further narrowed down the list on the basis of Value Style Score . We have selected only those with Value Score of more than C.
Newton, MA-based Select Income REITSIR is a residential REIT formed to primarily own and invest in net leased, single tenant properties.
Zacks Rank: #4
% Change F1 Est. (four weeks) = -1.24%
Value Score= C
SELECT INCOME Price
SELECT INCOME Price | SELECT INCOME Quote
LTC Properties Inc.LTC is a Westlake Village, CA-based health care REIT which mainly invests in long-term care and other health care related facilities.
Zacks Rank: #4
% Change F1 Est. (four weeks) = -0.07%
Value Score= D
LTC PROPERTIES Price
LTC PROPERTIES Price | LTC PROPERTIES Quote
Milwaukee, WI-based Physicians Realty TrustDOC is a healthcare REIT which is engaged in acquiring, developing, owning and managing healthcare properties.
Zacks Rank: #4
% Change F1 Est. (four weeks) = -0.26%
Value Score= F
PHYSICIANS RLTY Price
PHYSICIANS RLTY Price | PHYSICIANS RLTY Quote
Investors Real Estate TrustIRET is a Minot, ND-based REIT, primarily engaged in investment and operation of the real estate assets.
Zacks Rank: #4
% Change F1 Est. (four weeks) = -4.1%
Value Score= C
INVESTORS RL ES Price
INVESTORS RL ES Price | INVESTORS RL ES Quote
Washington, DC-based Easterly Government Properties, Inc.DEA is mainly focused on the acquisition, development and management of commercial properties in the U.S.
Zacks Rank: #4
% Change F1 Est. (four weeks) = 0%
Value Score= D
EASTRLY GOV PPT Price
EASTRLY GOV PPT Price | EASTRLY GOV PPT Quote
Zacks' Best Investment Ideas for Long-Term Profit
Today you can gain access to long-term trades with double and triple-digit profit potential rarely available to the public. Starting now, you can look inside our stocks under $10, home run and value stock portfolios, plus more. Want a peek at this private information? Click here >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
LTC PROPERTIES (LTC): Free Stock Analysis Report
SELECT INCOME (SIR): Free Stock Analysis Report
INVESTORS RL ES (IRET): Free Stock Analysis Report
EASTRLY GOV PPT (DEA): Free Stock Analysis Report
PHYSICIANS RLTY (DOC): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
(four weeks) = -4.1% Value Score= C INVESTORS RL ES Price INVESTORS RL ES Price | INVESTORS RL ES Quote Washington, DC-based Easterly Government Properties, Inc.DEA is mainly focused on the acquisition, development and management of commercial properties in the U.S. Zacks Rank: #4 % Change F1 Est. (four weeks) = 0% Value Score= D EASTRLY GOV PPT Price EASTRLY GOV PPT Price | EASTRLY GOV PPT Quote Zacks' Best Investment Ideas for Long-Term Profit Today you can gain access to long-term trades with double and triple-digit profit potential rarely available to the public. Click to get this free report LTC PROPERTIES (LTC): Free Stock Analysis Report SELECT INCOME (SIR): Free Stock Analysis Report INVESTORS RL ES (IRET): Free Stock Analysis Report EASTRLY GOV PPT (DEA): Free Stock Analysis Report PHYSICIANS RLTY (DOC): Free Stock Analysis Report To read this article on Zacks.com click here.
|
(four weeks) = 0% Value Score= D EASTRLY GOV PPT Price EASTRLY GOV PPT Price | EASTRLY GOV PPT Quote Zacks' Best Investment Ideas for Long-Term Profit Today you can gain access to long-term trades with double and triple-digit profit potential rarely available to the public. Click to get this free report LTC PROPERTIES (LTC): Free Stock Analysis Report SELECT INCOME (SIR): Free Stock Analysis Report INVESTORS RL ES (IRET): Free Stock Analysis Report EASTRLY GOV PPT (DEA): Free Stock Analysis Report PHYSICIANS RLTY (DOC): Free Stock Analysis Report To read this article on Zacks.com click here. (four weeks) = -4.1% Value Score= C INVESTORS RL ES Price INVESTORS RL ES Price | INVESTORS RL ES Quote Washington, DC-based Easterly Government Properties, Inc.DEA is mainly focused on the acquisition, development and management of commercial properties in the U.S. Zacks Rank: #4 % Change F1 Est.
|
(four weeks) = -4.1% Value Score= C INVESTORS RL ES Price INVESTORS RL ES Price | INVESTORS RL ES Quote Washington, DC-based Easterly Government Properties, Inc.DEA is mainly focused on the acquisition, development and management of commercial properties in the U.S. Zacks Rank: #4 % Change F1 Est. Click to get this free report LTC PROPERTIES (LTC): Free Stock Analysis Report SELECT INCOME (SIR): Free Stock Analysis Report INVESTORS RL ES (IRET): Free Stock Analysis Report EASTRLY GOV PPT (DEA): Free Stock Analysis Report PHYSICIANS RLTY (DOC): Free Stock Analysis Report To read this article on Zacks.com click here. (four weeks) = 0% Value Score= D EASTRLY GOV PPT Price EASTRLY GOV PPT Price | EASTRLY GOV PPT Quote Zacks' Best Investment Ideas for Long-Term Profit Today you can gain access to long-term trades with double and triple-digit profit potential rarely available to the public.
|
(four weeks) = -4.1% Value Score= C INVESTORS RL ES Price INVESTORS RL ES Price | INVESTORS RL ES Quote Washington, DC-based Easterly Government Properties, Inc.DEA is mainly focused on the acquisition, development and management of commercial properties in the U.S. Zacks Rank: #4 % Change F1 Est. (four weeks) = 0% Value Score= D EASTRLY GOV PPT Price EASTRLY GOV PPT Price | EASTRLY GOV PPT Quote Zacks' Best Investment Ideas for Long-Term Profit Today you can gain access to long-term trades with double and triple-digit profit potential rarely available to the public. Click to get this free report LTC PROPERTIES (LTC): Free Stock Analysis Report SELECT INCOME (SIR): Free Stock Analysis Report INVESTORS RL ES (IRET): Free Stock Analysis Report EASTRLY GOV PPT (DEA): Free Stock Analysis Report PHYSICIANS RLTY (DOC): Free Stock Analysis Report To read this article on Zacks.com click here.
|
1656dccc-e08f-4fe4-b42c-bd22908b4fde
|
723570.0
|
2016-09-22 00:00:00 UTC
|
Marijuana Stocks Could Get Lit This November
|
DEA
|
https://www.nasdaq.com/articles/marijuana-stocks-could-get-lit-this-november-2016-09-22
|
nan
|
nan
|
InvestorPlaceInvestorPlace - Stock Market News, Stock Advice & Trading Tips
Unless you've been living under a rock, you know the 2016 elections are coming up in November. Shareholders of marijuana stocks like GW Pharmaceuticals PLC-ADR (NASDAQ: GWPH ), Terra Tech Corp (OTCMKTS: TRTC ) and Insys Therapeutics Inc (NASDAQ: INSY ) have much more important votes on their minds than the one to elect the next president.
Marijuana Stocks Watching These 9 States
Source: MarihuanayMedicina via Flickr
In the 2016 elections, voters in nine states will be weighing in on marijuana legalization. Montana will be voting on whether to loosen restrictions on its medical marijuana program. Voters in Florida, Arkansas and North Dakota will be voting on legal marijuana for medical use.
Voters in California, Arizona, Nevada, Massachusetts and Maine will all be voting on legalizing weed for recreational use.
Of course, investors of weed stocks will be watching California closest of all.
California made history by becoming the first state to legalize medical marijuana way back in 1996. Not only is California's economy the largest of any U.S. state, it has 53 House of Representative members. These Congressmen could prove critical in the campaign for federal marijuana legalization.
Twitter Stock Charges on Potential Google, Salesforce Buyout (TWTR)
Marijuana stocks have a lot riding on the federal legalization movement. Today, 25 states and the District of Columbia have legalized medical marijuana in some form. Four states (Alaska, Colorado, Washington and Oregon) have legalized recreational marijuana use as well.
Why Would The 2016 Elections Impact Marijuana Stocks?
If California and the majority of the other states voting on the issue in the 2016 elections approve legal marijuana, it will up the pressure on Congress to discuss federal legalization.
Earlier this year, the Drug Enforcement Administration (DEA) denied requests to change the classification of marijuana to clear the path for possible federal legalization. Marijuana is currently classified as a Schedule 1 drug, alongside heroin and LSD.
If marijuana is ever legalized on a federal level, the size of the legal marijuana business will be staggering. Earlier this year, Ackrell Capital projected that the U.S. marijuana market will be worth $100 billion by 2029.
However, if California and other state voters reject legal marijuana in the 2016 elections, the federal legalization movement will lose its short-term momentum.
Investing In Marijuana Stocks Is Tricky Business
While investors wait for potential federal legalization, U.S. weed companies remain in limbo. Even in states that have legal marijuana, operating a marijuana business is still a federal crime. In that sense, many large, reputable pharmaceutical and agricultural companies are not touching marijuana with a 10-foot pole.
Instead, investment options include only a handful of biotech companies like GWPH and INSY working on marijuana-related drugs, as well as sketchy OTC-listed marijuana stocks with questionable management and loose regulatory oversight.
FINRA has repeatedly warned investors of "potential for fraud" when investing in OTC-listed marijuana stocks.
To make matters worse, the majority of marijuana stocks are down more than 70% in recent years .
Marijuana agriculture stock Terra Tech has been one of the exceptions to the trend. Despite its OTC listing, TRTC is up nearly 50% in the past two years.
GW Pharmaceuticals is another, up more than 55% both on positive drug developments and buyout potential.
However, if other marijuana stocks want their businesses to pay off in the long-term, they need the 2016 elections to deliver some good news for the marijuana movement.
As of this writing, Wayne Duggan did not hold a position in any of the aforementioned securities.
More From InvestorPlace
10 Stocks That Should Be in Your Portfolio Right Now
8 Small-Cap Stocks With Straight-A Potential
Has Apple Inc.'s (AAPL) iPhone 7 Lost Its Shine in a Week?
The post Marijuana Stocks Could Get Lit This November appeared first on InvestorPlace .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Earlier this year, the Drug Enforcement Administration (DEA) denied requests to change the classification of marijuana to clear the path for possible federal legalization. Investing In Marijuana Stocks Is Tricky Business While investors wait for potential federal legalization, U.S. weed companies remain in limbo. Instead, investment options include only a handful of biotech companies like GWPH and INSY working on marijuana-related drugs, as well as sketchy OTC-listed marijuana stocks with questionable management and loose regulatory oversight.
|
Earlier this year, the Drug Enforcement Administration (DEA) denied requests to change the classification of marijuana to clear the path for possible federal legalization. Shareholders of marijuana stocks like GW Pharmaceuticals PLC-ADR (NASDAQ: GWPH ), Terra Tech Corp (OTCMKTS: TRTC ) and Insys Therapeutics Inc (NASDAQ: INSY ) have much more important votes on their minds than the one to elect the next president. However, if California and other state voters reject legal marijuana in the 2016 elections, the federal legalization movement will lose its short-term momentum.
|
Earlier this year, the Drug Enforcement Administration (DEA) denied requests to change the classification of marijuana to clear the path for possible federal legalization. Marijuana Stocks Watching These 9 States Source: MarihuanayMedicina via Flickr In the 2016 elections, voters in nine states will be weighing in on marijuana legalization. If marijuana is ever legalized on a federal level, the size of the legal marijuana business will be staggering.
|
Earlier this year, the Drug Enforcement Administration (DEA) denied requests to change the classification of marijuana to clear the path for possible federal legalization. California made history by becoming the first state to legalize medical marijuana way back in 1996. However, if California and other state voters reject legal marijuana in the 2016 elections, the federal legalization movement will lose its short-term momentum.
|
7a19d398-7336-40d4-851f-a98671cb951b
|
723571.0
|
2016-08-31 00:00:00 UTC
|
VFH, PSJ: Big ETF Inflows
|
DEA
|
https://www.nasdaq.com/articles/vfh-psj-big-etf-inflows-2016-08-31
|
nan
|
nan
|
Comparing units outstanding versus one week ago at the coverage universe of ETFs at ETF Channel, the biggest inflow was seen in the Vanguard Financials ETF, which added 9,975,000 units, or a 13.7% increase week over week. Among the largest underlying components of VFH, in morning trading today Texas Pacific Land Trust is up about 0.3%, and Easterly Government Properties is higher by about 0.3%.
And on a percentage change basis, the ETF with the biggest increase in inflows was the PowerShares Dynamic Software Portfolio, which added 650,000 units, for a 39.4% increase in outstanding units. Among the largest underlying components of PSJ, in morning trading today Microsoft is down about 0.5%, and CA Incorporated is lower by about 0.4%.
VIDEO: VFH, PSJ: Big ETF Inflows
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Among the largest underlying components of VFH, in morning trading today Texas Pacific Land Trust is up about 0.3%, and Easterly Government Properties is higher by about 0.3%. And on a percentage change basis, the ETF with the biggest increase in inflows was the PowerShares Dynamic Software Portfolio, which added 650,000 units, for a 39.4% increase in outstanding units. Among the largest underlying components of PSJ, in morning trading today Microsoft is down about 0.5%, and CA Incorporated is lower by about 0.4%.
|
Among the largest underlying components of VFH, in morning trading today Texas Pacific Land Trust is up about 0.3%, and Easterly Government Properties is higher by about 0.3%. Among the largest underlying components of PSJ, in morning trading today Microsoft is down about 0.5%, and CA Incorporated is lower by about 0.4%. VIDEO: VFH, PSJ: Big ETF Inflows The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Comparing units outstanding versus one week ago at the coverage universe of ETFs at ETF Channel, the biggest inflow was seen in the Vanguard Financials ETF, which added 9,975,000 units, or a 13.7% increase week over week. Among the largest underlying components of VFH, in morning trading today Texas Pacific Land Trust is up about 0.3%, and Easterly Government Properties is higher by about 0.3%. VIDEO: VFH, PSJ: Big ETF Inflows The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Comparing units outstanding versus one week ago at the coverage universe of ETFs at ETF Channel, the biggest inflow was seen in the Vanguard Financials ETF, which added 9,975,000 units, or a 13.7% increase week over week. Among the largest underlying components of VFH, in morning trading today Texas Pacific Land Trust is up about 0.3%, and Easterly Government Properties is higher by about 0.3%. And on a percentage change basis, the ETF with the biggest increase in inflows was the PowerShares Dynamic Software Portfolio, which added 650,000 units, for a 39.4% increase in outstanding units.
|
05ab4f52-edc4-4bfd-9de9-14797933a8b8
|
723572.0
|
2016-08-26 00:00:00 UTC
|
Why You Should (and Shouldn't) Buy GW Pharmaceuticals Plc
|
DEA
|
https://www.nasdaq.com/articles/why-you-should-and-shouldnt-buy-gw-pharmaceuticals-plc-2016-08-26
|
nan
|
nan
|
IBB data by YCharts .
GW's unusual strength during this turbulent period for biopharma stems from its top clinical asset, Epidiolex, hitting the mark in two late-stage studies for the rare forms of childhood epilepsy known as Lennox-Gastaut syndrome (LGS) and Dravet syndrome.
Given the stock's ability to swim against the stream, so to speak, we asked two of our regular healthcare contributors if investors should continue to buy this top performer, or simply watch GW from the safety of the sidelines. Here's what they had to say.
Epidiolex and bureaucracy say buy
Cory Renauer : A couple of recent developments have GW Pharmaceuticals looking like a buy right now. The most encouraging sign is application-supporting clinical trial data that shows Epidiolex significantly reduced seizure frequency in two groups of patients unresponsive to existing antiepileptics.
For patients with Dravet syndrome, Epidiolex reduced monthly seizures by 39% compared to a 13% reduction among patients receiving a placebo. In a similar trial with Lennox-Gastaut patients, it reduced monthly seizures by 44% compared to a 22% reduction in the placebo group.
That may not seem like a huge win, but it's enough to improve these patients' overall well-being by a mile. The majority of Dravet patients tested suffered from 13 or more seizures per month during the pre-dosing period, and had tried four or more antiepileptics without success. In the Lennox-Gastaut trial, most patients suffered 74 or more monthly seizures during the pre-dosing observation despite using an average of three antiepileptics after failing to respond to an average of six drugs.
Epidiolex is an oral formulation of cannabidiol, which is purified from natural marijuana. One of the biggest fears surrounding its commercial viability is a chance that certain strains of marijuana in its natural state might be equally effective at reducing these patients' seizures at a fraction of the cost. Luckily for GW Pharma, the U.S. Drug Enforcement Agency (DEA) recently reiterated its stance on marijuana's Schedule 1 status. The status makes researching whether any strain of natural marijuana is an effective epilepsy treatment (or a treatment for anything at all, for that matter) practically impossible. Since the DEA's reiteration was effectively based on a lack of available research, the status quo will probably remain for quite some time.
GW's valuation is simply too rich
George Budwell: I readily concede that Epidiolex appears headed for continued success in the clinic, and should eventually gain regulatory approvals for both LGS and Dravet syndrome as a result. After all, the drug produced a highly significant reduction in seizure rate compared to placebo for LGS (p = 0.0135), and significantly reduced the rate of convulsive seizures relative to placebo in Dravet syndrome (p = 0.01).
Image Source: GW Pharmaceuticals.
Despite Epidiolex's promise, GW appears to be overvalued at the moment. The first issue to understand is that GW's multiple sclerosis treatment, Sativex, has so far been a non-factor from a valuation standpoint. In fact, the company hasn't even bothered to waste much ink on the progress of the drug's commercialization overseas in its recent quarterly filings, and instead has chosen to refocus the investing community's attention primarily on Epidiolex's broad clinical program. The point is that GW's current valuation is likely based almost exclusively on Epidiolex's commercial potential, and that's where this story runs into problems.
Digging into the details, GW's present market cap is roughly $1.83 billion. Now, some estimates suggest that Epidiolex could generate around $800 million in peak sales for these first two indications. And if true, GW's present valuation wouldn't be particularly hard to swallow. But this sales forecast is highly optimistic, to put it mildly.
As an orphan drug, Epidiolex would certainly garner a premium pricing point. However, it won't grab prices near the astronomical figures for orphan cancer drugs or enzyme replacement therapies -- yet that's exactly what this estimate of $800 million -- or worse still, the $3 billion sales figures being floated by some uber-bullish firms -- is implying.
Specifically, the bull models are forecasting Epidiolex's wholesale price for a year's supply to come in at an astounding $45,000 USD, on average, and they're also assuming significant off-label use for the drug..
A more realistic figure -- especially in this new era of heavy scrutiny from pharmacy benefit managers -- is a wholesale price perhaps a little more than double the average cost for branded epilepsy medications, meaning somewhere around $24,000 per year.
There's also no good reason to assume that doctors are going to prescribe a more expensive drug off-label for common types of epilepsy. Payers, after all, will no doubt balk at covering Epidiolex off-label due to its premium pricing structure, and not many patients will be able to pay out of pocket.
That's why the "bearish" peak sales figure of around $300 million is probably closer to the mark. As such, GW's shares are probably trading at around six times Epidiolex's likely peak sales at this stage, suggesting that this high-flying biopharma could fall back to Earth soon.
A secret billion-dollar stock opportunity
The world's biggest tech company forgot to show you something, but a few Wall Street analysts and the Fool didn't miss a beat: There's a small company that's powering their brand-new gadgets and the coming revolution in technology. And we think its stock price has nearly unlimited room to run for early in-the-know investors! To be one of them, just click here .
Cory Renauer has no position in any stocks mentioned. George Budwell owns shares of iShares NASDAQ Biotechnology Index. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days . We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Luckily for GW Pharma, the U.S. Drug Enforcement Agency (DEA) recently reiterated its stance on marijuana's Schedule 1 status. Since the DEA's reiteration was effectively based on a lack of available research, the status quo will probably remain for quite some time. Given the stock's ability to swim against the stream, so to speak, we asked two of our regular healthcare contributors if investors should continue to buy this top performer, or simply watch GW from the safety of the sidelines.
|
Luckily for GW Pharma, the U.S. Drug Enforcement Agency (DEA) recently reiterated its stance on marijuana's Schedule 1 status. Since the DEA's reiteration was effectively based on a lack of available research, the status quo will probably remain for quite some time. The most encouraging sign is application-supporting clinical trial data that shows Epidiolex significantly reduced seizure frequency in two groups of patients unresponsive to existing antiepileptics.
|
Luckily for GW Pharma, the U.S. Drug Enforcement Agency (DEA) recently reiterated its stance on marijuana's Schedule 1 status. Since the DEA's reiteration was effectively based on a lack of available research, the status quo will probably remain for quite some time. GW's unusual strength during this turbulent period for biopharma stems from its top clinical asset, Epidiolex, hitting the mark in two late-stage studies for the rare forms of childhood epilepsy known as Lennox-Gastaut syndrome (LGS) and Dravet syndrome.
|
Luckily for GW Pharma, the U.S. Drug Enforcement Agency (DEA) recently reiterated its stance on marijuana's Schedule 1 status. Since the DEA's reiteration was effectively based on a lack of available research, the status quo will probably remain for quite some time. The status makes researching whether any strain of natural marijuana is an effective epilepsy treatment (or a treatment for anything at all, for that matter) practically impossible.
|
84392a06-4884-4a7f-8de4-f467043dfc4d
|
723573.0
|
2016-08-13 00:00:00 UTC
|
Denied! Here's What You Need to Know About the DEA's Decision Not to Reclassify Marijuana
|
DEA
|
https://www.nasdaq.com/articles/denied-heres-what-you-need-know-about-deas-decision-not-reclassify-marijuana-2016-08-13
|
nan
|
nan
|
Image source: Getty Images.
However, this utopic dream will have to wait for another day.
The DEA declines to reschedule marijuana
After a long analysis of the risks and benefits of medical marijuana by the U.S. Drug Enforcement Agency (DEA), which was supplemented by the recommendation of the Department of Health and Human Services (HHS), the DEA announced on Thursday that it plans to leave the current Schedule 1 status of medical marijuana unchanged, with one small caveat. The agency will relax certain regulations surrounding marijuana research for medical purposes, presumably allowing for more legal grow farms with the expressed purpose of medical marijuana research. There's currently only one approved cannabis grow farm for medical research in the U.S., located in Mississippi.
Based on the recommendation it received from the HHS, as well as its own research into marijuana's medical risks and benefits profile, the DEA chose to keep medical marijuana illegal for three specific reasons , quoted below directly from the DEA:
Image source: Getty Images.
Inherent disadvantages remain
The biggest downer is that the two inherent disadvantages the cannabis industry is currently facing are likely to perpetuate. First, businesses that sell marijuana products are unable to take normal business deductions come tax time. This leaves marijuana businesses to pay tax on their gross profit rather than their net profit, reducing income they could have used to expand and hire.
The other issue is that cannabis-based businesses have veritably no access to basic banking solutions, such as a checking account or line of credit. Having to deal solely in cash is a security concern for marijuana businesses, and it can hamper their ability to expand, hire, and buy new product.
The other issue with the DEA's decision is that it does absolutely nothing to help investors that want to take advantage of marijuana's exceptional growth rate. According to cannabis research firm ArcView, cannabis could grow by 30% annually throughout the remainder of the decade. Investors, though, probably won't be able to take advantage of this growth rate since bigger companies won't have a chance to thrive. Most investable options can be found as penny stocks on the over-the-counter exchanges, and finding accurate financial information can prove challenging for OTC penny stocks.
Legal marijuana sales, from both a recreational and medical standpoint, could very well keep growing at a double-digit percentage, fueled by the passage of initiatives and amendments at the state level. But as an investment, marijuana still appears to be off-limits, even for the most risk-tolerant, long-term investors.
A secret billion-dollar stock opportunity
The world's biggest tech company forgot to show you something, but a few Wall Street analysts and the Fool didn't miss a beat: There's a small company that's powering their brand-new gadgets and the coming revolution in technology. And we think its stock price has nearly unlimited room to run for early in-the-know investors! To be one of them, just click here .
Sean Williams has no material interest in any companies mentioned in this article. You can follow him on CAPS under the screen nameTMFUltraLong, and check him out on Twitter, where he goes by the handle@TMFUltraLong.
The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter servicesfree for 30 days. We Fools may not all hold the same opinions, but we all believe thatconsidering a diverse range of insights makes us better investors. The Motley Fool has adisclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Having to deal solely in cash is a security concern for marijuana businesses, and it can hamper their ability to expand, hire, and buy new product. The DEA declines to reschedule marijuana After a long analysis of the risks and benefits of medical marijuana by the U.S. Drug Enforcement Agency (DEA), which was supplemented by the recommendation of the Department of Health and Human Services (HHS), the DEA announced on Thursday that it plans to leave the current Schedule 1 status of medical marijuana unchanged, with one small caveat. Based on the recommendation it received from the HHS, as well as its own research into marijuana's medical risks and benefits profile, the DEA chose to keep medical marijuana illegal for three specific reasons , quoted below directly from the DEA: Image source: Getty Images.
|
Based on the recommendation it received from the HHS, as well as its own research into marijuana's medical risks and benefits profile, the DEA chose to keep medical marijuana illegal for three specific reasons , quoted below directly from the DEA: Image source: Getty Images. The DEA declines to reschedule marijuana After a long analysis of the risks and benefits of medical marijuana by the U.S. Drug Enforcement Agency (DEA), which was supplemented by the recommendation of the Department of Health and Human Services (HHS), the DEA announced on Thursday that it plans to leave the current Schedule 1 status of medical marijuana unchanged, with one small caveat. Having to deal solely in cash is a security concern for marijuana businesses, and it can hamper their ability to expand, hire, and buy new product.
|
The DEA declines to reschedule marijuana After a long analysis of the risks and benefits of medical marijuana by the U.S. Drug Enforcement Agency (DEA), which was supplemented by the recommendation of the Department of Health and Human Services (HHS), the DEA announced on Thursday that it plans to leave the current Schedule 1 status of medical marijuana unchanged, with one small caveat. Based on the recommendation it received from the HHS, as well as its own research into marijuana's medical risks and benefits profile, the DEA chose to keep medical marijuana illegal for three specific reasons , quoted below directly from the DEA: Image source: Getty Images. Having to deal solely in cash is a security concern for marijuana businesses, and it can hamper their ability to expand, hire, and buy new product.
|
Based on the recommendation it received from the HHS, as well as its own research into marijuana's medical risks and benefits profile, the DEA chose to keep medical marijuana illegal for three specific reasons , quoted below directly from the DEA: Image source: Getty Images. The DEA declines to reschedule marijuana After a long analysis of the risks and benefits of medical marijuana by the U.S. Drug Enforcement Agency (DEA), which was supplemented by the recommendation of the Department of Health and Human Services (HHS), the DEA announced on Thursday that it plans to leave the current Schedule 1 status of medical marijuana unchanged, with one small caveat. Having to deal solely in cash is a security concern for marijuana businesses, and it can hamper their ability to expand, hire, and buy new product.
|
d8842cc6-6bce-41fe-88ca-627f41d7cd43
|
723574.0
|
2016-08-12 00:00:00 UTC
|
Friday 8/12 Insider Buying Report: PRTY, DEA
|
DEA
|
https://www.nasdaq.com/articles/friday-812-insider-buying-report-prty-dea-2016-08-12
|
nan
|
nan
|
Bargain hunters are wise to pay careful attention to insider buying, because although there are many various reasons for an insider to sell a stock, presumably the only reason they would use their hard-earned cash to make a purchase, is that they expect to make money. Today we look at two noteworthy recent insider buys.
At Party City Holdco, a filing with the SEC revealed that on Monday, Chief Executive Officer James M. Harrison bought 20,969 shares of PRTY, for a cost of $17.94 each, for a total investment of $376,184. So far Harrison is in the green, up about 4.2% on their purchase based on today's trading high of $18.69. Party City Holdco is trading up about 0.8% on the day Friday. Before this latest buy, Harrison made one other purchase in the past year, buying $126,200 shares for a cost of $12.62 each.
And at Easterly Government Properties, there was insider buying on Tuesday, by Director Cynthia A. Fisher who purchased 18,448 shares at a cost of $19.68 each, for a total investment of $362,982. Easterly Government Properties is trading up about 0.5% on the day Friday.
VIDEO: Friday 8/12 Insider Buying Report: PRTY, DEA
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
VIDEO: Friday 8/12 Insider Buying Report: PRTY, DEA The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Bargain hunters are wise to pay careful attention to insider buying, because although there are many various reasons for an insider to sell a stock, presumably the only reason they would use their hard-earned cash to make a purchase, is that they expect to make money. At Party City Holdco, a filing with the SEC revealed that on Monday, Chief Executive Officer James M. Harrison bought 20,969 shares of PRTY, for a cost of $17.94 each, for a total investment of $376,184.
|
VIDEO: Friday 8/12 Insider Buying Report: PRTY, DEA The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. And at Easterly Government Properties, there was insider buying on Tuesday, by Director Cynthia A. Fisher who purchased 18,448 shares at a cost of $19.68 each, for a total investment of $362,982. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
VIDEO: Friday 8/12 Insider Buying Report: PRTY, DEA The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Bargain hunters are wise to pay careful attention to insider buying, because although there are many various reasons for an insider to sell a stock, presumably the only reason they would use their hard-earned cash to make a purchase, is that they expect to make money. And at Easterly Government Properties, there was insider buying on Tuesday, by Director Cynthia A. Fisher who purchased 18,448 shares at a cost of $19.68 each, for a total investment of $362,982.
|
VIDEO: Friday 8/12 Insider Buying Report: PRTY, DEA The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. At Party City Holdco, a filing with the SEC revealed that on Monday, Chief Executive Officer James M. Harrison bought 20,969 shares of PRTY, for a cost of $17.94 each, for a total investment of $376,184. So far Harrison is in the green, up about 4.2% on their purchase based on today's trading high of $18.69.
|
c6bda717-fe66-4676-b432-359ea7a47f81
|
723575.0
|
2016-08-06 00:00:00 UTC
|
Clinton or Trump? Find Out Which Candidate the Marijuana Industry Favors
|
DEA
|
https://www.nasdaq.com/articles/clinton-or-trump-find-out-which-candidate-marijuana-industry-favors-2016-08-06
|
nan
|
nan
|
In November, residents in at least eight states, and perhaps more, will be voting on whether or not to legalize recreational or medical marijuana. Currently, 25 states have legalized medical marijuana, while four, along with Washington, D.C., have legalized the sale of recreational-use marijuana for adults. By the time the elections are over, up to 28 states may have legalized medical marijuana, and the number of recreation-legal states could more than double to nine -- at least based on the certain-to-vote states.
It's not difficult to understand why certain states are eager to pass laws legalizing cannabis. In addition to potential medical benefits, the sale of medical and/or recreational cannabis is a new source of tax and licensing revenue for marijuana-legal states. In Colorado, for example, $135 million was raised in legal marijuana tax and licensing revenue in 2015, with sales hitting $996 million. Sales in 2016 are expected to easily top $1 billion in Colorado, probably leading to a surge in tax and licensing revenue collected by the state.
Furthermore, the U.S. Drug Enforcement Agency (DEA) is currently conducting an eight-point review of marijuana that could lead to its rescheduling. Marijuana's schedule 1 status relegates the cannabis industry to two inherent disadvantages -- the inability of legal marijuana businesses to take normal business deductions on their income taxes since they're selling an illicit substance, and minimal-to-no access to basic banking services, such as checking accounts or lines of credit. A move to schedule II could open new doors for the cannabis industry.
However, an under-the-radar game-changer for the industry could be which candidate -- Hillary Clinton from the Democratic Party, or Donald Trump from the Republican Party -- heads into the Oval Office.
An under-the-radar problem for the cannabis industry is that a rescheduling of marijuana from schedule I to schedule II could open Pandora's Box. Though it would signify that marijuana has medically beneficial qualities, and it would open the door for medical research of the drug, it could also make life for marijuana businesses quite complicated.
If marijuana is rescheduled, it would allow for tight regulation from the Food and Drug Administration. The FDA would have a say on cannabis industry packaging and marketing, and it would likely regulate the manufacturing process of marijuana grow farms to ensure that THC content remains consistent. But, most damaging of all, the FDA could require that marijuana companies run clinical trials to confirm the touted medical benefits of the drug. All of these additional regulations could prove very costly to the industry, and they could put smaller cannabis shops out of business.
This cannabis conundrum makes investing in the marijuana space a risky bet. Until the outlook for the marijuana industry becomes more certain, my suggestion remains the same as it's always been: avoid putting your money into marijuana stocks, at least for now.
A secret billion-dollar stock opportunity
The world's biggest tech company forgot to show you something, but a few Wall Street analysts and the Fool didn't miss a beat: There's a small company that's powering their brand-new gadgets and the coming revolution in technology. And we think its stock price has nearly unlimited room to run for early in-the-know investors! To be one of them, just click here .
Sean Williams has no material interest in any companies mentioned in this article. You can follow him on CAPS under the screen nameTMFUltraLong, and check him out on Twitter, where he goes by the handle@TMFUltraLong.
The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter servicesfree for 30 days. We Fools may not all hold the same opinions, but we all believe thatconsidering a diverse range of insights makes us better investors. The Motley Fool has adisclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Furthermore, the U.S. Drug Enforcement Agency (DEA) is currently conducting an eight-point review of marijuana that could lead to its rescheduling. Sales in 2016 are expected to easily top $1 billion in Colorado, probably leading to a surge in tax and licensing revenue collected by the state. The FDA would have a say on cannabis industry packaging and marketing, and it would likely regulate the manufacturing process of marijuana grow farms to ensure that THC content remains consistent.
|
Furthermore, the U.S. Drug Enforcement Agency (DEA) is currently conducting an eight-point review of marijuana that could lead to its rescheduling. In addition to potential medical benefits, the sale of medical and/or recreational cannabis is a new source of tax and licensing revenue for marijuana-legal states. In Colorado, for example, $135 million was raised in legal marijuana tax and licensing revenue in 2015, with sales hitting $996 million.
|
Furthermore, the U.S. Drug Enforcement Agency (DEA) is currently conducting an eight-point review of marijuana that could lead to its rescheduling. Currently, 25 states have legalized medical marijuana, while four, along with Washington, D.C., have legalized the sale of recreational-use marijuana for adults. Marijuana's schedule 1 status relegates the cannabis industry to two inherent disadvantages -- the inability of legal marijuana businesses to take normal business deductions on their income taxes since they're selling an illicit substance, and minimal-to-no access to basic banking services, such as checking accounts or lines of credit.
|
Furthermore, the U.S. Drug Enforcement Agency (DEA) is currently conducting an eight-point review of marijuana that could lead to its rescheduling. In addition to potential medical benefits, the sale of medical and/or recreational cannabis is a new source of tax and licensing revenue for marijuana-legal states. The Motley Fool has no position in any of the stocks mentioned.
|
e87dbe71-f840-4817-b4c4-40b43371ea24
|
723576.0
|
2016-07-31 00:00:00 UTC
|
Bad News for Marijuana Supporters: The DEA Just Delayed This Critical Decision
|
DEA
|
https://www.nasdaq.com/articles/bad-news-marijuana-supporters-dea-just-delayed-critical-decision-2016-07-31
|
nan
|
nan
|
Image source: Getty Images.
This decision is a very big deal
Currently, the marijuana plant is defined as a schedule 1 substance. This means it has no federally recognized medical benefits and is considered to be an illicit drug. As long as marijuana remains an illicit drug, businesses that sell marijuana face two very big disadvantages.
First, cannabis-based businesses have little to no access to basic financial services. Although banks could probably serve the cannabis industry and add to their profits, most banks fear the potential for legal action from the federal government. Because the marijuana plant is still illegal, allowing a marijuana business to open a checking account or take out a loan could be construed as money laundering. Without access to checking accounts or credit, these businesses are forced to deal primarily in cash, which is both a security concern and an expansion inhibitor.
The other issue for marijuana businesses is that they pay a much higher tax rate than normal businesses. Internal Revenue Service tax code 280E disallows normal tax deductions in instances where the product being sold is illicit. This means companies in the marijuana industry have to pay tax on gross profits, rather than net profits.
If the DEA were to reschedule marijuana to anything other than a schedule 1 substance (i.e., schedule 2 through 5), then cannabis would be deemed to have medically beneficial properties, which would allow physicians throughout the country to prescribe medical marijuana for patients. Furthermore, it would allow medical researchers to study the effects of marijuana on certain diseases without having to jump through a long series of hoops. Presumably, the inherent financial disadvantages would fall by the wayside as well, as banks could serve marijuana businesses without fear of repercussions.
Image source: Getty Images.
Bad news for marijuana supporters
Originally, the DEA was rumored to be making its decision on whether or not to reschedule medical marijuana by July 1, or, as the Santa Monica Observer claimed, Aug. 1. But the DEA is certainly in no rush to make up its mind on what it considers a critical issue.
In an interview with online publication aNewDomain, DEA staff coordinator Russ Baer noted, "What is under-reported right now is how complex the marijuana plant is." According to aNewDomain, the plant itself contains about 480 compounds, and medical marijuana can be administered in multiple ways, which means the scope of research being conducted by the DEA could be far beyond what marijuana supporters initially expected.
When pressed about the July 1 or Aug. 1 deadlines for a decision, Baer added, "We are not holding ourselves to any artificial timeframe." However, it is worth noting that the DEA has received the scientific and health recommendations from the Food and Drug Administration that are required as part of its own eight-part review process, which may or may not lead to the rescheduling of cannabis.
So what does this mean for the cannabis industry and the potential for reclassification? Essentially, it means a decision is coming, but it will likely come much later than most people had expected. In other words, for the foreseeable future, the marijuana industry will continue to face inherent disadvantages.
Image source: Getty Images.
Rescheduling may not be a cure-all for cannabis
The biggest concern is that cannabis will be reclassified as a schedule 2 substance -- one that has medical benefits but is considered addictive and prone to abuse. If that happens, then the FDA will have enormous power over the cannabis industry. For example, the FDA could control how the marijuana industry markets to adults, including how packaging material is labeled. It could, and probably would, regularly inspect growing and processing facilities to ensure that consistent manufacturing standards are being met (e.g., consistent THC content).
But most worrisome of all, it could require cannabis businesses to run clinical trials to confirm that marijuana offers the health benefits being advertised. All of these added regulations could be incredibly costly for the cannabis industry, which could wind up pushing smaller players out in favor of bigger businesses that could afford the higher regulatory costs. Strict regulation could also hinder marijuana businesses' efforts to lower their prices and thus make their products more competitive with black-market alternatives.
Don't get me wrong: A reclassification to anything other than schedule 1 should be seen as a step forward for the industry. But how big of a step it will be depends on the DEA -- if it ever reclassifies the drug at all.
For the time being, marijuana supporters, as well as investors hoping to take advantage of a possible reclassification, would be wise to temper their expectations and exercise some patience, as the DEA is in no rush to issue its decision.
A secret billion-dollar stock opportunity
The world's biggest tech company forgot to show you something, but a few Wall Street analysts and the Fool didn't miss a beat: There's a small company that's powering their brand-new gadgets and the coming revolution in technology. And we think its stock price has nearly unlimited room to run for early in-the-know investors! To be one of them, just click here .
Sean Williams has no material interest in any companies mentioned in this article. You can follow him on CAPS under the screen nameTMFUltraLong, and check him out on Twitter, where he goes by the handle@TMFUltraLong.
The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter servicesfree for 30 days. We Fools may not all hold the same opinions, but we all believe thatconsidering a diverse range of insights makes us better investors. The Motley Fool has adisclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
In an interview with online publication aNewDomain, DEA staff coordinator Russ Baer noted, "What is under-reported right now is how complex the marijuana plant is." However, it is worth noting that the DEA has received the scientific and health recommendations from the Food and Drug Administration that are required as part of its own eight-part review process, which may or may not lead to the rescheduling of cannabis. For the time being, marijuana supporters, as well as investors hoping to take advantage of a possible reclassification, would be wise to temper their expectations and exercise some patience, as the DEA is in no rush to issue its decision.
|
This decision is a very big deal Currently, the marijuana plant is defined as a schedule 1 substance. Without access to checking accounts or credit, these businesses are forced to deal primarily in cash, which is both a security concern and an expansion inhibitor. If the DEA were to reschedule marijuana to anything other than a schedule 1 substance (i.e., schedule 2 through 5), then cannabis would be deemed to have medically beneficial properties, which would allow physicians throughout the country to prescribe medical marijuana for patients.
|
If the DEA were to reschedule marijuana to anything other than a schedule 1 substance (i.e., schedule 2 through 5), then cannabis would be deemed to have medically beneficial properties, which would allow physicians throughout the country to prescribe medical marijuana for patients. Bad news for marijuana supporters Originally, the DEA was rumored to be making its decision on whether or not to reschedule medical marijuana by July 1, or, as the Santa Monica Observer claimed, Aug. 1. According to aNewDomain, the plant itself contains about 480 compounds, and medical marijuana can be administered in multiple ways, which means the scope of research being conducted by the DEA could be far beyond what marijuana supporters initially expected.
|
According to aNewDomain, the plant itself contains about 480 compounds, and medical marijuana can be administered in multiple ways, which means the scope of research being conducted by the DEA could be far beyond what marijuana supporters initially expected. This decision is a very big deal Currently, the marijuana plant is defined as a schedule 1 substance. Without access to checking accounts or credit, these businesses are forced to deal primarily in cash, which is both a security concern and an expansion inhibitor.
|
8598c660-0b36-44ab-a145-753733bed5da
|
723577.0
|
2016-06-25 00:00:00 UTC
|
Arguably the Most Important Marijuana Decision Ever Is Just Weeks Away
|
DEA
|
https://www.nasdaq.com/articles/arguably-most-important-marijuana-decision-ever-just-weeks-away-2016-06-25
|
nan
|
nan
|
Image source: Getty Images.
Since it was first approved in California 20 years ago, medical marijuana has become legalized throughout half the country. Most interestingly, the last two states to legalize medical marijuana -- Pennsylvania and Ohio -- have done so entirely through the legislative process (i.e., without bringing the matter to vote by residents of the state). We've also witnessed four states (Colorado, Washington, Oregon, and Alaska), as well as Washington, D.C., legalize recreational cannabis.
The growth figures are huge. ArcView Market Research, a leading cannabis research company, suggests that 30% compound annual growth is possible between 2015 and 2020. This would put the legal-marijuana industry on pace for nearly $22 billion in sales by 2020, based on ArcView's estimated $6.7 billion in legal sales for 2016.
The taxable revenue that could be generated from marijuana is equally impressive. A NerdWallet report from 2014 suggested at the time that a nationwide legalization of marijuana would net states approximately $3.1 billion in tax revenue on an annual basis. Keep in mind that states are often generating revenue from licensing fees for businesses, growers, and processors, too. The revenue currently being generated by legal marijuana sales won't close major budget deficits, but it is providing much-needed funds for education, law enforcement, and drug abuse programs in select states.
Image source: Getty Images.
This marijuana decision could be a game-changer
Sometime within the next couple of weeks, the U.S DEA is expected to rule on whether or not it will reschedule marijuana away from its current schedule 1 classification. If the regulatory agency were to reclassify marijuana as anything other than a schedule 1 substance, then medical marijuana would immediately become legal throughout the U.S., thus opening the door for medical marijuana businesses to prosper. It would also remove those aforementioned disadvantages holding the industry back.
The U.S. Food and Drug Administration has already submitted its recommendation on marijuana's scheduling to the DEA. However, DEA administrator Chuck Rosenberg has been tight-lipped as to what that recommendation was. The DEA is in the process of conducting its own eight-factor analysis, according to Inc.com, which will help the regulatory agency decipher what sort of abuse potential cannabis may possess.
There are, of course, a variety of options for the DEA to choose. It could completely deschedule marijuana, putting the plant on par with tobacco and alcohol. It could also choose to place a scheduling ranging from 2 through 5 on the substance. Drugs scheduled between 2 and 5 are deemed to have medical benefits, but as you get closer to schedule 2 (moving up the scale from schedule 5), the drug's perceived addictiveness increases. Finally, certain substances within cannabis could be legalized, while the plant itself could remain illegal. The DEA has plenty of options.
Image source: Getty Images.
A rescheduling isn't necessarily good news
However, if marijuana is only rescheduled , then chaos could ensue.
Although a schedule 2 classification would legalize cannabis and affirm it has beneficial medical properties, it would also completely transform the marijuana industry. Schedule 2 drugs are considered prone to abuse, meaning the FDA would almost assuredly step in and tightly regulate the industry. This would mean closely regulating the growth and processing of marijuana. More importantly, it would also mean the FDA would get involved in the clinical aspects of its medicinal use. This could mean clinical studies would need to be conducted to prove to the FDA that medical benefits exist on an ailment-by-ailment basis. If cannabis producers continued to sell their product without adhering to FDA guidelines, they could face fines or criminal punishments. Packaging, labeling, and advertising would also need to be approved by the FDA.
All of this regulation means one thing to the marijuana industry: spending money! Transforming into a pharmaceutical-based industry could be very costly, and it could potentially put smaller players out of business. Only huge players with deep pockets would presumably be able to survive and thrive in a tightly regulated schedule 2 market, in my opinion.
Although no specific date has been given as to when the DEA will make its ruling, it's expected within weeks, and it will undoubtedly have major implications for the marijuana industry -- as well as investors.
A secret billion-dollar stock opportunity
The world's biggest tech company forgot to show you something, but a few Wall Street analysts and the Fool didn't miss a beat: There's a small company that's powering their brand-new gadgets and the coming revolution in technology. And we think its stock price has nearly unlimited room to run for early, in-the-know investors! To be one of them, just click here .
Sean Williams has no material interest in any companies mentioned in this article. You can follow him on CAPS under the screen nameTMFUltraLong, and check him out on Twitter, where he goes by the handle@TMFUltraLong.
The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter servicesfree for 30 days. We Fools may not all hold the same opinions, but we all believe thatconsidering a diverse range of insights makes us better investors. The Motley Fool has adisclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
The DEA is in the process of conducting its own eight-factor analysis, according to Inc.com, which will help the regulatory agency decipher what sort of abuse potential cannabis may possess. This marijuana decision could be a game-changer Sometime within the next couple of weeks, the U.S DEA is expected to rule on whether or not it will reschedule marijuana away from its current schedule 1 classification. The U.S. Food and Drug Administration has already submitted its recommendation on marijuana's scheduling to the DEA.
|
This marijuana decision could be a game-changer Sometime within the next couple of weeks, the U.S DEA is expected to rule on whether or not it will reschedule marijuana away from its current schedule 1 classification. The U.S. Food and Drug Administration has already submitted its recommendation on marijuana's scheduling to the DEA. However, DEA administrator Chuck Rosenberg has been tight-lipped as to what that recommendation was.
|
This marijuana decision could be a game-changer Sometime within the next couple of weeks, the U.S DEA is expected to rule on whether or not it will reschedule marijuana away from its current schedule 1 classification. The U.S. Food and Drug Administration has already submitted its recommendation on marijuana's scheduling to the DEA. However, DEA administrator Chuck Rosenberg has been tight-lipped as to what that recommendation was.
|
This marijuana decision could be a game-changer Sometime within the next couple of weeks, the U.S DEA is expected to rule on whether or not it will reschedule marijuana away from its current schedule 1 classification. The U.S. Food and Drug Administration has already submitted its recommendation on marijuana's scheduling to the DEA. However, DEA administrator Chuck Rosenberg has been tight-lipped as to what that recommendation was.
|
0337bfc8-6a89-4a89-9a93-972467ad8552
|
723578.0
|
2016-06-03 00:00:00 UTC
|
Easterly Government Properties, Inc. (DEA) Ex-Dividend Date Scheduled for June 06, 2016
|
DEA
|
https://www.nasdaq.com/articles/easterly-government-properties-inc-dea-ex-dividend-date-scheduled-june-06-2016-2016-06-03
|
nan
|
nan
|
Easterly Government Properties, Inc. ( DEA ) will begin trading ex-dividend on June 06, 2016. A cash dividend payment of $0.23 per share is scheduled to be paid on June 23, 2016. Shareholders who purchased DEA prior to the ex-dividend date are eligible for the cash dividend payment. This represents an 4.55% increase over the prior quarter. At the current stock price of $18.64, the dividend yield is 4.94%.
The previous trading day's last sale of DEA was $18.64, representing a -2.25% decrease from the 52 week high of $19.07 and a 22.23% increase over the 52 week low of $15.25.
DEA is a part of the Consumer Services sector, which includes companies such as Simon Property Group, Inc. ( SPG ) and American Tower Corporation (REIT) ( AMT ). DEA's current earnings per share, an indicator of a company's profitability, is $.07. Zacks Investment Research reports DEA's forecasted earnings growth in 2016 as 18.27%, compared to an industry average of 5.4%.
For more information on the declaration, record and payment dates, visit the DEA Dividend History page. Our Dividend Calendar has the full list of stocks that have an ex-dividend today.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
DEA is a part of the Consumer Services sector, which includes companies such as Simon Property Group, Inc. ( SPG ) and American Tower Corporation (REIT) ( AMT ). Zacks Investment Research reports DEA's forecasted earnings growth in 2016 as 18.27%, compared to an industry average of 5.4%. For more information on the declaration, record and payment dates, visit the DEA Dividend History page.
|
DEA's current earnings per share, an indicator of a company's profitability, is $.07. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Easterly Government Properties, Inc. ( DEA ) will begin trading ex-dividend on June 06, 2016.
|
Shareholders who purchased DEA prior to the ex-dividend date are eligible for the cash dividend payment. The previous trading day's last sale of DEA was $18.64, representing a -2.25% decrease from the 52 week high of $19.07 and a 22.23% increase over the 52 week low of $15.25. For more information on the declaration, record and payment dates, visit the DEA Dividend History page.
|
Shareholders who purchased DEA prior to the ex-dividend date are eligible for the cash dividend payment. DEA's current earnings per share, an indicator of a company's profitability, is $.07. Easterly Government Properties, Inc. ( DEA ) will begin trading ex-dividend on June 06, 2016.
|
75951c54-adac-4796-a6c7-d3f362bd554a
|
723579.0
|
2016-06-02 00:00:00 UTC
|
Financial Sector Update for 06/02/2016: FCBS,SMMF,AHT,DEA
|
DEA
|
https://www.nasdaq.com/articles/financial-sector-update-06022016-fcbssmmfahtdea-2016-06-02
|
nan
|
nan
|
Top Financial Stocks
JPM -0.36%
BAC -0.37%
WFC -0.29%
C -0.43%
USB -0.29%
Financial stocks were declining Thursday, with the NYSE Financial Sector Index posting a 0.3% retreat while financial companies in the S&P 500 Index were losing around 0.3% this afternoon.
In company news, First Century Bankshares ( FCBS ) jumped to a six-year high after Summit Financial Group Inc. ( SMMF ) offered to acquire the bank holding company for around $42.8 million in cash and stock.
Under terms of the merger agreement, Summit will exchange $22.50 in cash or 1.2433 of a share of its stock for each First Century share. Summit is capping the amount of cash available for the deal to $15 million, or 35% of the total, with the remaining compensation paid with stock.
The transaction is expected to close shortly before the end of the year, pending regulatory approvals and the approval of First Century shareholders.
The boards of directors at both firms already have signed off on the deal.
FCBS shares were up almost 10% at $21.30 apiece, earlier climbing to their best price since March 2008 at $22.00 a share. SMMF shares were down more than 1% at $17.06 each in recent trade, matching their session low.
In other sector news,
(+) AHT, (+7.2%) Announces $36 mln sale of Courtyard Palm Desert hotel. Also completes $142 mln cash sale of five select-service hotels in New Jersey, Georgia, and Florida, to the Noble Investment Group.
(-) DEA, (-3.6%) Prices $68.4 mln sale of 3.8 mln shares at $18 apiece, a 5.2% discount to Wednesday's closing price. Also sells 1.5 mln shares through forward-sale agreements while selected investors sell another 826,967 shares.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Summit is capping the amount of cash available for the deal to $15 million, or 35% of the total, with the remaining compensation paid with stock. The boards of directors at both firms already have signed off on the deal. (-) DEA, (-3.6%) Prices $68.4 mln sale of 3.8 mln shares at $18 apiece, a 5.2% discount to Wednesday's closing price.
|
(-) DEA, (-3.6%) Prices $68.4 mln sale of 3.8 mln shares at $18 apiece, a 5.2% discount to Wednesday's closing price. Summit is capping the amount of cash available for the deal to $15 million, or 35% of the total, with the remaining compensation paid with stock. The boards of directors at both firms already have signed off on the deal.
|
(-) DEA, (-3.6%) Prices $68.4 mln sale of 3.8 mln shares at $18 apiece, a 5.2% discount to Wednesday's closing price. Summit is capping the amount of cash available for the deal to $15 million, or 35% of the total, with the remaining compensation paid with stock. The boards of directors at both firms already have signed off on the deal.
|
(-) DEA, (-3.6%) Prices $68.4 mln sale of 3.8 mln shares at $18 apiece, a 5.2% discount to Wednesday's closing price. Summit is capping the amount of cash available for the deal to $15 million, or 35% of the total, with the remaining compensation paid with stock. The boards of directors at both firms already have signed off on the deal.
|
1b5e1559-bb40-49f7-96f2-a61ef71af293
|
723580.0
|
2016-04-18 00:00:00 UTC
|
Outfront Media (OUT) Partners with New York-Based Waltz
|
DEA
|
https://www.nasdaq.com/articles/outfront-media-out-partners-with-new-york-based-waltz-2016-04-18
|
nan
|
nan
|
Outfront Media Inc.OUT announced an investment in a digital payment system start up company, named Waltz. This partnership is in line with its strategy to improve transit ecosystem and is likely to interlink digital advertising experience with mobile payment systems to create an innovative transit experience.
New York-based Waltz is working on a smart mobile-focused transit fare payment system for efficient transaction. The smart and digitalized payment systems will be highly beneficial to the riders. It will not lower the operating expenses for transit systems significantly, but open up revenue opportunities for the operators.
Outfront Media is a leading provider of out-of-home advertising space in key markets throughout the U.S., Canada, Mexico and South America. With billboard and transit advertising displays, the company provides advertising services to diverse industries across the 25 largest markets in the U.S. and more than 180 markets in the U.S, Canada and Latin America.
The company is of the opinion that mobile payments systems at turnstiles will help transit advertising partners to draw greater audience and ensure seamless payment solution in future. Currently, Outfront Media sells advertising for more than 70 transit authorities, which include Los Angeles, New York, Washington, D.C., Atlanta, Detroit, San Francisco, and Miami.
Outfront Media currently carries a Zacks Rank #3 (Hold). Investors interested in the REIT industry may consider stocks like DCT Industrial Trust Inc. DCT , Easterly Government Properties, Inc. DEA and Douglas Emmett Inc DEI . Each of these stocks holds a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days . Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
OUTFRONT MEDIA (OUT): Free Stock Analysis Report
DOUGLAS EMMETT (DEI): Free Stock Analysis Report
DCT INDUSTRIAL (DCT): Free Stock Analysis Report
EASTRLY GOV PPT (DEA): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Investors interested in the REIT industry may consider stocks like DCT Industrial Trust Inc. DCT , Easterly Government Properties, Inc. DEA and Douglas Emmett Inc DEI . Click to get this free report OUTFRONT MEDIA (OUT): Free Stock Analysis Report DOUGLAS EMMETT (DEI): Free Stock Analysis Report DCT INDUSTRIAL (DCT): Free Stock Analysis Report EASTRLY GOV PPT (DEA): Free Stock Analysis Report To read this article on Zacks.com click here. New York-based Waltz is working on a smart mobile-focused transit fare payment system for efficient transaction.
|
Click to get this free report OUTFRONT MEDIA (OUT): Free Stock Analysis Report DOUGLAS EMMETT (DEI): Free Stock Analysis Report DCT INDUSTRIAL (DCT): Free Stock Analysis Report EASTRLY GOV PPT (DEA): Free Stock Analysis Report To read this article on Zacks.com click here. Investors interested in the REIT industry may consider stocks like DCT Industrial Trust Inc. DCT , Easterly Government Properties, Inc. DEA and Douglas Emmett Inc DEI . This partnership is in line with its strategy to improve transit ecosystem and is likely to interlink digital advertising experience with mobile payment systems to create an innovative transit experience.
|
Click to get this free report OUTFRONT MEDIA (OUT): Free Stock Analysis Report DOUGLAS EMMETT (DEI): Free Stock Analysis Report DCT INDUSTRIAL (DCT): Free Stock Analysis Report EASTRLY GOV PPT (DEA): Free Stock Analysis Report To read this article on Zacks.com click here. Investors interested in the REIT industry may consider stocks like DCT Industrial Trust Inc. DCT , Easterly Government Properties, Inc. DEA and Douglas Emmett Inc DEI . This partnership is in line with its strategy to improve transit ecosystem and is likely to interlink digital advertising experience with mobile payment systems to create an innovative transit experience.
|
Investors interested in the REIT industry may consider stocks like DCT Industrial Trust Inc. DCT , Easterly Government Properties, Inc. DEA and Douglas Emmett Inc DEI . Click to get this free report OUTFRONT MEDIA (OUT): Free Stock Analysis Report DOUGLAS EMMETT (DEI): Free Stock Analysis Report DCT INDUSTRIAL (DCT): Free Stock Analysis Report EASTRLY GOV PPT (DEA): Free Stock Analysis Report To read this article on Zacks.com click here. Outfront Media Inc.OUT announced an investment in a digital payment system start up company, named Waltz.
|
a0828be0-442c-4f5a-a436-f60c41e7d756
|
723581.0
|
2016-04-14 00:00:00 UTC
|
Outfront Aids Local Business Growth with Mobile Advertising
|
DEA
|
https://www.nasdaq.com/articles/outfront-aids-local-business-growth-with-mobile-advertising-2016-04-14
|
nan
|
nan
|
The Mobile Network platform of Outfront Media Inc.OUT is helping local business. In fact, the New York-based real estate investment trust ("REIT") made the announcement that more than 200 local businesses in the U.S. are using the Outfront Mobile Network.
Outfront Mobile Network is part of the company's strategic solution for location-based mobile marketing capabilities which is linked to the out-of-home campaign. The technology comes with a customized geo-fenced solution, powered by xAd, a location-based mobile marketing company. This enables it to aid businesses of every size, industry and digital style with advanced mobile advertising capabilities.
Outfront Media is a leading provider of out-of-home advertising space in key markets throughout the U.S., Canada, Mexico and South America. With billboard and transit advertising displays, the company provides advertising services to diverse industries across the 25 largest markets in the U.S. and more than 180 markets in the U.S, Canada and Latin America. Nevertheless, the Outfront Mobile Network creates a virtual radius around a business' out-of-home assets and other secondary locations to deliver a mobile banner ad that takes their target consumer to a dynamic landing page.
Outfront Media currently carries a Zacks Rank #3 (Hold). Investors interested in the REIT industry may consider stocks like DCT Industrial Trust Inc. DCT , Easterly Government Properties, Inc. DEA and Douglas Emmett Inc DEI . Each of these stocks holds a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days . Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
DOUGLAS EMMETT (DEI): Free Stock Analysis Report
DCT INDUSTRIAL (DCT): Free Stock Analysis Report
OUTFRONT MEDIA (OUT): Free Stock Analysis Report
EASTRLY GOV PPT (DEA): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Investors interested in the REIT industry may consider stocks like DCT Industrial Trust Inc. DCT , Easterly Government Properties, Inc. DEA and Douglas Emmett Inc DEI . Click to get this free report DOUGLAS EMMETT (DEI): Free Stock Analysis Report DCT INDUSTRIAL (DCT): Free Stock Analysis Report OUTFRONT MEDIA (OUT): Free Stock Analysis Report EASTRLY GOV PPT (DEA): Free Stock Analysis Report To read this article on Zacks.com click here. In fact, the New York-based real estate investment trust ("REIT") made the announcement that more than 200 local businesses in the U.S. are using the Outfront Mobile Network.
|
Investors interested in the REIT industry may consider stocks like DCT Industrial Trust Inc. DCT , Easterly Government Properties, Inc. DEA and Douglas Emmett Inc DEI . Click to get this free report DOUGLAS EMMETT (DEI): Free Stock Analysis Report DCT INDUSTRIAL (DCT): Free Stock Analysis Report OUTFRONT MEDIA (OUT): Free Stock Analysis Report EASTRLY GOV PPT (DEA): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Click to get this free report DOUGLAS EMMETT (DEI): Free Stock Analysis Report DCT INDUSTRIAL (DCT): Free Stock Analysis Report OUTFRONT MEDIA (OUT): Free Stock Analysis Report EASTRLY GOV PPT (DEA): Free Stock Analysis Report To read this article on Zacks.com click here. Investors interested in the REIT industry may consider stocks like DCT Industrial Trust Inc. DCT , Easterly Government Properties, Inc. DEA and Douglas Emmett Inc DEI . Outfront Mobile Network is part of the company's strategic solution for location-based mobile marketing capabilities which is linked to the out-of-home campaign.
|
Investors interested in the REIT industry may consider stocks like DCT Industrial Trust Inc. DCT , Easterly Government Properties, Inc. DEA and Douglas Emmett Inc DEI . Click to get this free report DOUGLAS EMMETT (DEI): Free Stock Analysis Report DCT INDUSTRIAL (DCT): Free Stock Analysis Report OUTFRONT MEDIA (OUT): Free Stock Analysis Report EASTRLY GOV PPT (DEA): Free Stock Analysis Report To read this article on Zacks.com click here. The Mobile Network platform of Outfront Media Inc.OUT is helping local business.
|
5a5f99b1-ac1e-4049-bb4c-544d7f93d591
|
723582.0
|
2016-04-11 00:00:00 UTC
|
Outfront Media (OUT) Inks Athletic Rights Deal with LSU
|
DEA
|
https://www.nasdaq.com/articles/outfront-media-out-inks-athletic-rights-deal-with-lsu-2016-04-11
|
nan
|
nan
|
Outfront Media Sports Inc., a division of Outfront Media Inc.OUT has inked a deal with Louisiana State University ("LSU") for athletics marketing and multimedia rights. The new exclusive deal, through the 2025-2026 season with the New York-based real estate investment trust ("REIT") across LSU's athletic facilities and events, highlights the commitment of Outfront Media to promote sports opportunities across the out-of-home media platforms.
The partnership with Outfront Media guarantees the most effective media experience for the fans of LSU and aids in sustaining excellence. Outfront Media is well aware of the natural excitement associated with LSU athletics, and the student athletes, coaches and fans gain enormously from the resources the company offers to LSU.
In fact, Outfront Media and LSU have been working in tandem since 2005 and the relationship hinges on trust and tradition. The latest agreement for another decade epitomizes the quality of relationships that Outfront Media has with various universities and sports franchises.
Outfront Media is a leading provider of out-of-home advertising space in key markets throughout the U.S., Canada, Mexico and South America. With billboard and transit advertising displays, the company provides advertising services to diverse industries across the 25 largest markets in the U.S. and more than 180 markets in the U.S, Canada and Latin America.
Outfront Media currently carries a Zacks Rank #3 (Hold). Investors interested in the REIT industry may consider stocks like DCT Industrial Trust Inc. DCT , Easterly Government Properties, Inc. DEA and Douglas Emmett Inc DEI . Each of these stocks holds a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days . Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
DOUGLAS EMMETT (DEI): Free Stock Analysis Report
DCT INDUSTRIAL (DCT): Free Stock Analysis Report
OUTFRONT MEDIA (OUT): Free Stock Analysis Report
EASTRLY GOV PPT (DEA): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Outfront Media Sports Inc., a division of Outfront Media Inc.OUT has inked a deal with Louisiana State University ("LSU") for athletics marketing and multimedia rights. The new exclusive deal, through the 2025-2026 season with the New York-based real estate investment trust ("REIT") across LSU's athletic facilities and events, highlights the commitment of Outfront Media to promote sports opportunities across the out-of-home media platforms. Investors interested in the REIT industry may consider stocks like DCT Industrial Trust Inc. DCT , Easterly Government Properties, Inc. DEA and Douglas Emmett Inc DEI .
|
Investors interested in the REIT industry may consider stocks like DCT Industrial Trust Inc. DCT , Easterly Government Properties, Inc. DEA and Douglas Emmett Inc DEI . Click to get this free report DOUGLAS EMMETT (DEI): Free Stock Analysis Report DCT INDUSTRIAL (DCT): Free Stock Analysis Report OUTFRONT MEDIA (OUT): Free Stock Analysis Report EASTRLY GOV PPT (DEA): Free Stock Analysis Report To read this article on Zacks.com click here. Outfront Media Sports Inc., a division of Outfront Media Inc.OUT has inked a deal with Louisiana State University ("LSU") for athletics marketing and multimedia rights.
|
Outfront Media Sports Inc., a division of Outfront Media Inc.OUT has inked a deal with Louisiana State University ("LSU") for athletics marketing and multimedia rights. The new exclusive deal, through the 2025-2026 season with the New York-based real estate investment trust ("REIT") across LSU's athletic facilities and events, highlights the commitment of Outfront Media to promote sports opportunities across the out-of-home media platforms. Click to get this free report DOUGLAS EMMETT (DEI): Free Stock Analysis Report DCT INDUSTRIAL (DCT): Free Stock Analysis Report OUTFRONT MEDIA (OUT): Free Stock Analysis Report EASTRLY GOV PPT (DEA): Free Stock Analysis Report To read this article on Zacks.com click here.
|
Outfront Media Sports Inc., a division of Outfront Media Inc.OUT has inked a deal with Louisiana State University ("LSU") for athletics marketing and multimedia rights. The new exclusive deal, through the 2025-2026 season with the New York-based real estate investment trust ("REIT") across LSU's athletic facilities and events, highlights the commitment of Outfront Media to promote sports opportunities across the out-of-home media platforms. Investors interested in the REIT industry may consider stocks like DCT Industrial Trust Inc. DCT , Easterly Government Properties, Inc. DEA and Douglas Emmett Inc DEI .
|
d98c4d0b-6ad8-4c21-b0a7-e5d292d5a6dd
|
723583.0
|
2016-04-11 00:00:00 UTC
|
Digital Realty (DLR) Prices Euro 600M Guaranteed Notes
|
DEA
|
https://www.nasdaq.com/articles/digital-realty-dlr-prices-euro-600m-guaranteed-notes-2016-04-11
|
nan
|
nan
|
Digital Realty Trust Inc.DLR made the announcement of pricing of notes by Digital Euro Finco, LLC, a subsidiary of its operating partnership, Digital Realty Trust, L.P. The pricing of guaranteed notes offering of a principal amount of €600 million aggregate is anticipated to add to the liquidity strength of the San Francisco, CA-based real estate investment trust ("REIT").
The interest on the guaranteed notes due in 2024 will be paid at a rate of interest of 2.625% per annum, payable yearly. Subject to the fulfillment of certain customary closing conditions, the offering is anticipated to close on Apr 15, 2016. Digital Realty has plans to utilize the net proceeds generated from this offering for temporary repayment of borrowing under its revolving credit facility.
Digital Realty is engaged in owning, acquiring, repositioning and managing technology-related real estate. The portfolio of the company includes applications and operations critical to the day-to-day operations of technology industry tenants.
Digital Realty currently carries a Zacks Rank #3 (Hold). Investors interested in the REIT industry may consider stocks like DCT Industrial Trust Inc. DCT , Easterly Government Properties, Inc. DEA and Douglas Emmett Inc DEI . Each of these stocks holds a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days . Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
DIGITAL RLTY TR (DLR): Free Stock Analysis Report
DOUGLAS EMMETT (DEI): Free Stock Analysis Report
DCT INDUSTRIAL (DCT): Free Stock Analysis Report
EASTRLY GOV PPT (DEA): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Investors interested in the REIT industry may consider stocks like DCT Industrial Trust Inc. DCT , Easterly Government Properties, Inc. DEA and Douglas Emmett Inc DEI . Click to get this free report DIGITAL RLTY TR (DLR): Free Stock Analysis Report DOUGLAS EMMETT (DEI): Free Stock Analysis Report DCT INDUSTRIAL (DCT): Free Stock Analysis Report EASTRLY GOV PPT (DEA): Free Stock Analysis Report To read this article on Zacks.com click here. The pricing of guaranteed notes offering of a principal amount of €600 million aggregate is anticipated to add to the liquidity strength of the San Francisco, CA-based real estate investment trust ("REIT").
|
Investors interested in the REIT industry may consider stocks like DCT Industrial Trust Inc. DCT , Easterly Government Properties, Inc. DEA and Douglas Emmett Inc DEI . Click to get this free report DIGITAL RLTY TR (DLR): Free Stock Analysis Report DOUGLAS EMMETT (DEI): Free Stock Analysis Report DCT INDUSTRIAL (DCT): Free Stock Analysis Report EASTRLY GOV PPT (DEA): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Click to get this free report DIGITAL RLTY TR (DLR): Free Stock Analysis Report DOUGLAS EMMETT (DEI): Free Stock Analysis Report DCT INDUSTRIAL (DCT): Free Stock Analysis Report EASTRLY GOV PPT (DEA): Free Stock Analysis Report To read this article on Zacks.com click here. Investors interested in the REIT industry may consider stocks like DCT Industrial Trust Inc. DCT , Easterly Government Properties, Inc. DEA and Douglas Emmett Inc DEI . Digital Realty Trust Inc.DLR made the announcement of pricing of notes by Digital Euro Finco, LLC, a subsidiary of its operating partnership, Digital Realty Trust, L.P.
|
Investors interested in the REIT industry may consider stocks like DCT Industrial Trust Inc. DCT , Easterly Government Properties, Inc. DEA and Douglas Emmett Inc DEI . Click to get this free report DIGITAL RLTY TR (DLR): Free Stock Analysis Report DOUGLAS EMMETT (DEI): Free Stock Analysis Report DCT INDUSTRIAL (DCT): Free Stock Analysis Report EASTRLY GOV PPT (DEA): Free Stock Analysis Report To read this article on Zacks.com click here. Digital Realty Trust Inc.DLR made the announcement of pricing of notes by Digital Euro Finco, LLC, a subsidiary of its operating partnership, Digital Realty Trust, L.P.
|
c5235db3-9867-4cc9-918e-99cb5861f7a2
|
723584.0
|
2016-04-06 00:00:00 UTC
|
Prologis (PLD) Rewards its Shareholders: Should You Buy?
|
DEA
|
https://www.nasdaq.com/articles/prologis-pld-rewards-its-shareholders%3A-should-you-buy-2016-04-06
|
nan
|
nan
|
On Apr 5, 2016, we issued an updated research report on Prologis, Inc.PLD . This San Francisco, CA-based real estate investment trust (REIT) is engaged in acquisition, development, operation and management of industrial real estate space in the Americas, Asia and Europe.
In Jan 2016, Prologis reported fourth-quarter 2015 core funds from operations ("FFO") of 64 cents per share, beating the Zacks Consensus Estimate by 2 cents and improving from the year-ago quarter figure of 48 cents. Results were driven by growth in revenues and occupancy gains. Further, the company expects 2016 core FFO in the range of $2.50-$2.60 per share, reflecting an expected growth of 14% year over year.
Notably, Prologis follows the long-term strategy of providing attractive risk-adjusted returns. In Feb 2016, Prologis' board approved a 10.5% hike in its annualized dividend rate to $1.68 from the prior year, rewarding the shareholders. In 2015, on a combined basis, Prologis raised dividend by 21% from that of 2014, on a run-rate basis.
Prologis currently carries a Zacks Rank #2 (Buy). Investors interested in the REIT industry may consider stocks like DCT Industrial Trust Inc. DCT , Easterly Government Properties, Inc. DEA and Douglas Emmett Inc DEI . Each of these stocks holds the same Zacks Rank as Prologis.
Note: FFO, a widely used metric to gauge the performance of REITs, is obtained after adding depreciation and amortization and other non-cash expenses to net income.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days . Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
PROLOGIS INC (PLD): Free Stock Analysis Report
DOUGLAS EMMETT (DEI): Free Stock Analysis Report
DCT INDUSTRIAL (DCT): Free Stock Analysis Report
EASTRLY GOV PPT (DEA): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Investors interested in the REIT industry may consider stocks like DCT Industrial Trust Inc. DCT , Easterly Government Properties, Inc. DEA and Douglas Emmett Inc DEI . Click to get this free report PROLOGIS INC (PLD): Free Stock Analysis Report DOUGLAS EMMETT (DEI): Free Stock Analysis Report DCT INDUSTRIAL (DCT): Free Stock Analysis Report EASTRLY GOV PPT (DEA): Free Stock Analysis Report To read this article on Zacks.com click here. This San Francisco, CA-based real estate investment trust (REIT) is engaged in acquisition, development, operation and management of industrial real estate space in the Americas, Asia and Europe.
|
Investors interested in the REIT industry may consider stocks like DCT Industrial Trust Inc. DCT , Easterly Government Properties, Inc. DEA and Douglas Emmett Inc DEI . Click to get this free report PROLOGIS INC (PLD): Free Stock Analysis Report DOUGLAS EMMETT (DEI): Free Stock Analysis Report DCT INDUSTRIAL (DCT): Free Stock Analysis Report EASTRLY GOV PPT (DEA): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Click to get this free report PROLOGIS INC (PLD): Free Stock Analysis Report DOUGLAS EMMETT (DEI): Free Stock Analysis Report DCT INDUSTRIAL (DCT): Free Stock Analysis Report EASTRLY GOV PPT (DEA): Free Stock Analysis Report To read this article on Zacks.com click here. Investors interested in the REIT industry may consider stocks like DCT Industrial Trust Inc. DCT , Easterly Government Properties, Inc. DEA and Douglas Emmett Inc DEI . In Jan 2016, Prologis reported fourth-quarter 2015 core funds from operations ("FFO") of 64 cents per share, beating the Zacks Consensus Estimate by 2 cents and improving from the year-ago quarter figure of 48 cents.
|
Investors interested in the REIT industry may consider stocks like DCT Industrial Trust Inc. DCT , Easterly Government Properties, Inc. DEA and Douglas Emmett Inc DEI . Click to get this free report PROLOGIS INC (PLD): Free Stock Analysis Report DOUGLAS EMMETT (DEI): Free Stock Analysis Report DCT INDUSTRIAL (DCT): Free Stock Analysis Report EASTRLY GOV PPT (DEA): Free Stock Analysis Report To read this article on Zacks.com click here. Further, the company expects 2016 core FFO in the range of $2.50-$2.60 per share, reflecting an expected growth of 14% year over year.
|
ee5e8b16-f2e4-4d1b-9fe5-f7abc28445fd
|
723585.0
|
2016-04-05 00:00:00 UTC
|
STAG Industrial (STAG) Unveils 1Q16 Transaction Activities
|
DEA
|
https://www.nasdaq.com/articles/stag-industrial-stag-unveils-1q16-transaction-activities-2016-04-05
|
nan
|
nan
|
STAG Industrial, Inc.STAG , the Boston, MA-based real estate investment trust ("REIT") recently declared its acquisition, disposition and leasing activities for first-quarter 2016.
STAG Industrial focuses on acquisition, ownership and management of single-tenant industrial properties throughout the U.S. In first-quarter 2016, the company acquired five buildings, two in the state of Maine, two in Indiana and one in the state of Tennessee, for around $27.9 million. The buildings, spanning 710,754 square feet, were 62.7% occupied. Two buildings in Portland-South Portland, ME, covering an area of 265,126 square feet, were purchased for $12.5 million. Further, two properties in Cincinnati, OH-KY-IN covering an area of 206,448 and 108,620 square feet were bought for $5.3 million and $5.6 million respectively. The 130,560 square feet Knoxville, TN-based property was acquired for $4.5 million.
Also, during the first-quarter 2016, STAG Industrial sold four buildings, spanning over an area of around 1.2 million square feet for a sum of $32.8 million.
During first-quarter 2016, STAG Industrial leased around 2 million square feet of space which included 172,689 square feet of new leases, 1,533,041 square feet of renewal leases and 315,620 square feet of temporary leases.
Currently, STAG Industrial carries a Zacks Rank #3 (Hold).
Investors interested in the REIT industry may consider stocks like DCT Industrial Trust Inc. DCT , Easterly Government Properties, Inc. DEA and Douglas Emmett Inc DEI . Each of these stocks holds a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days . Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
DOUGLAS EMMETT (DEI): Free Stock Analysis Report
DCT INDUSTRIAL (DCT): Free Stock Analysis Report
STAG INDUSTRIAL (STAG): Free Stock Analysis Report
EASTRLY GOV PPT (DEA): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Investors interested in the REIT industry may consider stocks like DCT Industrial Trust Inc. DCT , Easterly Government Properties, Inc. DEA and Douglas Emmett Inc DEI . Click to get this free report DOUGLAS EMMETT (DEI): Free Stock Analysis Report DCT INDUSTRIAL (DCT): Free Stock Analysis Report STAG INDUSTRIAL (STAG): Free Stock Analysis Report EASTRLY GOV PPT (DEA): Free Stock Analysis Report To read this article on Zacks.com click here. STAG Industrial, Inc.STAG , the Boston, MA-based real estate investment trust ("REIT") recently declared its acquisition, disposition and leasing activities for first-quarter 2016.
|
Investors interested in the REIT industry may consider stocks like DCT Industrial Trust Inc. DCT , Easterly Government Properties, Inc. DEA and Douglas Emmett Inc DEI . Click to get this free report DOUGLAS EMMETT (DEI): Free Stock Analysis Report DCT INDUSTRIAL (DCT): Free Stock Analysis Report STAG INDUSTRIAL (STAG): Free Stock Analysis Report EASTRLY GOV PPT (DEA): Free Stock Analysis Report To read this article on Zacks.com click here. During first-quarter 2016, STAG Industrial leased around 2 million square feet of space which included 172,689 square feet of new leases, 1,533,041 square feet of renewal leases and 315,620 square feet of temporary leases.
|
Click to get this free report DOUGLAS EMMETT (DEI): Free Stock Analysis Report DCT INDUSTRIAL (DCT): Free Stock Analysis Report STAG INDUSTRIAL (STAG): Free Stock Analysis Report EASTRLY GOV PPT (DEA): Free Stock Analysis Report To read this article on Zacks.com click here. Investors interested in the REIT industry may consider stocks like DCT Industrial Trust Inc. DCT , Easterly Government Properties, Inc. DEA and Douglas Emmett Inc DEI . Also, during the first-quarter 2016, STAG Industrial sold four buildings, spanning over an area of around 1.2 million square feet for a sum of $32.8 million.
|
Investors interested in the REIT industry may consider stocks like DCT Industrial Trust Inc. DCT , Easterly Government Properties, Inc. DEA and Douglas Emmett Inc DEI . Click to get this free report DOUGLAS EMMETT (DEI): Free Stock Analysis Report DCT INDUSTRIAL (DCT): Free Stock Analysis Report STAG INDUSTRIAL (STAG): Free Stock Analysis Report EASTRLY GOV PPT (DEA): Free Stock Analysis Report To read this article on Zacks.com click here. The 130,560 square feet Knoxville, TN-based property was acquired for $4.5 million.
|
b5f5e24b-014b-4074-a815-d0cfe15fb8cb
|
723586.0
|
2016-04-04 00:00:00 UTC
|
One Liberty Acquires Properties in Greenville for $17.1M
|
DEA
|
https://www.nasdaq.com/articles/one-liberty-acquires-properties-in-greenville-for-%2417.1m-2016-04-04
|
nan
|
nan
|
One Liberty Properties Inc.OLP , the Great Neck, NY-based real estate investment trust ("REIT") has made the announcement of acquiring two multi-tenant properties, located in Greenville, SC for a total price of $17.1 million. Acquisition of these Class A industrial properties, spanning over an area of 270,000 square feet, is in sync with the company's long-term strategic aims. It also indicates the ability of the company to deploy capital so as to reshape its portfolio.
The acquired properties are net leased to six tenants, of which three are subsidiaries to companies listed in the NYSE. These two acquisitions are likely to be accretive for the company, going forward, as this will add to the modern industrial assets in the strategically located and developing area of Greenville-Spartanburg.
One Liberty Properties is engaged in the acquisition, ownership, and management of commercial real estate properties in the U.S., primarily under long-term net lease.
Investors interested in the REIT industry may consider stocks like DCT Industrial Trust Inc. DCT , Easterly Government Properties, Inc. DEA and Douglas Emmett Inc DEI . Each of these stocks holds a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days . Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
DOUGLAS EMMETT (DEI): Free Stock Analysis Report
DCT INDUSTRIAL (DCT): Free Stock Analysis Report
EASTRLY GOV PPT (DEA): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Investors interested in the REIT industry may consider stocks like DCT Industrial Trust Inc. DCT , Easterly Government Properties, Inc. DEA and Douglas Emmett Inc DEI . Click to get this free report DOUGLAS EMMETT (DEI): Free Stock Analysis Report DCT INDUSTRIAL (DCT): Free Stock Analysis Report EASTRLY GOV PPT (DEA): Free Stock Analysis Report To read this article on Zacks.com click here. Acquisition of these Class A industrial properties, spanning over an area of 270,000 square feet, is in sync with the company's long-term strategic aims.
|
Investors interested in the REIT industry may consider stocks like DCT Industrial Trust Inc. DCT , Easterly Government Properties, Inc. DEA and Douglas Emmett Inc DEI . Click to get this free report DOUGLAS EMMETT (DEI): Free Stock Analysis Report DCT INDUSTRIAL (DCT): Free Stock Analysis Report EASTRLY GOV PPT (DEA): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Investors interested in the REIT industry may consider stocks like DCT Industrial Trust Inc. DCT , Easterly Government Properties, Inc. DEA and Douglas Emmett Inc DEI . Click to get this free report DOUGLAS EMMETT (DEI): Free Stock Analysis Report DCT INDUSTRIAL (DCT): Free Stock Analysis Report EASTRLY GOV PPT (DEA): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Investors interested in the REIT industry may consider stocks like DCT Industrial Trust Inc. DCT , Easterly Government Properties, Inc. DEA and Douglas Emmett Inc DEI . Click to get this free report DOUGLAS EMMETT (DEI): Free Stock Analysis Report DCT INDUSTRIAL (DCT): Free Stock Analysis Report EASTRLY GOV PPT (DEA): Free Stock Analysis Report To read this article on Zacks.com click here. One Liberty Properties Inc.OLP , the Great Neck, NY-based real estate investment trust ("REIT") has made the announcement of acquiring two multi-tenant properties, located in Greenville, SC for a total price of $17.1 million.
|
3310c858-4b0c-4936-9679-63937d35d5f6
|
723587.0
|
2016-03-29 00:00:00 UTC
|
Outfront (OUT) and WMATA Extend Long-term Relationship
|
DEA
|
https://www.nasdaq.com/articles/outfront-out-and-wmata-extend-long-term-relationship-2016-03-29
|
nan
|
nan
|
Outfront Media Inc.OUT recently announced a move that extends its long-term relationship with the Washington Metropolitan Area Transit Authority ("WMATA"). On Mar 23, 2016, the New York-based real estate investment trust ("REIT") deployed ON Smart Media displays at the entrance/exit way Navy Yard station of Green Line, just a block away from Nationals Park baseball stadium.
This ON Smart Media platform has not only provided WMATA a smart technology to keep countless passengers updated, but also the advertising partners of Outfront has received a wonderful platform with huge audience. The 15-second visual advertising slots, alternating with important information for the passengers, have opened up huge opportunities for WMATA.
Outfront is a lessor of advertising space on out-of-home advertising structures and sites across the United States, Canada and Latin America. The company's portfolio mainly consists of billboard displays.
Notably, Outfront reported fourth-quarter 2015 net loss per share of 54 cents, as against net income of 23 cents per share recorded in the prior-year quarter. Earnings, excluding the losses on sale of real estate assets, were recorded at 21 cents per share during fourth-quarter 2015, down from 25 cents earned in the prior-year quarter. The Zacks Consensus Estimate for fourth-quarter earnings was pegged at 53 cents per share.
Outfront currently carries a Zacks Rank #3 (Hold).
Investors interested in the REIT industry may consider stocks like DCT Industrial Trust Inc. DCT , Easterly Government Properties, Inc. DEA and Douglas Emmett Inc DEI . Each of these stocks holds a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days . Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
DOUGLAS EMMETT (DEI): Free Stock Analysis Report
DCT INDUSTRIAL (DCT): Free Stock Analysis Report
OUTFRONT MEDIA (OUT): Free Stock Analysis Report
EASTRLY GOV PPT (DEA): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Investors interested in the REIT industry may consider stocks like DCT Industrial Trust Inc. DCT , Easterly Government Properties, Inc. DEA and Douglas Emmett Inc DEI . Click to get this free report DOUGLAS EMMETT (DEI): Free Stock Analysis Report DCT INDUSTRIAL (DCT): Free Stock Analysis Report OUTFRONT MEDIA (OUT): Free Stock Analysis Report EASTRLY GOV PPT (DEA): Free Stock Analysis Report To read this article on Zacks.com click here. Outfront Media Inc.OUT recently announced a move that extends its long-term relationship with the Washington Metropolitan Area Transit Authority ("WMATA").
|
Click to get this free report DOUGLAS EMMETT (DEI): Free Stock Analysis Report DCT INDUSTRIAL (DCT): Free Stock Analysis Report OUTFRONT MEDIA (OUT): Free Stock Analysis Report EASTRLY GOV PPT (DEA): Free Stock Analysis Report To read this article on Zacks.com click here. Investors interested in the REIT industry may consider stocks like DCT Industrial Trust Inc. DCT , Easterly Government Properties, Inc. DEA and Douglas Emmett Inc DEI . On Mar 23, 2016, the New York-based real estate investment trust ("REIT") deployed ON Smart Media displays at the entrance/exit way Navy Yard station of Green Line, just a block away from Nationals Park baseball stadium.
|
Click to get this free report DOUGLAS EMMETT (DEI): Free Stock Analysis Report DCT INDUSTRIAL (DCT): Free Stock Analysis Report OUTFRONT MEDIA (OUT): Free Stock Analysis Report EASTRLY GOV PPT (DEA): Free Stock Analysis Report To read this article on Zacks.com click here. Investors interested in the REIT industry may consider stocks like DCT Industrial Trust Inc. DCT , Easterly Government Properties, Inc. DEA and Douglas Emmett Inc DEI . Notably, Outfront reported fourth-quarter 2015 net loss per share of 54 cents, as against net income of 23 cents per share recorded in the prior-year quarter.
|
Investors interested in the REIT industry may consider stocks like DCT Industrial Trust Inc. DCT , Easterly Government Properties, Inc. DEA and Douglas Emmett Inc DEI . Click to get this free report DOUGLAS EMMETT (DEI): Free Stock Analysis Report DCT INDUSTRIAL (DCT): Free Stock Analysis Report OUTFRONT MEDIA (OUT): Free Stock Analysis Report EASTRLY GOV PPT (DEA): Free Stock Analysis Report To read this article on Zacks.com click here. Each of these stocks holds a Zacks Rank #2 (Buy).
|
048e0eaa-0acf-471d-9457-624680094614
|
723588.0
|
2016-03-10 00:00:00 UTC
|
Financial Sector Update for 03/10/2016: BKCC,AGM,DEA, C
|
DEA
|
https://www.nasdaq.com/articles/financial-sector-update-for-03-10-2016%3A-bkccagmdea-c-2016-03-10
|
nan
|
nan
|
Top Financial Stocks
PM -1.89%
BAC -0.69%
WFC -1.43%
C -0.99%
USB -1.45%
Financial stocks were extending their prior declines in early afternoon trade, with the NYSE Financial Sector Index dropping about 0.7% while financial companies in the S&P 500 Index were falling about 0.7%.
In company news, BlackRock Capital Investment ( BKCC ) was climbing back from an earlier retreat that followed the debt and equity investor's reporting lower Q4 revenue compared with year-ago levels, also trailing analyst estimates, despite adjusted net income for the period that beat the Street view.
Excluding one-time items, the company earned $0.29 per share, up from $0.26 per share during the year-ago period and topping the $0.23 per share consensus.
Revenue declined 19.1% from the same quarter last year to $31.8 million, missing the $36.2 million consensus.
Separately, BlackRock Capital declared a $0.23 per share dividend, unchanged from the previous quarter and payable on April 1 to shareholders of record on March 18.
BKCC shares were back within 0.3% of breaking even this afternoon at $8.78 each, bouncing back from a session low of $8.57 a share soon after the opening bell.
In other sector news,
(+) AGM, (+11.4%) Report Q4 core earnings of $1.17 per share, up from $0.84 per share during year-ago period and beating Capital IQ consensus by $0.01 per share. Increases quarterly dividend by 63% from prior quarter to $0.26 per share.
(-) DEA, (-1.9%) Hires Meghan Baivier from Citigroup ( C ) group to be chief financial officer and chief operating officer, effective immediately. Former CFO Alison Bernard is staying with the company and will become chief accounting officer.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
(-) DEA, (-1.9%) Hires Meghan Baivier from Citigroup ( C ) group to be chief financial officer and chief operating officer, effective immediately. In company news, BlackRock Capital Investment ( BKCC ) was climbing back from an earlier retreat that followed the debt and equity investor's reporting lower Q4 revenue compared with year-ago levels, also trailing analyst estimates, despite adjusted net income for the period that beat the Street view. Separately, BlackRock Capital declared a $0.23 per share dividend, unchanged from the previous quarter and payable on April 1 to shareholders of record on March 18.
|
(-) DEA, (-1.9%) Hires Meghan Baivier from Citigroup ( C ) group to be chief financial officer and chief operating officer, effective immediately. In company news, BlackRock Capital Investment ( BKCC ) was climbing back from an earlier retreat that followed the debt and equity investor's reporting lower Q4 revenue compared with year-ago levels, also trailing analyst estimates, despite adjusted net income for the period that beat the Street view. Excluding one-time items, the company earned $0.29 per share, up from $0.26 per share during the year-ago period and topping the $0.23 per share consensus.
|
(-) DEA, (-1.9%) Hires Meghan Baivier from Citigroup ( C ) group to be chief financial officer and chief operating officer, effective immediately. Financial stocks were extending their prior declines in early afternoon trade, with the NYSE Financial Sector Index dropping about 0.7% while financial companies in the S&P 500 Index were falling about 0.7%. Excluding one-time items, the company earned $0.29 per share, up from $0.26 per share during the year-ago period and topping the $0.23 per share consensus.
|
(-) DEA, (-1.9%) Hires Meghan Baivier from Citigroup ( C ) group to be chief financial officer and chief operating officer, effective immediately. Excluding one-time items, the company earned $0.29 per share, up from $0.26 per share during the year-ago period and topping the $0.23 per share consensus. In other sector news, (+) AGM, (+11.4%) Report Q4 core earnings of $1.17 per share, up from $0.84 per share during year-ago period and beating Capital IQ consensus by $0.01 per share.
|
5eb5ff5f-4f37-4f5d-847f-00c3cc86cd1a
|
723589.0
|
2016-03-07 00:00:00 UTC
|
Easterly Government Properties, Inc. (DEA) Ex-Dividend Date Scheduled for March 08, 2016
|
DEA
|
https://www.nasdaq.com/articles/easterly-government-properties-inc-dea-ex-dividend-date-scheduled-march-08-2016-2016-03-07
|
nan
|
nan
|
Easterly Government Properties, Inc. ( DEA ) will begin trading ex-dividend on March 08, 2016. A cash dividend payment of $0.22 per share is scheduled to be paid on March 25, 2016. Shareholders who purchased DEA prior to the ex-dividend date are eligible for the cash dividend payment.
The previous trading day's last sale of DEA was $17.39, representing a -7.6% decrease from the 52 week high of $18.82 and a 14.03% increase over the 52 week low of $15.25.
DEA is a part of the Consumer Services sector, which includes companies such as Simon Property Group, Inc. ( SPG ) and Public Storage ( PSA ). Zacks Investment Research reports DEA's forecasted earnings growth in 2016 as 15.38%, compared to an industry average of 5.5%.
For more information on the declaration, record and payment dates, visit the DEA Dividend History page. Our Dividend Calendar has the full list of stocks that have an ex-dividend today.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
DEA is a part of the Consumer Services sector, which includes companies such as Simon Property Group, Inc. ( SPG ) and Public Storage ( PSA ). Zacks Investment Research reports DEA's forecasted earnings growth in 2016 as 15.38%, compared to an industry average of 5.5%. For more information on the declaration, record and payment dates, visit the DEA Dividend History page.
|
Easterly Government Properties, Inc. ( DEA ) will begin trading ex-dividend on March 08, 2016. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Shareholders who purchased DEA prior to the ex-dividend date are eligible for the cash dividend payment.
|
Easterly Government Properties, Inc. ( DEA ) will begin trading ex-dividend on March 08, 2016. Shareholders who purchased DEA prior to the ex-dividend date are eligible for the cash dividend payment. For more information on the declaration, record and payment dates, visit the DEA Dividend History page.
|
Shareholders who purchased DEA prior to the ex-dividend date are eligible for the cash dividend payment. The previous trading day's last sale of DEA was $17.39, representing a -7.6% decrease from the 52 week high of $18.82 and a 14.03% increase over the 52 week low of $15.25. Easterly Government Properties, Inc. ( DEA ) will begin trading ex-dividend on March 08, 2016.
|
6614ab6b-4650-45e7-8f85-dc2f94e1da03
|
723590.0
|
2016-01-27 00:00:00 UTC
|
Terreno Realty (TRNO) Buys Industrial Property in Seattle
|
DEA
|
https://www.nasdaq.com/articles/terreno-realty-trno-buys-industrial-property-in-seattle-2016-01-27
|
nan
|
nan
|
In a notable development, Terreno Realty Corp.TRNO announced the acquisition of an industrial property in Seattle, WA. Valued at around $6.5 million, this buyout is consistent with this industrial real estate investment trust's ("REIT") strategy of enhancing its industrial property portfolio in major U.S. markets.
The acquired property comprises one industrial distribution building, spanning about 35,000 square feet and spread over an area of around 1.7 acres. This industrial property is located at 4930 3rd Avenue South, close to Seattle's Port and SoDo district.
Notably, the property is fully leased to one tenant and offers 4 dock-high and 1 grade level loading positions, parking facility for 37 cars and an excess yard.
We expect the latest acquisition to boost Terreno Realty's bottom line, going forward. This San Francisco, CA-based REIT actively focuses on leveraging the improving fundamentals of industrial markets, bolstering its business in key coastal U.S. markets like Los Angeles, Northern New Jersey/New York City, San Francisco Bay Area, Seattle, Miami and Washington, D.C./Baltimore.
Terreno Realty currently carries a Zacks Rank #3 (Hold).
Better-ranked stocks in the REIT space include Crown Castle International Corp. CCI , Easterly Government Properties, Inc. DEA and Mack-Cali Realty Corp. CLI . All three stocks sport a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days . Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
CROWN CASTLE (CCI): Free Stock Analysis Report
MACK CALI CORP (CLI): Free Stock Analysis Report
TERRENO REALTY (TRNO): Free Stock Analysis Report
EASTRLY GOV PPT (DEA): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Better-ranked stocks in the REIT space include Crown Castle International Corp. CCI , Easterly Government Properties, Inc. DEA and Mack-Cali Realty Corp. CLI . Click to get this free report CROWN CASTLE (CCI): Free Stock Analysis Report MACK CALI CORP (CLI): Free Stock Analysis Report TERRENO REALTY (TRNO): Free Stock Analysis Report EASTRLY GOV PPT (DEA): Free Stock Analysis Report To read this article on Zacks.com click here. The acquired property comprises one industrial distribution building, spanning about 35,000 square feet and spread over an area of around 1.7 acres.
|
Click to get this free report CROWN CASTLE (CCI): Free Stock Analysis Report MACK CALI CORP (CLI): Free Stock Analysis Report TERRENO REALTY (TRNO): Free Stock Analysis Report EASTRLY GOV PPT (DEA): Free Stock Analysis Report To read this article on Zacks.com click here. Better-ranked stocks in the REIT space include Crown Castle International Corp. CCI , Easterly Government Properties, Inc. DEA and Mack-Cali Realty Corp. CLI . Click to get this free report >> Want the latest recommendations from Zacks Investment Research?
|
Click to get this free report CROWN CASTLE (CCI): Free Stock Analysis Report MACK CALI CORP (CLI): Free Stock Analysis Report TERRENO REALTY (TRNO): Free Stock Analysis Report EASTRLY GOV PPT (DEA): Free Stock Analysis Report To read this article on Zacks.com click here. Better-ranked stocks in the REIT space include Crown Castle International Corp. CCI , Easterly Government Properties, Inc. DEA and Mack-Cali Realty Corp. CLI . Valued at around $6.5 million, this buyout is consistent with this industrial real estate investment trust's ("REIT") strategy of enhancing its industrial property portfolio in major U.S. markets.
|
Better-ranked stocks in the REIT space include Crown Castle International Corp. CCI , Easterly Government Properties, Inc. DEA and Mack-Cali Realty Corp. CLI . Click to get this free report CROWN CASTLE (CCI): Free Stock Analysis Report MACK CALI CORP (CLI): Free Stock Analysis Report TERRENO REALTY (TRNO): Free Stock Analysis Report EASTRLY GOV PPT (DEA): Free Stock Analysis Report To read this article on Zacks.com click here. In a notable development, Terreno Realty Corp.TRNO announced the acquisition of an industrial property in Seattle, WA.
|
ffb6a8a9-b714-4f9d-9ece-d9e5554a42ed
|
723591.0
|
2016-01-21 00:00:00 UTC
|
Lexington Realty Acquires Industrial Facility in Detroit
|
DEA
|
https://www.nasdaq.com/articles/lexington-realty-acquires-industrial-facility-in-detroit-2016-01-21
|
nan
|
nan
|
In a major development, Lexington Realty TrustLXP closed the acquisition of a 190,000-square foot industrial facility in Detroit, MI for $29.7 million. Notably, the New York-based real estate investment trust ("REIT") had previously announced this deal. The high-quality industrial property in a prime location marks a good addition to Lexington Realty's portfolio and will likely be accretive to its financials, going forward.
Lexington Realty is primarily engaged in ownership, operation and management of a diverse portfolio of single-tenant real estate properties. Set up in 2015, the acquired property is fully leased to FCA US LLC (previously known as Chrysler Group LLC) ("FCA"), a leading global automaker, for an initial term period of 20 years. Importantly, the property is situated close to the corporate headquarters of FCA and conveniently connected with highways, port, airport, international crossing and rail carriers. Inclusion of an international player like FCA as a tenant is expected to support Lexington Realty's growth in the future.
Currently, Lexington Realty carries a Zacks Rank #3 (Hold).
Better-ranked stocks in the REIT space include Crown Castle International Corp. CCI , Easterly Government Properties, Inc. DEA and Getty Realty Corp. GTY . All three stocks sport a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days . Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
CROWN CASTLE (CCI): Free Stock Analysis Report
GETTY REALTY CP (GTY): Free Stock Analysis Report
LEXINGTON PPTY (LXP): Free Stock Analysis Report
EASTRLY GOV PPT (DEA): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Better-ranked stocks in the REIT space include Crown Castle International Corp. CCI , Easterly Government Properties, Inc. DEA and Getty Realty Corp. GTY . Notably, the New York-based real estate investment trust ("REIT") had previously announced this deal. Click to get this free report CROWN CASTLE (CCI): Free Stock Analysis Report GETTY REALTY CP (GTY): Free Stock Analysis Report LEXINGTON PPTY (LXP): Free Stock Analysis Report EASTRLY GOV PPT (DEA): Free Stock Analysis Report To read this article on Zacks.com click here.
|
Better-ranked stocks in the REIT space include Crown Castle International Corp. CCI , Easterly Government Properties, Inc. DEA and Getty Realty Corp. GTY . Click to get this free report CROWN CASTLE (CCI): Free Stock Analysis Report GETTY REALTY CP (GTY): Free Stock Analysis Report LEXINGTON PPTY (LXP): Free Stock Analysis Report EASTRLY GOV PPT (DEA): Free Stock Analysis Report To read this article on Zacks.com click here. Notably, the New York-based real estate investment trust ("REIT") had previously announced this deal.
|
Better-ranked stocks in the REIT space include Crown Castle International Corp. CCI , Easterly Government Properties, Inc. DEA and Getty Realty Corp. GTY . Click to get this free report CROWN CASTLE (CCI): Free Stock Analysis Report GETTY REALTY CP (GTY): Free Stock Analysis Report LEXINGTON PPTY (LXP): Free Stock Analysis Report EASTRLY GOV PPT (DEA): Free Stock Analysis Report To read this article on Zacks.com click here. Notably, the New York-based real estate investment trust ("REIT") had previously announced this deal.
|
Notably, the New York-based real estate investment trust ("REIT") had previously announced this deal. Better-ranked stocks in the REIT space include Crown Castle International Corp. CCI , Easterly Government Properties, Inc. DEA and Getty Realty Corp. GTY . Click to get this free report CROWN CASTLE (CCI): Free Stock Analysis Report GETTY REALTY CP (GTY): Free Stock Analysis Report LEXINGTON PPTY (LXP): Free Stock Analysis Report EASTRLY GOV PPT (DEA): Free Stock Analysis Report To read this article on Zacks.com click here.
|
d6424808-1bfe-4aca-9625-0af866b31d23
|
723592.0
|
2016-01-20 00:00:00 UTC
|
Sovran Discloses $398M of Acquisitions, Enters New Market
|
DEA
|
https://www.nasdaq.com/articles/sovran-discloses-%24398m-of-acquisitions-enters-new-market-2016-01-20
|
nan
|
nan
|
In a major development, Sovran Self Storage Inc.SSS recently inked a deal to acquire 25 self storage facilities for around $371 million, spread over 8 states of the U.S. Also, the Williamsville, NY-based self-storage real estate investment trust ("REIT") acquired 5 facilities in fourth-quarter 2015 and Jan 2016 for around $27 million.
Additionally, the company entered into contracts to buy 8 properties, spanning over 2.3 million square feet of rentable storage space, in the Los Angeles, CA metro area, which is a new market for Sovran Self Storage. These acquisitions are likely to bolster the REIT's strategic position in its existing markets as well provide it with better opportunities to explore a dynamic new market.
The new transactions comprise 21 stabilized properties in the company's existing markets of Boston/SE New Hampshire, Central/Southern Florida, Connecticut, Dallas, Denver, New York City metro area and Philadelphia. Further, Sovran Self Storage has plans to acquire a newly developed facility in Phoenix, AZ. These high-quality properties are excellent additions to the company's portfolio and will likely be accretive to its funds from operations ("FFO") on a leverage-neutral basis in 2016.
Also, the company announced the public offering of 2.3 million of common shares and intends to utilize the net proceeds generated to fund acquisitions as well as for general corporate purposes.
Currently, Sovran Self Storage carries a Zacks Rank #2 (Buy).
Other top-ranked stocks in the REIT space include Crown Castle International Corp. CCI , Easterly Government Properties, Inc. DEA and Getty Realty Corp. GTY . All three stocks sport a Zacks Rank #1 (Strong Buy).
Note: FFO, a widely accepted and reported measure of the performance of REITs, is derived by adding depreciation, amortization and other non-cash expenses to net income.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days . Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
CROWN CASTLE (CCI): Free Stock Analysis Report
SOVRAN SLF STOR (SSS): Free Stock Analysis Report
GETTY REALTY CP (GTY): Free Stock Analysis Report
EASTRLY GOV PPT (DEA): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Other top-ranked stocks in the REIT space include Crown Castle International Corp. CCI , Easterly Government Properties, Inc. DEA and Getty Realty Corp. GTY . In a major development, Sovran Self Storage Inc.SSS recently inked a deal to acquire 25 self storage facilities for around $371 million, spread over 8 states of the U.S. Also, the Williamsville, NY-based self-storage real estate investment trust ("REIT") acquired 5 facilities in fourth-quarter 2015 and Jan 2016 for around $27 million. Click to get this free report CROWN CASTLE (CCI): Free Stock Analysis Report SOVRAN SLF STOR (SSS): Free Stock Analysis Report GETTY REALTY CP (GTY): Free Stock Analysis Report EASTRLY GOV PPT (DEA): Free Stock Analysis Report To read this article on Zacks.com click here.
|
Other top-ranked stocks in the REIT space include Crown Castle International Corp. CCI , Easterly Government Properties, Inc. DEA and Getty Realty Corp. GTY . Click to get this free report CROWN CASTLE (CCI): Free Stock Analysis Report SOVRAN SLF STOR (SSS): Free Stock Analysis Report GETTY REALTY CP (GTY): Free Stock Analysis Report EASTRLY GOV PPT (DEA): Free Stock Analysis Report To read this article on Zacks.com click here. In a major development, Sovran Self Storage Inc.SSS recently inked a deal to acquire 25 self storage facilities for around $371 million, spread over 8 states of the U.S. Also, the Williamsville, NY-based self-storage real estate investment trust ("REIT") acquired 5 facilities in fourth-quarter 2015 and Jan 2016 for around $27 million.
|
In a major development, Sovran Self Storage Inc.SSS recently inked a deal to acquire 25 self storage facilities for around $371 million, spread over 8 states of the U.S. Also, the Williamsville, NY-based self-storage real estate investment trust ("REIT") acquired 5 facilities in fourth-quarter 2015 and Jan 2016 for around $27 million. Click to get this free report CROWN CASTLE (CCI): Free Stock Analysis Report SOVRAN SLF STOR (SSS): Free Stock Analysis Report GETTY REALTY CP (GTY): Free Stock Analysis Report EASTRLY GOV PPT (DEA): Free Stock Analysis Report To read this article on Zacks.com click here. Other top-ranked stocks in the REIT space include Crown Castle International Corp. CCI , Easterly Government Properties, Inc. DEA and Getty Realty Corp. GTY .
|
In a major development, Sovran Self Storage Inc.SSS recently inked a deal to acquire 25 self storage facilities for around $371 million, spread over 8 states of the U.S. Also, the Williamsville, NY-based self-storage real estate investment trust ("REIT") acquired 5 facilities in fourth-quarter 2015 and Jan 2016 for around $27 million. Other top-ranked stocks in the REIT space include Crown Castle International Corp. CCI , Easterly Government Properties, Inc. DEA and Getty Realty Corp. GTY . Click to get this free report CROWN CASTLE (CCI): Free Stock Analysis Report SOVRAN SLF STOR (SSS): Free Stock Analysis Report GETTY REALTY CP (GTY): Free Stock Analysis Report EASTRLY GOV PPT (DEA): Free Stock Analysis Report To read this article on Zacks.com click here.
|
90369b73-2605-42d4-a231-0e87698601a2
|
723593.0
|
2016-01-20 00:00:00 UTC
|
Hudson Pacific Sells Office Center to YouTube for $215M
|
DEA
|
https://www.nasdaq.com/articles/hudson-pacific-sells-office-center-to-youtube-for-%24215m-2016-01-20
|
nan
|
nan
|
In a notable development, Hudson Pacific Properties, Inc.HPP recently sold its Bayhill Office Center, situated in San Bruno, CA, to the online video sharing company YouTube. The all-cash transaction was valued at $215 million. Notably, the Los Angeles, CA-based real estate investment trust ("REIT") sold this non-core property at a premium to the original purchase price.
Hudson Pacific is engaged in ownership, operation and acquisition of office, media and entertainment properties in select growth markets of the U.S, mainly in Northern and Southern California regions. The REIT had acquired the 554,328-square foot Class A office campus in Apr 2015 from Blackstone as part of the buyout of San Francisco Peninsula and Silicon Valley portfolio. This latest sell-off underscores huge demand for top-quality office space along the Peninsula from leading technology firms across the globe.
Currently, Hudson Pacific carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the REIT space include Crown Castle International Corp. CCI , Easterly Government Properties, Inc. DEA and Getty Realty Corp. GTY . All three stocks sport a Zacks Rank# 1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days . Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
CROWN CASTLE (CCI): Free Stock Analysis Report
HUDSON PAC PPTY (HPP): Free Stock Analysis Report
GETTY REALTY CP (GTY): Free Stock Analysis Report
EASTRLY GOV PPT (DEA): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Some better-ranked stocks in the REIT space include Crown Castle International Corp. CCI , Easterly Government Properties, Inc. DEA and Getty Realty Corp. GTY . Click to get this free report CROWN CASTLE (CCI): Free Stock Analysis Report HUDSON PAC PPTY (HPP): Free Stock Analysis Report GETTY REALTY CP (GTY): Free Stock Analysis Report EASTRLY GOV PPT (DEA): Free Stock Analysis Report To read this article on Zacks.com click here. In a notable development, Hudson Pacific Properties, Inc.HPP recently sold its Bayhill Office Center, situated in San Bruno, CA, to the online video sharing company YouTube.
|
Some better-ranked stocks in the REIT space include Crown Castle International Corp. CCI , Easterly Government Properties, Inc. DEA and Getty Realty Corp. GTY . Click to get this free report CROWN CASTLE (CCI): Free Stock Analysis Report HUDSON PAC PPTY (HPP): Free Stock Analysis Report GETTY REALTY CP (GTY): Free Stock Analysis Report EASTRLY GOV PPT (DEA): Free Stock Analysis Report To read this article on Zacks.com click here. Click to get this free report >> Want the latest recommendations from Zacks Investment Research?
|
Click to get this free report CROWN CASTLE (CCI): Free Stock Analysis Report HUDSON PAC PPTY (HPP): Free Stock Analysis Report GETTY REALTY CP (GTY): Free Stock Analysis Report EASTRLY GOV PPT (DEA): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the REIT space include Crown Castle International Corp. CCI , Easterly Government Properties, Inc. DEA and Getty Realty Corp. GTY . In a notable development, Hudson Pacific Properties, Inc.HPP recently sold its Bayhill Office Center, situated in San Bruno, CA, to the online video sharing company YouTube.
|
Click to get this free report CROWN CASTLE (CCI): Free Stock Analysis Report HUDSON PAC PPTY (HPP): Free Stock Analysis Report GETTY REALTY CP (GTY): Free Stock Analysis Report EASTRLY GOV PPT (DEA): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the REIT space include Crown Castle International Corp. CCI , Easterly Government Properties, Inc. DEA and Getty Realty Corp. GTY . In a notable development, Hudson Pacific Properties, Inc.HPP recently sold its Bayhill Office Center, situated in San Bruno, CA, to the online video sharing company YouTube.
|
f6d6738c-6480-4ecf-8aee-7e5653afc00b
|
723594.0
|
2016-01-08 00:00:00 UTC
|
Mack-Cali Buys 3 Sylvan Way; Closes a $350-Million Loan
|
DEA
|
https://www.nasdaq.com/articles/mack-cali-buys-3-sylvan-way-closes-a-%24350-million-loan-2016-01-08
|
nan
|
nan
|
Mack-Cali Realty Corp.CLI recently announced the acquisition of 3 Sylvan Way, a three-story, class A office property, spanning 417.241 square feet and located in Parsippany, NJ.
3 Sylvan Way, which features 50,000-square feet floor plates with a saw-tooth design, is the latest addition to Mack-Cali Business Campus. The latter consists of 15 class A office properties covering approximately 2.1 million square feet.
The company plans to build an "interconnected three-building mini campus" by repositioning the recently acquired 3 Sylvan Way office building, along with One and 5 Sylvan Way bought previously.
Moreover, these buildings are expected to undergo varied renovations, inlcuding "lobby renovations, the creation of a full-service fitness center with yoga rooms and a golf simulator, an upgraded business-class conference center, and numerous dining options, including a full-service cafe and coffee bar."
The latest acquisition is expected to be accretive to overall portfolio and create value for its tenants. As such, the company expects renovation plans to drive higher leasing rates, going forward.
Given Mack-Cali's recent emphasis on transit-oriented real estate properties, Mack-Cali Business Campus' convenient location at the confluence of I-287 and routes 10 and 202, as well as its proximity to the Morris Plain train station, make it a core portfolio holding for this Edison-based office real estate investment trust ("REIT").
Separately, the company announced the closure of a $350-million unsecured term loan, scheduled to mature in Jan 2019, and carrying two 1-year extension options. Interest rate on the loan is fixed at LIBOR plus 140 basis points, and currently stands at 3.12%.
Notably, loan proceeds were utilized by the REIT to meet outstanding borrowings on its $600-million unsecured credit facility; and repay 5.8% unsecured bonds worth $200 million. More importantly, the new borrowing represents significant interest savings over the above-mentioned unsecured bond scheduled to mature on Jan 16.
Mack-Cali currently carries a Zacks Rank #1 (Strong Buy).
Investors interested in the REIT space may also consider stocks like Arbor Realty Trust Inc. ABR , Crown Castle International Corp. CCI and Easterly Government Properties, Inc. DEA . All three stocks sport the same Zacks Rank as Mack-Cali.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days . Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
CROWN CASTLE (CCI): Free Stock Analysis Report
ARBOR RLTY TRST (ABR): Free Stock Analysis Report
MACK CALI CORP (CLI): Free Stock Analysis Report
EASTRLY GOV PPT (DEA): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Investors interested in the REIT space may also consider stocks like Arbor Realty Trust Inc. ABR , Crown Castle International Corp. CCI and Easterly Government Properties, Inc. DEA . Click to get this free report CROWN CASTLE (CCI): Free Stock Analysis Report ARBOR RLTY TRST (ABR): Free Stock Analysis Report MACK CALI CORP (CLI): Free Stock Analysis Report EASTRLY GOV PPT (DEA): Free Stock Analysis Report To read this article on Zacks.com click here. Mack-Cali Realty Corp.CLI recently announced the acquisition of 3 Sylvan Way, a three-story, class A office property, spanning 417.241 square feet and located in Parsippany, NJ.
|
Investors interested in the REIT space may also consider stocks like Arbor Realty Trust Inc. ABR , Crown Castle International Corp. CCI and Easterly Government Properties, Inc. DEA . Click to get this free report CROWN CASTLE (CCI): Free Stock Analysis Report ARBOR RLTY TRST (ABR): Free Stock Analysis Report MACK CALI CORP (CLI): Free Stock Analysis Report EASTRLY GOV PPT (DEA): Free Stock Analysis Report To read this article on Zacks.com click here. Mack-Cali Realty Corp.CLI recently announced the acquisition of 3 Sylvan Way, a three-story, class A office property, spanning 417.241 square feet and located in Parsippany, NJ.
|
Click to get this free report CROWN CASTLE (CCI): Free Stock Analysis Report ARBOR RLTY TRST (ABR): Free Stock Analysis Report MACK CALI CORP (CLI): Free Stock Analysis Report EASTRLY GOV PPT (DEA): Free Stock Analysis Report To read this article on Zacks.com click here. Investors interested in the REIT space may also consider stocks like Arbor Realty Trust Inc. ABR , Crown Castle International Corp. CCI and Easterly Government Properties, Inc. DEA . Given Mack-Cali's recent emphasis on transit-oriented real estate properties, Mack-Cali Business Campus' convenient location at the confluence of I-287 and routes 10 and 202, as well as its proximity to the Morris Plain train station, make it a core portfolio holding for this Edison-based office real estate investment trust ("REIT").
|
Investors interested in the REIT space may also consider stocks like Arbor Realty Trust Inc. ABR , Crown Castle International Corp. CCI and Easterly Government Properties, Inc. DEA . Click to get this free report CROWN CASTLE (CCI): Free Stock Analysis Report ARBOR RLTY TRST (ABR): Free Stock Analysis Report MACK CALI CORP (CLI): Free Stock Analysis Report EASTRLY GOV PPT (DEA): Free Stock Analysis Report To read this article on Zacks.com click here. Mack-Cali Realty Corp.CLI recently announced the acquisition of 3 Sylvan Way, a three-story, class A office property, spanning 417.241 square feet and located in Parsippany, NJ.
|
56e0190f-e83d-4860-97f0-b376883e71d3
|
723595.0
|
2016-01-07 00:00:00 UTC
|
STAG Industrial Closes 49 Buyouts & 6 Disposals in 2015
|
DEA
|
https://www.nasdaq.com/articles/stag-industrial-closes-49-buyouts-6-disposals-in-2015-2016-01-07
|
nan
|
nan
|
STAG Industrial, Inc.STAG , the Boston, MA-based real estate investment trust ("REIT") recently announced its acquisition, disposal and leasing activities for the month, quarter and year ended Dec 2015. Further, the company declared its at-the-money ("ATM") stock offering results for the month of December.
Acquisitions & Disposals
STAG Industrial, which is engaged in acquisition, ownership and management of single-tenant industrial properties throughout the U.S, acquired 10 buildings for $108.7 million during Dec 2015. These properties, spanning 2.2 million square feet, were 93% occupied. In the same month, the company disposed a 270,000-square feet building for $3.7 million.
For the fourth quarter ended Dec 31, 2015, STAG Industrial acquired 14 buildings, covering approximately 3.1 million square feet, for $138.5 million. The weighted average cap rate for the acquired buildings was estimated at 8.7%, and these buildings were 95.6% occupied.
Overall, in 2015, the company bought a total of 49 buildings, covering 8.7 million square feet, reportedly shelling out $427.7 million. Further, the REIT disposed a total of 6 office buildings, consisting of 808,387 square feet, for $22 million during the year.
Leasing
In Dec 2015, the company leased a total of 731,585 square feet, including 529,785 square feet in new leases and 201,800 in lease renewals.
For the fourth quarter ended Dec 31, 2015, the REIT executed 10 leases for nearly 1.4 million square feet; of which 529,785 square feet consisted of new leases; 251,800 square feet pertained to renewal leases; and 657,970 square feet comprised temporary leases. Additionally, 6 leases, totaling 806,030 square feet, expired during the quarter. The tenant retention rate for the same stood at 49.2%.
For full-year 2015, the company executed a total of 55 leases for approximately 5.7 million square feet; including 1.4 million square feet of new leases, 3.0 million square feet of renewal leases, and 1.4 million square feet of temporary leases. Tenant retention rate for 2015 stood at 69.8%.
ATM Offering & Pipeline for 2016
The company announced that it has not issued any shares under its ATM program since the last issuance on Jul 6, 2015.
As of Jan 5, 2016, the company has inked 2 acquisition deals for $18 million, and has executed non-binding letters of intent to acquire 3 additional buildings for $20 million. As of the same date, the company's pipeline for 2016 features 133 potential acquisitions worth $1.4 billion.
Currently, STAG Industrial carries a Zacks Rank #3 (Hold).
Investors interested in the REIT industry may consider stocks like Arbor Realty Trust Inc. ABR Crown Castle International Corp. CCI and Easterly Government Properties, Inc. DEA . All these stocks sport a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days . Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
CROWN CASTLE (CCI): Free Stock Analysis Report
ARBOR RLTY TRST (ABR): Free Stock Analysis Report
STAG INDUSTRIAL (STAG): Free Stock Analysis Report
EASTRLY GOV PPT (DEA): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Investors interested in the REIT industry may consider stocks like Arbor Realty Trust Inc. ABR Crown Castle International Corp. CCI and Easterly Government Properties, Inc. DEA . As of Jan 5, 2016, the company has inked 2 acquisition deals for $18 million, and has executed non-binding letters of intent to acquire 3 additional buildings for $20 million. Click to get this free report CROWN CASTLE (CCI): Free Stock Analysis Report ARBOR RLTY TRST (ABR): Free Stock Analysis Report STAG INDUSTRIAL (STAG): Free Stock Analysis Report EASTRLY GOV PPT (DEA): Free Stock Analysis Report To read this article on Zacks.com click here.
|
Click to get this free report CROWN CASTLE (CCI): Free Stock Analysis Report ARBOR RLTY TRST (ABR): Free Stock Analysis Report STAG INDUSTRIAL (STAG): Free Stock Analysis Report EASTRLY GOV PPT (DEA): Free Stock Analysis Report To read this article on Zacks.com click here. As of Jan 5, 2016, the company has inked 2 acquisition deals for $18 million, and has executed non-binding letters of intent to acquire 3 additional buildings for $20 million. Investors interested in the REIT industry may consider stocks like Arbor Realty Trust Inc. ABR Crown Castle International Corp. CCI and Easterly Government Properties, Inc. DEA .
|
Click to get this free report CROWN CASTLE (CCI): Free Stock Analysis Report ARBOR RLTY TRST (ABR): Free Stock Analysis Report STAG INDUSTRIAL (STAG): Free Stock Analysis Report EASTRLY GOV PPT (DEA): Free Stock Analysis Report To read this article on Zacks.com click here. As of Jan 5, 2016, the company has inked 2 acquisition deals for $18 million, and has executed non-binding letters of intent to acquire 3 additional buildings for $20 million. Investors interested in the REIT industry may consider stocks like Arbor Realty Trust Inc. ABR Crown Castle International Corp. CCI and Easterly Government Properties, Inc. DEA .
|
As of Jan 5, 2016, the company has inked 2 acquisition deals for $18 million, and has executed non-binding letters of intent to acquire 3 additional buildings for $20 million. Investors interested in the REIT industry may consider stocks like Arbor Realty Trust Inc. ABR Crown Castle International Corp. CCI and Easterly Government Properties, Inc. DEA . Click to get this free report CROWN CASTLE (CCI): Free Stock Analysis Report ARBOR RLTY TRST (ABR): Free Stock Analysis Report STAG INDUSTRIAL (STAG): Free Stock Analysis Report EASTRLY GOV PPT (DEA): Free Stock Analysis Report To read this article on Zacks.com click here.
|
7f4a6cbb-2ffa-4223-8e6d-b8eb6c780835
|
723596.0
|
2016-01-06 00:00:00 UTC
|
Brandywine Realty Disposes 3 Properties for $56.3 Million
|
DEA
|
https://www.nasdaq.com/articles/brandywine-realty-disposes-3-properties-for-%2456.3-million-2016-01-06
|
nan
|
nan
|
Brandywine Realty TrustBDN recently announced the disposal of two office properties in Austin, TX and a 137-room hotel in Conshohocken, PA. These divestitures fetched net proceeds of $56.3 million, which the Radnor, PA-based real estate investment trust (REIT) is likely to use for financing its existing development activities, lowering debt burden and general corporate purposes.
Notably, Brandywine Realty sold the 2 Austin, TX-based office properties, Encino Trace I and II, to an existing joint venture ("JV") between itself and DRA Advisors LLC. While Encino Trace I is fully leased, Encino Trace II is 17% leased; and together, these two properties cover an area of 320,000 square feet. Completed on Dec 31, 2015, the transaction generated net proceeds of $35.9 million after excluding closing and transaction costs. The REIT financed Encino Trace I with a $30-million five-year first mortgage at a rate of London Interbank Offered Rate ("LIBOR") plus 185 basis points. The company intends to finance Encino Trace II with a similar type of mortgage.
Also, Brandywine Realty sold The Residence Inn Tower Bridge in Conshohocken, PA for a price of $26.5 million. The net cash proceeds (at company's share) totaled $6.1 million, after repayment of debt, transaction costs and holdbacks.
This Zacks Rank #3 (Hold) stock is one of the largest, publicly traded, full-service, integrated real estate companies in the U.S., with a portfolio comprising 239 properties and 30.7 million square feet as of Sep 30, 2015.
Better-ranked stocks in the same industry include Mack-Cali Realty Corp. CLI , Crown Castle International Corp. CCI and Easterly Government Properties, Inc. DEA . All three stocks sport a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days . Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
CROWN CASTLE (CCI): Free Stock Analysis Report
MACK CALI CORP (CLI): Free Stock Analysis Report
BRANDYWINE RT (BDN): Free Stock Analysis Report
EASTRLY GOV PPT (DEA): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Better-ranked stocks in the same industry include Mack-Cali Realty Corp. CLI , Crown Castle International Corp. CCI and Easterly Government Properties, Inc. DEA . Click to get this free report CROWN CASTLE (CCI): Free Stock Analysis Report MACK CALI CORP (CLI): Free Stock Analysis Report BRANDYWINE RT (BDN): Free Stock Analysis Report EASTRLY GOV PPT (DEA): Free Stock Analysis Report To read this article on Zacks.com click here. These divestitures fetched net proceeds of $56.3 million, which the Radnor, PA-based real estate investment trust (REIT) is likely to use for financing its existing development activities, lowering debt burden and general corporate purposes.
|
Click to get this free report CROWN CASTLE (CCI): Free Stock Analysis Report MACK CALI CORP (CLI): Free Stock Analysis Report BRANDYWINE RT (BDN): Free Stock Analysis Report EASTRLY GOV PPT (DEA): Free Stock Analysis Report To read this article on Zacks.com click here. Better-ranked stocks in the same industry include Mack-Cali Realty Corp. CLI , Crown Castle International Corp. CCI and Easterly Government Properties, Inc. DEA . Notably, Brandywine Realty sold the 2 Austin, TX-based office properties, Encino Trace I and II, to an existing joint venture ("JV") between itself and DRA Advisors LLC.
|
Click to get this free report CROWN CASTLE (CCI): Free Stock Analysis Report MACK CALI CORP (CLI): Free Stock Analysis Report BRANDYWINE RT (BDN): Free Stock Analysis Report EASTRLY GOV PPT (DEA): Free Stock Analysis Report To read this article on Zacks.com click here. Better-ranked stocks in the same industry include Mack-Cali Realty Corp. CLI , Crown Castle International Corp. CCI and Easterly Government Properties, Inc. DEA . This Zacks Rank #3 (Hold) stock is one of the largest, publicly traded, full-service, integrated real estate companies in the U.S., with a portfolio comprising 239 properties and 30.7 million square feet as of Sep 30, 2015.
|
Better-ranked stocks in the same industry include Mack-Cali Realty Corp. CLI , Crown Castle International Corp. CCI and Easterly Government Properties, Inc. DEA . Click to get this free report CROWN CASTLE (CCI): Free Stock Analysis Report MACK CALI CORP (CLI): Free Stock Analysis Report BRANDYWINE RT (BDN): Free Stock Analysis Report EASTRLY GOV PPT (DEA): Free Stock Analysis Report To read this article on Zacks.com click here. Notably, Brandywine Realty sold the 2 Austin, TX-based office properties, Encino Trace I and II, to an existing joint venture ("JV") between itself and DRA Advisors LLC.
|
bb4c90f1-578a-4cd8-bd2c-19071cb74a2b
|
723597.0
|
2015-12-31 00:00:00 UTC
|
Brandywine Realty Sells 6 Office Buildings, Refinances Debt
|
DEA
|
https://www.nasdaq.com/articles/brandywine-realty-sells-6-office-buildings-refinances-debt-2015-12-31
|
nan
|
nan
|
Brandywine Realty TrustBDN announced the disposal of 6 Mount Laurel, NJ-based office buildings, spanning 560,100 square feet, for $56.5 million.
Additionally, the company refinanced its Philadelphia-based One Commerce Square property with a mortgage of $130 million due in Apr 2023, thereby replacing the previous $121.2-million mortgage due in Jan 2016. Notably, the new mortgage bears a fixed interest rate of 3.64%, lower than the rate of 5.67% on previous mortgage.
Together, these actions generated net proceeds of $65.8 million for Brandywine Realty, which the company intends to utilize for financing its development pipeline, improving leverage and meeting other general corporate needs.
Moreover, earlier in December, this real estate investment trust ("REIT") announced the divestiture of five office properties and a 1.6-acre development site for $395.5 million.
In fact, this REIT generated $15.8 million from sale of properties in the third quarter 2015, and is targeting $450 million in sales activity during 2016. This comes as Brandywine Realty remains focused on monetizing non-core land holdings, and deploying proceeds from the same to fund development and/or redevelopment activities in its core markets of Philadelphia, Washington, D.C., and Austin.
At the same time, the asset sale program is aimed at de-leveraging the company's balance sheet, which is encouraging. For 2016, the company targets a debt-to-EBITDA ratio of 6.0x or lower. As of Sep 30, 2015, the ratio stood at 7.0x.
This Zacks Rank #3 (Hold) stock is one of the largest, publicly traded, full-service, integrated real estate companies in the U.S., with a portfolio comprising 239 properties and 30.7 million square feet as of Sep 30, 2015.
Better-ranked stocks in the same industry include Mack-Cali Realty Corp. CLI , Crown Castle International Corp. CCI and Easterly Government Properties, Inc. DEA . All three stocks sport a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days . Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
CROWN CASTLE (CCI): Free Stock Analysis Report
MACK CALI CORP (CLI): Free Stock Analysis Report
BRANDYWINE RT (BDN): Free Stock Analysis Report
EASTRLY GOV PPT (DEA): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Better-ranked stocks in the same industry include Mack-Cali Realty Corp. CLI , Crown Castle International Corp. CCI and Easterly Government Properties, Inc. DEA . Click to get this free report CROWN CASTLE (CCI): Free Stock Analysis Report MACK CALI CORP (CLI): Free Stock Analysis Report BRANDYWINE RT (BDN): Free Stock Analysis Report EASTRLY GOV PPT (DEA): Free Stock Analysis Report To read this article on Zacks.com click here. Together, these actions generated net proceeds of $65.8 million for Brandywine Realty, which the company intends to utilize for financing its development pipeline, improving leverage and meeting other general corporate needs.
|
Click to get this free report CROWN CASTLE (CCI): Free Stock Analysis Report MACK CALI CORP (CLI): Free Stock Analysis Report BRANDYWINE RT (BDN): Free Stock Analysis Report EASTRLY GOV PPT (DEA): Free Stock Analysis Report To read this article on Zacks.com click here. Better-ranked stocks in the same industry include Mack-Cali Realty Corp. CLI , Crown Castle International Corp. CCI and Easterly Government Properties, Inc. DEA . Click to get this free report >> Want the latest recommendations from Zacks Investment Research?
|
Click to get this free report CROWN CASTLE (CCI): Free Stock Analysis Report MACK CALI CORP (CLI): Free Stock Analysis Report BRANDYWINE RT (BDN): Free Stock Analysis Report EASTRLY GOV PPT (DEA): Free Stock Analysis Report To read this article on Zacks.com click here. Better-ranked stocks in the same industry include Mack-Cali Realty Corp. CLI , Crown Castle International Corp. CCI and Easterly Government Properties, Inc. DEA . Additionally, the company refinanced its Philadelphia-based One Commerce Square property with a mortgage of $130 million due in Apr 2023, thereby replacing the previous $121.2-million mortgage due in Jan 2016.
|
Better-ranked stocks in the same industry include Mack-Cali Realty Corp. CLI , Crown Castle International Corp. CCI and Easterly Government Properties, Inc. DEA . Click to get this free report CROWN CASTLE (CCI): Free Stock Analysis Report MACK CALI CORP (CLI): Free Stock Analysis Report BRANDYWINE RT (BDN): Free Stock Analysis Report EASTRLY GOV PPT (DEA): Free Stock Analysis Report To read this article on Zacks.com click here. In fact, this REIT generated $15.8 million from sale of properties in the third quarter 2015, and is targeting $450 million in sales activity during 2016.
|
f5a9fda0-61e2-45c9-843a-29597d3f8dd7
|
723598.0
|
2015-12-21 00:00:00 UTC
|
Arbor Realty Trust (ABR) Catches Eye: Stock Jumps 6.3%
|
DEA
|
https://www.nasdaq.com/articles/arbor-realty-trust-abr-catches-eye%3A-stock-jumps-6.3-2015-12-21
|
nan
|
nan
|
Arbor Realty Trust Inc.ABR was a big mover last session, as the company saw its shares rise above 6% on the day. The move came on solid volume with far more shares changing hands than in a normal session. This breaks the recent trend of the company, as the stock is now trading above the volatile price range of $6.56-$6.89 in the past one-month time frame.
In the last 30 days, the company has seen no estimate revisions and the Zacks Consensus Estimate also remained unchanged. The recent price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
Arbor Realty Trust currently sports a Zacks Rank #1 (Strong Buy) while its Earnings ESP is 0.00%.
Another favorably-placed REIT/equity/trust stock is Easterly Government Properties, Inc. DEA , which sports the same Zacks Rank as Arbor Realty Trust.
Is ABR going up? Or down? Predict to see what others think: Up or Down
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ARBOR RLTY TRST (ABR): Free Stock Analysis Report
EASTRLY GOV PPT (DEA): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Another favorably-placed REIT/equity/trust stock is Easterly Government Properties, Inc. DEA , which sports the same Zacks Rank as Arbor Realty Trust. Click to get this free report ARBOR RLTY TRST (ABR): Free Stock Analysis Report EASTRLY GOV PPT (DEA): Free Stock Analysis Report To read this article on Zacks.com click here. Arbor Realty Trust Inc.ABR was a big mover last session, as the company saw its shares rise above 6% on the day.
|
Click to get this free report ARBOR RLTY TRST (ABR): Free Stock Analysis Report EASTRLY GOV PPT (DEA): Free Stock Analysis Report To read this article on Zacks.com click here. Another favorably-placed REIT/equity/trust stock is Easterly Government Properties, Inc. DEA , which sports the same Zacks Rank as Arbor Realty Trust. Click to get this free report >> Want the latest recommendations from Zacks Investment Research?
|
Another favorably-placed REIT/equity/trust stock is Easterly Government Properties, Inc. DEA , which sports the same Zacks Rank as Arbor Realty Trust. Click to get this free report ARBOR RLTY TRST (ABR): Free Stock Analysis Report EASTRLY GOV PPT (DEA): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Another favorably-placed REIT/equity/trust stock is Easterly Government Properties, Inc. DEA , which sports the same Zacks Rank as Arbor Realty Trust. Click to get this free report ARBOR RLTY TRST (ABR): Free Stock Analysis Report EASTRLY GOV PPT (DEA): Free Stock Analysis Report To read this article on Zacks.com click here. Arbor Realty Trust Inc.ABR was a big mover last session, as the company saw its shares rise above 6% on the day.
|
706fc30b-33f0-4196-ba52-d5e462bf9370
|
723599.0
|
2015-11-12 00:00:00 UTC
|
Easterly Government Properties, Inc. (DEA) Ex-Dividend Date Scheduled for November 13, 2015
|
DEA
|
https://www.nasdaq.com/articles/easterly-government-properties-inc-dea-ex-dividend-date-scheduled-november-13-2015-2015-11
|
nan
|
nan
|
Easterly Government Properties, Inc. ( DEA ) will begin trading ex-dividend on November 13, 2015. A cash dividend payment of $0.22 per share is scheduled to be paid on December 03, 2015. Shareholders who purchased DEA prior to the ex-dividend date are eligible for the cash dividend payment. This represents an 4.76% increase over the prior quarter. At the current stock price of $17.28, the dividend yield is 5.09%.
The previous trading day's last sale of DEA was $17.28, representing a -4.79% decrease from the 52 week high of $18.15 and a 13.83% increase over the 52 week low of $15.18.
DEA is a part of the Consumer Services sector, which includes companies such as Simon Property Group, Inc. ( SPG ) and American Tower Corporation (REIT) ( AMT ).
For more information on the declaration, record and payment dates, visit the DEA Dividend History page. Our Dividend Calendar has the full list of stocks that have an ex-dividend today.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Shareholders who purchased DEA prior to the ex-dividend date are eligible for the cash dividend payment. DEA is a part of the Consumer Services sector, which includes companies such as Simon Property Group, Inc. ( SPG ) and American Tower Corporation (REIT) ( AMT ). For more information on the declaration, record and payment dates, visit the DEA Dividend History page.
|
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Easterly Government Properties, Inc. ( DEA ) will begin trading ex-dividend on November 13, 2015. Shareholders who purchased DEA prior to the ex-dividend date are eligible for the cash dividend payment.
|
Shareholders who purchased DEA prior to the ex-dividend date are eligible for the cash dividend payment. The previous trading day's last sale of DEA was $17.28, representing a -4.79% decrease from the 52 week high of $18.15 and a 13.83% increase over the 52 week low of $15.18. For more information on the declaration, record and payment dates, visit the DEA Dividend History page.
|
Easterly Government Properties, Inc. ( DEA ) will begin trading ex-dividend on November 13, 2015. Shareholders who purchased DEA prior to the ex-dividend date are eligible for the cash dividend payment. The previous trading day's last sale of DEA was $17.28, representing a -4.79% decrease from the 52 week high of $18.15 and a 13.83% increase over the 52 week low of $15.18.
|
9efecf80-d277-4ffc-9965-aa36a24aa5e0
|
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.